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ABSTRACT 
Background: Hydrotherapy is frequently indicated in the management of rheumatoid 
arthritis (RA) patients. Few randomised controlled trials (RCTs) have investigated the 
effects of hydrotherapy in RA and their findings are inconclusive. 
Aims: The aim of this thesis was to evaluate the difference in outcomes (including 
physical function, quality of life, disease activity, psychological wellbeing and cost) 
between a 6-week course of hydrotherapy compared to land-based therapy for patients 
with RA. 
Methods: Forty-three patients (mean age = 60 years; SD = 15.3) diagnosed with RA 
were randomly assigned into either a hydrotherapy plus home exercise (n = 21) or land 
based therapy plus home exercise group (n = 22). Hydrotherapy included a weekly 45 
minutes session for six weeks in addition to a home-exercise programme. Land-therapy 
included weekly 45 minutes sessions over six weeks plus home-exercise therapy. Patients 
were assessed at baseline (Test 1); six weeks (Test 2), three months (Test 3), and six 
months (Test 4) post-treatment. The Primary outcome measured was functional ability 
using the Health Assessment Questionnaire-Disability Index (HAQ-DI). Secondary 
outcomes, including HAQ VAS (pain scale), HAQ-GWB (general wellbeing), HRQoL 
using the EQ-5D VAS, EQ-5D tariff, EQ-5D profile and Quality Adjusted Life Years 
(QALYs) were calculated. Disease Activity was measured using RA Disease Activity 
Index (RADAI) and Disease Activity Score 28 (DAS28). Hospital Anxiety and 
Depression Scale (HADs) was used to measure psychological wellbeing. Costs to the 
provider (NHS), society and patient were also collected. 
Results: Change scores were calculated for all outcome measures between Test 1 and 2; 
Test 1 and 3; Test 2 and 3 and were used for data analysis. Patients treated with 
hydrotherapy experienced improvement in functional ability (HAQ-DI; p < 0.001), pain 
(HAQ VAS; p < 0.001), general wellbeing (HAQ-GWB; p < 0.001), HRQoL (EQ-5D VAS; 
p = 0.021), psychological wellbeing (HADs; p = 0.023). Moderate correlation was found 
in all RA patients between the RADAI and DAS28 (r = 0.328, p = 0.032). Moderate 
correlation was found between depression score (HAD-D) and RADAI (r = 0.578, p < 
0.001); there was also moderate significant correlation between anxiety score (HAD-A) 
and RADAI (r = 0.425, p = 0.005). Predictors of functional disability in patients with RA 
were RADAI, EQ-5D tariff, GWB, depression score and anxiety score. The 
characteristics of patients recruited to this study reflected the RA population in Greater 
Manchester in terms of age, disease duration (DD), gender, body mass index (BMI) and 
DAS28. Finally, there were no difference between hydrotherapy and land-based treatment 
in terms of costs to the patient or society, however, when four patients were treated in the 
pool compared to one patient on land, hydrotherapy was less costly and more effective in 
improving functional disability. 
Conclusions: RA patients in the hydrotherapy group showed significant improvement in 
physical function, psychological well-being, quality of life and reduced health care 
utilisation compared to those in the land-therapy group. Group hydrotherapy is also less 
costly compared to one–to-one treatment on land. 
 
Keywords: Rheumatoid Arthritis, exercise therapy, hydrotherapy, land therapy, aquatic 
exercise, functional ability, functional disability, physical function, disease activity, 
psychological well-being, health related quality of life and quality of life. 
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CRP: C-reactive protein 
C/S: Corticosteroids 
CVD: Cardiovascular disease 
DAS: Disease Activity Score; DAS28: Disease Activity Score 28 
DD: Disease duration 
DIP: Distal interphalangeal joint 
DMARDs: Disease-modifying anti-rheumatic drugs 
DoS: Director of studies  
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EBV: Epstein-Barr virus 
ELs: Educational levels 
EMBASE: Excerpta Medica Database 
ESR: Erythrocyte sedimentation rate 
EQ-5D: EuroQoL 
Fc: Fragment crystallisable 
FMS: Fibromyalgia syndrome 
FSQ: Functional status questionnaire 
GCP: Good clinical practice 
GP: General practitioner 
GWB: General wellbeing 
HAD-A: Hospital anxiety depression-anxiety;  
HAD-D: Hospital anxiety depression-depression 
HADs: Hospital anxiety depression scale 
HAQ: Health Assessment Questionnaire  
HAQ-DI: Health Assessment Questionnaire-Disability Index 
HEP: Home-exercise programme 
HLA: Human leukocyte antigen 
HRQoL: Health-related quality of life 
HT: Hypertension 
ICC: Intraclass correlation coefficient 
ICER: Incremental cost-effectiveness ratio 
IgG: Immunoglobulin G 
IHD: Ischaemic heart disease 
ILAR: International League Against Rheumatism  
JIA: Juvenile idiopathic arthritis 
JRA: Juvenile rheumatoid arthritis 
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MACTAR: McMaster-Toronto Arthritis Patient Preference Questionnaire 
MCP: Metacarpophalangeal joint 
MDT: Multidisciplinary team 
MEDLINE: Medical Literature Analysis and Retrieval System Online  
MHC: Major histocompatibility complex 
MHIQ: McMaster Health Index Questionnaire  
MI: Myocardial infarction 
MRC: Medical Research Council 
MRI: Manchester Royal Infirmary 
MS: Morning stiffness 
MTX: Methotrexate 
NHP: Nottingham Health Profile 
NHS: National Health Service 
NICE: National Institute for Health and Clinical Excellence 
NNT: Numbers needed to treat 
NR: Not reported 
NSAIDs: Non-steroidal anti-inflammatory drugs 
OA: Osteoarthritis 
PIP: Proximal interphalangeal joint 
PQoL: Perceived Quality of Life Scale  
ProQuest: ProQuest Research Library  
Pub-Med: PubMed Central  
QALY: Quality-adjusted life year 
QoL: Quality of life 
QWB: Quality of wellbeing scale 
RA: Rheumatoid arthritis 
RADAI: Rheumatoid arthritis disease activity index   
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RADAR: Rapid assessment of disease activity in rheumatology 
RAI: Ritchie articular index 
RAPID 3: Routine assessment of patient index data 3 
RAQoL: Rheumatoid arthritis quality of life 
RCT: Randomised controlled trial 
RF: Rheumatoid factor 
ROM: Range of motion 
SAARDs: Slow-acting anti-rheumatic drugs 
SDAI: Simplified disease activity index 
SD: Standard deviation 
SF-36: Short Form (36) 
SIP: Sickness impact profile 
SJC44: 44 swollen joint count 
SLAs: Second-line agents 
SLE: Systemic lupus erythematosus 
SPSS: Statistical Package for the Social Sciences 
SRFT: Salford Royal Foundation Trust 
TAG: Transport analysis guidance  
TB: Tuberculosis 
TJC: Tender joint count 
TTO: Time trade off  
UK: United Kingdom 
USA: United States of America 
VAS: Visual analogue scale 
WHO: World Health Organisation 
WOMAC: Western Ontario and McMaster Universities 
WBP: Whole body programmes 
20 
 
 
1.1 Background to the study 
Rheumatoid Arthritis (RA) is defined as a chronic, inflammatory, autoimmune 
systemic disease with exacerbation and remission (Hochberg et al., 1992; 
McCarty & Bundy, 2008). RA affects many organs and tissues in the body, 
although the joints are usually the most severely affected part (Eberhardt et al., 
1990; Jacoby et al., 1973; Tehlirian & Bathon, 2008). This disease of unknown 
aetiology affects all ethnic groups worldwide (Quinn et al., 2004). 
 
The overall prevalence of RA worldwide in the general population is 1-2% 
(National Institute for Health and Clinical Excellence (NICE), 2009; Symmons et 
al., 2002; Symmons et al., 1994). Onset of RA is most commonly in the fourth 
and fifth decades of life with a peak onset between the ages of 35 and 50 years 
(Symmons et al., 2002; Tehlirian & Bathon, 2008; Waldburger and Firestein, 
2008). It affects between 0.5% and 1% of the population, or approximately 
400,000 people, in England and Wales; of these, approximately 15% have a 
severe case of the disease (NICE, 2010). In the United Kingdom (UK), the first 
study to report prevalence of RA was published in 1961 by Lawrence, who 
estimated that 1.1% of the population of Leigh and Wensleydale had RA 
(Lawrence, 1961). On the other hand, Symmons et al. (2002) found that the 
prevalence of this condition was about 0.8%, and this suggests that approximately 
400,000 people in the UK may have RA (Symmons et al., 2002). 
 
CHAPTER ONE: INTRODUCTION 
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The main clinical features of RA are pain, swelling, tenderness and morning 
stiffness (MS) that are symmetrical in nature and involve small joints of the hands 
and feet (Jeffery, 2010; Tehlirian & Bathon, 2008). Other large peripheral joints 
such as knee joints and elbow joints may also be affected as the disease progresses 
(Jeffery, 2010). The distal interphalangeal joints (DIP) and thoraco-lumbar spine 
are spared (Tehlirian & Bathon, 2008). Other common features of RA are fever, 
fatigue, weight loss, limited functional ability, depression and poor self-esteem 
(Tehlirian & Bathon, 2008; Tinsley, 1997). All of these symptoms play a role in a 
decreasing range of movement, functional limitation, loss of independence and 
reduction of quality of life (QoL), which are all important concerns for patients 
with RA (Bowling, 2003; Quinn et al., 2004). Although RA is associated with 
severe disability, it may not directly affect mental functioning but it does have an 
impact on psychological and social well-being (Bowling, 2003). The disease also 
has a major impact on physical function, QoL and may lead to premature death 
(Toussirot, 2010). 
 
The course of RA is unpredictable, and its severity varies widely (Jeffery, 2010; 
Welsing et al., 2001). Periods of exacerbation and remission of disease activity 
may interchange (Jeffery, 2010; Quinn et al., 2004). If left untreated, this disease 
leads to progressive joint destruction and deformity, with resultant deterioration in 
QoL because of functional limitation due to pain and disability, as well as 
increased health care utilisation (Jeffery, 2010; Quinn et al., 2004). It is estimated 
that the cost of treating RA in the UK is about £1.3 billion annually (NICE, 2009; 
NICE, 2010; Pincus & Callahan, 1993). Each year, the direct cost to the National 
Health Service (NHS) is estimated at £560 million, while the cost to the wider 
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economy (such as loss of earnings due to ill health) is estimated at £1.8 billion 
(NICE, 2010; The Comptroller and Auditor General, 2009), whereas the total cost 
of RA in the UK, together with the indirect costs and the effects of early mortality 
and lost productivity, have been approximated at between £3.8 and £4.75 billion 
per year (NICE, 2009). 
  
The treatment of RA is complex because it is a systemic disease that affects any 
part of the patient's body. Moreover, this disease has a very significant impact on 
every aspect of the patient’s physical, psychological and social activities (Emery, 
2006; Oliver & Clair, 2008; Schur & Moreland, 2011). The treatment of RA can 
be divided into pharmacological, non-pharmacological and sometimes surgical 
interventions (Emery, 2006; Luqmani et al., 2009; Schur & Moreland, 2011). 
Non-pharmacological therapy includes different types of therapy such as rest, 
educational advice, exercise treatment, hot and cold applications, electrical 
stimulation and occupational therapy (Oliver & Clair, 2008; Schur & Moreland, 
2011). Pharmacological medication involves the main four lines of treatment 
which are Non-Steroidal Anti-inflammatory drugs (NSAIDs), Disease Modifying 
Anti-Rheumatic Drugs (DMARDs), Cortico-Steroids (C/S) and Biologic drugs 
(Luqmani et al., 2009; Oliver & Clair, 2008). In patients with a chronic disease 
such as RA, rehabilitation therapy is recommended in order to maximise the 
efficacy of pharmacological treatment and improve health status, physical 
function and QoL (Hammond, 2004; Vlieland & Thea, 2003).  
 
The management of RA aims to control the symptoms, minimise or avoid joint 
damage and erosions, preserve physical capacity and prevent or delay disability 
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(Hurley et al., 2002; Oliver & Clair, 2008). This treatment involves a combination 
of pharmacological, non-pharmacological (rehabilitation therapy) and if necessary 
surgical intervention (Hurley et al., 2002; Oliver & Clair, 2008). 
 
Exercise programmes have been suggested to be the cornerstone of rehabilitation 
for RA as they improve function, muscle strength, and general wellbeing (GWB) 
(Hurkmans et al., 2009; Vliet Vlieland & Van den Ende, 2011). Exercise 
programmes for patients with RA are often administered via hydrotherapy 
(Bender et al., 2005; Schrepfer, 2002; Verhagen et al., 2012). Hydrotherapy has 
been used since the Roman era as a form of exercising in warm water for 
therapeutic purposes in order to increase range of motion (ROM), muscle 
strength, physical function, reduction of pain and improvement of QoL (Verhagen 
et al., 2012). In the UK, rehabilitation professionals generally define hydrotherapy 
as heated-pool exercise therapy specifically designed for an individual in an 
attempt to improve neuromuscular and musculoskeletal function (Bender et al., 
2005; Bender et al., 2002).  
 
In this thesis, the terms hydrotherapy, aquatic exercise, aquatic therapy and 
aquatic physiotherapy are used interchangeably to refer to the use of immersion 
pools, of a variety of depths, that help the application of various established 
therapeutic interventions, such as stretching, strengthening, joint mobilisation, 
balance and gait training (HyDAT Team, 2009; Schrepfer, 2002). In the literature, 
there is a lack of clarity regarding the differences between hydrotherapy and the 
terms balneotherapy/whirlpool therapy, spa therapy, thalassotherapy, Kneipp 
therapy and hydrokinesiotherapy. It is important to recognise the difference 
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between these modalities (Bender et al., 2005). Although hydrotherapy and 
balneotherapy are sometimes used interchangeably in the literature, hydrotherapy 
is accessible to health care professionals and is used in the UK. As such, only the 
terms hydrotherapy, aquatic exercise, aquatic therapy and aquatic physiotherapy 
are used in this thesis. Other water-related definitions are described in chapter 
three (p.67-68). 
 
1.1.1 Hydrotherapy 
Hydrotherapy is sometimes used in the treatment of RA by utilising the buoyancy, 
assistance and resistance of warm water to relieve pain, inducing muscle 
relaxation, relieving stress on weight bearing joints and promoting more effective 
exercise (Eversden et al., 2007; Hall et al., 1996; Schrepfer, 2002). Although 
hydrotherapy is used for RA patients including children or adults age groups, little 
scientific evidence exists to support the use of this mode of treatment (Hackett et 
al., 1996). The definitive effectiveness of hydrotherapy on functional ability and 
QoL in RA patients is inconclusive (Beardmore, 2008; Eversden et al., 2007; 
Verhagen et al., 2012). 
 
Unblinded studies examining the efficacy of hydrotherapy in RA patients have 
shown some improvements in pain, Quality of Life (QoL), muscle strength, 
aerobic conditioning and physical functioning (Danneskiold-Samsoe et al., 1987; 
Hart et al., 1994; Suomi & Collier, 2003). However, the findings and 
generalisability of these studies are limited because of the small sample sizes, lack 
of randomisation, poor allocation concealment and lack of a controlled 
intervention. A small number of inconclusive studies have investigated the effects 
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of hydrotherapy in RA with none evaluating the effects on QoL, anxiety and 
depression, cost-effectiveness (CE) or observing the simultaneous effect on 
physical function and RA disease activity. To date, the effectiveness of 
hydrotherapy on functional ability, QoL, depression and anxiety has not been 
adequately examined in patients with RA, and the cost-effectiveness of 
hydrotherapy for patients with RA is unknown. 
 
1.2 Study aims 
The aims of this thesis are divided into primary and secondary.  
1.2.1 Primary aim 
The primary aim of the present study was to:  
 Evaluate the difference in outcomes for RA patients when treated with 
hydrotherapy as opposed to land-based therapy.  
1.2.2 Objectives 
The secondary aims of the present study were to:  
 Determine the effect of hydrotherapy in the management of patients with 
RA by conducting a systematic review. 
 Identify and evaluate the differences in demographic factors between the 
hydrotherapy and land-therapy groups. 
 Identify and understand the reasons for the difference in functional ability 
measured by Health Assessment Questionnaire-Disability Index (HAQ-
DI) between those receiving hydrotherapy and those having land therapy. 
 Evaluate if hydrotherapy could improve pain and GWB; health related 
quality of life (HRQoL); disease activity; mood symptoms (depression and 
anxiety) more effectively than land therapy in patients with RA.  
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 Determine the association between variables measuring disease activity. 
 Determine the association between variables measuring psychological 
status with socio-demographic features and disease activity indices. 
 Determine which factors predict functional disability. 
 Describe and compare patient characteristics from Study One with patients 
from a regional rheumatology centre and previous rheumatology studies. 
 Evaluate the cost of hydrotherapy compared to the land-based treatment, 
from the viewpoint of the provider [NHS], patient and society. 
  
1.3 Hypothesis 
H0: There will be no significant difference in HAQ-DI score between 
hydrotherapy and land-therapy arms in patients with RA. 
H1: There will be a significant difference in HAQ-DI score between hydrotherapy 
and land-therapy arms in patients with RA. 
 
This study was divided into three major sections: 
Study One (43 RA patients): Investigated the clinical effectiveness of 
hydrotherapy plus home exercises vs. land therapy plus home exercises for 
patients with RA using RCT.  
Study Two (200 RA patients): Examined RA patients’ pathway in Greater 
Manchester from a collected data sample of 10% of all RA patients in the Greater 
Manchester using descriptive statistics to compare it with the RCT Study One and 
other comparator literature rheumatology studies. 
Study Three (36 RA patients): Examined the cost-effectiveness of hydrotherapy 
compared to land therapy in RA patients. 
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1.4 Outline of thesis 
Section 1.2 has defined the aims of the thesis, and section 1.3 has described the 
hypothesis on which the thesis is based. The rest of the thesis is structured as 
follows:  
Chapter 2 describes the background of RA in terms of the definition, 
epidemiology, anatomy, pathogenesis, diagnostic criteria, clinical features and 
management. Study of the more comprehensive details has attempted to determine 
the type of treatment (pharmacological or non-pharmacological) suitable for 
management of RA patients. 
Chapter 3 provides a detailed description of hydrotherapy in terms of definitions, 
history, physical property of water, indications, and contraindications. 
Chapter 4 critically evaluates the effectiveness of hydrotherapy in RA patients 
using a systematic review of the updated available literature. The results of this 
chapter are based on the previously published papers. 
Chapter 5 discusses the methodology, illustrating the study design as well as the 
intervention, development and application of the treatment protocol prescribed to 
the intervention groups (RCT Study One). It also describes the preparations 
carried out prior to data collection; patient sample; patient recruitment process; a 
rationale for the choice of outcome measures and planned data analysis. 
Chapter 6 describes the results and overall summary of findings from Study One. 
Chapter 7 presents data from the RCT and compares it with general RA data of 
Kellgren rheumatology centre (Study Two) and some data from the literature. 
Chapter 8 evaluates the cost and CE of hydrotherapy compared to land therapy 
from the perspective of the healthcare provider, patient and society (Study Three). 
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Chapter 9 ‘Discussion’: The findings from all the three studies are discussed. 
Chapter 10 contains ‘Summary, conclusions, clinical implications and 
recommendations’ from the present research, including the strengths, limitations, 
key learning, methodological quality and economic evaluation. Suggestions for 
future studies are also highlighted. 
 
1.5 Summary 
RA is an intermittent, sporadic condition of unknown cause; that may affect any 
age group. It is accepted that RA is a chronic progressive disease in most cases, if 
not particularly managed appropriately; it can progress to cause joint damage and 
disability. This may result in a wide range of complications for people with the 
disease, which can influence their QoL and occupations, and may increase cost to 
the NHS and society in general. Deciding on a particular type of treatment for RA 
patients is a major role and is a challenge to reduce the inflammation, relieve pain 
and stiffness, and control signs and symptoms. The decision of which treatment 
strategy to choose is valuable in that it could prevent further damage to the joint 
or irreversible disability, and that it could preserve the body from permanent 
damage, thus permitting the patient to live the life style they desire. 
 
The next chapter presents the definition, epidemiology, anatomy, pathogenesis, 
diagnostic criteria, clinical features and management of RA. 
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2.1 Introduction 
One of the most common rheumatic diseases is RA, named in 1859 by Garrod 
(Garrod, 1876). RA is a chronic, inflammatory, deforming, destructive and 
systemic disease that can be exacerbated and can go into remission. The objective 
of this chapter is to provide an overview of RA – including its definition, 
diagnostic criteria, anatomy, pathophysiology and the epidemiology of the 
disease; it also discusses the clinical features of RA and the pharmacological and 
non-pharmacological management. 
  
2.2 Definitions and clinical features 
RA is a chronic, inflammatory, symmetrical polyarthritis systemic disease that can 
be erosive and deforming (Hochberg et al., 1992; Mitchell et al., 2005). This 
disease is characterised by joint pain, swelling, tenderness and the destruction of 
synovial joints, leading to severe disability and premature mortality (Mitchell et 
al., 2005; Wolfe et al., 2005).  
 
RA courses are classified into early, established and late (Jacoby et al., 1973; 
Shipley et al., 2005). It typically affects the small joints of the hands as well as 
wrists, knees, ankles, elbows, shoulders and feet (Tehlirian & Bathon, 2008; 
Temprano & Smith, 2011). The thoraco-lumbar spine, distal interphalangeal joint 
(DIP) and hips are often not affected (Tehlirian & Bathon, 2008; Temprano & 
CHAPTER TWO: RHEUMATOID ARTHRITIS: 
BACKGROUND 
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Smith, 2011). The hallmark symptom of RA is symmetrical joint pain and MS 
lasting more than an hour (Tehlirian & Bathon, 2008). Sleep may be disturbed and 
the patient feels permanently tired and generally unwell (Shipley et al., 2005) 
contributing to fatigue (Pinals et al., 1981).  
 
Fatigue is the most common complaint among RA patients (Schur & Moreland, 
2011) and one of the key factors leading to decreased QoL (Swain, 2000). More 
than 70% of RA patients have fatigue and it is more severe and frequent than pain 
(Wolfe et al., 1996). Many aspects might influence the impact of fatigue such as 
physical, psychological and social functioning (Trendall, 2000). 
 
It has been suggested that one of the main limitations of clinical trials is that 
fatigue is rarely identified as one of the core outcomes and therefore is rarely 
addressed as a treatment target in its own right, dissimilar to pain and functional 
disability (Felson et al., 1993). However, multifactorial agents influence RA 
fatigue, such as the inflammatory process of RA, personal life issues, and 
cognitive and behavioural issues (Hewlett et al., 2011). RA inflammatory 
processes cause fatigue by different mechanisms. Pain, poor sleep, muscle effort 
(resulting from joint damage and reduced physical activity), anaemia and RA 
medication, all might cause fatigue in RA (Hewlett et al., 2011). Personal factors 
that potentially influence RA fatigue are related to personal responsibilities in 
terms of caring for family members, going to work to earn an income, difficult 
personal environments (e.g. stairs, lack of assistive devices) and a lack of social 
support (Hewlett et al., 2011). Cognitive behavioural factors such as thoughts, 
feelings, low mood and low self-efficacy might also influence fatigue. These 
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multiple causes of fatigue should be taken in to account when considering 
management (Hewlett et al., 2011). 
  
The clinical course of RA is one of exacerbations and remissions (McMahone & 
Allard, 2002; Temprano & Smith, 2011). Before the use of biologics drugs, it 
appears that about 20-25% of sufferers had mild cases of RA; approximately 50% 
of patients were very limited and became unable to work 10-years post- diagnosis, 
and 20-25% had severe joint damage and early mortality caused by complications 
of RA, such as cardiovascular diseases (CVDs) (Gordon & Hastings, 2004; 
MacAuley, 2007; McMahone & Allard, 2002; Temprano & Smith, 2011). 
However, these percentages have improved greatly recently due to the efficacy of 
biologic drugs (Arthritis Research UK, 2011; Singh et al., 2009). 
 
The majority of RA patients 75% have some damage to joints, swellings and 
flare-ups, some 20% have mild symptoms causing few problems, and some 5% 
develop severe conditions with extensive disability (Arthritis Research UK, 2011; 
Mitchell et al., 2005). The factors associated with poor prognosis are positive 
rheumatoid factor, female gender, Human leukocyte antigen-DR4 (HLA-DR4), 
extra-articular features, severe disability at presentation and insidious onset 
(Hochberg et al., 2004; Mitchell et al., 2005; Tehlirian & Bathon, 2008). Disease 
onset can take many forms. RA results in peripheral poly arthritis and has 
detrimental psychological consequences for patients (Mella et al., 2010). Thus, 
severe pain, functional incapacity, fatigue, economic restrictions and the side-
effects of medication may lead to decreased QoL and are associated with 
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biopsycho-social problems and psychological symptoms such as anxiety and 
depression (Mella et al., 2010; Pollard et al., 2005). 
 
Longitudinal studies have reported variables that are associated in patients with 
RA including exacerbation of disease activity, radiological damage, impaired QoL 
and functional disability (Paget, 2007; Ward, 2007). These variables are closely 
inter-linked and may increase the burden in patients with RA (Scott et al., 2000; 
Scott et al., 2003). Disability is a major factor, which contributes to dependency 
on others for activities of daily living; decrease in social interaction; and early 
retirement due to ill health in patients with RA. In addition, studies have reported 
that increased physical disability was associated with psychological status, 
educational levels (ELs), employment, social support and presence of comorbidity 
(Lillegraven & Kvien, 2007). Furthermore, about 10% of RA patients are most 
likely to suffer from severe joint damage within two years of disease onset, 
leading to substantial increased functional disability (Paget, 2007; Morel & 
Combe, 2005).  
 
2.3 Diagnostic criteria of rheumatoid arthritis (RA) 
The diagnosis of RA depends on specific criteria as stated (Table 2.1, p.33). RA 
must be differentiated from other rheumatic diseases, such as osteoarthritis (OA), 
systemic lupus erythematosus (SLE) and other sero-negative spondyloarthropathy, 
which can have similar clinical features (Akil & Amos, 1995a; Arnett et al., 1988; 
Arnett et al., 2005; Temprano & Smith, 2011). A person can be classified as 
having RA if > 4 criteria are present at any time. The criteria method is a practical 
33 
 
way for making a diagnosis, also it may aid the differential diagnoses from other 
rheumatic diseases (Arnett et al., 1988; Arnett et al., 2005). 
 
Table 2.1: 1987 revised American College of Rheumatology (ACR) criteria for the 
classification of RA (“Reproduced from Arnett et al., 1988, with kind permission of John 
Wiley and Sons, Inc."). 
Criteria 
item 
Definitions 
1 
Stiffness in and around the joints lasting > one hour before 
maximal   improvement 
2 Arthritis of > three joints, simultaneously 
3 
Arthritis of the proximal interphalangeal (PIP), metacarpo-phalangeal (MCP) 
& wrist joints 
4 Symmetrical arthritis 
5 Rheumatoid nodules 
 
6 
A positive test for serum rheumatoid factor/might be positive in other 
rheumatic diseases such as systemic lupus, psoriatic arthropathy 
 
7 
Radiolographic changes, characteristic of RA (erosion and/or periarticular 
osteopenia in hand and/or wrist joints. It would take three years for the 
erosion to be seen by X-ray 
 
 
Recently, the ACR/European League against Rheumatism developed a new set of 
criteria for classification of RA (Aletaha et al., 2010) (Table 2.2, p.34). 
Application of these new criteria provides a score of 0-10, a score of > six being 
indicative of the presence of definite RA (Aletaha et al., 2010). 
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Table 2.2: 2010 American College of Rheumatology/European League against 
Rheumatism classification criteria for RA (“Reproduced from (Aletaha et al., 2010), with 
kind permission of John Wiley and Sons, Inc."). 
 
 
A. Joint involvement Score 
 1 large joint 
 2-10 large joints 
 1-3 small joints (with or without involvement of large joints) 
 4-10 small joints (with or without involvement of large joints)  
 >10 joints (at least 1 small joint)   
0 
1 
2 
3 
5 
B. Serology (at least 1 test result is needed for classification) Score 
 Negative RF and negative anti-CCP 
 Low-positive RF or low-positive anti-CCP 
 High-positive RF or high-positive anti-CCP                              
0 
2 
3 
C. Acute-phase reactants (at least 1 test result is needed for 
classification) 
Score 
 Normal CRP and normal ESR 
 Abnormal CRP or abnormal ESR 
0 
1 
D. Duration of symptoms Score 
 < 6 weeks                                                                                   
 ≥ 6 weeks                                                                                    
0 
1 
Key: 
Anti-CCP: Anti-cyclic citrullinated peptide antibody (anti-citrullinated protein)  
CRP: C-reactive protein  
ESR: Erythrocyte sedimentation rate 
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2.4 Epidemiology of rheumatoid arthritis (RA) 
The most common form of inflammatory arthritis is RA; it affects 1-2% of the 
population in all racial groups and 0.5–1% of the UK population (Alamanos & 
Drosos, 2005; Riise et al., 2000; Symmons et al., 2002). 
  
In the UK, there are 100 new cases of inflammatory joint disease per hundred 
thousand people per year, of whom 24 would have RA (Riise et al., 2000; 
Söderlin et al., 2002; Symmons et al., 2002). In England and Wales, RA affects 
between 0.5% and 1% of the population, or approximately 400,000 people; 
approximately 15% of these have severe disease (NICE, 2010). In the United 
States of America (USA), the average annual incidence of RA is 0.5 per 1000 
persons’ per year (Drosos, 2004). 
 
The disease occurs more frequently in women, the female to male ratio being 4:2, 
and it may start at any age (Tehlirian & Bathon, 2008; Temprano & Smith, 2011; 
Waldburger & Firestein, 2008). The consensus is that RA affects individuals 
during the fourth and fifth decades of life with peak onset between the ages of 35 
and 50 years (Drosos, 2004; Symmons et al., 2002). Almost half the people with 
RA are of working age, and > 60 % have had the disease for more than ten years 
(Wolfe & Hawley, 1998). One third of people will have stopped working within 
two years of diagnosis (NICE, 2009). This potential disabling disease has a 
significant impact on QoL, with job loss resulting in increased healthcare costs to 
the community (Lerner et al., 2005). 
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Figure 2.1 (p.37) and Table 2.3 (p.38) summarise the prevalence of the worldwide 
population of RA. There is no general agreement on the prevalence of RA. 
Studies in Asia and the Far East (Dans et al., 1997; Shichikawa et al., 1999; Zeng 
et al., 1997) report low rates of incidence – approximately 0.3%, 0.2% and 0.17% 
respectively. Conversely, significantly higher prevalence is reported in some 
native American-Indian populations as shown by Del Puente et al. (1989) (5.3%) 
and by Harvey et al. (1981) (6.8%); the reason for these findings can probably be 
related to the poorly defined genetic factors (Waldburger & Firestein, 2008). The 
estimated prevalence of RA is relatively constant, between 0.5% and 1%, as 
shown in European RA population studies – Symmons et al. (2002) (UK); 
Carmona et al. (2002) (Spain); Riise et al. (2000) (Norway); Kvien et al. (1997) 
(Norway); Power et al. (1999) (Ireland); Neovius et al. (2011) (Sweden); 
Adomaviciute et al. (2008) (Lithuania) and Aho et al. (1998) (Finland). This 
finding is similar to North American RA population studies Gabriel et al. (1999) 
and Gabriel (2001); and studies in developing countries Al-Rawi et al. (1978) 
(Iraq); Pountain, (1991) (Oman). 
 
There are several possible explanations for the discrepancy in the data reported on 
the prevalence rate among RA studies:  
 The authors used different diagnostic criteria and cut-off points. 
 RA patients of different ages were studied and this may have affected their 
findings; some studies used 15 years as minimum for RA adult age 
(Cimmino et al. 1998, Pedersen et al. 2011 and Symmons et al. 2002) 
whereas other studies (Riise et al. 2000) used 18 or 20 years as a minimum 
adult age. 
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 Participants presented in Figure 2.1 (p.37) and Table 2.3 (p.38) were 
recruited from different populations with a variable sample size (range 
227-356,000). 
 The inclusion and exclusion criteria and method of participant recruitment 
were not stated in other studies such as Zeng et al. (1997); Kvien et al. 
(1997). 
 
Figure 2.1: Prevalence of RA worldwide. Data were taken from Harvey et al. (1981); Del 
Puente et al. (1989); Gabriel et al. (1999); Al-Rawi et al. (1978) Symmons et al. (2002); 
Aho et al. (1998); Neovius et al. (2011); Adomaviciute et al. (2008); Carmona et al. 
(2002); Power et al. (1999); Kvien et al. (1997); Pountain (1991); Del Puente et al. 
(1989); Pedersen et al. (2011); Cimmino et al. (1998); Guillemin et al. (2005); Zeng et al. 
(1997); Shichikawa et al. (1999). 
 
No nation is spared and the geographical distribution of the disease is remarkably 
homogeneous with a few exceptions such as the Far East Figure 2.1 (p.37) and 
Table 2.3 (p.38). In all population studies, the marked female excess remains 
unexplained.
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Table 2.3: Summary of epidemiological studies worldwide. 
Authors Country Criteria used Sample size Age Total prevalence 
Female 
prevalence 
% 
Male 
prevalence 
% 
Carmona et al. (2002) Spain ACR 1987 2998 ≥ 20 0.5% 0.8% 0.2% 
Shichikawa et al. (1999) China ARA 1961 Rome criteria 3000 NR 0.2% NR NR 
Zeng et al. (1997) Japan NR 22,049 NR 0.32% 0.39% 0.29% 
Guillemin et al. (2005) France 
ACR 1987 + clinical 
examination by 
rheumatologists 
9395 ≥ 18 0.31% 0.51% 0.09% 
Pedersen et al. (2011) Denmark 
Modified ACR 1987 or 
ACR 1987 
4995 ≥ 15 0.35% 0.46% 0.24% 
Del Puente et al. (1989) 
Pima Indians of 
Arizona/ 
USA 
ARA & modified ACR 
1987 
3,868 ≥ 20 5.3% 6.95% 3.23% 
Harvey et al. (1981) 
Central 
Minnesota, USA 
NR 227 NR 6.8% NR NR 
Symmons  et al. (2002) UK ACR 1987 6000 ≥ 16 0.8% 1.16% 0.44% 
Riise et al. (2000) Norway ACR 1987 100,000 ≥ 20 
0.39% (1989) 
0.47% (1994) 
0.54% (1989) 
0.63% (1994) 
0.24% (1989) 
0.30% (1994) 
Cimmino et al. (1998) Italy ACR 1987 4456 ≥ 16 0.33% 0.51% 0.13% 
Kvien et al. (1997) Norway NR 356,486 ≥ 20 0.5-1% NR NR 
Power et al. (1999) Ireland ARA criteria 1987 2,500 NR 0.5% NR NR 
Neovius et al. (2011) Sweden NR 96 560 ≥ 16 0.68% 1.11% 0.43% 
Adomaviciute et al. 
(2008) 
Lithuania NR 6542 NR 0.55% NR NR 
Aho et al. (1998) Finland NR 100,000 > 30 0.8% NR NR 
Gabriel et al. (1999) 
Rochester, 
Minnesota, USA 
ACR 1987 425 ≥ 30 1% NR NR 
Dans et al. (1997) Filipino ACR criteria 1987 3065 NR 0.17% NR NR 
Al-Rawi et al. (1978) Iraq ARA criteria 1957 6999 ≥ 16 1% NR NR 
Pountain (1991) Oman ARA criteria 1987 1925 ≥ 16 0.84% NR NR 
Key: 
  
ACR: American College of Rheumatology; ARA: American Rheumatism Association; NR: Not reported 
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2.5 Risk factors for rheumatoid arthritis (RA) 
RA is considered as a heterogeneous disease with variable severity and 
unpredictable response to therapy. There are many risk factors predisposing to RA 
occurrence. Different risk factors will be discussed below. 
 
2.5.1 Genetic factors 
These contribute to the disease susceptibility through a genetic basis (Kelley & 
Kimberly, 2008; Silman & Pearson, 2002; Tobón et al., 2010). In first-degree 
relatives, the risk of developing RA is approximately 1.5-fold higher than the 
general population (Kelley & Kimberly, 2008; Lawrence, 1970; Lawrence & Ball, 
1958; Tobón et al., 2010). Arthritis Research UK stated in 2011 that the disease 
may run genetically in some families, but that the method of inheritance is not 
transferred directly to individuals who carry the defective gene, but that it might 
increase the susceptibility of developing RA.  
 
The most potent genetic risk factor for RA is related to major histocompatibility 
complex alleles (MHC) or human leukocyte antigen (HLA) when peptides are 
bound and can be recognised by T-cells; the commonest T-cell is the HLA DRB1 
alleles (Barton & Worthington, 2009; Silman & Pearson, 2002). Only 50% of the 
genetic contribution to RA can be explained by HLA, while others related to 
polymorphisms may play a role in RA for the incremental risk (MacGregor et al., 
2000; Tobón et al., 2010). 
 
2.5.2 Non-genetic risk factors 
Non-genetic risk factors describe all susceptible factors implicated with RA 
disease without an obvious genetic basis (Silman & Pearson, 2002; Tobón et al., 
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2010). Investigations into the role of hormones and pregnancy in RA have been 
made to try to discover what factor influences the higher number of women 
affected with RA (2 to 4 times more than men) (Barrett et al., 1999; Silman, 1994; 
Symmons et al., 2002). Hormones such as oestrogen or progesterone could 
potentially explain some of this gender inequality (Klareskog et al., 2006; 
Temprano & Smith, 2011; Tobón et al., 2010). The development of RA disease is 
alleviated by oestrogen and pregnancy, while SLE tends to flare during pregnancy 
and in response to oestrogen (Ostensen, 1999). Exogenous hormonal effects are 
also implicated in disease risk (Silman & Pearson, 2002; Silman, 1994; Symmons 
et al., 2002; Tobón et al., 2010). There have been several studies affirming that 
adult females taking the oral birth-control pill were at less risk of developing RA 
(Brennan et al., 1997; Doran et al., 2004; Silman, 1994; Symmons et al., 2002; 
Tobón et al., 2010). 
 
Numerous studies have attempted to explain the association between RA and 
other comorbidities such as thyroid diseases and diabetes, which present an 
increased frequency in both diseases and in their families (Silman & Pearson, 
2002; Tobón et al., 2010). Other research studies confirmed that there might be a 
common genetic link between RA, autoimmune thyroid disease and insulin-
dependent diabetes (Myerscough et al., 2000; Silman, 1994; Silman & Pearson, 
2002; Tobón et al., 2010). The significance of these findings is yet unclear. One 
conclusion might be that endogenous or exogenous hormones may postpone, 
rather than totally protect against, the development of RA. 
 
41 
 
2.5.3 Environmental factors 
The term environment is frequently used to describe all those susceptibility 
factors implicated in RA that are based on a recognisable genetic marker, but are 
unexplainable (Silman & Pearson, 2002; Tobón et al., 2010). Tobacco smoking is 
the best example of exposure to environmental factors; several studies have 
shown that cigarette smoking is associated with an increased risk of RA 
(Hutchinson et al., 2001; Papadopoulos et al., 2005; Symmons et al., 2002; Uhlig 
et al., 1999; Tobón et al., 2010). It has been proved conclusively that the strong 
correlation between RA and smoking increases in patients with positive RF 
(Silman & Pearson, 2002; Tobón et al., 2010). 
 
Large numbers of infectious diseases such as viruses (Epstein-Barr virus (EBV) 
and parvovirus) including bacteria (proteus and mycoplasma) have been 
implicated as risk factors in developing RA (Silman & Pearson, 2002; Tobón et 
al., 2010). Several observations have suggested a relationship between EBV and 
RA. Viral products might participate indirectly to inflammatory arthritis in 
genetically susceptible individuals through stimulation of the immune system 
(Paget & Routh, 2010; Silman & Pearson, 2002; Tobón et al., 2010). 
 
Diet is another non-infectious environmental factor examined for its significance 
in RA outcomes (Symmons et al., 2002; Tobón et al., 2010). Some studies show 
that treatment with Omega3 fatty acid is associated with improvement in some 
RA outcomes such as diminishing the severity of inflammation (Kremer, 2000; 
Tobón et al., 2010; Volker et al., 2000). However, it is unclear whether these 
dietary factors do have a protective role against RA. Although the exact cause for 
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developing RA is poorly stated, it appears that people with a genetic 
predisposition who are also exposed to risky environmental factors or significant 
hormonal imbalance are the most susceptible candidates. Much evidence is 
available through the interplay of genetic, hormonal, immunological and 
environmental factors, which act as trigger factors in RA. 
 
2.6 Pathophysiology  
The pathogenesis of RA is complex; however, there have been advances in 
understanding the cellular and molecular mechanisms in chronic inflammation 
and tissue damage (Gregersen et al., 2005; Harris Jr, 1986; Shipley et al., 2005). 
The provoking effects in the pathogenesis of RA are thought to be activation of T-
cells by an unknown antigen in a genetically susceptible individual, such as first- 
degree relatives and identical twins (Harris Jr, 1986; Weissmann, 2004; Weyand 
& Goronzy, 1997). Proliferation of synoviocytes, endothelial cells and other pro-
inflammatory cells all occur through activation of the T-cells (Harris Jr, 1986; 
McInnes & Schett, 2007; Weyand & Goronzy, 1997). The finding of the 
rheumatoid factor (RF) in the blood of patients with RA has led to the 
immunological hypothesis of disease pathogenesis (Firestein, 2005; Weissmann, 
2004; Weyand & Goronzy, 1997). Since RF is an autoantibody, the concept that 
RA is an autoimmune disease has gained reliability (Firestein, 2005; Song & 
Kang, 2010; Weissmann, 2004).  
 
B-cells may contribute to the pathogenesis of RA through production of 
rheumatoid factor and other autoantibodies (Edwards & Cambridge, 2006; Harris 
Jr, 1986; Weissmann, 2004). The production of rheumatoid factors (anti-IgG 
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immunoglobulin) requires the interaction of T- and B-lymphocytes (Firestein, 
2005; Weissmann, 2004; Weyand & Goronzy, 1997). RF and anti-cyclic 
citrullinated peptide antibodies (anti-CCP) with other autoantibodies, which target 
systemic and synovial auto-antigens, may contribute to the inflammatory response 
through activation of complement (Firestein, 2005; McInnes & Schett, 2007; 
Weissmann, 2004; Weyand & Goronzy, 1997). 
 
Although the pathogenesis of RA is incompletely understood, it involves both T 
and B-lymphocytes as a complex network of cytokines and growth factors 
offering many different targets for pharmacological intervention. Joint damage in 
RA starts with the proliferation of synovial macrophages and fibroblasts after a 
trigger incident, possibly an autoimmune or infectious episode (Firestein, 2005; 
Weyand & Goronzy, 1997). The initial trigger for the RA pathological changes is 
unknown, but joint heat and redness caused by increased vascularity to the joint, 
then proliferation of the synovial membrane with increased synovial fluid, results 
in severe pain (Firestein, 2005; Weissmann, 2004; Weyand & Goronzy, 1997). 
  
The most common causes of joint pain in RA are: 
 Capsular stretching caused by swelling in the joint, leading to stretching of 
pain receptors (Arthritis Research UK, 2011; NICE, 2009; Waldburger & 
Firestein, 2008). 
 Irritation of nerve endings by the inflammatory chemicals (Arthritis 
Research UK, 2011; Waldburger & Firestein, 2008). 
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Wasting of the muscles around the joints has been attributed, at least in part to 
joint pain, tenderness and swelling leading to loss of joint function. Continuation 
of the condition will lead to inflammation of the synovial membrane leading to 
increased joint damage and progressing deformities (NICE, 2009; McInnes & 
Schett, 2007; Waldburger & Firestein, 2008). Thus, joint pain indirectly causes 
muscle wasting by the disuse of muscles due to pain and tenderness. 
 
Another cause of muscle wasting is rheumatoid cachexia (Walsmith & Roubenoff, 
2002). RA is accompanied by a loss of body cell mass, a metabolic abnormality 
known as ‘rheumatoid cachexia’, which predominates in skeletal muscle and 
occurs in the viscera and immune system (Walsmith & Roubenoff, 2002). 
Typically, rheumatoid cachexia results from the reduced muscle mass and 
increased fat mass that occurred in patients with normal or increased BMI 
(Summers et al., 2010). Currently there is no established mechanism for this 
phenomenon, but it is attributed to increased production of pro-inflammatory 
cytokines (mainly tumour necrosis factor-α and interleukin-1β), elevated resting 
energy expenditure, and accelerated whole-body protein catabolism (Summers et 
al., 2010; Walsmith & Roubenoff, 2002). Thus, rheumatoid cachexia in RA leads 
to muscle weakness and a loss of functional capacity and is believed to accelerate 
morbidity and mortality (Walsmith & Roubenoff, 2002).  
 
Inflammatory processes sometime spread to the tendon sheath, which leads to 
tendon rupture (NICE, 2009; Waldburger & Firestein, 2008). The suppression of 
inflammation in the early stages of the disease can result in improvements in long-
term outcomes for joints, muscles, tendons and nerves (NICE, 2009). 
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To conclude, it is clear that immune disturbances play a key role in susceptibility 
to RA, and that variation in the same loci may predispose the patient to other 
autoimmune diseases. It remains unclear as to what determines the pattern, extent, 
and progression of the disease. In RA, the synovial membrane is the primary 
target organ to which the main changes occur, and joint inflammation and damage 
occur through the interconnection between cellular and molecular immunity 
(Firestein, 2005; Gregersen et al., 2005). 
  
2.7 Anatomy of synovial joints 
Understanding how the inflammatory process develops in most autoimmune 
inflammatory diseases like RA requires the knowledge of how a normal joint 
works (Arthritis Research UK, 2011). Figure 2.2 and 2.3 (p.46) illustrate the 
differences between a normal joint and an inflamed joint (Arthritis Research UK, 
2011). The cartilage is characterised by its very smooth, slippery surface, which 
allows an easy frictionless movement of bones (Arthritis Research UK, 2011; 
NICE, 2009; Waldburger & Firestein, 2008). The capsule that covers the 
synovium acts as joint stabiliser and prevents excessive bone movement (Arthritis 
Research UK, 2011; Waldburger & Firestein, 2008). 
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Figure 2.2: Normal joint [Reproduced from Arthritis research UK (2011) with kind 
permission]. 
 
 
 
Figure 2.3: RA joint [Reproduced from Arthritis research UK (2011) with kind 
permission]. 
 
 
2.8 Musculoskeletal and extra-articular manifestations 
RA can affect any synovial joint but has a predilection to the small joints of the 
hands and feet (Cojocaru et al., 2010; McMahone & Allard, 2002). In the early 
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stages, there is only swelling and inflammation of the affected joint, but 
deformities occur if the disease is left untreated (Tehlirian & Bathon, 2008). 
Typical deformities include: Radial deviation at wrist, ulnar deviation at MCP 
joints, dorsal subluxation of MCP, Boutonniere deformities of fingers (with 
flexion of proximal interphalangeal joints (PIPs) and hyperextension of distal 
interphalangeal joints (DIPs) resulting from a lack of collateral ligament support), 
swan-neck deformities of fingers (hyperextension of PIP and flexion of DIP) and 
Z-deformity of thumb (McMahone & Allard, 2002; Tehlirian & Bathon, 2008). 
There are varieties of soft tissue disorders that may be associated with RA, such 
as tendon inflammation and tendon rupture (Gordon & Hastings, 2004; 
McMahone & Allard, 2002). 
 
Other features of RA are fever, fatigue, loss of appetite, weight loss, limited 
functional ability, depression and poor self-esteem (Jeffery, 2010; Tehlirian & 
Bathon, 2008). These are all important concerns for patients with RA and play a 
role in decreasing range of movement, functional limitation, loss of independence 
and reduction of QoL, (Bowling, 2003; Quinn et al., 2004). Any organ in the body 
(Table 2.4, p.48) may be involved in RA during the illness trajectory (Cojocaru et 
al., 2010; Gordon & Hastings, 2004; Turesson et al., 2003). These extra-articular 
manifestations can be seen in 40-50% of RA patients at some point during their 
lifetime of living with RA (Cojocaru et al., 2010; Tehlirian & Bathon, 2008). 
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Table 2.4: Common extra-articular manifestations of RA (adapted from Tehlirian and 
Bathon, 2008, with kind permission of Springer Science + Business Media). 
 
 
2.9 Treatment strategies 
RA affects any part of the patient's body, not just the articular and locomotor 
systems; therefore, the treatment for this disease is complex (Oliver & Clair, 
2008; Shipley et al., 2005). Treatment of RA may differ among rheumatologists 
and currently, clear and consensual international recommendations on RA 
System(s) affected Nature of extra-articular manifestations 
Ophthalmology 
(eye) 
Keratoconjunctivitis sicca (dry eyes and dry mouth), episcleritis, 
scleritis, uveitis, ulcerative keratitis 
Neurology (nervous 
system) 
Peripheral entrapment neuropathy, cervical myelopathy due to 
cervical spine subluxation (rarely) 
Cardiac (heart) Pericarditis, accelerated atherosclerotic disease, valvulitis 
Pulmonary (lung) 
pleural effusions, pulmonary nodules, diffuse interstitial lung 
disease, fibrosing alveolitis, caplan’s syndrome, cricoarytenoid 
arthritis (pulmonary arteritis, shrinking lung) 
Renal (kidney) Amyloidosis 
Hepatic (liver) Elevated liver enzymes (non-specific transaminitis) 
Spleen 
Splenomegaly,  Felt’s syndrome (neutropenia, large granular 
lymphocytes, thrombocytopenia) 
Skin Rheumatoid nodules, leg ulcer, nail fold lesions of vasculitis 
Muscular Muscle atrophy, inflammatory myositis 
Vascular blood 
vessels 
Small vessel vasculitis, systemic vasculitis, anaemia and 
lymphadenopathies 
Psychosocial  
(non-specific) 
Fatigue, depression, weight loss, cachexia, malaise, fever 
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treatment are not available (Smolen et al., 2010). Patients need clear explanations 
and reassurance during the period of diagnosis because diagnosis of RA causes 
great concern and fear (Arthritis Research UK, 2011; Shipley et al., 2005). Thus, 
in addition to non-pharmacological and pharmacological therapy, input from the 
multidisciplinary team (MDT) - including rheumatologist, orthopaedist, nurse, 
occupational therapist, physiotherapist, social worker and psychologist – is 
needed (Luqmani et al., 2009; Schur & Moreland, 2011). Moreover, surgical 
intervention may be required for joint replacement or other surgical procedures in 
cases of chronic RA (Oliver & Clair, 2008; Shipley et al., 2005).  
 
It is believed that in optimal care of RA, there is no specific standard treatment, 
but monitoring disease activity outcomes provide a clue to determining if patients 
need changes in therapy (Luqmani et al., 2009; Oliver & Clair, 2008). The main 
aim of RA treatment sort by the British Society for Rheumatology and British 
Health Professionals in Rheumatology Standards, Guidelines and Audit Working 
Group, are to control synovitis early and effectively, to prevent joint damage, 
achieve functional ability, maintain employability, improve psychosocial 
functioning, monitor for drug toxicity, and manage and screen for comorbidities 
(Luqmani et al., 2009). 
 
2.9.1 Pharmacological treatment 
There are many different types of drugs used in treatment of RA disease: Non-
steroidal anti-inflammatory drugs (NSAIDs), disease modifying antirheumatic 
drugs (DMARDs), glucocorticoids, immunosuppressant biologic modifier agents 
(Akil & Amos, 1995b; O'Dell, 2004; Oliver & Clair, 2008). The main goal of 
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pharmacological treatment is to reinforce the overall main aim as outlined by the 
BSR. The decision of choosing the appropriate treatment intervention is important 
in preventing further damage to the affected joints or irreversible disability, and to 
preserve the body from permanent deformity. 
 
2.9.1.1 Non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs are a first line of treatment and are commonly used in the symptomatic 
treatment of many rheumatic diseases and other associated medical conditions 
(Akil & Amos, 1995b; Oliver & Clair, 2008). NSAIDs reduce swelling and pain 
in RA patients. These drugs are divided into two groups: 
A) Non-selective NSAIDs, such as naproxen, ketoprofen, ibuprofen, diclofenac, 
piroxicam and indomethacin. These drugs inhibit both cyclooxygenase-1(COX-1) 
and cyclooxygenase-2 (COX-2), which is when the central enzyme is involved in 
synthesis of prostaglandins and related compounds (Hilliquin & Menkes, 1994; 
Oliver & Clair, 2008; Temprano & Smith, 2011). This group negatively triggers 
gastrointestinal irritation and precipitates asthma and fluid retention, due to 
decreased kidney function. 
 B) COX-2 selective inhibitor (COX-1 sparing agents) such as nemisulide, 
meloxicam, rofecoxib, valdecoxib. This type has a much superior gastrointestinal 
tolerance, but gives a considerable risk of cardiovascular problems, minimum or 
no effect on platelets, and no susceptibility to produce asthma (Firestein et al., 
2006; Hilliquin & Menkes, 1994; Oliver & Clair, 2008). 
 
All NSAIDs are analgesic, antipyretic and anti-inflammatory to relieve pain, 
reduce fever and eliminate inflammation. They have a rapid inhibitory result on 
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exacerbations of inflammation like pain and MS; unfortunately, this group has no 
inhibitory effect on the progression of RA and controls the symptoms only, 
without retarding the disease progression. A treatment strategy depends on the 
patient’s response (Breedveld & Kalden, 2004; Oliver & Clair, 2008). A patient’s 
response is variable and while it may necessitate trying several NSAIDs, the 
simultaneous combination of two NSAIDs should be avoided (Breedveld & 
Kalden, 2004; Oliver & Clair, 2008). Before assessing the treatment’s efficacy to 
control pain, it should be used at full dosage continuously for at least two to four 
weeks, in order to maximise the anti-inflammatory effect (Oliver & Clair, 2008). 
 
2.9.1.2 Disease modifying anti-rheumatic drugs (DMARDs) 
DMARDs are one of the potent anti-inflammatory drugs that have a significant 
role in altering disease progression. They can be called slow acting anti-rheumatic 
drugs (SAARDs) or second-line agents (SLAs) (O'Dell, 2004; Oliver & Clair, 
2008; Saag et al., 2008). DMARDs can significantly modify or control the disease 
through reduction of inflammation, lessening damage and maintaining joint 
function (Akil & Amos, 1995b; Oliver & Clair, 2008; Temprano & Smith, 2011). 
With different sites of action, most DMARDs’ the mode of action of remains 
unclear and controversial but overall it is difficult to explain the multiple 
pathogenesis theories (Firestein et al., 2006; Oliver & Clair, 2008). 
 
It has been proven and recommended that early initiation of DMARDs should be 
prescribed in order to induce more remissions and retard disease progression 
(Luqmani et al., 2009; Oliver & Clair, 2008; Temprano & Smith, 2011). There is 
good evidence that joint inflammation is controlled by DMARDs, and that 
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withdrawal of the drug leads to exacerbation of inflammation (Breedveld & 
Kalden, 2004; Saag et al., 2008; Shipley et al., 2005). Methotrexate (MTX), 
Sulphasalazine, leflunamide, and cyclosporine have been shown to reduce the rate 
of progressive joint damage (Breedveld & Kalden, 2004; Shipley et al., 2005). 
MTX is one of the most common DMARDs used because of its recognised 
clinical benefits, effectual combination with other DMARDs and its well-
understood, long-term efficacy and toxicity profile (Oliver & Clair, 2008; 
Temprano & Smith, 2011). The mode of action of DMARDs is delayed a few 
months after use, and this gap can be covered by low-dose C/S, which provide 
rapid control of the signs and symptoms and thus act as bridge therapy (Oliver & 
Clair, 2008; Smolen et al., 2010). 
 
The ultimate goal of drug therapy is to achieve remission; if the single drug of 
DMARDs does not achieve this goal, then combination of two or three drugs may 
be more effective than MTX alone (O'Dell et al., 1996; Oliver & Clair, 2008; 
Saag et al., 2008; Smolen et al., 2010). In a study by Boers et al. (1997), the use of 
sulphasalazine (2g/day), prednisolone (60 mg/day), and MTX (7.5 mg/week) was 
investigated in 155 early RA  patients for 52 weeks compared to those receiving 
Sulphasalazine alone (Boers et al., 1997). The results showed that joint damage 
was significantly less in the combination regimen. DMARDs, in spite of their 
therapeutic effectiveness, cause adverse effects; some are temporary while others 
might be fatal. Although the incidence of fatalities is unknown, most of the side 
effects are related to toxicity or bone marrow suppression (Breedveld & Kalden, 
2004; Dixon & Daniel, 1993). 
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It is logical to start treatment with drugs that have the least toxicity, for instance: 
hydroxychloroquine and sulphasalazine. DMARDs are crucial to the control of 
disease activity and consequential joint damage. They offer outstanding disease 
control and deter permanent joint injury; therefore, combinations of DMARD 
regimens are recommended. If the onset of action is delayed or there are adverse 
toxic reactions to DMARDs, the administration of the third-line agent, C/S, could 
be substituted. 
 
2.9.1.3 Corticosteroids (C/S) 
C/S, steroids and glucocorticoids, play a vital role in medicine and particularly in 
rheumatology (Oliver & Clair, 2008; Saag et al., 2005). The actions of C/S are 
strongly anti-inflammatory and immunosuppressive, reducing activation, 
proliferation, differentiation and survival of a variety of inflammatory cells such 
as macrophages and T-lymphocytes (Firestein et al., 2006; Oliver & Clair, 2008). 
However, they are powerful disease-controlling drugs with inevitable side effects; 
therefore, they should be avoided in the long term (Oliver & Clair, 2008; Shipley 
et al., 2005). 
 
Corticosteroids are used in the following ways: 
 Started and maintained in low dose (5-10 mg) as additional therapy to 
improve known symptoms of RA (Oliver & Clair, 2008; Saag et al., 2005). 
Some centres use early intensive short-term regimens (Shipley et al., 
2005). Because of side effects such as osteoporosis, they should not be 
used for long-term therapy (Saag et al., 2005). 
 As a bridge therapy to relieve the symptoms while waiting for the 
therapeutic effect of DMARDs (Oliver & Clair, 2008). 
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 Sometimes steroids are prescribed in serious systemic active RA such as 
vasculitis and serositis in suitable infusion dose therapy as pulse dose to 
induce remission and dramatic response (Hilliquin & Menkes, 1994; 
Kadioglu & Sheldon, 1998; Oliver & Clair, 2008).  
 Intra-articular injections are administered in acute inflammatory arthritis to 
improve function, mainly in weight-bearing joints with effusion. Intra–
articular injection is indicated in tenosynovitis, bursitis, and carpal tunnel 
syndrome (Hilliquin & Menkes, 1994; Oliver & Clair, 2008). 
 Steroids have many adverse side effects, such as osteonecrosis, 
osteoporosis, hyperglycaemia, glaucoma, cataract, impaired wound 
healing, truncal obesity, flushing face, amenorrhea, myopathy, peptic 
ulcer, hypertension (HT), skin thinning and psychosis; some of these 
adverse reactions might be temporary, while others could be permanent 
(Hilliquin & Menkes, 1994; Oliver & Clair, 2008). The adverse publicity 
about the potential side effects of steroids has meant that their use is now 
controversial (Myasoedova et al., 2011; Shipley et al., 2005). Another 
main problem associated with steroids is withdrawal symptoms in those 
patients with long-term usage, which occurs due to potential side effects 
(Hilliquin & Menkes, 1994; Oliver & Clair, 2008; Shipley et al., 2005). To 
avoid flare up of disease activity, tapering of the dosage must be done 
carefully depending on duration of treatment, severity and clinical 
response. 
 
C/S are valuable mainly in active inflammatory diseases with reasonably 
scheduled dose either alone or in combination with NSAIDs and DMARDs as 
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bridge, additive or pulse therapy. Moreover, careful assessment of the patient’s 
history as well as a full examination is recommended if the patient complains of 
other chronic systemic diseases. This is especially important among elderly 
people who already might have a compromised immune system. It is necessary to 
advise those patients on long-term steroid therapy to be aware of the dangers of 
falling over and/or mal-nourishment due to the fact that steroids can cause 
decreased bone density.  
 
2.9.1.4 Biologic response modifier 
This group of drugs was designed in the past decade and has revolutionised the 
treatment of RA. These drugs can reduce inflammation without causing 
permanent joint damage and can increase damaged joint function (Gordon & 
Hastings, 2004; Singh et al., 2009; Weaver, 2004). They work as modifiers in 
pathogenesis of RA, principally in binding molecules onto the cells of the immune 
system (Gordon & Hastings, 2004; Oliver & Clair, 2008). The molecules of 
immune cells cause inflammation followed by joint destruction (Gordon & 
Hastings, 2004; Shipley et al., 2005; Weaver, 2004). The evidence from use of 
biologic drugs suggests that a new direction in RA therapy has begun, wherein it 
depends on immune-regulatory interference (Luqmani et al., 2009). 
This group is characterised by a rapid mode of action, within two weeks for some 
medications, and four to six weeks for others. However, most anti-TNF drugs 
require a minimum of three months’ treatment before effectiveness can be 
determined, and several need six months of therapy to show significant changes in 
RA symptoms (Gordon & Hastings, 2004; Oliver & Clair, 2008; Saag et al., 
2008). These drugs are very expensive compared to DMARDs or C/S (Oliver & 
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Clair, 2008; Weaver, 2004). The guideline from the British Society of 
Rheumatology (BSR) UK recommend that biological therapy should be reserved 
for patients with active disease and who have not responded to at least two 
DMARDs, including MTX, for a minimum of two months (Ledingham & 
Deighton, 2005; Luqmani et al., 2009). Moreover, the contra-indications and side 
effects of these drugs should be highlighted (Singh et al., 2012). 
  
Recently, the ACR has updated the recommendation for the use of DMARDs and 
Biologic agents in terms of: 
 Indications of both DMARDs and biologics; 
 Switching between drugs (Singh et al., 2012); 
 Screening for tuberculosis (TB) reactivation in patients starting or 
currently receiving biologic agents (Singh et al., 2012); 
 Initiation of biologic agents in high-risk cases with hepatitis, congestive 
heart failure and malignancy (Singh et al., 2012); 
 Vaccination for those patients starting or currently receiving DMARDs or  
biologic agents (Singh et al., 2012). 
  
The main side effects of biologic drugs are upper respiratory tract infections and 
erythematous skin reaction at the injection site, which will disappear after a few 
days (Weaver, 2004). Symptomatic relief of pain and swelling can be achieved by 
using NSAIDs. Early treatment with DMARDs and introducing biologics are the 
most important factors to be considered (Weaver, 2004). Sometimes effective 
control of disease activity will require more than one medication (Weaver, 2004). 
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2.9.2 Non-pharmacological treatment 
Varieties of non-pharmacological treatment approaches to manage the symptoms 
of RA and improve overall wellbeing for RA patients have been investigated 
(Schur & Moreland, 2011). It has been recommended that some important factors 
should take into account the rehabilitation of people with rheumatic diseases, such 
as the restriction of mobility and activity (Schur & Moreland, 2011). 
Rehabilitation is concerned with managing the consequences of disease (Vlieland 
& Thea, 2003). As no drug therapies at present lead to long-term remission of RA, 
patients will continue to suffer physical, psychological, functional and social 
disease consequences, the severity/impact of RA consequences could be reduced 
by rehabilitation (Vlieland & Thea, 2003).  
 
The major components of rehabilitation therapy include education and 
counselling, relative rest, pain-relieving modalities, nutrition, adaptive devices 
and exercise (Beardmore, 2008; Schur & Moreland, 2011). The main objectives of 
rehabilitation are to maintain or improve joint mobility, increase muscle strength 
to prevent further joint damage and achieve maximum physical function 
(Beardmore, 2008; Schur & Moreland, 2011). 
2.9.2.1 Education and counselling 
Education and counselling are vital in order for RA patients and their carers to 
understand the nature, onset, and complications of the disease (Beardmore, 2008; 
Schur & Moreland, 2011). There is a need to plan long-term treatment in order to 
appraise and assess alternative treatment options and identify reasonable 
expectations (Beardmore, 2008; Schur & Moreland, 2011). An understanding of 
the disease helps patients and carers to cope psychologically with the impact of 
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the disease’s symptoms, such as pain and disability, and minimises visits to 
physicians (Temprano & Smith, 2011). Education and self-management may be 
the most cost-effective intervention for RA (Temprano & Smith, 2011). 
 
2.9.2.2 Physical modalities 
2.9.2.2.1 Bed rest 
An inflamed joint needs to be rested using either splints or taking bed rest to avoid 
further destruction and deformity (Hurley et al., 2002; Schur & Moreland, 2011). 
However, because the most common symptom of RA is fatigue (Schur & 
Moreland, 2011), long-term periods of rest should be avoided, and instead short-
term periods of rest should be alternated with physical activity in order to prevent 
muscle atrophy (Oliver & Clair, 2008; Schur & Moreland, 2011). Rest and 
splinting for fingers and wrists, which work to reduce joint swelling and pain, are 
commonly used during active disease (Beardmore, 2008; Schur & Moreland, 
2011). Tradition recommends admission to hospital for prolonged bed rest and 
immobilisation to control disease activity (Mills et al., 1971; Ropes, 1961). 
However, muscle atrophy often accompanies RA and is exacerbated by prolonged 
bed rest, immobilisation, splints and medications (Temprano & Smith, 2011).  
 
It is best to rest the joints that are inflamed in RA patients during flare-ups 
(worsening of joint inflammation) (Scott & Wolman, 1992). This may be 
accomplished by the temporary use of adaptive devices or joint splints (Hurley et 
al., 2002; Schur & Moreland, 2011). When joint inflammation is decreased, 
guided exercise programmes are necessary to maintain flexibility of the joints and 
to strengthen the muscles that surround the joints. Range of motion exercises 
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should be carried out regularly in order to maintain joint mobility (Hurkmans et 
al., 2009; Hurley et al., 2002; Vliet Vlieland & Van den Ende, 2011). However, 
Patients with RA should not stay in bed for more than 48 hours without having a 
medical consultation (Hurkmans et al., 2009; Hurley et al., 2002; Scott & 
Wolman, 1992; Vliet Vlieland & Van den Ende, 2011). 
 
2.9.2.2.2 Exercise therapy 
Exercise is the cornerstone of the non-pharmacological treatment of RA; its main 
function is to improve muscle strength, endurance and GWB (Hurkmans et al., 
2009; Vliet Vlieland & Van den Ende, 2011). Terms such as physical activity and 
exercise can describe different concepts (Caspersen et al., 1985). These terms are 
sometimes used interchangeably and they are often difficult to distinguish 
between (Caspersen et al., 1985).  In this thesis, physical activity is referred to in 
the context of: any body movement generated by skeletal muscles, resulting in 
energy expenditure, such as activities of daily life in terms of occupational, sport 
conditioning and household (Caspersen et al., 1985). Exercise is referred to as a 
division of physical activity that is planned, structured, and repetitive, and has a 
target for the improvement or maintenance of physical fitness (Caspersen et al., 
1985). Patients with RA experience severe pain and stiffness because of joint 
inflammation, the consequences of which may lead to loss of joint motion, loss of 
muscle strength, muscle atrophy and contractures. This, in turn, leads to decreased 
joint stability and further increased fatigue (Hurley et al., 2002; Schur & 
Moreland, 2011). 
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In RA patients, one of the most important points is to strike a balance between rest 
and exercise, which can be tailored and modified depending on the clinical 
condition (Frank, 2010). A variety of exercises may be considered as beneficial to 
RA patients in helping improve range of movement, strength and endurance. 
These may include isometric, isotonic, isokinetic, walking, swimming and cycling 
(Beardmore, 2008; Hurley et al., 2002; Schur & Moreland, 2011). One question 
that needs to be asked, however, is whether or not some interventions that are 
aimed principally at improving other variables also reduce fatigue. For instance, 
pharmacological interventions were prescribed to reduce inflammation, exercise 
interventions administered to improve physical activity and psychological 
behavioural therapy indicated to improve psychological distress and all these 
treatment modalities might reduce fatigue in RA (Hewlett et al., 2011; Hewlett et 
al., 2008). 
 
Recent evidence suggests that exercise has a positive effect on joints, and has no 
harmful effect on the patient in relation to disease activity or pain. A systematic 
review by Van den Ende et al. (2007) emphasised that there were no detrimental 
effects on RA patients of dynamic exercise therapy, but rather that there was a 
positive effect from exercise. 
 
Hydrotherapy 
Hydrotherapy is a combination of therapeutic exercises and immersion in warm 
water (Beardmore, 2008). ‘Hydrotherapy’, otherwise known as ‘aquatic exercise’ 
or ‘aquatic therapy’, is defined as the controlled exercise in warm water using the 
buoyancy, assistance and resistance of warm water to relieve pain, induce muscle 
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relaxation and promote more effective exercise (Ahern et al., 1995). It is now 
called ‘aquatic physiotherapy’ and is highly valued as an excellent exercise for 
patients with arthritis (HyDAT Team, 2009). 
 
The main aim of hydrotherapy is to relieve pain, improve joint motion, promote 
feelings of comfort, and consequently improve function and QoL (Ahern et al., 
1995; Foley et al., 2003). Hydrotherapy is advocated as a safe and efficient 
medium for achieving exercise-related goals, and it is commonly used for patients 
with rheumatic disease (Beardmore, 2008; Rintala et al., 1996). The difference 
between aquatic exercise and exercise on land is that floating in water has been 
found useful in relaxing the muscles. Some exercises are made easier due to the 
buoyancy of the water; some are made more difficult due to the resistance 
provided by the water (Foley et al., 2003; Rintala et al., 1996). 
 
Immersion in the thermo-neutral water temperature has a soothing effect and 
plays an important role providing an optimum environment for exercise (Eversden 
et al., 2007; Verhagen et al., 2008). Water is an appropriate environment for 
treating RA patients because it helps relax tense muscles and increases blood flow 
to the tissues (Bood et al., 2007; Kjellgren et al., 2001; Melzack & Wall, 1967). It 
also has a sedative effect on nerve endings, and therefore reduces pain and 
discomfort (Bood et al., 2007; Kjellgren et al., 2001; Melzack & Wall, 1967). It is 
suggested that this form of treatment helps RA patients manage their disease 
independently for longer, preventing or reducing hospital admissions and enabling 
a speedy return to occupations, which therefore reduces the cost impact on 
employers and society. 
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2.9.2.2.3 Heat and cold therapy 
The use of hot and cold water has been commonly indicated for centuries in most 
musculoskeletal illnesses and impairments, especially in acute injury (Beardmore, 
2008; Hurley et al., 2002). Heat and cold are used to reduce pain and decrease 
stiffness in many rheumatic and musculoskeletal conditions such as OA (Hurley 
et al., 2002). This treatment is easy to use, is low-cost, and can be used in the 
home, outpatient clinic and private office (Beardmore, 2008). A Cochrane review 
in 2002 by Robinson et al. supported also by Welch et al. (2011), found that heat 
and cold had no effects on the objective measures of disease activity, and no 
harmful effects of thermotherapy were reported (Robinson et al., 2002; Welch et 
al., 2011). 
  
Heat therapy can be applied as hot packs, water baths, paraffin wax, or thermal 
packs. Water baths or Whirlpools can be combined with active or passive motion 
of exercises to increase the range of joint movement (Beardmore, 2008; Hurley et 
al., 2002; Welch et al., 2011). Thermal packs contain chemical agents, which 
produce heat through the occurrence of an exothermic reaction upon activation 
(Beardmore, 2008; Hurley et al., 2002; Welch et al., 2011). Heat therapy is 
contraindicated in the absence of normal sensation or impairment or diminished 
blood supply, mainly in people with diabetes (Beardmore, 2008; Hurley et al., 
2002; Welch et al., 2011). 
 
Application of cold is used for immediate care after musculoskeletal injury 
because it causes vasospasm and is associated with reduction in tissue 
inflammation and oedema; therefore, it reduces pain, muscle spasm and 
63 
 
circulation (Beardmore, 2008). This type of treatment should be applied locally 
for up to 30 minutes, but deep cooling is reliant on application time and soft tissue 
depth (Beardmore, 2008). 
 
2.9.2.2.4 Electrotherapy 
There are many types of electrotherapy such as transcutaneous electrical nerve 
stimulation (TENS), interferential and laser, all of  which may be used to relieve 
pain in non-inflammatory chronic conditions such as back pain, knee pain, 
chronic shoulder pain or other joint pain (Beardmore, 2008). The evidence for 
effectiveness of these treatments in RA is uncertain and poorly evaluated 
(Beardmore, 2008; Hurley et al., 2002; Minor & Sanford, 1993). 
 
2.9.2.2.5 Joint protection, the provision of adaptive devices and walking aids  
Walking aids and adaptive devices are frequently prescribed to RA patients (De 
Boer et al., 2009) with the aim of improving or maintaining functional ability and 
independence, relieve pain and improve mobility by reducing lower-limb loading 
(De Boer et al., 2009; Hurley et al., 2002). 
 
Gutter frames and fisher sticks, are effective at redistributing the load onto the 
small joints of the upper limbs (Hurley et al., 2002). There is a strong relationship 
between the usage of adaptive devices with patients of an older age, more severe 
disease and more acute disability (De Boer et al., 2009), although these aids may  
enhance the negative perceptions of patients’ feeling of being old and infirm  
(Hurley et al., 2002). Moreover, a number of factors have not been taken into 
account – factors which are more likely to be relevant for the actual usage of 
adaptive devices, such as the process of prescription and provision and the 
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patient’s evaluation of the design and comfort of adaptive devices (De Boer et al., 
2009). 
 
2.9.2.2.6 Nutrition and dietary therapy 
A nutritionist is another professional needed for the holistic care of all RA 
patients. This is due to the fact that people with RA have many challenges related 
to appetite loss, adequate amount of calories and nutrients, risk factors for 
coronary disease, and the need to reduce stress on inflamed joints in overweight 
and obese patients (Ariza-Ariza et al., 1998; James & Cleland, 1997; Kremer, 
2000).  
 
2.10 Overall summary 
This chapter has discussed the background of RA, in terms of definition, 
epidemiology, clinical features and pathophysiology. Furthermore, this chapter 
provided an overview of non-pharmacological and pharmacological therapy. It is 
reported that RA affects approximately 1% of all ethnic groups in the UK 
(Symmons et al., 2002). Although, RA can present at any age, it is more common 
in females and classically presents in middle age. The cause of RA is unknown; 
however, 30% of its aetiology is related to genetic factors. 
 
The treatment goal in RA patients is to control synovitis early and to prevent joint 
damage, disability and complications. Physiotherapy or rehabilitation services 
play a major role in the management of RA by relieving pain and stiffness and 
providing patient education and advice. While exercise is the cornerstone of RA 
rehabilitation, many other modalities such as electrotherapy and thermotherapy 
are also commonly used.  
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The next chapter focuses upon hydrotherapy in terms of definition, physical 
properties, history, indications, contra-indications, and applications. 
66 
 
 
3.1 Introduction 
The term hydrotherapy was derived from the Greek, hydro that refers to (water) 
and therapeia, which refers to (healing) (Duffield, 1976). Hydrotherapy treatment 
is regarded as one of the most ancient remedies in the world, and it is accepted 
that its use is as old as the history of humanity (Bender et al., 2005; Jackson, 
1990; Sinclair, 2007). The use of hydrotherapy dates back several centuries before 
other treatments indicated in physical medicine (Bender et al., 2005; Schrepfer, 
2002). The use of aquatic therapy to facilitate exercise began to grow in 
popularity near the end of the 19
th
, century, mainly in Europe but also followed by 
the USA (Schrepfer, 2002). 
 
Aquatic exercise has been successfully indicated for a wide variety of 
rehabilitation programmes including paediatric, rheumatic, orthopaedics, 
cardiopulmonary and neurological patients (Geytenbeek, 2008; Hall et al., 2008; 
Schrepfer, 2002). In rheumatic and orthopaedic conditions, the use of 
hydrotherapy as a treatment is widely accepted and recognised, even though there 
is little objective evaluation of its therapeutic efficacy (Becker, 2009; Geytenbeek, 
2008; Schrepfer, 2002). To date, there is limited published data on the 
effectiveness of hydrotherapy as a treatment modality for RA (Geytenbeek, 2008; 
Hall et al., 2008; Hall et al., 1996). It also appears that there is conflicting 
evidence regarding hydrotherapy experiences in patients with RA (Bilberg et al., 
2005; Hall et al., 1996; Rintala et al., 1996; Stenström et al., 1991). The use of 
CHAPTER THREE: HYDROTHERAPY DETAILS 
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hydrotherapy in RA was monitored to assess its ability to enhance performance 
and wellbeing (Eversden et al., 2007). Hydrotherapy is regarded anecdotally as 
one of the most effective treatments for long-term management of symptoms of 
rheumatological disorders (Bilberg et al., 2005; Hall et al., 1996; Rintala et al., 
1996; Stenström et al., 1991). 
 
Objective 
The objective of this chapter is to review the water-based definitions and 
historical background of hydrotherapy and discuss issues related to the principles, 
physical properties, indications and contra-indications of hydrotherapy. 
  
Definitions 
Numerous terms or definitions related to water-based treatments have been found 
in the literature such as: 
Whirlpool: Submersion of the external body in forced pressurised water 
(Geytenbeek, 2008). 
Spa therapy: A specific thermal water spring that was found to have therapeutic 
qualities was discovered in the sixteenth century in a Belgian village named Spa. 
(Sukenik et al., 1999). In this type of therapy, the patients receive not only thermal 
mineral water but also other modalities such as massage, electrotherapy, and 
exercise (Bender et al., 2005).  
Balneotherapy: This involves exercises in naturally mineralised water by the use 
of baths (hot or cold springs or naturally occurring waters) and other natural 
remedies (including mud) for healing (Bender et al., 2005; March & Stenmark, 
2001; Strauss-Blasche et al., 2002). This type of therapy includes minerals and 
elements such as sodium, potassium, calcium, iodine and magnesium (Bender et 
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al., 2005). Moreover, it includes the Anion of SO4
-2
, CI
-
, and HCO
3-
, the waters 
must be bacteriologically pure (Bender et al., 2005). 
Thalassotherapy: Originally derived from the Greek word thalassa, meaning 
"sea" (Charlier & Chaineux, 2009; de Andrade et al., 2008), this term refers to 
seawater therapy and originated from the French Sea and Health Federation in 
1986 (Charlier & Chaineux, 2009; de Andrade et al., 2008). Under the supervision 
of medical staff, thalassotherapy is a combination therapy with a curative and 
preventive goal that utilises the benefits of the marine environment, such as the 
marine climate, seawater, mud, sand, seaweed and other substances derived from 
the sea, (Charlier & Chaineux, 2009; de Andrade et al., 2008). 
Kneipp therapy This term was created relatively recently by the Bavarian 
almoner and Dominican priest, Sebastian Kneipp (1821-1897), who used it to 
refer to alternate warm- and cold-water therapy (Goedsche et al., 2007; Koeppen 
& Kostka, 1960; Schencking et al., 2009). Also known as ‘Kneipping’ or ‘The 
Kneipp Cure’ it was first used by German physicians (Koeppen & Kostka, 1959). 
It is an application of cold and warm water of varying degrees of temperature and 
pressure by showers and towels (Koeppen & Kostka, 1959; Schencking et al., 
2009).  
Hydrokinesiotherapy: Patients perform exercises in warm seawater by taking 
advantage of the buoyancy and the therapeutic capacities of seawater; this therapy 
has been suggested for people with musculoskeletal problems (Balogova et al., 
2003; Geytenbeek, 2008). 
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3.2 Historical background 
The application of water as a healing therapy dates back several centuries 
(Schrepfer, 2002; Roberts, 1981; Sinclair, 2007). Historical background study of 
hydrotherapy (curative and recreational) is well documented and has been 
intensively reviewed by many authors such as Jackson (1990) and Campion 
(1997). A number of reviews of the history of hydrotherapy have been published 
(Campion, 1997; Jackson, 1990; Price, 1981; Wyman & Glazer, 1944). 
 
The history of hydrotherapy in physical medicine goes back many thousands of 
years with records dating back to 2,400 BC (Jackson, 1990; Karel & Tolliver, 
2003). It has been suggested that Egyptians, Assyrians and Mohammedans used 
mineral waters for curative purposes, and proto-Indian culture created and 
manufactured hygienic installation (Campion, 1997; Sinclair, 2007). A great 
upsurge in the use of water treatment was revealed in the first century BC and in 
1500 BC, and there is evidence showing that the Hindus used water to treat fevers 
(Campion, 1997; Jackson, 1990).  
 
Jackson (1990) gives examples of the use of thermal baths in treatment of many 
conditions such as soothing chest and back pain, treating pneumonia to improve 
respiration, reducing fatigue, relaxing joints and relieving headaches. Moreover, 
herbal oil extract was added to warm baths and the use of aromatic vapour baths 
was advised in cases of ‘female disorders’ (Jackson, 1990). The Greeks also used 
hydrotherapy as part of remedial therapy, and were among the first to be aware of 
the benefits of physical and mental well-being in general. They developed 
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hydrotherapy centres close to springs and rivers using them for bathing and 
recreation (Campion, 1997; Jackson, 1990; Sinclair, 2007). 
 
In 1924, Franklin Roosevelt visited the warm springs to receive aquatic therapy 
(Becker, 2009; Campion, 1997). During the 1930s, professional journals 
published many papers on pool and spa therapy because of the Presidential visit 
(Becker, 2009). In 1935, at hot springs in Arkansas City, Smith designed a 
swimming pool with warm water for patients with chronic atrophic arthritis for 
special underwater exercises and pool therapy (Becker, 2009). 
 
One of the most important events that resulted from World War II, was the 
knowledge about maintaining the fitness of the army through exercising in water 
(Ahern et al., 1995; Campion, 1997; Rorke, 1996). This new knowledge also 
further fuelled the current upsurge of the use of hydrotherapy as a means of 
rehabilitation for a wide range of conditions (Ahern et al., 1995; Campion, 1997).  
 
3.3 Principles of hydrotherapy 
It is advisable for all practitioners to understand the physical principles of 
hydrotherapy and characteristics of water in order to make the medical use more 
rational and efficient (Becker, 2009; Salzman, 2003). Most movement in water is 
regarded as a learned skill that takes time to develop. However, movement 
response and activity in water is subtle and needs to be developed and closely 
monitored (Campion, 1997; Prins, 2009). Thus, the person who is unfamiliar with 
hydrotherapy can be expected to be more apprehensive than someone who has 
previous aquatic experience. This experience can be a barrier to recovery because 
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of the risk of counterproductive movements, utilisation of previous movement 
patterns that may exacerbate symptoms and prolong the recovery period (Edl et 
al., 2004; Prins, 2009). 
  
In water two forces apply, one for gravity (down thrust) and the other for 
buoyancy (up thrust), which concurrently act upon the body (Edl et al., 2004; 
Prins, 2009). Thus, it provides the body with an exercise medium and experience 
that are not available with land-based treatments (Salzman, 2003). Water permits 
movement and activities for non-weight bearing joints to be activated (Edl et al., 
2004; Prins, 2009). The hydrodynamic principles are responsible for the 
development of hydrotherapy practice in physiotherapy (Becker, 2009; Schrepfer, 
2002). This includes buoyancy and hydrostatic pressure, depending on 
Archimedes’ principle and Pascal’s Law (Campion, 1997; Prins, 2009; Salzman, 
2003; Schrepfer, 2002). 
  
Archimedes' principle states that (Campion, 1997, pp.14) 
"When a body is immersed in a fluid, it 
experiences a buoyant force equal to the 
weight of fluid which the body has displaced." 
 
 
In other words, according to Archimedes, if the upward thrust is greater than or 
equal to the weight of the immersed body, the body will float; if not, the body will 
sink. Anybody wholly or partially submerged in a fluid experiences an up-thrust 
force equal to the weight of the fluid displaced by the object (Salzman, 2003). 
Some exercises in water are made easier by the presence of the water, while 
others, such as walking, are more difficult according to Archimedes’ law 
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(Campion, 1997; Salzman, 2003). When discussing hydrostatic pressure, 
Schrepfer (2002, pp.275), who was familiar with Pascal's Law, states that: 
"The pressure exerted by fluid on an immersed 
object is equal on all surfaces of the object.” 
 
 
3.4 Mechanism of action 
Many factors, such as buoyancy, immersion pressure, resistance and temperature, 
play an important role in the mechanism of hydrotherapy (Bender et al., 2005; 
Hall et al., 2008; Melzack & Wall, 1967). Buoyancy effect eliminates or 
counteracts the effect of gravity and allows for freedom and comfort of movement 
of joints and muscles, resulting in an apparent reduction in weight-bearing load 
through the spine and lower extremities (Campion, 1997; Edl et al., 2004; 
Salzman, 2003).  
 
According to the pain gate theory in hydrotherapy, pain relief may be due to the 
water pressure and temperature. The warmth of the water has a sedative effect on 
nerve endings and therefore reduces pain and discomfort (Bender et al., 2005; 
Kjellgren et al., 2001; Melzack & Wall, 1967). Moreover, warm water relaxes 
tense muscles and increases blood flow to the tissues, facilitating muscle 
relaxation (Bender et al., 2005; Hall et al., 2008; Kjellgren et al., 2001; Lange et 
al., 2006). Water immersion induces an increase in methionine-encephalin plasma 
levels, which is associated with a significant fall in mean arterial pressure and 
heart rate. Conversely, the effect of water pressure on skin suppresses plasma b-
endorphin, corticotrophin, and prolactin levels (Coruzzi et al., 1988). This 
pressure also has an effect on the light and deep touch receptors in nerve endings, 
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helping to dissipate the pain-carrying fibres from passing their ‘painful’ messages 
to the brain (Bender et al., 2005; Yamazaki et al., 2000). 
  
Other mechanisms are based around the effects of hydrostatic pressure, which 
because of its effect on the cardiovascular system, may relieve pain by reducing 
peripheral oedema and offset the pooling of blood in the lower extremities, 
offering graduated pressure at a greater depth (Becker, 2009; Butler, 2005; 
Campion, 1997; Salzman, 2003). 
 
3.5 The physical properties of water 
Two important physical properties of water, buoyancy and viscosity are key 
elements in designing effective aquatic exercises. It is due to hydrodynamics 
principles that immersion in water has biological effects that are recommended for 
medical applications (Bender et al., 2005; Campion, 1997; Salzman, 2003; 
Schrepfer, 2002). The physical properties of water that have the potential of 
physiological changes are relative water density, hydrostatic pressure, buoyancy 
(resilience) and thermodynamics (Becker, 2009; Campion, 1997; Edl et al., 2004; 
Schrepfer, 2002). 
 
3.5.1 Relative density 
The relative density of water is defined as the ratio of the density of a substance to 
the density of water, based on Archimedes’ principle (Campion, 1997; Edl et al., 
2004). Therefore, any object with less than a density of one will float in water, 
and any object with a density greater than 1.0 will sink (Campion, 1997; Edl et al., 
2004; Schrepfer, 2002). 
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The relative density of the human body varies with age and is dependent upon 
gender (Becker, 2009; Campion, 1997). Men, on average, have higher density 
than women due to bone density and lower body fat. In young children, relative 
density is about 0.86 (Becker, 2009; Campion, 1997; Edl et al., 2004). Density of 
the mass of lean body, such as bone, muscle, connective tissue and organs is about 
1.1, while the mass of body fat and excess fat has a density of approximately 0.9 
(Bloomfield & Fitch, 1995; Edl et al., 2004). According to Archimedes’ theory of 
principle, the human body is able to displace a volume of water greater than the 
weight of the body because the water pushes the body upward by a force 
equivalent to the displaced volume of water (Becker, 2009; Edl et al., 2004). 
 
3.5.2 Hydrostatic pressure 
By definition, hydrostatic pressure is the pressure that is exerted equally on any 
immersed objects depending on Pascal’s law, at any level in a horizontal direction 
at a constant depth (Campion, 1997; Edl et al., 2004; Schrepfer, 2002). Thus, fluid 
pressure is exerted on all surfaces of an immobile immersed body at a certain 
depth (Campion, 1997; Edl et al., 2004). The main clinical significance of this 
pressure force is to eliminate oedema in the injured body part (Becker, 2009; 
Butler, 2005; Campion, 1997).  
 
There is a positive correlation between density of water and depth of immersion; 
if the depth of the immersion increases, the pressure force is increased, and 
therefore the hydrostatic pressure also increases (Becker, 2009; Edl et al., 2004; 
Schrepfer, 2002). When the body is immersed in the water, the pressure it exerts 
will increase the distal venous pressure (blood is displaced ascending through one-
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way circulatory system and the shift of blood to the thorax is increased), which 
assists in the venous return and increases the preload of the heart because of 
central hypovolaemia with subsequent cardiovascular response (Becker, 2009; Edl 
et al., 2004; O'Hare et al., 1985; Salzman, 2003; Schrepfer, 2002; Weston et al., 
1987). As a result, heart rate may slow leading to an increase in stroke volume and 
ejection fractions (Becker, 2009; Edl et al., 2004; O'Hare et al., 1985; Salzman, 
2003; Schrepfer, 2002; Weston et al., 1987). 
 
Additionally, this pressure will give increased pulmonary blood flow, centralised 
peripheral blood flow, and increased central blood volume and pressure, which 
leads to greater perfusion of coronary arteries and more efficient cardiopulmonary 
system during exercise (Becker, 2009; Edl et al., 2004; Salzman, 2003; Schrepfer, 
2002). 
 
Hydrostatic pressure also serves as a progressive resistive exercise program for 
respiration because it restricts chest wall expansion (Edl et al., 2004; Salzman, 
2003). Blood displaces vertically, leads to increased right atrial pressure and 
pleural surface pressure, the chest wall compresses, and the diaphragm is 
displaced vertically. Finally, the relationship of depth to pressure means that 
performing exercises below the water’s surface smooth’s out jerky movements, 
increasing coordination (Becker, 2009; Campion, 1997; Schrepfer, 2002).  
 
3.5.3 Buoyancy (resilience) 
Buoyancy can be defined as the upward force exerted by a fluid acting in the 
opposite direction to the gravity force, or opposite to the weight of an object 
(Campion, 1997; Edl et al., 2004; Schrepfer, 2002). Thus, two opposing forces 
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affect a body in water: gravity acting through centre of gravity and buoyancy 
acting through the centre of buoyancy (Campion, 1997; Edl et al., 2004; 
Schrepfer, 2002). When both centres are not aligned perfectly a rotational force 
occurs which assists the flotation of the body (Campion, 1997; Edl et al., 2004; 
Schrepfer, 2002). The advantages derived from buoyancy can be used in 
rehabilitation programmes; when a person enters the water, there is an immediate 
reduction in the effect of gravity on the body so that the water can assist and 
support body movement on the water’s surface (Becker, 2009). The degree of 
effort is determined by the size of the moving body or limb, coupled with the 
velocity of the movement (Prins, 2009; Becker & Cole, 1997; Schrepfer, 2002; 
Skinner & Thomson, 1983; Ruoti et al., 1997). 
 
Buoyancy assists free movement with less risk of injury and enables the therapists 
to facilitate resistance exercises (Bruce & Cole, 2011; Eversden et al., 2007; Prins, 
2009; Schrepfer, 2002). Buoyancy offers weightlessness and joint unloading; this 
promotes muscle relaxation and allows exercise against water resistance, 
permitting the performance of active motion and increasing active exercise, and 
can help to improve functional ability (Schrepfer, 2002).  
 
When the body is gradually immersed, water is displaced, which creates the force 
of buoyancy to counterbalance gravity and support the body, therefore gradually 
relieving the load on weight-bearing joints (Becker, 2009). The human centre of 
buoyancy is in the mid-chest, while the human centre of gravity is located 
posteriorly at the level of second sacral vertebrae (Becker, 2009; Edl et al., 2004; 
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Schrepfer, 2002). The more of the body immersed in water, the less it weighs 
(Becker, 2009; Schrepfer, 2002). 
  
People immersed up to the symphysis pubis have effectively offloaded 33-40% of 
the weight of their bodies, and when further immersed to the umbilicus it 
increases to approximately 50% (Becker, 2009). Xiphoid immersion offloads 
bodyweight by 60% or more based on whether the arms are overhead or at the 
trunk level (Becker, 2009).  
 
Buoyancy has the potential of being a very useful therapeutic utility; for instance, 
painful hips or knees may not be mechanically stable under full-body loading. 
However, during water immersion, gravitational forces and buoyancy provide 
relative weightlessness, and joint unloading may be partial or complete so that 
only muscle torque forces act on the joint, allowing active assisted range-of-
motion activities, gentle strength-building, and gait training (Becker, 2009; 
Schrepfer, 2002). 
 
To sum up, the effect of gravity is decreased by the buoyancy effect of water, 
allowing for more freedom and comfort of movement of joints and muscles. 
Therefore, exercise in water produces less joint compression compared to land 
exercise, and provides a suitable environment for rheumatic patients to exercise 
aerobically. 
 
3.5.4 Viscosity and turbulence 
Viscosity describes resistance of the internal friction of fluid molecules during 
motion (Becker, 2009; Salzman, 2003; Schrepfer, 2002). On this basis, a limb 
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moving in water is subjected to the resistance effects of the fluid, and this 
resistance is correlated positively to the velocity of movement through liquid – 
this is also called the ‘drag force and turbulence’ (Becker, 2009; Schrepfer, 2002). 
Resistance of water viscosity is proportional to the velocity of movement in the 
water, and this resistance increases when more force is exerted against water 
(Becker, 2009). Thus during treatment in water when a person feels pain and stops 
movement, the force drops abruptly as water viscosity dampens movement almost 
immediately (Becker, 2009). It is important to remember that fluid is more 
viscous than air, and that as the temperature increases, the viscosity decreases 
because the molecules are increasingly separated by heat (Salzman, 2003). 
 
Turbulence refers to the eddies that follow in the wake of an individual moving 
through a fluid (Becker, 2009; Salzman, 2003; Schrepfer, 2002). The production 
of turbulence is greatly dependent on body shape, and the degree of turbulence is 
dependent on the speed of the movement. If the movement is slow then the flow 
of the particles is almost parallel to the object and proceeds in a smooth, 
continuous curve (Campion, 1997; Schrepfer, 2002). Faster movement produces 
eddies, and the energy in these eddies is dissipated, reducing the pressure and 
increasing the drag on the body (Campion, 1997; Schrepfer, 2002). 
 
Turbulence might be used in hydrotherapy to assist movement. Turbulence creates 
resistance with all active movements, and a long lever arm, for example, results in 
increased resistance (Schrepfer, 2002). Increasing the surface area of the object 
moving through water also increases resistance. Moreover, proximally stabilising 
an extremity during manual resistance exercises in the water requires the patient 
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to perform more work (Schrepfer, 2002). Conversely, distally stabilising an 
extremity requires the patient to perform less work. A significant clinical 
implication of this is the possibility that using the physical properties alone to 
create turbulence results in challenges to balance and coordination, problems that 
are experienced by RA patients. 
 
3.5.5 Thermodynamics 
It has been suggested that water conducts heat 25 times faster than air, and that it 
also retains heat 1000 times more than air (Becker, 2009; Edl et al., 2004; 
Schrepfer, 2002). The use of water for therapeutic purposes depends on its ability 
to retain heat and transfer heat energy (Becker, 2009). On this basis, the use of 
water in the treatment is very versatile because water keeps hot or cold and it 
surrounds the immersed body part (Becker, 2009). However, Table 3.1 (p.81) 
shows immersion temperatures for variable conditions. For instance, it is believed 
in some controversial studies that cool plunge tanks at a temperature of 10-15°C 
are sometimes used to treat overuse injury, to relieve severe muscle pain and 
speed recovery in athletic individuals (Becker, 2009).  
 
Additionally, therapy pools with temperatures in the range of 27-29°C are used 
for less active patients such as those with multiple sclerosis or who require 
vigorous exercise (Becker, 2009). The most common type of therapy pool 
operates in range of 33.5°–35.5°C (Becker, 2009), they are commonly used in 
arthritis, spinal cord injury programme, Parkinson’s programming, cardiac 
rehabilitation and other typical aquatic therapy indications. This temperature will 
produce therapeutic effects, and despite long sessions in the pool, sufficient 
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exercise will be achieved (Becker, 2009). Similarly, hot tubs are usually kept at 
37.5°– 41°C, although 41°C is not recommended for active comfortable exercise, 
and may be used only for short periods of relaxation (maximum of 5-10 minutes).  
Use for long periods in cases of severe/recent bruising or circulation disorders 
should be avoided (Becker, 2009; Butler, 2005). 
 
 
 
 
 
 
 
81 
 
Table 3.1: Immersion temperatures (in °C) for rehabilitation issues. Reproduced with 
kind permission from Becker, 2009. 
Suitable Activities 
Cold 
(10-15) 
Cool 
(26-29.5) 
Neutral 
(33.5-5.5) 
Warm 
(36-38.5) 
Hot 
(37.5-41) 
Post exertional recovery 
 
X     
Contrast baths X   X X 
Vigorous exercise 
 
 X    
Arthritis exercise 
 
  X   
Typical aquatic therapy 
 
  X   
Cardiac rehabilitation 
 
  X   
Multiple sclerosis 
exercise 
 
 X    
SCI programming 
 
  X   
Parkinson’s programming 
 
  X   
Relaxation    X X 
 
 
3.6 Equipment for aquatic exercise 
Many types of equipment exist for use in aquatic exercises. Floatation devices are 
sometimes employed to help the practitioner control and increase exercise 
intensity by using buoyant support to the body, for example to alter positioning or 
movement, challenge problems, assist balance and generate resistance to 
movement (Schrepfer, 2002). These devices have advantages in increasing the 
buoyancy effect to offer support, reduce compressive forces and lessen impact, 
increase resistance in movement away from the water’s surface and assist 
movement to the water surface (Edl et al., 2004; Schrepfer, 2002). They are useful 
for support and balance and as resistance instrument (Edl et al., 2004; Schrepfer, 
2002). 
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3.6.1 Collars, rings, belts, and vests 
Inflatable cervical collars are used primarily to support the patient in a supine 
position and keep the head out of the water by providing buoyancy assistance  
(Edl et al., 2004; Schrepfer, 2002). 
 
 
Figure 3.1: Cervical collars used in hydrotherapy (used with kind permission from 
Salford Royal Foundation Trust). 
Variable sizes of floatation rings are used to support the extremities, wrists and 
ankles as part of patient positioning and relaxation (Edl et al., 2004; Schrepfer, 
2002). These devices are also used for resistive movement exercises wherein the 
patient works against the buoyant forces. Moreover, there are many types of belt 
and vest that are used as buoyancy aids for extremities or the entire body in any 
position, whether vertical, prone or supine (Edl et al., 2004; Schrepfer, 2002). 
Floatation belts are available in different sizes and some have removable parts so 
that the amount of buoyancy can be changed. Sometimes bands can be attached to 
the belts.  
 
Figure 3.2: Floatation rings used in hydrotherapy (used with kind permission from 
Salford Royal Foundation Trust). 
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3.6.2 Swim bars (buoyancy dumbbells) 
These bars are available in both short and long lengths. They are indicated for use 
in supine or prone position for lower limb activities, and indicated for use in the 
upright position for upper limbs and trunk support (Edl et al., 2004; Schrepfer, 
2002). Buoyancy dumbbells can be used for balance or proprioception in shallow 
water (Edl et al., 2004; Schrepfer, 2002). The long dumbbell can be used to 
strengthen the trunk in a seated or standing position in deep water (Edl et al., 
2004; Schrepfer, 2002). 
 
 
Figure 3.3: Swim bars used in hydrotherapy (used with kind permission from Salford 
Royal Foundation Trust). 
 
3.6.3 Gloves, hand paddles and hydro-tone balls 
The main goal of applying webbed gloves or large paddles to the hands is to 
enhance motion resistance in the direction of upper extremity movements, because 
these devices do not work as buoyancy aids (Edl et al., 2004; Schrepfer, 2002). In 
addition, hydro-tone bells, which are large slotted plastic devices, are indicated to 
generate resistance and increase turbulence for upper limb movements (Edl et al., 
2004; Schrepfer, 2002). 
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Figure 3.4: Gloves and paddles used in hydrotherapy (used with kind permission from 
Salford Royal Foundation Trust). 
 
3.6.4 Fins and hydro-tone boots 
This equipment is indicated to increase the surface area that’s moving through the 
water (Edl et al., 2004; Schrepfer, 2002). Fins and boots are indicated for the 
lower limbs in order to increase resistance during movement (Edl et al., 2004; 
Schrepfer, 2002). Fins can be applied to strengthen the muscle around ankle, hip 
and knee joints, whereas boots are used mainly for deep water walking and 
running (Edl et al., 2004; Schrepfer, 2002). 
 
 
Figure 3.5:  Fins used in hydrotherapy (used with kind permission from Salford Royal 
Foundation Trust). 
 
3.6.5 Kickboards and woggles 
Variable types and styles are indicated for any exercise programme, mainly to 
provide buoyancy and create resistance in any position, whether supine or prone 
(Edl et al., 2004; Schrepfer, 2002). These also apply in deep water for help with 
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seating kneeling and balance problems (Edl et al., 2004; Schrepfer, 2002). 
Woggles or ‘noodles’ can be used for upper and lower extremities at the same 
time because they encircle the body (Edl et al., 2004). 
 
 
Figure 3.6: Woggles and kickboards, used in hydrotherapy (used with kind permission 
from Salford Royal Foundation Trust). 
 
3.7 Indication, contraindication and precaution 
In general, facilitation of functional recovery is the main purpose of aquatic 
exercise, by offering an environment that enhances a patients and/or practitioners’ 
ability to perform various therapeutic interventions (Edl et al., 2004; Schrepfer, 
2002). Indications for aquatic therapy include (Edl et al., 2004; Schrepfer, 2002): 
 Facilitation of ROM exercise in cases of loss of joint mobility; 
 Assistance with weight-bearing activities; 
 Initiation of resistance training and muscle strengthening; 
 Facilitation of cardiovascular exercise; 
 Enhancement of patient relaxation; 
 Enhancement of functional activity; 
 Provision of three-dimensional access to the patient; 
 Improvement of the delivery of manual techniques; 
 Improvement of co-ordination or balance; 
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 Improvement of gait training; 
 Relief from pain and lack of confidence; 
 Minimisation of the risk of injury or recurrent injury after rehabilitation. 
 
The aquatic exercise selected should be easily accessible and tolerated by most 
individuals. However, the practitioner working in this field should consider all 
aspects of immersion in terms of physiological, clinical and psychological that 
affects the selection of aquatic pools (Edl et al., 2004; Schrepfer, 2002). When 
assessing the value of hydrotherapy for individual patients, there are some 
important factors to consider. Therapists need to exercise caution when faced with 
some situations such as hydrophobia (fear of water), which can restrict the 
effectiveness of any immersion activity (Edl et al., 2004; Schrepfer, 2002). 
  
Apprehensive patients often experience increased symptoms because of muscle 
guarding, stress response, and improper form with exercise (Edl et al., 2004; 
Egan, 1981; Schrepfer, 2002). Patients with neurological disorders such as 
confusion, disorientation and ataxia may struggle in controlling purposeful 
movements. Multiple sclerosis patients may experience fatigue and other 
detrimental effects with immersion in temperatures greater than 33°C because of 
heat intolerance (Ruoti et al., 1997; Schrepfer, 2002). 
 
However, patients with multiple sclerosis are not precluded from hydrotherapy in 
lower temperatures (Roehrs & Karst, 2004). Other conditions that require close 
monitoring during immersion treatment, such as controlled epilepsy (seizure), 
haemophilia, behavioural problems, angina and abnormal blood pressure, require 
close monitoring (Edl et al., 2004; Schrepfer, 2002). Patients with small open 
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wounds and respiratory problems such as tracheotomies can be immersed with 
caution (Edl et al., 2004; Schrepfer, 2002). The following conditions are regarded 
as absolute contraindication for hydrotherapy. These are: 
 Cardiac failure and unstable angina (Edl et al., 2004; Schrepfer, 2002). 
 Open wound and infective skin conditions such as tinea pedis and 
ringworm (Cole & Becker, 2001; Edl et al., 2004; Schrepfer, 2002). 
 Respiratory failure, active TB and episodes of status asthmaticus 
(Campion, 1997; Edl et al., 2004; Schrepfer, 2002). 
 Danger of bleeding or haemorrhage (Edl et al., 2004; Schrepfer, 2002).  
 Severe peripheral vascular disease (Edl et al., 2004; Schrepfer, 2002). 
 Very low, high or uncontrolled blood pressure (Campion, 1997; Edl et al., 
2004). 
 Uncontrolled seizures (epilepsy) (Edl et al., 2004; Schrepfer, 2002).  
 Colostomy (Edl et al., 2004; Schrepfer, 2002). 
 
 
3.8 Hydrotherapy in rheumatic diseases 
The suggested benefits of hydrotherapy in rheumatic disease are similar for all 
other conditions; these benefits which can be related particularly to the warmth of 
the water (which relieves pain and muscle spasm) and buoyancy (which relieves 
stress on weight bearing joints) (Bender et al., 2005; Eversden et al., 2007; Hall et 
al., 1996; Schrepfer, 2002). For most rheumatic conditions like RA, the goals of 
treating patients by hydrotherapy are as follows (Ahern et al., 1995; Geytenbeek, 
2002; Hall et al., 1996): 
 Alleviation of joint pain and relax muscle spasm; 
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 Recovery and restoration of muscle strength; 
 Minimisation of deformity and improvement of range of joint motion; 
 Stretching of contractures in order to prevent further contractures; 
 Preservation of muscle power around unaffected joints; 
 Promotion of relaxation and joint mobilisation; 
 Enhancement of coordination and improve functional ability; 
 Amelioration of morale. 
 
3.9 Overall summary 
This chapter has explained the central importance of hydrotherapy in the treatment 
of many conditions and diseases. It is the suggestion of this research study that 
hydrotherapy, balneotherapy, and spa resort treatment should be considered as 
separate entities, similar to the classification of any other categories such as 
simple NSAIDs (Bender et al., 2005). It is clear that immersing the body in water 
produces many physiologic effects, the benefits of which have been used for 
treatment purposes over centuries of medical therapy.  
 
It is recommended that aquatic programmes should be designed for treating 
individuals to enable them achieve fitness and restore body function. 
Hydrotherapy has been proven to protect the health and prolong lives and has 
been shown to be a good all-round workout because it involves most muscles and 
joints for those with RA (Arthritis Research UK, 2011; Becker, 2009). The next 
chapter examines the effectiveness of hydrotherapy as a modality for RA in a 
systematic review. 
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4.1 Introduction 
Exercise is the cornerstone of the non-pharmacological treatment of RA, and it is 
recommended to improve function, muscle strength, and GWB; however, it 
cannot replace the pharmacological treatment (Hurkmans et al., 2009; Van den 
Ende et al., 2007; Vliet Vlieland & Van den Ende, 2011). Hydrotherapy is a safe 
and suitable treatment modality for achieving exercise-related goals, and it is 
sometimes used as part of rehabilitation intervention for patients with RA 
(Beardmore, 2008; Rintala et al., 1996).  
 
Unblinded studies that examined the efficacy of hydrotherapy in patients with RA 
demonstrated a reduction in pain and an improvement in QoL, muscle strength, 
aerobic conditioning and physical functioning (Danneskiold-Samsoe et al., 1987; 
Hart et al., 1994; Minor et al., 1989). However, the generisability of the findings 
were limited because of the small sample sizes and a lack of controlled 
intervention. 
 
Aim  
 To determine the effect of hydrotherapy in the management of patients with 
RA by conducting a systematic review.  
CHAPTER FOUR: THE EFFECTIVENESS OF 
HYDROTHERAPY IN THE MANAGEMENT OF 
RHEUMATOID ARTHRITIS:  
A SYSTEMATIC REVIEW 
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To the knowledge of the present researcher, there has been no recent exclusive 
systematic review to examine the efficacy of hydrotherapy for patients with RA. 
The hypothesis of this research study is that hydrotherapy is far superior 
compared to other types of therapy – including ‘usual care’ – for improving QoL 
and physical activity in patients with RA. The aim of this review was to 
synthesise the available literature on the efficacy of hydrotherapy in the 
management of patients with RA.  
  
4.2 Materials and methods 
4.2.1 Identification and selection criteria 
An electronic database search of Allied and Complementary Medicine (AMED), 
Cumulative Index to Nursing & Allied Health Literature (CINAHL), the 
Cochrane Library, Excerpta Medica Database (EMBASE), Medical Literature 
Analysis and Retrieval System Online (MEDLINE), ProQuest Research Library 
(ProQuest), PubMed Central (Pub-Med), Science Direct, and the Web of Science 
was conducted (1988 to September 2013). In order to standardise the patient 
sample included, the search was conducted from 1988 [which was the date of the 
publication of the ACR criteria for RA] to September 2013 (Arnett et al., 1988).  
 
The search was limited to human adults (age >18 years) across all articles 
published in English. The keywords used were `rheumatoid arthritis`, 
`hydrotherapy`, `aquatic physiotherapy`, `aqua therapy`, and `water therapy`. 
Keyword combinations were ‘rheumatoid arthritis and hydrotherapy’, ‘rheumatoid 
arthritis and aquatic physiotherapy’, ‘rheumatoid arthritis and aqua therapy’, 
‘rheumatoid arthritis and water therapy’. Studies that used the following keywords 
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were excluded from this literature search: ‘colonic irrigation’, ‘water birth’, 
‘Kneipp therapy’, ‘spa therapy’, ‘whirlpool therapy’, ‘contrast baths’ and 
‘balneotherapy’. 
 
There is a lack of clarity in the usage of terms ‘hydrotherapy’ and ‘balneotherapy’ 
(Bender et al., 2005). Hydrotherapy uses water as a treatment, while 
balneotherapy uses natural thermal mineral water (Bender et al., 2005). Although 
these terms have often been used interchangeably, balneotherapy is not easily 
accessible to healthcare professionals, and so studies involving this treatment 
were excluded. Trials investigating solely the physiological responses (such as 
heart rate, blood pressure and renal function) of subjects immersed or exercising 
in water were also excluded.  
 
The database search was supplemented by a manual search of: the Clinical Journal 
of Rheumatology, Annals of the Rheumatic Disease, British Medical Journal, 
Physiotherapy, Arthritis and Rheumatism, Rheumatology and Journal of 
Rheumatology and Physical therapy. Journals were searched from 1988 to 
September 2013, and were selected because they publish articles on 
rheumatological diseases. A further hand search of the bibliographic references in 
the extracted articles and existing reviews was also conducted to identify potential 
studies that were not captured by the electronic database searches. In addition, 
published theses in grey literature were examined to identify the relevant papers. 
To ensure that all of the relevant articles were obtained, an iterative process was 
used. 
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4.2.2 Inclusion and exclusion criteria for considering studies for this review 
 
Studies were included if:  
 They were randomised controlled trials (RCTs). 
 They were published in the English language. 
 They included participants aged 18 years or older who had been diagnosed 
with RA according to the 1987 ACR criteria (Arnett et al., 1988) or they 
used the criteria of Steinbrocker (Steinbrocker et al., 1949). 
 A water-based intervention (hydrotherapy) was used in the study and 
compared with an alternative such as land therapy, home exercises, routine 
daily activities or standard physiotherapy. 
 Patients had attended a minimum of four weeks’ hydrotherapy 
intervention. 
 They used one of the following outcome measures: pain, patient global 
assessment, activities of daily living (ADL), physical function, disease 
activities or QoL. 
 
Articles were excluded if: 
 They had insufficient information available (abstract only); 
 They did not involve an RCT; 
 They were not adult trials; 
 They did not involve human trials; 
 They included participants without rheumatic diseases; 
 The treatment modality included balneotherapy, Kneipp therapy, mud 
therapy or sulphur therapy; 
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 They were not written in English (even if the abstract was in English). 
 Participants were primarily and predominantly diagnosed with OA, 
fibromyalgia syndrome (FMS), back pain, neurological disease, or 
osteoporosis. 
 
4.2.3 Assessment of the validity of the study 
The researcher (KA) conducted the original search for the relevant articles and 
carried out the data extraction. The abstracts were reviewed first and, if deemed 
appropriate, the full papers were then reviewed and scored. The methodological 
quality of each study was reviewed by using the Physiotherapy Evidence 
Database (PEDro) scale (Maher et al., 2003). In addition, two researchers 
independently checked and confirmed the researcher’s decisions regarding the 
inclusion of the relevant articles in the present review. Where decisions were 
unclear, they independently applied the inclusion/exclusion criteria to papers 
identified by the literature search, and classified the identified studies according to 
the predetermined criteria. A consensus method was used to solve any dispute 
regarding the inclusion or exclusion of a particular study. When there was 
disagreement, consensus was sought, but when disagreement persisted, a third 
independent reviewer made the final decision. The PEDro scale contains 11 items 
(Table 4.1, p.95). The first item represents the external validity of the trial. This 
item was not included in the calculation of the total PEDro score (maximum 10); 
therefore, the score in this study was based on items 2 to 11 and the PEDro score 
was thus a score out of 10. These items are scored either yes (1 point) or no (0-
point). The individual item scores and the total PEDro scores have been shown to 
be reliable (Maher et al., 2003). 
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A study that scores 7 (scores positive in seven out of ten criteria) is considered to 
have a high methodological quality, a score of 5–6 a moderate methodological 
quality and a score between 0 and 4 is regarded as having poor methodological 
quality (Kollen et al., 2009; Maher et al., 2003; Moseley et al., 2002). The 
maximum achievable score for a high-quality study is 8 because it is difficult to 
blind either the therapist delivering the intervention or those participating in a 
hydrotherapy rehabilitation trial (Kollen et al., 2009; Maher et al., 2003; 
Sherrington et al., 2000).  
 
4.3 Data collection and analysis 
Articles fulfilling the inclusion criteria were subsequently assessed for 
methodological quality using the criteria list and operational instruction outlined 
and recommended by the PEDro for the quality assessment of RCTs (Maher et al., 
2003; Sherrington et al., 2000). As shown in Table 4.1 (p.95). 
 
4.4 Data extraction 
To ensure that no significant information was omitted from the review, the 
researcher extracted data using a standardised form regarding: the author(s), place 
and date of publication, study design, sample size and percentage of female 
sample, mean age, the interventions, the type of outcome measures and follow-
up/failure to follow-up. 
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Table 4.1: Criteria list for methodological quality assessment [Physiotherapy Evidence 
Database (PEDro)]. Adapted from Maher et al. (2003).  Except the first item, each PEDro 
scale item achieved contributes 1 point to the total PEDro score (range 0–10 points). 
Category 
number 
PEDro Items Answer 
1 Eligibility criteria were specified Y/N 
2 
Subjects were randomly allocated to groups (in a crossover 
study, subjects were randomly allocated an order in which 
treatments were received) 
Y/N 
3 Allocation was concealed Y/N 
4 
The groups were similar at baseline regarding the most 
important prognostic indicators 
Y/N 
5 There was blinding of all subjects Y/N 
6 
There was blinding of all therapists who administered the 
therapy 
Y/N 
7 
There was blinding of all assessors who measured at least one 
key outcome 
Y/N 
8 
Measurements of at least one key outcome were obtained 
from more than 85% of the subjects initially allocated to 
groups 
Y/N 
9 
All subjects for whom outcome measurements were available 
received the treatment or control condition as allocated, or 
where this was not the case, data for at least one key outcome 
were analysed by ‘intention to treat’ 
Y/N 
10 
The results of between-group statistical comparisons are 
reported for at least one key outcome 
Y/N 
11 
The study provides both point measurements of variability 
for at least one key outcome 
Y/N 
Key: 
 
Y = Yes; N = No 
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4.5 Results 
Two hundred and forty two studies were identified based on the key search terms 
and the hand search of bibliography references (CINAHL 22; Medline 47; 
PubMed 137; AMED 28; manual search eight). After the initial screening of the 
titles and abstracts, 34 studies were found to satisfy the inclusion criteria and were 
further scrutinised for the present systematic review (Figure 4.1, p.98). 
Twenty-eight of 34 were excluded and reasons for exclusion are listed in Figure 
4.1 (p.98). Data from six studies are presented in Table 4.2 (p.99 to 103).  
 
Of the six studies included in this review, two were from the UK, two from 
Sweden, one from Finland and one from Canada. Studies were conducted as part 
of collaboration between physiotherapy and rheumatology departments (Eversden 
et al., 2007; Bilberg et al., 2005; Sanford Smith et al., 1998; Hall et al., 1996; 
Rintala et al., 1996; Stenström et al., 1991). One study compared hydrotherapy 
with no formal treatment (Rintala et al., 1996). All other studies compared 
hydrotherapy to single or multiple alternative interventions (Eversden et al., 2007; 
Bilberg et al., 2005; Sanford Smith et al., 1998; Hall et al., 1996; Stenström et al., 
1991) (Table 4.2, p.99 to 103). None of the studies investigated costs. The PEDro 
scores for the present review ranged from 5 to 8 out of the maximum possible 
score of 10, without including the first item of the PEDro scale because it refers to 
external validity (Table 4.3, p.104) (Kollen et al., 2009; Maher et al., 2003). 
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4.6 Methodological quality of the studies 
The methodological quality of the studies ranged from 5 to 8 on the PEDro scale 
of internal validity (Table 4.3, p.104), with a mean score of 6.8.  Four studies 
were of high quality, whereas two were of moderate quality. Two studies (Sanford 
Smith et al., 1998; Stenström et al., 1991) failed to report or describe whether an 
intention-to-treat analysis or concealment of the treatment allocation was used. In 
three studies (Eversden et al., 2007; Hall et al., 1996; Sanford Smith et al., 1998), 
the outcome assessor was blinded to the intervention. While all of the participants 
were randomised in the included trials, only three studies (Bilberg et al., 2005; 
Eversden et al., 2007; Hall et al., 1996) specified the methods used. Two studies 
used optimal allocation using a computer programme (Bilberg et al., 2005; 
Eversden et al., 2007) and one used block randomisation (Hall et al., 1996). 
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Figure 4.1: Flowchart of the literature search. 
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Table 4.2: Summary of studies meeting the selection criteria for inclusion in the systematic review for RA. 
Authors, 
country, 
year of 
study 
Sample 
n 
female 
% 
Study 
design 
Drop 
outs 
Mean age 
(SD) in 
years 
Intervention/ 
duration/ 
programme 
setting 
Outcome measures 
Patient 
assessment/ 
follow up 
Results/comments 
Hydrotherapy versus land-therapy 
Hall et 
al., 1996;  
UK 
 
139 
(66%) 
RCT 1 58.2 
(11.1) 
 
A: Aquatic exercise 30 minutes 
twice weekly for 4 weeks. 
 
B: Supervised land-based 
exercise. 
 
C: Supervised seated water 
immersion. 
 
D: Supervised land relaxation. 
Pain using McGill questionnaire. 
 
 
 
 
Ritchie articular index (RAI). 
 
 
 
Morning stiffness duration. 
 
Grip strength (digital monitor 
inflated to 20 mm Hg). 
 
Wrist and knee ROM using a 
standard goniometer. 
 
 
 
 
AIMS2 for health status. 
 
 
 
 
 
 
Patient perception. 
Baseline 
 
 
4 weeks 
post treatment 
 
 
3 months 
follow-up 
 
No significant differences between 
groups in terms of pain (all patients 
demonstrated a significant pain 
reduction (p ≤ 0. 005). 
 
All groups have significant reduction in 
joint tenderness between pre and post 
treatment with greater reduction in the 
hydrotherapy group (p = 0.03). 
 
Grip strength, wrist ROM, duration of 
morning stiffness, and CRP levels did 
not change significantly (p ≥ 0.05). 
 
 
Significant increase in knee ROM 
occurred mainly in women with 
hydrotherapy group (p ≤ 0.02). 
 
Significant improvement in mood and 
tension occurred for all patients after 
treatment and in follow up for all 
groups markedly in women (p = 0.02). 
At follow up, greater effect in 
hydrotherapy group (p = 0.03). 
 
All groups reported similar perceptions 
of the effectiveness of the interventions 
at pre-test and post-test (p ≤ 0.0001). 
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Table 4.2 (Continued): Summary of studies meeting the selection criteria for inclusion in the systematic review for RA. 
Authors, 
country, 
year of 
study 
Sample 
n 
female 
% 
Study 
design 
Drop 
outs 
Mean age 
(SD) in 
years 
Intervention/ 
duration/ 
programme 
setting 
Outcome measures 
Patient 
assessment/ 
follow up 
Results/comments 
Eversden 
et al., 
2007; UK 
 
115 
(69%) 
RCT 30 55.2 
(13.3) 
A: Hydrotherapy – One 
session/week for six weeks; 
pool at 35°C. 
 
B: Supervised land exercise.  
Primary outcome measure was 
self-rated overall effects on a 
Likert 7-point scale. 
 
 
Secondary outcome measure 
included: VAS pain, ten-meter 
walk speed, HAQ, EQ-5D utility, 
EQ-VAS. 
Baseline 
 
Post-treatment 
(six weeks) 
  
Follow-up 
(three months) 
  
Patients in the hydrotherapy group felt 
very much better in their overall health 
status compared to patients treated in 
the land exercise group (p < 0.001). 
 
No significant differences between 
groups in terms of changes to HAQ (p 
= 0.09), EQ-5D utility score (p = 0.61), 
EQ-VAS (p = 0.57) or pain VAS (p = 
0.40). 
Stenström 
et al., 
1991; 
Sweden 
60 (86%) RCT 5 52 (11.2) A: Hydrotherapy – One 
session/week in group of five, 
for 40 minutes, for four years in 
temperature of 34˚C (each year 
there is a two-and-a-half-month 
vacation). 
 
B: Supervised standard 
physiotherapy on land. 
Ritchie’s articular index for disease 
activity. 
 
Larsen radiological index. 
 
Laboratory inflammatory markers 
Sphygmo-manometer cuff for grip 
strength. 
 
VAS for pain. 
  
Functional tests such as outdoor 
walking, indoor walking, lifting, 
leaning forward and rising. 
 
Two open-ended questions about 
activity level/exercise habits. 
Post training 
(four years)  
 
No significant difference between the 
groups in Ritchie’s articular index, 
Larsen’s radiological index, soft tissue 
swelling or laboratory markers (p > 
0.05). 
 
Improved right-hand grip strength in 
hydrotherapy group (p ≤ 0.01); 
decreased left hand grip strength in 
comparison group (p > 0.05).  
No significant difference between the 
groups in VAS or functional tests (p > 
0.05). 
 
Significant difference in activity levels 
between the hydrotherapy group 
compared with comparison group (p ≤ 
0.01). 
 
Two-year follow-up at the end of the 
training period; the difference between 
the hydrotherapy and comparison 
groups was significant (p ≤ 0.001). 
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Table 4.2 (Continued): Summary of studies meeting the selection criteria for inclusion in the systematic review for RA. 
Authors, 
country, 
year of 
study 
Sample 
n 
female 
% 
Study 
design 
Drop 
outs 
Mean age 
(SD) in 
years 
Intervention/ 
duration/ 
programme 
setting 
Outcome measures 
Patient 
assessment/ 
follow up 
Results/comments 
Hydrotherapy versus home exercise programme 
Sanford 
Smith 
1998; 
Canada 
 
24 (75%) RCT 4 58.4 
(11.6) 
A: Hydrotherapy three 
times/week for 10 weeks.  
 
B:  Home exercise programme. 
AJC 
 
ESR 
 
 
Grip strength measured using 
Martin Vigorimeter (Hillside 
Medical Supplies Limited, 
Nottingham, UK). 
 
 
 
 
HAQ for function. 
 
 
 
 
 
 
Treadmill stress test. 
 
Baseline (one 
week prior). 
 
 
 
 
One week after 
10 weeks' 
exercise 
period. 
 
No follow up 
There were no between-group 
differences; however, both groups 
showed a similar decrease in AJC and 
ESR (p ≥ 0.05). 
 
Both groups demonstrated an 
improvement in grip strength (p ≤ 
0.05), but there was no significant 
difference between the groups. 
 
Both groups showed an increase in 
exercise tolerance (p ≤ 0.05). 
 
HAQ result showed a statistically 
significant improvement in two 
components of HAQ in the control 
group (p ≤0.05) and no significant 
improvement in the aqua-aerobics 
group (p ≥ 0.05). 
 
No significant between-group effects 
for duration or peak workload on 
treadmill (p ≥ 0.05). 
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Table 4.2 (Continued): Summary of studies meeting the selection criteria for inclusion in the systematic review for RA. 
Authors, 
country, 
year of 
study 
Sample 
n 
female 
% 
Study 
design 
Drop 
outs 
Mean age 
(SD) in 
years 
Intervention/ 
duration/ 
programme 
setting 
Outcome measures 
Patient 
assessment/ 
follow up 
Results/comments 
Bilberg et 
al., 2005; 
Sweden 
 
47 (89%) RCT 4 49 A: Hydrotherapy twice weekly 
for 12 weeks in a group of eight 
or nine, for 45 minutes, 
experiencing moderate aerobic 
intensity. 
 
B: Home exercise programme 
and routine daily activities. 
Sub-maximum ergometer cycle 
(Åstrand, Varberg, Sweden) for 
aerobic capacity as primary 
outcome measure. 
 
SF-36 for health status as primary 
outcome measure. 
 
 
Chair test as secondary outcome 
measure. 
 
 
 
Shoulder endurance test as 
secondary outcome measure. 
 
 
 
Grip strength (using electronic 
instrument, Grippit). 
  
HAQ for functional disability and 
AIMS2 for QoL. 
Baseline 
 
Post treatment 
(3 months) 
 
6 months 
follow-up for 
hydrotherapy 
group 
No significant changes were found for 
the primary outcome measure between 
baseline and post-treatment (p ≥ 0.05). 
 
At follow up, SF-36 showed significant 
improvement within the training group 
(p < 0.05); no significant changes were 
found in between-group differences (p 
≥ 0.05). 
 
Performance on the chair test increased 
significantly in the training group 
compared with the control group (p = 
0.005). 
 
Performance on the shoulder endurance 
test increased significantly in the 
training group compared with the 
control group (p ≤ 0.001). 
 
Grip strength of the left hand increased 
significantly in the hydrotherapy group 
compared with the home exercise group 
(p ≤ 0.001). 
 
AIMS-2 and HAQ displayed a 
significant within-group improvement 
(p = 0.007) and 0.04, respectively), but 
there was no significant differences 
between the groups (p ≥ 0.05). 
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Table 4.2 (Continued): Summary of studies meeting the selection criteria for inclusion in the systematic review for RA. 
Authors, 
country, 
year of 
study 
Sample 
n 
female 
% 
Study 
design 
Drop 
outs 
Mean age 
(SD) in 
years 
Intervention/ 
duration/ 
programme 
setting 
Outcome measures 
Patient 
assessment/ 
follow up 
Results/comments 
Hydrotherapy versus control (no formal treatment) 
Rintala et 
al., 
1996; 
Finland 
 
34 (85%) RCT 0 48 (10) A: Aquatic exercise 45-60 min 
twice a week for 12 weeks, 
pool temperature 30˚C. 
 
B: Unsupervised routine daily 
activities.  
VAS pain. 
 
Joint mobility by using signals of 
functional impairment. 
 
Muscle strength & endurance by 
using digital dynamometer. 
Baseline 
 
Post-treatment 
(12weeks)  
 
No follow up 
Pain more diminished in experimental 
group than in control group (p ≤ 0.05). 
 
Joint mobility improved in 
experimental group (p ≤ 0.05). 
 
Muscle strength and endurance 
improved in experimental group 
compared with control group (p ≤ 
0.001). 
 
 
 
 
 
 
Key: 
 
AIMS2 = Arthritis Impact Measurement Scale version 2; AJC =Active-Joint Count; CRP = C-reactive protein; ESR = Erythrocyte Sedimentation Rate; HAQ = Health Assessment 
Questionnaire; SF-36 = Short Form (36); VAS = Visual Analogue Scale. A: Hydrotherapy group; B: Comparator groups 
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Table 4.3: Methodological quality using the Physiotherapy Evidence Database (PEDro) scale scoring the items out of 10. 
Study 
Item 
1 
Item 
2 
Item 
3 
Item 
4 
Item 
5 
Item 
6 
Item 
7 
Item 
8 
Item 
9 
Item 
10 
Item 
11 
Total score 
(/10) 
Stenström et al. 
(1991) 
 
Y Y N Y N N N Y N Y Y 
5/10 
moderate 
quality 
Hall et al. 
(1996) 
Y Y Y Y N N Y Y Y Y Y 
8/10 
high quality 
Rintala et al. 
(1996) 
Y Y Y Y N N N Y Y Y Y 
7/10 
high quality 
Sanford Smith et 
al. (1998) 
Y Y N Y N N N Y N Y Y 
5/10 
moderate 
quality 
Bilberg et al. 
(2005) 
Y Y Y Y N N Y Y Y Y Y 
8/10 
high quality 
Eversden et al. 
(2007) 
Y Y Y Y N N Y Y Y Y Y 
8/10 
high quality 
Key: 
 
Y, yes (= 1); N, no (= 0) 
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4.6.1 Participants 
The six studies described above included both men and women (total no = 419); 
326 (78%) of the participants were women. The participants’ age across the 
studies ranged from 18–80 years. The average number of participants in the 
treatment group post-randomisation and before any withdrawals was 29 and 
ranged between 12–57, with only three studies having groups with more than 30 
participants (Eversden et al., 2007; Hall et al., 1996; Rintala et al., 1996). 
 
4.6.2 Interventions summary 
 
Hydrotherapy versus land therapy 
Hall et al. (1996) tested the hypothesis that the combined effects of water 
immersion and exercises in that water were therapeutically superior to either 
modalities used singly. They did this by designing a parallel RCT randomising all 
the participants in four groups (hydrotherapy, seated immersion, land exercise and 
land relaxation). Hall et al. (1996) showed that all the four groups showed 
physical and emotional improvements.  
 
Hydrotherapy proved superior in improving the physical and emotional aspects of 
patients with RA. AIMS-2 measured mood and tension, and patients in each of the 
four groups improved significantly over time, but a greater effect of improvement 
in mood and tension was found in women. During the follow-up period, 
participants continued to experience significant improvement, but the participants 
in the hydrotherapy group reported the greatest effect. Participants in all the four 
groups reported reduction in joint tenderness over time. However, participants in 
the hydrotherapy group show the greatest reduction. 
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Eversden et al. (2007) evaluated the effects of hydrotherapy with exercises versus 
land exercises on the overall response to treatment, physical function and QoL of 
patients with RA. These authors designed a programme of 30-minute 
hydrotherapy sessions once a week for six weeks (at 35°C) with a control group 
on land-based programme for six weeks. Patients were randomly allocated to 
hydrotherapy or land-based exercises using sealed opaque envelopes that 
indicated their treatment allocation. The participants performed warm-up 
exercises for ten minutes using mobilising and stretching exercises. The core 
exercises, repeated ten times a week, focused on joint mobility, muscle strength 
and functional activities.  
 
The primary outcome measure applied in this study was self-rated QoL, in which 
the effect of treatment was measured as the change on a seven-point scale ranging 
from 1 (very much worse) to 7 (very much better) (Richards & Scott, 2002). 
Secondary outcomes were collected at baseline, both on the day of the last 
treatment session and three months post-treatment. Pain was assessed using a 10-
cm VAS, where 0 cm represented no pain and 10 cm represented severe pain 
(Langley & Sheppeard, 1984). Physical function was assessed using the HAQ 
(Bruce & Fries, 2005; Felson et al., 1993; Fries et al., 1980). The ten-metre walk 
speed test was used to assess lower-limb function. This test was previously used 
for patients with neurological problems and had been used by Eversden et al. 
(2001), who carried out the previous pilot study (Eversden, 2001). The primary 
outcome measure of Eversden et al. (2007) showed that RA patients who attended 
outpatient clinics were more likely to report feeling much better or very much 
better if they were treated with hydrotherapy (40/46, 87%) than if they were 
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treated with exercises on land (19/40, 47.5%)  (p < 0.001 Fisher's exact test). This 
benefit was reported immediately after completion of the treatment. There was no 
difference between treatment groups in the secondary outcome measures. In the 
follow up period of three months, no significant differences were observed in 
either primary or secondary outcome measures. 
 
A Scandinavian study (Stenström et al.,1991) failed to show any statistically 
significant differences in pain rating, functional outcomes tests (Stenström, 1990), 
Ritchie’s articular index (Ritchie et al., 1968), Larsen’s radiological index (Larsen 
et al., 1977), soft tissue swelling and laboratory parameters between the 
hydrotherapy group and a comparator group. Participants answered a 
questionnaire using self-reported questions with two open-ended questions on 
exercise habits e.g. ‘what do you think is positive regarding the training?’ and 
‘what do you think is negative regarding the training?’. 
 
Doleys et al. (1982) were the first to use these self-reported questions on exercise 
habits for training patients with chronic pain. Post-treatment, four out of 27 
participants in the hydrotherapy group stated that they never or seldom exercised 
(in addition to the training protocol) compared to 16 out of 28 participants in the 
comparator group. This indicated that there was a statistically significant 
difference in their response on exercise habits between the hydrotherapy group 
compared with the comparator group (supervised standard physiotherapy) (p ≤ 
0.01). Similarly, the two years follow-up data showed that two out of 27 of the 
hydrotherapy group and 16 out of 28 in the comparator group stated that they 
never or seldom exercised, indicating that there was a statistically significant 
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difference in the response about exercise habits between the hydrotherapy and the 
comparator group (supervised standard physiotherapy) (p ≤ 0.001). 
  
Hydrotherapy versus home exercise (HE) programme 
Sanford Smith et al. (1998) recruited 24 participants (19 of them females) with a 
mean age of 58.4 years to participate in their study. Subjects were randomly 
allocated to the hydrotherapy group or the home exercise group. The hydrotherapy 
sessions were held three times a week for 10 weeks. Each session consisted of an 
hour of exercises performed in a hydrotherapy pool heated to 36°C. Fifteen 
minutes of warm-up aerobic stretches for the spine, chest and extremities was 
followed by 20-25 minutes of aerobics exercise. Participants exercised to a 
maximum target heart rate of 70% exercise tolerance (Ekblom et al., 1974; Minor 
et al., 1988; Nordemar et al., 1981). The other group participants received a ROM 
exercise and isometric strength exercises programme for ten weeks. Nonetheless, 
the results failed to reveal a differential effect between the hydrotherapy and home 
exercise group. Moreover, there was no improvement in functional ability 
measured by HAQ.  
 
Bilberg et al. (2005) hypothesised that three months of hydrotherapy would 
improve patients’ aerobic capacity, functional ability and perception of physical 
health. Forty-seven participants (42 women) were divided into two groups (the 
hydrotherapy group and the home exercise group). The treatment group exercised 
twice a week for 12 weeks in groups of eight or nine patients in a temperate pool. 
The duration of each session was 45 minutes and the exercise was of moderate 
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aerobic intensity. The patients in the home exercise group continued with their 
usual daily activities and were prescribed a home exercise programme (HEP). 
 
Outcome measurements were carried out at baseline and at three months post-
intervention for both groups. The patients in the hydrotherapy group were 
followed up for six months after completion of the study. Aerobic capacity was 
estimated using a sub maximum ergometer cycle (Bilberg et al., 2005), and the 
physical component of the Short Form (36) (SF-36) was chosen as the primary 
outcome measure.  
 
The study was unable to confirm whether the intervention was effective in 
improving aerobic capacity and QoL. However, the differences showed significant 
improvement in the hydrotherapy group for the secondary outcome measures – 
isometric shoulder endurance, grip force, dynamic endurance of the lower 
extremities (chair test) and muscle function of the lower extremities – compared 
with the home exercise group. The chair test was assessed by counting the 
maximum number of times that the patient was able to get up from a chair during 
one minute (Mannerkorpi & Ekdahl, 1997). The isometric shoulder endurance 
test, which is used to measure the isometric endurance of the shoulder abductor 
muscles, was assessed by monitoring the maximum length of time that a person 
was able to hold his/her arm at 90 abduction with a 1-kg cuff attached proximally 
to the wrist joint (Mannerkorpi et al., 1999), and was carried out at baseline and 
three months post-treatment. The differences in all of the primary and secondary 
outcome measures between baseline and 6 months follow-up were statistically 
significant within the hydrotherapy group, with the exception of aerobic capacity.  
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Hydrotherapy versus control 
Rintala et al. (1996) studied the effects of hydrotherapy on chronic pain and 
functional performance in patients with RA. Pain was assessed using VAS. 
Functional performance was assessed by measuring joint mobility, muscle 
strength and endurance.  
 
Thirty-four participants were randomly allocated to aquatic exercise (n = 18) or 
the routine daily activities group (n = 16). The aquatic exercise group undertook 
muscle strength, endurance, and joint mobility exercises in sessions lasting 
between 45 and 60 minutes, twice a week for 12 weeks. The routine daily 
activities group participated in their daily activity with no additional exercise 
during the study period. The major findings of this study at the end the 12-week 
training period were that the hydrotherapy group experienced less pain, increased 
muscle strength and increased endurance compared to the routine daily activities 
group. It seems that the type and duration of the training provided in this study 
was sufficient to maintain joint mobility in the hydrotherapy group. 
 
4.6.3 Outcome measures 
RA affects physical, social and psychological aspects of patients’ health status or 
QoL. The outcome measures that were used in the included studies reflected one 
or more of the variables (Fitzpatrick et al., 1992; Hakala, 1997). 
 
4.6.3.1 Pain  
A pain scale was used in all the reviewed studies. Scores on these scales were 
measured before and after the intervention. Various instruments were used to 
measure pain. The 10-cm visual analogue scale (VAS) was the tool used the most 
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commonly in three studies (Eversden et al., 2007; Rintala et al., 1996; Stenström 
et al., 1991). Another instrument that was used by Hall et al. (1996) to assess pain 
was the McGill Pain Questionnaire. The pain subscales from a variety of self-
reported questionnaires were also used, such as the Arthritis Impact Measurement 
Scale (AIMS) (Hall et al., 1996), Health Assessment Questionnaire (HAQ) 
(Bilberg et al., 2005; Eversden et al., 2007; Sanford Smith et al., 1998), and the 
SF-36 (Bilberg et al., 2005). 
 
Rintala et al. (1996) used pain as a primary outcome measure and found that there 
was a statistically significant reduction in the pain level after use of a water 
exercise programme in patients with RA compared to the control group. None of 
the studies used pain as an outcome measure for a power calculation to determine 
the sample size. 
 
4.6.3.2 Physical function 
HAQ and VAS were the most commonly used instrument in the reviewed studies 
(Bruce & Fries, 2005; Felson et al., 1993; Fries et al., 1980). They were used in 
three studies (Bilberg et al., 2005; Eversden et al., 2007; Sanford Smith et al., 
1998). However, only one of these (Bilberg et al., 2005) found a significant 
improvement observed in physical function compared with the home exercise 
group. HAQ was used as a primary outcome measure in one study (Sanford Smith 
et al., 1998). Sanford Smith et al. (1998) showed a trend for an improvement in 
physical function using the total HAQ score in the aqua-aerobics group compared 
with the home exercise group but this was not statistically significant. 
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4.6.3.3 Health status  
Three studies (Bilberg et al. 2005; Eversden et al., 2007; Hall et al. 1996) 
investigated health status using three different types of questionnaires (SF-36; 
EQ-5D and AIMS-2, respectively). Eversden et al. (2007) showed that there was 
no statistically significant difference in EQ-5D scores between hydrotherapy and 
land-based exercise. Bilberg et al. (2005) showed that in the hydrotherapy group, 
whilst there was a significant within-group improvement in SF-36 scores over 
time, these differences were not statistically significant when compared to the 
home exercise group. Finally, Hall et al. (1996) reported significant improvement 
in the level of tension and mood for all participants in all groups over time; 
although at three months follow-up, patients receiving hydrotherapy demonstrated 
the greatest improvement effect in the level of tension and mood. 
 
4.6.3.4 Disease activity  
In terms of disease activity, a variety of categories, such as MS, joint tenderness, 
joint swelling, grip strength and laboratory markers [acute phase reactant such as 
C- reactive protein (C-RP)], were measured separately in four studies (Bilberg et 
al., 2005; Hall et al., 1996; Sanford Smith et al., 1998; Stenström et al., 1991). 
The results of Bilberg et al. (2005) indicated that grip strength of the left hand 
increased significantly in the hydrotherapy group compared with the home-
exercise group (p < 0.001). This contrasted with the findings of Hall et al. (1996) 
and Sanford Smith et al. (1998), who did not find any significant difference 
between the hydrotherapy group and home exercise group in terms of grip 
strength, duration of MS and C-RP level or Erythrocyte Sedimentation Rate (ESR 
– a blood marker of inflammation) (p > 0.05). In Stenström et al. (1991), the right-
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hand grip strength of participants improved significantly in the hydrotherapy 
group (p ≤ 0.01), while in the standard physiotherapy group, participants’ left-
hand grip strength deteriorated (p ≥ 0.05). Hall et al. (1996) also showed that all 
patients have significant improvement in joint tenderness between pre- and post- 
treatment, but that patients in the hydrotherapy group had the greatest reduction in 
joint tenderness between pre- and post-treatment. 
 
4.6.3.5 Patient perception  
Patients’ perception of hydrotherapy treatment was investigated in two studies 
(Eversden et al., 2007; Hall et al., 1996). Hall et al. (1996) used a five point 
Likert-type perception scale, which was designed by Langley and Sheppeard 
(1984), their findings were unexpected and showed that all groups reported 
similar perceptions of the effectiveness of the intervention with overall mean 
ratings (on a 1-5 scale) of 3.6 (SD 0.9) at pre-test and 3.4 (SD 1.15) at post-test. 
Eversden et al. (2007) used a seven-point Likert scale and their findings showed 
that the largest set of significant clusters of feeling ‘very much better’ was in the 
hydrotherapy group compared with the land exercise group.  
 
After reviewing all six studies, neither meta-analysis nor statistical pooling were 
considered because of the heterogeneity among the studies, including the small 
sample size, variations in symptoms and duration, interventions and the reporting 
of the outcomes. 
 
4.7 Discussion 
The objective(s) of the present systematic review was to evaluate the available 
evidence for the effectiveness of hydrotherapy in the treatment of RA patients 
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compared to an alternative. These findings suggest that patients who received 
hydrotherapy treatment for RA gained some beneficial effects in improving their 
health status (for example reduced pain scores). Further additional benefits 
included a substantial increase in physical activity and emotional wellbeing in 
patients in the aquatic programmes compared with control groups in the short 
term. There is no cure for RA, and it is therefore important to look into non-
pharmacological treatment that reduces the disease progression. A treatment for 
RA that reduces or slows down the inflammatory process would be of great 
benefit, both from a health service perspective and also from the perspective of 
the RA patient, in terms of the perceived benefit to improving their QoL.  
 
The PEDro scores for the papers reviewed ranged from 5-8 and were regarded as 
being of moderate to high quality. The average methodological quality of all the 
studies was 6.8 and was regarded as moderate. However, all of the studies 
reviewed suffered from methodological flaws that limited their generalisability to 
the wider population of RA patients. These limitations included lack of control 
group in the follow-up period in the study of Bilberg et al. (2005); inappropriate 
primary outcome measures in the study of Eversden et al. (2007); small sample 
size in the study of Rintala et al. (1996) and Sanford Smith et al. (1998); and 
finally, poor concealment allocation in the study of Stenström et al. (1991) and 
Sanford Smith et al. (1998). 
 
The six studies that were appraised differed in the frequency and duration of the 
hydrotherapy sessions given to participants: twice weekly over four weeks,  once 
weekly over six weeks, three times weekly over ten weeks, twice weekly over 12 
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weeks  and once weekly over four years (long term study). Therefore, we are 
unable to determine from the present review the ideal number of hydrotherapy 
sessions that are needed for RA patients to derive clinically significant benefits 
from this intervention. A possible explanation for this might be that each study 
was designed with specific targets and goals, and different primary outcome 
measures. A recent national survey in the UK by HyDAT Team (2009) reported 
that the median optimal number of sessions for the treatment of RA patients were 
six sessions.  
 
4.8 Methodological critique of the reviewed articles  
The choice of outcome measures used in the reviewed studies should be examined 
with caution. The Health Assessment Questionnaire (HAQ) was the most 
common instrument used to measure physical function. In terms of the efficacy of 
hydrotherapy, it was used as a primary outcome measure in only one study 
(Sanford Smith et al., 1998). Significant improvements in health status (health-
related QoL (EQ-VAS) were found in two studies (Bilberg et al., 2005; Hall et al., 
1996) by using two different health-related QoL scales of measurement. This 
means that a standardised, specific scale, superior to any other, was not used when 
measuring health status or QoL in RA patients. 
  
Grip strength and joint tenderness were the most frequent disease activity indices, 
and were examined in three studies – Bilberg et al. (2005); Hall et al. (1996); 
Stenström et al. (1991). The contradictory results of grip-strength measures can be 
explained by the different methods of assessment tools employed in various 
studies. Hall et al. (1996) measured the grip strength of the dominant hand by 
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using a digital grip strength monitor inflated to 20 mm Hg (Rhind et al., 1980). 
The mean of three readings was recorded, whereas Bilberg et al. (2005) measured 
grip strength by using an electronic instrument (Grippit, manufactured by AB 
Detektor in Göteborg, Sweden), recording the maximum and mean strength and 
the best performance of three (Nordenskiöld, 1990). Conversely, Stenström et al. 
(1991) measured grip strength manually by using a sphygmomanometer cuff 
rolled up two turns and inflated to 20mm Hg (Lansbury, 1958). Sanford Smith 
and colleagues (Sanford Smith et al., 1998) did not report the method of 
assessment used to measure the grip strength. Therefore, future studies should 
consider using an appropriate procedure in measuring grip strength in patients 
with RA with dexterity malfunction and pain. 
  
The reduced joint tenderness observed in the hydrotherapy group of Hall et al. 
(1996) might be attributed to the reduction in joint loading supported by 
buoyancy. Furthermore, the hydrostatic pressure of water immersion is considered 
effective in reducing oedema (Poyhonen et al., 2000). These findings will help 
researchers to assess different aspects of the underlying disease due to high 
variability of the disease presentation and progression. 
 
It was noted that there were many substantial methodological shortcomings in the 
research that had been reviewed, mainly in the inadequate reporting of 
interventions in terms of their settings, water temperature, depth of pool, and the 
type and intensity of the exercise programme. In addition, there were other 
methodological flaws relating to RCT design, such as inappropriate 
randomisation, concealment of allocation to groups, and the blinding procedure to 
117 
 
the outcome measurements. Moreover, some of the studies did not give detailed 
information about their data analysis. This might have affected the conclusions 
drawn from these studies, so caution is required in the interpretation of their 
findings. Lastly, the variation in the dosages of intervention in the six studies 
makes it difficult to provide clear guidance in this area. Overall, many of the 
studies involved in the present review had a relatively small sample size and 
lacked adequate statistical power to examine the effectiveness of hydrotherapy 
intervention in the treatment of patients with RA. In addition, the studies reviewed 
used different primary outcome measures and a few studies had inadequate and 
variable follow-up periods. 
 
The present review had several limitations. Firstly, the review focused only on 
studies published in English, and therefore potentially relevant articles that have 
been published in other languages may have been missed. Such studies were 
excluded because of the limited resources available for translation. Secondly, the 
searches were limited to already-published articles because all such papers had 
been peer-reviewed, which ensures their good quality and thus improves external 
validity. Thirdly, the cost effectiveness (CE) of hydrotherapy was not investigated 
and therefore not featured in the review. Unfortunately, none of the studies 
reviewed reported the cost-effectiveness of their intervention. Costs-versus-
benefits assessment will become increasingly important in medical rehabilitation 
and physiotherapy research, as RA patients are more likely to continue to use 
healthcare services for a long period because of the chronic nature of the 
condition. Therefore, future studies should consider the cost-effectiveness of 
hydrotherapy intervention for patients with this condition.  
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4.9 Implications for practice  
The results of the present review indicate the beneficial effects of hydrotherapy 
compared with an alternative intervention such as land-based therapy, home-
exercise or daily routine activities. An important practical implication is that the 
outcome measures used to assess pain, physical function, disease activity and QoL 
scales are appropriate for the assessment of patients with RA. In addition, some of 
the studies reviewed showed that hydrotherapy is an effective intervention to 
alleviate the symptoms associated with RA such as pain, disease activity (grip 
strength, joint tenderness) and health status (mood and tension). The evidence 
from this review might give further option for rheumatologists to refer appropriate 
RA patients for hydrotherapy treatment as part of their medical rehabilitation. 
 
4.10 Implications for research 
Few RCTs have examined the effects of a hydrotherapy intervention on RA. The 
present review indicated that there is no consistency in the literature in terms of 
the type of exercise and the dose (intensity, frequency and duration) used in 
hydrotherapy treatment for patients with RA. In addition, future studies should 
consider examining the CE of hydrotherapy and the optimal use of aquatic 
exercise for patients with RA. Considerably more work is needed to determine the 
effectiveness of hydrotherapy on disease activity, psychological aspects of RA 
(anxiety and depression), and physical function using appropriate outcome 
measures. Large, high-quality RCTs using rigorous methodology (such as 
adequate sample size) are needed due to the fact that they could provide more 
definitive evidence for the efficacy of hydrotherapy. 
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4.11 Conclusions 
There is some evidence to suggest that hydrotherapy is an effective modality for 
reducing pain and improving the health status of patients with RA in the short-
term. However, the long-term benefits of hydrotherapy are presently unknown. It 
is difficult to make specific recommendations at this stage because of lack of 
evidence (such as optimal duration and frequency) for clinical practice because of 
the heterogeneous nature of the interventions. Therefore further studies are needed 
using robust RCTs.  
 
The next chapter discusses the methodology giving a description of the patient 
sample, patient-recruitment process and hospitals involved. It provides a 
description of the development and application of the treatment protocol 
prescribed to the intervention groups in the RCT Study One. 
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5.1 Introduction 
This chapter describes the methodology for the single blind randomised-controlled 
trial (RCT) set out in this thesis. The methodology in this chapter illustrates the 
development and application of the treatment protocol prescribed for the 
hydrotherapy and land-therapy group. It also describes the preparation carried out 
prior to data collection: patient sample; patient recruitment process; referral 
process and amendments. Ethics committee approval was obtained and the pilot 
study performed. Details of how the challenges within the hospitals involved were 
addressed and the rationale behind the choice of outcome measures was provided. 
It is presented according to the 2010 CONSORT statement (Schulz et al., 2010). 
 
Aims of Study One 
Primary Aim: The primary aim of the RCT Study One was to: 
 Evaluate the difference in outcomes for RA patients when treated with 
hydrotherapy as opposed to land based therapy.  
Secondary Aims: The secondary aims of the RCT Study One were to: 
 Identify and evaluate the differences in demographic factors between the 
hydrotherapy and land-therapy groups. 
CHAPTER FIVE: METHODOLOGY OF 
RANDOMISED CONTROLLED TRIAL (RCT)  
(STUDY ONE) 
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 Identify and understand the reasons for the difference in functional ability 
measured by HAQ-DI between those receiving hydrotherapy and those 
receiving land therapy. 
 Evaluate whether or not hydrotherapy could improve pain and GWB, 
health-related quality of life (HRQoL), disease activity and mood 
symptoms (depression and anxiety) more effectively than land therapy in 
patients with RA.  
 Determine the association between variables measuring disease activity. 
 Determine the association between variables measuring psychological 
status with socio-demographic features and disease activity indices. 
 Determine which factors predict functional disability. 
 
5.2 Methods 
5.2.1 Research design 
In order to compare the effect of two different interventions, using two 
independent groups, simultaneously, over time, a parallel, longitudinal, 
randomised and controlled trial was carried out. Because of the interventions 
studied [hydrotherapy and land-based therapy] involving therapist-patient 
interaction, it was only possible to blind the researcher; the study was therefore 
classed as single blind. 
 
5.2.2 Participants 
According to the aims of the study, all RA patients referred and eligible for 
hydrotherapy were invited into the study. The recruitment for this study utilised a 
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gatekeeper approach, wherein the health professional involved in the potential 
participants’ care approached the participant (who fulfilled inclusion/exclusion 
criteria) on behalf of the researcher. There were no financial incentives and 
therefore no coercion. The hospital was paid for the services provided for the pool 
time to avoid delay for participants involved in the trial. 
 
5.2.2.1 Inclusion and exclusion criteria 
The samples of 86 RA patients were identified based on the following inclusion 
and exclusion criteria: 
 
5.2.2.1.1 Inclusion criteria 
 Age ≥ 18 years. This age and above differentiates adult onset of RA from 
juvenile rheumatoid arthritis (JRA). The trial included adult RA only. 
  Males and females. 
 All patients referred to physiotherapy with a diagnosis of RA. 
 Patients on a stable drug regimen for at least 2 weeks for NSAIDs and at 
least 6 weeks for DMARDs. 
 Treatment by corticosteroid orally or injection permitted during the study. 
Drug changes were permitted to emphasise the realistic nature of the 
clinical management of RA. 
5.2.2.1.2 Exclusion criteria 
Patients with history of any known condition contraindicated to aquatic 
physiotherapy (such as myocardial infarction, fear of water, uncontrolled epilepsy, 
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chlorine sensitivity, infected open wound, uncontrolled HT and incontinence of 
faeces) were excluded (Edl et al., 2004; Eversden et al., 2007; Schrepfer, 2002). 
 
5.2.2.2 Recruitment of rheumatologists 
Two consultant rheumatologists working at the Kellgren Centre Rheumatology 
department within the CMFT agreed to refer patients to the study, and another 
consultant rheumatologist from the SRFT agreed to refer patients to the study. A 
presentation and a letter to clinicians (Appendix 1) were prepared and sent to 
them illustrating the aims, protocol, design methodology and outcome measures 
intended as a proposal to invite  the consultants to be part of study team. All 
Rheumatologists used the ACR criteria (Arnett et al., 1988) to diagnose RA 
(Table 2.1, p.33). The ACR/European League against Rheumatism updated their 
diagnostic criteria in 2010 (Aletaha et al., 2010) (Table 2.2, p.34). This considered 
four additional criteria, which can be applied to any patient. All consultants 
agreed to use these criteria for diagnosis of RA and permitted their patients to be 
randomly allocated to either the hydrotherapy or the land-therapy group. 
 
5.2.2.3 Recruitment of rehabilitation staff 
Two specialist physiotherapists who were working in rheumatic rehabilitation, 
one from CMFT and one from SRFT, agreed to participate in this trial. A 
presentation was given in each department to explain the goals, impacts, 
procedure and methodology of the study, and possible difficulties that might be 
faced during the trial. After which all the personnel present agreed to partake and 
allowed their patients to be randomly allocated to either group. 
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5.2.2.4 Treatment sites 
Treatment for the hydrotherapy and land exercise group was offered on the two 
sites because participants were recruited from the two hospitals, which were 
spread over a wide geographical area around Greater Manchester. The researcher 
observed and followed treatment sessions between sites as part of quality 
assurance. 
 
5.2.2.5 Trust staff arrangement 
Overall management of the study was the responsibility of the researcher, but 
because each Trust had a specific policy and protocol for research and 
development (R&D), the researcher contacted individuals in each trust to find out 
their requirements for R&D. The Director of Studies (DoS) assisted the researcher 
only with the discussions, which were necessary to have with each Trust, in order 
to decide study-funding issues. Each Hospital Trust had individual requirements 
for payment for participants and the Trust logo was required on every study 
document. After the approval of the main NHS Ethical Committee (Appendix 15), 
other approvals were obtained from each R&D Trust office (Appendix 
16&Appendix 17). The researcher attended the Good Clinical Practice (GCP) 
course required for anyone who wishes to carry out NHS research. 
 
5.2.2.6 Researcher responsibility 
The researcher was responsible for the day-to-day running of the study. Prior to 
beginning the recruitment process, the researcher had visited the hydrotherapy 
pool and observed treatment protocols in order to understand their responsibilities 
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before designing the treatment protocol and embarking on their research. The 
researcher was responsible for sending and collecting questionnaires and, after 
interventions, inputting all the data onto the Statistical Package for the Social 
Sciences (SPSS). He organised the production and printing of all the necessary 
study documents (Appendix 2 –10). The researcher was in close contact with the 
three consultant rheumatologists and physiotherapists to take care of any issues 
concerning the participants or provide updates on the rehabilitation programme. 
 
5.2.3 Interventions 
 
5.2.3.1 The referral process 
Figure 5.1 (p.130) illustrates all stages of the referral process in this study. 
 
5.2.3.1.1 Pre-trial stage 
RA patients who were suitable for the study were referred to physiotherapy by the 
consultants’ rheumatologist. The rheumatology physiotherapy team performed an 
initial assessment to decide whether the participants were eligible for the study or 
not, depending on the inclusion and exclusion criteria. If they were eligible and 
agreed to take part, they signed a data access sheet (Appendix 2). In addition, a 
participant information sheet (Appendix 3) was provided 48 hours prior to their 
next physiotherapy appointment to allow a consultation period. If they were 
ineligible or unwilling to participate normal treatment was resumed with no 
further information on the study. The researcher contacted the willing participants 
by phone to inform them of the next step in the procedure – the questionnaires and 
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consent forms. The researcher received written consent (Appendix 4) and all the 
completed questionnaires by the time of the second physiotherapy appointment. 
 
5.2.3.1.2 Assessment stage 
After the initial physiotherapy assessment performed at the first appointment, the 
rheumatic physiotherapy team, using block randomisation by an independent 
coordinator, assigned each patient to one of two groups. All participants were 
given further advice and an appointment was made for their next treatment [either 
hydrotherapy or land therapy] depending on the randomisation. The researcher 
was blinded to the process of randomisation. 
 
5.2.3.1.3 Trial stage  
All participants completed outcome measures (five questionnaires) before the 
intervention (Test 1). The intervention started one week following randomisation. 
The intervention programme was for six weeks with one session per week. Both 
the hydrotherapy and land-based exercises consisted of warm-up, ROM, sustained 
stretching exercise, core stability, balance exercise and strengthening exercise 
(Appendix 12, 13). 
 
Design and development of intervention exercise protocol 
There has been little agreement to date on what evidence there is to suggest that 
exercise for RA patients improves general muscular endurance and strength 
without detrimental effects on disease activity or pain (Hurkmans et al., 2009). It 
has been demonstrated in the past that RA patients should be careful to use only 
the exercise prescribed because of issues of disease activity and potential 
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exacerbation of symptoms (Heine et al., 2012). However, recent evidence suggests 
that exercise does not have a negative impact on the disease process, and may in 
fact be beneficial (Hurkmans et al., 2009), including for the small joints of the 
hands and feet (De Jong et al., 2004).  
 
For any arthritis exercise programme, the key point is to identify an exercise 
regimen that best meets an individual's needs and expectations. It needs to be safe, 
effective, and personally pleasurable (Wing & Peterson, 2012). It has been 
suggested that a trial of any complex intervention should include a description of 
the intervention and its components as an essential step of reporting (Craig et al., 
2008; Medical Research Council, 2000).  
 
Complex interventions are usually described as interventions that contain 
numerous interacting components (Craig et al., 2008). However, other important 
points to be taken into account are the number and variability of outcome 
measures; number of groups or organisational levels targeted by the intervention; 
degree of flexibility or tailoring of the intervention permitted and the number of 
interacting components within the experimental and control interventions (Craig 
et al., 2008). 
 
In accordance with the principles of the Medical Research Council (MRC), 
framework guidance for complex interventions exercise protocols for each 
treatment arm should be founded on evidence-based knowledge acquired through 
treatment modality-specific training courses, peer-reviewed best practice and 
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clinical experience (Campbell et al., 2007; Craig et al., 2008; Medical Research 
Council, 2000). Therefore, a description of the intervention and its components 
should be included in any trial of complex intervention as an essential step of 
reporting (Heine et al., 2012; Medical Research Council, 2000). A pragmatic 
approach was taken to reporting the treatment of patients. 
 
A large and growing body of systematic reviews of the literature has started to 
establish the evidence base for exercise in RA. This has involved a general 
exercise programme being designed for the whole body called ‘Whole Body 
Programmes’ (WBP) (Heine et al., 2012). Several studies investigating the effects 
of various types of exercise on different aspects of the patient experience have 
been carried out, the majority reporting beneficial responses (Van den Ende et al., 
2007; Van den Ende et al., 2004). Almost all have involved WBPs that focus on 
aerobic fitness, strengthening and/or active range of movement. These 
programmes included all body joints such as small joints of hands and feet, large 
joint such as knee joints, elbows, ankle joints and shoulders. Exercise programmes 
from those studies that described the actual intervention in detail were also 
evaluated as part of designing the final RCT intervention protocol. 
 
NICE guidelines (2009) recommend that all RA patients should have easy access 
to physiotherapists and occupational therapists for treatment of the condition. 
These treatments include joint protection advice, electrotherapy, exercise, 
assistive devices, splints, and heat and joint mobilisation (Beardmore, 2008; 
Heine et al., 2012). In order to prevent discrepancies, the treatment provided to all 
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participants was an intervention based on a combination of movement exercises, 
core stability, sustained stretching and balance exercises designed by the treating 
physiotherapists. Treatment was individualised for each patient according to the 
patient’s needs. The researcher devised a treatment strategy sheet (Appendix 11) 
to record the treatment in collaboration with the senior therapists who provided 
the treatment on each site.  
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Figure 5.1: Flow diagram of participants’ progress through RCT. 
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There were minor differences in the type of rehabilitation exercises depending on 
therapist’s experiences, participants’ condition, and goals. The treatment was 
recorded using treatment strategy sheets (Appendix 11). The aim of the form was: 
 To accurately record the treatment received by patients for research 
purposes. 
 To permit easy transfer of data onto a database by the researcher. 
 To provide a quick and easy to complete record of the treatment provided 
for the clinician. 
This form was not meant as a substitute for medical records. 
  
Hydrotherapy group: Participants received a course of aquatic physiotherapy 
once a week for six weeks, each session lasting 45 minutes and taking place in 
water heated to between 34 and 36° Celsius (Becker, 2009; Eversden et al., 2007; 
Rintala et al., 1996). Because of the size of the therapy pools, each session 
included between two and four patients and was supervised by one therapist and 
one therapy assistant. The size of pool where the study was carried out was 7.4 m
2
 
in total (outer surface of the pool) (Figure 5.2, p.132) (Salford Royal Foundation 
NHS Trust, 2007). 
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Figure 5.2: Hydrotherapy pool, used with kind permission from WG (hydrotherapy lead 
within Salford Royal Foundation Trust). 
 
There were three sections of the exercise hydrotherapy programme (Appendix 
12). The first section, a warm up exercise lasting five minutes included such 
activities as walking, sidestepping, knee to chest walking, heel to bottom walking, 
hip abduction/adduction and flexion/extension. The second section was called the 
conditioning programme and consisted of a variety of movements in different 
positions (standing, sitting, supine) supported by hydrotherapy equipment such as 
floatation rings, fins, balls and woggles (Salford Royal Foundation NHS Trust, 
2007). This section included sustained stretching exercises, range of movement, 
core stability exercises, balance exercises, properioception and muscle 
strengthening exercises (Appendix 12). Finally, the cool down period (lasting five 
minutes) consisted of walking in the pool, side stepping, knee to chest walking/ 
heel to bottom walking, hip abduction/adduction and flexion/extension. 
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The participants in this group also performed home exercises (twice daily x six 
weeks or until they reached their target) (Appendix 12). All patients in both 
groups performed the exercises tailored to their conditions and goals. The 
treatment protocols were led by the clinician to make them applicable to current 
national best practice and allow the protocol to be followed in the future within 
the framework of NHS budget constraints. 
Land group: The land-therapy group exercises were undertaken once weekly for 
45 minutes per session for six weeks in one-to-one sessions with the therapist 
while continuing with the HEP. The land exercise was part of the exercise 
rehabilitation programme (Appendix 13) (designed for arthritis patients and is 
used in SRFT) (Salford Royal Foundation NHS Trust, 2007). In addition, 
participants performed their HEP (twice daily for six weeks or until participants 
reached their target) (Appendix 13). The type of movements in the land exercise 
programme were almost identical for all RA patients in that group. They included 
a range of exercises such as those that worked on stretching, strengthening and 
core stability (Appendix 13). The intensity level was also initially issued on a 
case-by-case basis in respect of the individual’s ability, after which it could be 
gradually increased if necessary. The excerise programme was devised by Salford 
Royal Foundation NHS Trust, 2007 and all  patients in both groups performed 
their exercise programme regularly. 
 
All participants were provided with a booklet containing pictures and advice about 
an exercise, describing the programme and resistance material required. Between 
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clinic sessions, all RA patients in both groups were also asked to perform the HEP 
daily. Moreover, patients in both groups were provided with a diary booklet 
during the first appointment for use at each exercise session, in order to record the 
completion of the exercise programme daily and every subsequent day until the 
next session.  
  
5.2.3.1.4 Follow-up stage 
The follow-up periods were three and six months. The researcher sent all the 
outcome measures to participants at three and six months. 
 
5.2.3.2 Pilot study 
Thirty-six patients were invited to take part in a pilot study to test the proposed 
protocol and increase the quality and internal validity of the study (Nyatanga, 
2005; Van Teijlingen & Hundley, 2002). Initially, it was planned to recruit 10 
participants for the pilot study; however, the hydrotherapy pool closed 
unexpectedly for refurbishment and recruitment stopped. Six patients were 
recruited to the pilot and 30 patients were not interested or excluded for the 
following reasons: 
 Not all RA patients wanted to be part of the study because they wanted to 
be guaranteed to receive hydrotherapy without randomisation. 
 Some were not appropriate for the study and did not fit the inclusion 
criteria. 
 Not all RA patients wanted to have hydrotherapy either because of fear of 
water or because of work commitments. 
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 Not all RA referrals who were referred to the physiotherapy department 
required hydrotherapy; some needed, for example, only wrist splint and 
neck brace. 
 They had commitments with other research studies. 
 
After the pilot study, a new site was found and the protocol was amended to 
change the lower age limit to ≥ 18 years, and the following exclusion criteria were 
removed to reflect that of the department: 
 Patients treated with intra-articular corticosteroid injection or physiotherapy 
treatment within four weeks of assessment were to be excluded to avoid 
overload effect on joint function. 
 Any patients who had surgery in the three months prior to study entry or those 
who had surgery planned were excluded. 
 
5.2.4 Outcome measures 
RA is a chronic inflammatory disease associated with highly variable features of 
presentation and disease trajectory both within and between individuals (Van Riel 
& Van Gestel, 2000). Thus in the past, mainly in clinical trials, a huge number of 
outcome variables have been used because of this variety in disease expression 
(Van Riel & Van Gestel, 2000).  
 
Boers et al. (1994) stated that the World Health Organisation (WHO) and the 
International League against Rheumatism (ILAR) had a core set of eight 
endpoints for RA. At least one of these endpoints had to be among this study’s 
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main outcome measures. WHO/ILAR core set of endpoints for RA clinical trials 
included the following: 
1.  Pain was assessed using a 10cm VAS or Likert scale (Langley & Sheppeard, 
1984). 
2.  Patient global assessment was examined using AIMS or Likert scale (Meenan 
et al., 1980). 
3. Physical disability or physical functioning was examined using the Stanford 
Health Assessment Questionnaire (Fries et al., 1982), AIMS (Meenan et al., 
1980), McMaster Health Index Questionnaire (MHIQ) (Chambers et al., 1982) or 
McMaster Toronto Arthritis Patient Preference Questionnaire (MACTAR) 
(Tugwell et al., 1987). 
4.  Swollen joints (Ritchie et al., 1968). 
5.  Tender joints (Ritchie et al., 1968). 
6.  Acute phase reactants (Felson et al., 1993). 
7.  Physician global assessment using VAS or Likert scale. 
8.  Radiographs of joints (in studies lasting more than one-year). 
 
To assess outcome measures in RA a wide range of measures may be used in 
terms of patient perspective (functional status, health status and health-related 
QoL) (Hakala, 1997; Pincus, 1995). All the outcome measures used in this study 
were patient self-reported, except DAS28, which was completed by the clinicians. 
The psychometric properties of these questionnaires are well established 
(Fitzpatrick et al., 1992). HAQ was used to measure physical function (functional 
ability, pain and GWB) using HAQ-DI, HAQ VAS and HAQ-GWB respectively; 
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DAS28 and RADAI measured disease activity through clinician assessment and 
the completion of a self-administered questionnaire respectively; EQ-5D tariff and 
EQ-5D VAS was used to measure HRQoL and health status; hospital anxiety 
depression scale (HADs), hospital anxiety depression-depression scale (HAD-D), 
hospital anxiety depression-anxiety scale (HAD-A) was used to measure 
psychological wellbeing and mood changes in terms of anxiety and/or depression. 
 
All the outcome measures were assessed at baseline within one week (before 
intervention), six weeks post-intervention (within one week, post-treatment), three 
months (after baseline) and six months follow-up (after baseline). The assessment 
was completed when questionnaires which had been distributed by the researcher 
at a set time point were returned. 
 
The primary end points were placed at six weeks to reflect clinical practice in the 
HYDAT team (2009) and other hydrotherapy studies. When checking for follow 
up periods some of the hydrotherapy studies only followed up their participants 
for three months (Eversden et al., 2007; Hall et al., 1996) whereas Bilberg et al. 
(2005) followed only the hydrotherapy group for six months. In order to further 
strengthen the veracity of the study, there were two periods of follow up. 
 
5.2.4.1 Physical function measurement 
The most important category of outcome in arthritis might well be disability 
(Boers et al., 1994; Fries et al., 1980; Fries, 1983). In RA, disability is a common 
outcome and has a major impact on daily life, as well as socioeconomic 
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consequences (Boers et al., 1994; Fries et al., 1980). The level of disability has a 
significant impact on patients and society in terms of the financial and social costs 
of the disease (Boers et al., 1994; Fries et al., 1980; Fries, 1983). There are 
different instruments for assessing disability in RA, but the most widely used are 
self-reported questionnaires (Lillegraven & Kvien, 2007). One of the most widely 
used disease-specific arthritis tools is the HAQ-DI which was used (ARAMIS, 
2009; Bruce & Fries, 2005; Felson et al., 1993; Fries et al., 1980). The two most 
frequently used questionnaires in arthritis are HAQ (ARAMIS, 2009; Fries et al., 
1982) and AIMS (Meenan et al., 1980). 
  
Many other instruments were developed to be used in RA, but only HAQ and 
AIMS offer the possibility to assess their potential value and have a sufficiently 
validated widespread focus (Fitzpatrick, 1996). Other older scales, on the other 
hand, tend to be fairly limited and insensitive to functional disability (Bowling, 
2003). Since disability in RA is multidimensional, other versions have been 
developed, such as the modified–HAQ (Pincus et al., 1983) and the 
multidimensional HAQ with more items (Anderson et al., 2010; Pincus et al., 
1999), but these are less commonly used in clinical trials and in daily practice. 
  
Fries et al. (1980) developed the HAQ in 1978. The HAQ was among the first 
instruments to have been based on generic, patient-centred dimensions for 
measurement of physical function (Fries et al., 1980), and use of this 
questionnaire is now indicated in most RA clinical trials (ARAMIS, 2009; Bruce 
& Fries, 2005; Fries et al., 1980) and it is regarded as the gold standard outcome 
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measure for assessing functional status (Bruce & Fries, 2005). Sensitive to change 
of functioning status, even over short time intervals, HAQ is authorised and 
recommended by the ACR. It is available in more than 60 languages and is 
supported by a bibliography of more than 500 references (ARAMIS, 2009; Bruce 
& Fries, 2005). 
 
The HAQ is originally designed as a disease‐specific questionnaire. However, it 
has been developed and successfully applied for assessing functional disability in 
a variety of rheumatic diseases (Bruce & Fries, 2005; Ramey et al., 1992). HAQ 
can be administered in diverse disciplines and, with properly designed 
adaptations, in different cultures without any impact on its reliability or validity 
(ARAMIS, 2009; Bruce & Fries, 2005).  
 
There are two versions of HAQ: full HAQ and short HAQ (2-pages HAQ) (Bruce 
& Fries, 2005). The full HAQ assesses the dimensions of postponing death, 
avoiding disability, drug side effects, discomfort and pain, and economic costs, 
while the short HAQ is comprised of the HAQ disability index (HAQ-DI) and the 
HAQ patient global health status and pain VAS (Bruce & Fries, 2005). The 
difference between full HAQ and short HAQ is that the items in the short HAQ 
remain constant, while in the full HAQ, items like drug side effects and costs as 
well as supplemental sections on demographics, lifestyle and costs are 
periodically tailored to uncover specific hypotheses or research questions to 
capture the long-term impact of chronic illness (Bruce & Fries, 2005).   
HAQ-DI (Appendix 5)  
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The HAQ-disability index (HAQ-DI) is used in this study as the primary outcome 
measure and consists of eight weighted categories that are designed to measure a 
person's ability to dress, arise from a chair or bed, eat, walk, perform basic 
toileting (hygiene), reach, grip, and perform normal activities. Sexual activity was 
included in an earlier version (Bowling, 2004) but was removed after a reluctance 
to report this (Fries et al., 1980). Each category is scored on a 4-point scale (Bruce 
& Fries, 2005; Bruce & Fries, 2003). 
 0 = Is able to perform the activity without any assistance. 
 1 = Is performing the activity with some difficulty. 
 2 = Is performing the activity with great difficulty (needs assistance of 
others to perform the specific activity). 
 3 = Unable to do the task (cannot perform the specific activity). 
 
 
Interpretation of the test result may be classified as follows (Bruce & Fries, 2003): 
 
 0. 00 to 1. 00 mild to moderate difficulty or disability. 
 1. 01 to 2. 00 moderate to severe difficulty or disability. 
 2. 01 to 3. 00 severe to very severe difficulty and disability; dependence on 
others. 
Thus, a high HAQ indicates loss of functional capacity – so the lower the HAQ 
score, the better the functional status (Bruce & Fries, 2003). 
 
 
Advantages of HAQ-DI 
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We chose the HAQ-DI as the primary outcome measure because functional 
limitation is an important factor in RA patients, which can be easily measured by 
the HAQ-DI. Functional disability is one of the main outcomes in a core set of 
eight endpoints for RA (Boers et al., 1994). Disability is a common outcome in 
RA and has an impact on daily life as well as socio-economic consequences. More 
than one third of working people are no longer able to work five years after the 
onset of the disease, indicating the consequence of the disease on working status 
(Scott et al., 2003; Scott et al., 2000). 
 
HAQ-DI rather than AIMS was chosen for this study for the following reasons: 
 The HAQ-DI is regarded as a self-administered questionnaire completed 
in five minutes and scored in less than one minute.  
 It can be administered face-to-face (ARAMIS, 2009; Bruce & Fries, 2005) 
or in a telephone interview and it has been validated for both.  
 The questionnaire can also be emailed to patients (ARAMIS, 2009; Bruce 
& Fries, 2005). 
 HAQ-DI is a good measure of function and it was used extensively among 
clinicians in USA, UK and Europe (Bruce & Fries, 2005; Ramey et al., 
1992).  
 HAQ-DI is regarded as concise, reliable, valid, sensitive to change and can 
be either self-administered or interviewer-administered. It is also suitable 
for use in the community (ARAMIS, 2009; Bruce & Fries, 2003).  
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 AIMS covers physical, social and emotional wellbeing. However, it was 
not used in this study because the emotional wellbeing was evaluated in a 
separate questionnaire (HADS). 
 HAQ-DI is designed to evaluate a patient's level of functional ability by 
including questions about activities involving both upper and lower 
extremities, also with fine movements (Bruce & Fries, 2003).  
 
Moreover, the main reasons to investigate predictors for HAQ-DI are as follows: 
1. To recognise the factors that predicts a poor outcome as early as possible in 
order to treat patients showing such characteristics more aggressively (Jansen et 
al., 2000). This approach may help to prevent joint damage and preserve 
functional capacity. 
2. To test whether the various disease parameters correlate with the functional 
 status. 
3. This study first used the univariate analysis to explore which factors are 
independently predicting functional disability in patients with RA. 
 
Reliability and validity of the HAQ-DI 
The HAQ-DI is sensitive to change and is a good predictor of prospective 
disability and costs (ARAMIS, 2009; Michaud et al., 2003; Wolfe & Zwillich, 
1998). It has had verified reliability and validity in different languages and 
contexts (ARAMIS, 2009). Literally hundreds of studies have demonstrated its 
validity (ARAMIS, 2009; Bruce & Fries, 2005). There is an agreement that the 
HAQ-DI has face and content validity (ARAMIS, 2009; Bruce & Fries, 2005; 
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Ramey et al., 1992). Correlations between the questionnaire or interview scores 
and task performance ranged from r = 0.71 to 0.95 demonstrating criterion 
validity among RA patients (ARAMIS, 2009; Bruce & Fries, 2005). 
 
HAQ-DI scoring 
A large and growing body of HAQ-DI literature has confirmed and emphasised 
that when there are scores for less than six of the eight categories, the score cannot 
be validly calculated (ARAMIS, 2009; Bruce & Fries, 2005). The Standard way 
of scoring takes into account the use of aids/devices. Three steps are needed for 
calculating HAQ-DI overall score (with aids/devices):  
1. Each category contains at least two specific subcategory questions; the highest 
subcategory score determines the value for each category, unless aids or devices 
are used. 
2. Adjust the score if there is any use of aids/devices and/or help from another 
person. 
3. To obtain a HAQ-DI score of 0-3, the sum of category scores is divided by the 
number of categories answered (zero = best-, three = worst-functioning). There 
must be responses in at least 6 of the 8 categories or else a HAQ-DI cannot be 
computed. 
 
HAQ VAS (pain score) (Appendix 5) 
The measurement of pain is an essential dimension in patients with RA. HAQ VAS 
a double-anchored VAS was designed to obtain data relative to the presence or 
absence of arthritis-related pain and its severity (Bruce & Fries, 2003; Bruce & 
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Fries, 2005). This scale measures pain on a horizontal VAS with “no pain” at one 
end (scored 0) and “severe pain” at the other (scored 100) (ARAMIS, 2009; Bruce 
& Fries, 2003; Bruce & Fries, 2005; Fries et al., 1982). The goal is to obtain 
information from patients on how their pain has tended to be over the past week, 
although it is understood that pain may be reported to have diverged over the 
course of a day or from day to day (ARAMIS, 2009; Bruce & Fries, 2003; Bruce 
& Fries, 2005). 
 
The VAS line is standardised to 15 centimetres in length. To indicate the severity 
of their pain, patients are instructed to place a vertical mark on the line (ARAMIS, 
2009; Bruce & Fries, 2005). 
                  
            
 
 
   
 
If a patient reports a percentage, multiply the percentage by three. Use the 
midpoint if a patient puts more than one mark. If a patient points a horizontal line 
below the pain scale, and not a vertical one, the midpoint of that line is taken. If 
the line starts at the beginning of the scale, measure to the end of the line, not the 
middle. 
 
Calculating the pain score: \Measure the distance in centimetres and multiply by 
0.2; this provides a score from 0 to 3. For example, if the mark is at 5cm, 5 x 0.2 
yields a pain score of 1.0. 
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Pain was used as a secondary outcome measure for the following reasons: 
 Pain is one of the most prominent symptoms in the majority of people with 
RA (McKenna & Wright, 1985; Walsh & McWilliams, 2012). 
 Pain is a common purpose for primary care consultation (Uhlig et al., 
2002). 
 Pain is a major cause for increased health care costs (Crook et al., 1984). 
 Previous studies have included pain as an outcome to measure the effects 
of hydrotherapy for patients with RA (Rintala et al., 1996). 
  Pain is one of the core set of eight endpoints for RA (Boers et al., 1994). 
 Pain is easy to score without being a burden to the patient (Huskisson, 
1974). 
 VAS is regarded as a reliable and valid measure of pain, primarily when 
comparing individuals over time for three to four times (Huskisson, 1974). 
 
HAQ-GWB (Wellbeing score) (Appendix 5) 
The scale that measures GWB is on a horizontal scale with “very well” at one end 
(scored 0) and “very poor” at the other (scored 100). GWB was used as a 
secondary outcome measure for the following reasons:  
 RA imposes an immense burden on the individual's ability to cope, and 
may greatly diminish QoL and psychological wellbeing (Fitzpatrick et al., 
1988). 
 It incorporates a VAS, which is easy to score and is without burden to the 
patient (Huskisson, 1974). 
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5.2.4.2 Health-related quality of life (HRQoL) measurement 
QoL is the awareness of a person’s position in life in the context of the culture and 
value systems in which they live, and in relation to their goals, expectations, 
standards and concerns (WHOQOL group, 1995). Across a wide spectrum of 
diseases and conditions, there has been an upsurge of interest in the development 
of a generic instrument that can be used to measure HRQoL (Hawthorne, et al., 
2000; Hurst et al., 1997; Hurst et al., 1994; Rabin et al., 2011a). These generic 
questionnaires have advantageous outcomes and, besides just the beneficial and 
detrimental effect of medication on the individual, capture the overall impact of 
disease (Cheung et al., 2009; Hawthorne, et al., 2000; Hurst et al., 1997; Rabin et 
al., 2011a). 
  
Health status profiles characteristically measure an individual’s health status 
across different dimensions, to reflect their HRQoL. In Study One, generic 
measures of HRQoL were measured by using EQ-5D (Brooks, 1996; Cheung et 
al., 2009; Hurst et al., 1997; Rabin et al., 2011a). There are other well-validated, 
popular, generic health-related QoL scales (also called health-status scales) that 
have been used to assess outcomes in rheumatology such as the SF-36 (Ware, 
1993; Ware & Sherbourne, 1992), the Nottingham Health Profile (NHP) (Hunt et 
al., 1985), the Sickness Impact Profile (SIP) (Bergner et al., 1976), the Quality of 
Wellbeing Scale (QWB) (Balaban et al., 1986), the Functional Status 
Questionnaire (FSQ) (Jette et al., 1986) and the Framer Quality of Life Scale 
(Rudick et al., 1992). 
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De Jong et al. (1997) developed a specific questionnaire called RA quality of life 
(RAQoL). This instrument is used to measure pain and fatigue in addition to other 
disease specific issues (De Jong et al., 1997). This instrument has been found to 
have excellent test-retest reliability, good internal consistency and good content 
validity; however, the main difference between the RAQoL and others is that it 
uses a qualitative approach and lengthy interviews (De Jong et al., 1997). It has 
been recommended that QoL should be assessed using questionnaires rather than 
interviews (Berndtsen et al., 1994; Guyatt et al., 1993). 
 
EQ-5D 
EQ-5D is a validated generic QoL instrument developed by the EuroQol Group 
(Hawthorne, et al., 2000; Rabin et al., 2011a). EQ-5D is a generic, simple measure 
of health for clinical and economic appraisal of healthcare. It consists of two 
parts: a descriptive profile (EQ-5D tariff) for measuring economic health 
(Appendix 6) and a VAS (EQ-5D VAS) (Appendix 7) for measuring health status 
(Drummond et al., 2005; EuroQol Group, 1990). EQ-5D essentially consists of 
two parts: the EQ-5D descriptive system called EQ-5D 3L or called EQ-5D tariff. 
The EQ-5D visual analogue scale (EQ-5D VAS) (Hawthorne, et al., 2000; Rabin et 
al., 2011a). Costs per quality-adjusted life year (QALY) were derived from health 
states measured for economic health (Drummond et al., 1997; Drummond et al., 
2005; EuroQol Group, 1990). EQ-5D is a self-administered questionnaire easily 
completed by respondents without the need for support or help within a few 
minutes (Hurst et al., 1997; Rabin et al., 2011a). 
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EQ-5D tariff (Appendix 6) 
The subjects report their level of ability on that day depending on five items; each 
item includes three ordinal response levels; this is called EQ-5D-3L. The five 
categories are namely mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression. Each category has three levels: no problems, some problems, 
severe problems. This decision results in a single-digit number expressing the 
level selected for that dimension. The digits for five dimensions can be combined 
in a five-digit number describing the respondent’s health state. It should be noted 
that the numerals 1-3 have no arithmetic properties and should not be used as a 
cardinal score. These categories are coded to form a health profile, for example 
11111 indicates no problems for any dimension, which therefore equals perfect 
health, while state 11223 indicates no problems with mobility or self-care, some 
problems with performing usual activities, moderate pain or discomfort and 
extreme anxiety or depression, and 33333 indicates extreme problems in every 
dimension, resulting in the worst imaginable health state possible (EuroQol 
Group, 1990; Rabin et al., 2011a). The health profiles classified them to one of 
245 unique EQ-5D tariffs (or ‘health states’) ranging from one, indicating the best 
imaginable health state, and zero, representing death. Some health states attract 
negative values (to -0.594) indicating that from a societal perspective, these health 
states are regarded as worse than death (Hurst et al., 1997; Rabin et al., 2011a). 
Instructions to respondents are included in the questionnaire (EuroQol Group, 
1990; Wolfe & Hawley, 1997). The EQ-5D has been used with patients with RA 
(Hurst et al., 1997), and there is evidence that it has moderate construct validity 
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(Spearman rho = .71) and reliability (ICC = .70) when used with patients (n = 82) 
with knee OA (Fransen & Edmonds, 1999). 
 
EQ-5D VAS (Appendix 7)  
Records of the response has self-rated health on a vertical, VAS, where the 
endpoints are labelled ‘best imaginable health state’ and ‘worst imaginable health 
state’.  
 
In Study One, the EQ-5D was used because it is widely accepted as an easy-to-use 
tool for measuring the relative cost-effectiveness of an intervention, while 
measuring health status at the same time (Hurst et al., 1997; Rabin et al., 2011a). 
The original intent in this study was to assess the CE of the two interventions in 
terms of cost per QALY gained. 
 
HRQoL or QoL was used interchangeably within this thesis. It was used in 
secondary outcome measures for the following reasons: 
 In RA patients, the assessment of HRQoL is relevant and is important 
in both clinical research and daily clinical practice (Hawthorne, et al., 
2000; Kvien & Uhlig, 2005). 
 Changes in HRQoL provide important information in RCTs & 
observational studies (Hawthorne, et al., 2000; Kvien & Uhlig, 2005). 
 Priorities for resource allocation within the NHS were based 
increasingly on evidence of the CE of medical interventions on 
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HRQoL, providing further consideration (Hawthorne, et al., 2000; 
Hurst et al., 1997). 
 
EQ-5D was chosen for this study rather than other outcome measures such as SF-
36, NHP, and SIP because:  
 The EQ-5D has been used with RA patients (Hurst et al., 1997). 
 There is evidence that it has moderate construct validity (Spearman rho = 
0.71) and reliability (intraclass correlation coefficient (ICC) = 0.70) when 
used with OA patients (n = 82) (Fransen and Edmonds, 1999). 
 EQ-5D is quick, simple to use and easy to complete (Hawthorne, et al., 
2000; Rabin et al., 2011a). 
 It offers less complex health-state descriptors over the others and is more 
easily comprehended by patients (Hawthorne, et al., 2000; Hurst et al., 
1997; Rabin et al., 2011a). 
 SF-36, NHP and SIP are lengthy and time consuming. SF-36 functional 
ability scale concentrates mainly on mobility; therefore, it is unlikely to be 
sufficiently sensitive as an outcome measure in rheumatology (Hurst et al., 
1997). 
 The reliability of the EQ-5D index and EQ-5D VAS is better than all other 
instruments except the HAQ, and is sufficiently reliable for group 
comparisons (Hurst et al., 1997). 
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 It is responsive to change and therefore valid as an outcome measure in 
clinical trials, audit and health economic studies (Drummond et al., 2005; 
Hawthorne, et al., 2000). 
 
An updated version of the EQ-5D, called the ‘EQ-5D-5L’, was published in 2011 
(Rabin et al., 2011b). It includes the five dimensions, but each dimension has five 
response levels rather than three (Rabin et al., 2011b). EQ-5D-5L was designed in 
order to potentially reduce ceiling effects, maintain feasibility and significantly 
improve reliability and sensitivity (discriminatory power) (Rabin et al., 2011b). It 
has been validated for arthritis but its reliability and responsiveness has not yet 
been demonstrated (Rabin et al., 2011b). 
 
5.2.4.3 Disease activity measurement 
Disease activity is an important factor – both in clinical care and in the research 
domain – in the evaluation and assessment of patients with RA (Fransen et al., 
2000). In rheumatic disease, quantitative assessment of patients differs from that 
of those with other chronic diseases, such as HT or hypercholesterolemia (Pincus, 
2006), thus there is the need to assess different aspects of the underlying disease 
due to high variability of presentation and trajectory. Many comprehensive simple 
tools have been developed for the evaluation of disease activity in RA, including 
the Disease Activity Score (DAS) (Van der Heijde et al., 1990), the Disease 
Activity Score 28 (DAS28) (Prevoo et al., 1995), the Simplified Disease Activity 
Index (SDAI) (Aletaha & Smolen, 2005; Smolen et al., 2003) and the Clinical 
Disease Activity Index (CDAI) (Aletaha & Smolen, 2005). Three further self-
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reporting questionnaires of disease activity are used in rheumatology, including 
the Rheumatoid Arthritis Disease Activity Index (RADAI) (Stucki et al., 1995), 
the Rapid Assessment of Disease Activity in Rheumatology (RADAR) (Mason et 
al., 1992) and Routine Assessment of Patient Index Data 3 (RAPID 3) (Pincus et 
al., 2008). Table 5.1 (p.158) provides a content summary of measures disease 
activity in RA (Fransen et al., 2003).  
  
The SDAI and CDAI are two new tools for the evaluation of disease activity in 
RA. They have been developed to give both physicians and patients simple, 
optional instruments (Aletaha & Smolen, 2005). Nevertheless, these two options 
have not currently replaced the more frequently used instrument, DAS28 (Aletaha 
& Smolen, 2005). The CDAI is the only option that does not consider acute-phase 
response as a variable in the measurement, and it can be applied to conduct 
disease activity anytime and anywhere (Aletaha & Smolen, 2005). Patient self-
reported measures are available in all these indices, which are defined as global 
health in DAS and DAS28, and referred to as ‘patient global assessment of 
disease activity’ in SDAI and CDAI (Aletaha & Smolen, 2005). 
 
Disease activity measurement was used in secondary outcome measures for the 
following reasons: 
 In RA, assessments of disease activity among rheumatologists have been 
shown to differ widely as shown by Kirwan et al. (1984). Many variables 
of disease activity are recorded to monitor the course of the disease in 
clinical practice and in clinical trials (Prevoo et al., 1995). 
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 Disease activity indices include a wide core set of eight endpoints for RA 
(Boers et al., 1994). 
 Joint swelling, joint tenderness, and destruction of synovial joints are the 
main symptoms of RA, and are main items of disease activity associated 
with it (Aletaha et al., 2010). Both joint swelling and tenderness are part of 
DAS28 and RADAI. 
 Disease activity is improved by early therapeutic intervention, which then 
reduces further joint damage and disability (Aletaha et al., 2010). 
 The treatment strategies of RA patients are influenced by the responses 
given in the DAS (Aletaha et al., 2010). 
 
The RADAI (Appendix 8) 
RADAI is a disease‐specific outcome measure developed to assess patient‐
reported disease activity in RA, and can be used as an alternative for, or 
complement to, the physician’s assessments of disease activity (Fransen et al., 
2003; Stucki et al., 1995). The DAS28 primarily consists of physician‐assessed 
and laboratory-based variables, while RADAI is a self-administered questionnaire 
combining five items into a single index (Stucki et al., 1995). It is a modification 
of the questionnaire introduced by Mason et al. (1992). Mason et al. found that 
there was a high consensus between patients and physicians in terms of scoring 
the RADAR questionnaire (Mason et al., 1992).  
 
The RADAI is a five-item questionnaire which includes: (1) global disease 
activity in the last six months, (2) disease activity in terms of current swollen and 
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tender joints, (3) arthritis pain, (4) the duration of MS and (5) tender joints to be 
rated in a joint list (Fransen et al., 2003; Stucki et al., 1995). The first three items 
are all rated on an anchored Numerical Rating Scale (NRS) from zero to 10, 
where higher scores indicate more disease activity (Fransen et al., 2003; Stucki et 
al., 1995). The scores on the last two items range from zero to six and zero to 48, 
respectively, but are transformed on the same scale of zero to 10. 
 
Validity and reliability of RADAI  
The RADAI has been shown to have adequate reliability, validity and 
responsiveness among Swiss patients with RA (Mason et al., 1992), and is a 
feasible and valid instrument completed easily by patients (Fransen et al., 2000). 
The internal consistency and validity of the RADAI is high for a questionnaire 
consisting of only five items (Fransen et al., 2000; Nunnally & Bernstein, 1994). 
Cronbach’s Alphas of 0.91 and 0.87 have been recorded (Fransen et al., 2000; 
Stucki et al., 1995). The association between internal consistency and RADAI 
items support the summation of item scores into total score (Fransen et al., 2000). 
Joint counts are the principal category used in most studies on reliability and 
validity to indicate patients’ perception of sign and symptoms (Fransen et al., 
2000). 
  
It has been shown that the joint count was reliable in several studies (Prevoo et al., 
1996; Stewart et al., 1990; Taal et al., 1998). Stucki et al. (1995) assessed test and 
retest reliability of joints listed in RADAI, and confirmed Kappa values ranging 
from r = 0.52 to 0.72 in different joints. For pain, global disease activity and MS, 
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there was good test-retest reliability found by Hanley et al. (1996) with ICC 
ranging from r = 0.81 to 0.85. Test-retest reliability of RADAI was very high 
(ICC 0.92) (Fransen et al., 2003). For convergent validity, the RADAI scores 
were correlated with the DAS28 (r = 0.53), the HAQ (r = 0.56), the correlation of 
RADAI with ESR was low (r = 0.27) (Fransen et al., 2003; Fransen et al., 2000). 
For responsiveness to change, the RADAI score was changed from mean 4.5 to 
2.9 (P < 0.0001) (Fransen et al., 2001). The RADAI and DAS28 were equally 
sensitive in detecting a flare (predictive ability 0.88) and had equal size effect 
(Fransen et al., 2001; Fransen et al., 2003). 
 
The DAS28 (Appendix 9)  
DAS28 is a measure of disease activity in RA, which has been shown to be a valid 
estimator of disease activity (Van Riel et al., 2001). Since the DAS28 contains 
summary joint counts, it is practical to use for monitoring RA disease activity in 
clinical practice (Fransen et al., 2003; Felson et al., 1998). 
 
The DAS is calculated by a complex mathematical formula from results of 28 
swollen joint counts and 28 tender joint counts (TJCs) and ESR; these will have 
already been taken in the clinic, and reflect the blood marker for inflammation and 
sometimes a general health assessment on a visual analogue (Felson et al., 1998; 
Fransen et al., 2003). The DAS28 can also be calculated using C-reactive protein 
(CRP) instead of ESR (Fransen et al., 2003). ESR ranges from 0 to 150, General 
Health ranges from 0 to 100, and the range of the DAS28 is (0 – 9.4) (Fransen et 
al., 2003). The DAS28 is easy and quick to administer and gives an internationally 
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acceptable objective assessment of disease activity that compares well with ACR 
criteria (Fransen et al., 2003; Prevoo et al., 1995). 
  
For score interpretation (Fransen et al., 2003), the level of RA disease activity can 
be interpreted as: 
 Low (DAS28 ≤ 3.2).  
 Moderate (3.2 < DAS28 ≤ 5.1). 
 High disease activity (DAS28 > 5.1).  
 
A DAS28 < 2.6 corresponds with being in remission, according to the ARA 
criteria. The EULAR response criteria classify patients as good, moderate, or non-
responders (Van Gestel et al., 1998). For example, a patient must show a 
significant change as well as low disease activity to be classified as a good 
responder (Fransen et al., 2003). The DAS28 is most easily calculated using a 
programmed calculator (online and downloadable calculators) and takes one 
minute. 
The following formulas are used (Fransen et al., 2003; Prevoo et al., 1995): 
DAS28-4 (four variables) = 0.56 × sqrt (28TJC) + 0.28 × sqrt (28SJC) + 0.70 × in 
(ESR) + 0.014 × GH. 
DAS28-3 (three variables) = (0.56 × sqrt (28TJC) + 0.28 × sqrt (28SJC) + 0.70 × 
in (ESR) × 1.08 + 0.16. 
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Reliability: Test-retest 
Reproducibility of the DAS was determined by an inter-period correlation matrix 
of RA patients with ≥ 3 year’s follow-up (Fransen et al., 2003). 
 
Validity 
For content validity, the DAS28 contains measures from the core set of eight 
points in assessment of RA efficacy after medications (Fransen et al., 2003). The 
DAS28 showed a high predictive ability (ICC = 0.88) in detecting a flare of RA 
disease activity (Fransen et al., 2001). 
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Table 5.1: Summary of content of measures of disease activity in RA (adapted from Fransen et al., 2003) and reproduced with permission of John 
Wiley & Sons, Inc. 
Measure 
/ Scale 
Content Assessment 
Blood 
sample 
Joint 
count 
General 
health 
Global 
disease 
activity 
Pain 
Morning 
stiffness 
Functional 
status 
DAS 
Disease Activity Score (consisting of 44- 
tender joint count (TJC44), 44-swollen 
joint count (SJC44), acute phase reactant 
(ESR)  and general health  
Physician & patient + + + +    
DAS28 
Disease Activity Score 28 (consisting of 
28- tender joint count (TJC28), 28- 
swollen joint count (SJC28), acute phase 
reactant (ESR) and general health  
Physician  & patient 
 
+ + + +    
RADAR 
Rapid Assessment of Disease Activity in 
Rheumatology (consisting of current and 
past disease activity, pain, morning 
stiffness, functional status and a tender 
joint list) 
Patient 
 
 +  + + + + 
RADAI 
RA disease activity index (consisting of 
current and past disease activity, pain, 
morning stiffness and a tender joint list) 
Patient 
 
 +  + + +  
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5.2.4.4 Anxiety and depression measurement 
Depression and anxiety are a part of psychological wellbeing assessment (Creed 
& Ash, 1992). These are the main psychiatric disorders reported in patients with 
RA, for example, phobia, stress, anxiety and depression (Isik et al., 2007; 
VanDyke et al., 2004). RA is a chronic systemic disabling disease with joint 
deformity, which leads to harmful psychological consequences because of pain, 
inability to work, functional limitations, and frequent hospitalisation (Mella et al., 
2010). All these factors contribute to psychosocial and psychiatric symptoms such 
as depression and anxiety (Mella et al., 2010). 
 
In RA the prevalence of depressive symptoms shows according to the screening 
methods used, clinical assessments and the samples studied results to be varied 
from 13%–20% and above (Covic et al., 2012; Dickens et al., 2002). Similarly, 
recent studies (El-Miedany & Rasheed, 2002; Isik et al., 2007; Söderlin et al., 
2000) have reported giving varying prevalence rates of anxiety in the wide range 
of 21–70% due to differences between study samples or instruments used (Covic 
et al., 2012; Uguz et al., 2009). A higher prevalence of anxiety rather than 
depression was reported in some studies (El-Miedany & Rasheed, 2002; Ødegård 
et al., 2007), but not in others (Isik et al., 2007; Uguz et al., 2009). It is for these 
reasons that this outcome has been included in this study. 
 
Previous studies have reported that a low education level (EL), increased disease 
duration (DD), morning stiffness (MS), rheumatoid factor (RF) and disease 
activity parameters are associated with psychiatric symptoms such as depression 
and anxiety (Covic et al., 2012; Katz & Yelin, 1993; Mella et al., 2010; Sheehy et 
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al., 2006; Wolfe & Michaud, 2009). It seemed intuitive therefore, to explore the 
relationship between psychological wellbeing (depression and anxiety) and socio-
demographic characteristics, disease activity, in terms of a self-administered 
questionnaire (RADAI) or physician assessed questionnaire (DAS28). 
 
The most commonly used scales for screening anxiety and/or depression in 
patients with RA include the Beck Depression Inventory (BDI) (Beck et al., 1961) 
and the Hospital Anxiety Depression scale (HAD scale) (Zigmond & Snaith, 
1983). This study chose the HADs as its tool because it has been extensively 
validated across various somatic and psychiatric populations, both in primary care 
and in the community (Bjelland et al., 2002; Covic et al., 2012).  
 
The main difference between HAD and BDI is that, rather than correlating with 
RA activity, BDI depends on somatic items in which the scores correlate well 
with the depression score only (Bishop et al., 1987), whereas HAD specifically 
excludes somatic items to avoid an overestimation of emotional symptoms, which 
are frequent in physically ill patients (Mella et al., 2010; Zigmond & Snaith, 
1983). Thus, this scale attempts to reduce bias caused by somatic complaints from 
the patients with RA. 
 
The HAD scale (Appendix 10) 
The HAD is a self-assessment mood scale specifically designed for use in non-
psychiatric patients (Zigmond & Snaith, 1983). It is used to assess the presence of 
mood disorder, especially anxiety and depression (Zigmond & Snaith, 1983). 
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The HAD contains 14 items (seven items for anxiety and seven for depression) 
and takes two to five minutes to complete; for each item, there is a four-level 
response scored from 0-3 with a possible overall score ranging from 0 to 21 
(Zigmond & Snaith, 1983). The depression subscale scores of 7 or less indicate 
normal cases, while scores of 8-10 in each subscale indicate probable cases, and 
scores of 11 or more indicate definite cases; this is the same for the anxiety 
subscale (Zigmond & Snaith, 1983). It means a score over 7 in each subscale is 
suggestive of anxiety or depression (Bjelland et al., 2002; Snaith, 2003; Zigmond 
& Snaith, 1983). 
  
The presence of psychiatric disorders in RA patients could compromise the 
efficacy of treatment and may expedite disease progression (Young, 1992). In 
contrast, the success of RA treatment has been shown to increase with the 
improvement of psychiatric disorders (Parker et al., 1995; Sharpe et al., 2001). For 
those patients with clinically significant anxiety and depression, HADs is 
indicated as a reliable instrument (Zigmond & Snaith, 1983). HADs is easy to use 
and therefore widely used in the assessment of many chronic conditions (Bjelland 
et al., 2002; Herrmann, 1997). It is considered to be a valid measure of the 
severity of mood disorder, and will provide physicians with useful information 
about disease progression (Covic et al., 2009; Covic et al., 2012; Zigmond & 
Snaith, 1983). 
 
5.2.5 Ethical application 
The Ethics Committees of Manchester Metropolitan University (Appendix 14) 
and North West NHS 2 Research Ethics Committee-Liverpool Central approved 
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this study (Appendix 15). Other approval was obtained from research and 
development offices in each trust in CMFT (Appendix 16) and SRFT (Appendix 
17). 
 
5.2.6 Amendments 
The study was submitted to the Ethics Committee on four separate occasions.  
Each submission led to amendments. The first requested the addition of an interim 
analysis, but this was advised against by the statistician as being inappropriate 
(Appendix 18). The title of the study was changed, patient information was 
ratified and made more patient-friendly, and various additions were made. 
Management permission was required from each host organisation prior to the 
study. A copy of the original RA disease activity index (RADAI) questionnaire by 
Stucki was provided to the Ethics Committee.  
 
A second submission was made in December 2010. Again title change was 
recommended by specialist rheumatologists to include all RA participants, not 
only those with early RA. Two further questionnaires were added: DAS28 
(Prevoo et al., 1995) (Appendix 9) and The HAD (Appendix 10). The next 
submission in March 2011 reflected feedback from Research & Development at 
CMFT. These included more changes in contact details and patient information. 
Other modifications related to comparisons between participating patients and 
general RA patients in the Manchester area to establish the generalisation of the 
study. August 2011 the fourth submission was made. Changes had been made to 
the protocol to permit the inclusion of patients at the physiotherapists’ discretion, 
and decided on an individual basis despite some non-adherence from patients. The 
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age range was extended to >18 with no upper limit. The reference criterion by 
which RA is diagnosed was expanded; acceptable diagnosis was made using the 
2010 ACR/European League against Rheumatism classification criteria. This 
submission was finally accepted.  
 
5.2.7 Sample size calculation 
Prior to data collection, sample size estimation was performed in order to 
determine the sample size target for the study. This calculation was based on 
existing data (Bilberg et al., 2005) rather than an estimation of effective size. The 
primary outcome measure that was used for this calculation was HAQ-DI (Fries et 
al., 1980). A power calculation was performed (power 80% and α = 0.05) based 
on two independent group comparisons, and using the HAQ-DI as the primary 
outcome measures (SD = 0.3, clinical worthwhile difference = 0.2) (Bilberg et al., 
2005), suggested that 35 patients were required in each group. Assuming 20% 
dropout during the follow-up period, 43 patients were required in each group. The 
study was powered to detect a significant difference in the primary outcome only 
and that all secondary analyses were exploratory. 
 
Power calculation formula:  
N = (2 (σ²)/clinically worthwhile difference ²) x 7.8 (Rigby & Vail, 1998). 
N = (2 (0.3) ²/(0.2) ²) x 7.8 = 35 patients were required in each group. 
Where N is the sample size, σ is the assumed SD for the group; the clinically 
worthwhile difference was based on data from Bilberg et al. (2005). 7.8 refers to 
the value given requiring a 0.80 chance to detect the difference at the 0.05 level of 
significance (two sided) as described by Rigby & Vail (1998). The study 
employed a statistician (JM) as an external monitor who confirmed the power 
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calculation (Appendix 18). This was to avoid patients receiving physiotherapy 
intervention if it was found to be ineffective at some point during the study, or the 
patients would continue treatment if it was appearing to be effective. 
 
5.2.8 Randomisation 
After recruitment, participants were assigned to one of two groups. Instructions 
were provided to each patient in a sealed opaque envelope provided by the 
receptionist. The participant was asked to keep this information from the 
researcher. The envelopes were pre-prepared by the DoS and delivered to the 
department. Appendix 19 presents the randomisation method using blocks of four. 
Block randomisation is a method used to ensure that the numbers of participants 
assigned to each group is equally distributed (Beller et al., 2002). Each possible 
permutation of groups A and B (A = land and B = hydrotherapy) in blocks of four 
was assigned a number. A random number sequence was used to choose a 
particular block, which in turn sets the sequence greater than the number of 
permuted blocks (Beller et al., 2002). This method can be used for assessing many 
outcomes or variables in one study (Ferrucci, et al., 2004; Kendall, 2003). A 
drawback of this method is that the numbers allocated to each group may not be 
well balanced enough for a small study (Beller et al., 2002), however a balanced 
number of participants were allocated to the hydrotherapy and land-therapy 
groups in this study. 
 
5.2.9 Data analysis and statistical consideration 
Data were analysed according to the principles of ‘intention to treat’. All data 
were analysed using IBM SPSS Statistics 19 for Windows statistical software 
(Armonk, New York 10504-1722, USA).  
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5.2.9.1 Test of normality/descriptive statistics 
The Shapiro-Wilks procedure (for samples < 50) was used in each test to 
investigate the null hypothesis that samples represented a normally distributed 
population of all outcome measures (Field, 2009) (Appendix 20).  
 
The mean and standard deviation (SD) of normally distributed data were 
calculated and reported for both groups (Morgan et al., 2010). The median and 
interquartile range of non-normally distributed and ordinal variables were 
calculated and reported (Morgan et al., 2010). 
5.2.9.2 Inferential statistics 
Between-group comparisons 
Comparisons between groups for normally distributed data were made using an 
independent-sample T-test (Leech et al., 2005; Munro, 2005). For non-normally 
distributed data, the Mann-Whitney U-test was used (Leech et al., 2005; Munro, 
2005). 
 
Within-group comparisons 
 
For outcome measures and satisfying normality conditions, repeated measures 
Analysis of Variance (ANOVA) were used together with a Bonferroni post-hoc 
analysis. The Friedman test with Wilcoxon post hoc tests were used for non-
normally distributed data (Leech et al., 2005; Munro, 2005). The Alpha threshold 
was set at 0.017 (0.05/3) (Field, 2009; Leech et al., 2005). It is necessary to 
emphasise here that the 6 month follow-up period (Test 4) was not included in the 
‘within group’ differences because the number of participants recruited were very 
small (9 in land group, 10 in the hydrotherapy group). 
166 
 
Relationships between variables 
The relationships between the variables of the study outcomes for the parametric 
data were investigated using Pearson’s rank correlation coefficient. The 
relationships of the variables for the non-parametric data were investigated using 
Spearman’s rank correlation coefficient (Morgan et al., 2010; Munro, 2005; 
Salkind, 2009). Values of (r < 0.30 = low; 0.30 to 0.60 = moderate; r > 0.60 = 
high) (Field, 2009; Terwee et al., 2007). 
 
Predictive factors of HAQ-DI 
Univariate and combined multiple regression analyses were performed with HAQ-
DI as the ‘dependent variable’ to examine factors that contribute to functional 
disability in patients with RA (Field, 2009). Multiple regression analyses cause 
less chance of predicting relationships because of the overlapping of symptoms 
and interaction of variables. Therefore, this study first used the univariate analysis 
to explore which factors were independently predicting functional disability in 
patients with RA. The following variables were used as independent factors to 
explore predictors of functional ability measured by ‘HAQ-DI’: depression and 
anxiety HAD scores, GWB, RADAI and EQ-5D tariff. However, the following 
variables that were tested using both multiple and univariate regression analyses 
were identified as not being predictors of functional disability such as age, gender, 
EL, smoking, HT, BMI, DD, medication, marital status, DAS28, RF and EQ-5D 
VAS. Significance level was set at p < 0.05. 
 
The next chapter demonstrates the results of the RCT Study One.
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6.1 Introduction 
The purpose of this Chapter is to report the results of the RCT Study One 
comparing the hydrotherapy group and the land-therapy group. The results will 
reflect the aims as outlined in chapter five, p.120-121: 
 
Primary aim: The primary aim of the RCT Study One was to: 
 Evaluate the difference in outcomes for RA patients when treated with 
hydrotherapy as opposed to land based therapy. 
  
Secondary aims: The secondary aims of the RCT Study One were to: 
 Identify and evaluate the differences in demographic factors between the 
hydrotherapy and land-therapy groups. 
 Identify and understand the reasons for the difference in functional ability 
measured by HAQ-DI between those receiving hydrotherapy and those 
receiving land therapy. 
 Evaluate whether or not the hydrotherapy could improve pain and GWB, 
HRQoL, disease activity and mood symptoms (depression and anxiety) 
more effectively than land therapy in patients with RA.  
 Determine the association between variables measuring disease activity. 
 Determine the association between variables measuring psychological 
status with socio-demographic features and disease activity indices. 
 Determine which factors predict functional disability. 
 
CHAPTER SIX: RESULTS OF STUDY ONE (RCT) 
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The intended goal of this study was to recruit 43 RA patients into each of the two 
treatment groups and follow them for three and six months. However, recruitment 
was terminated early in the CMFT site because a decision had been made to close 
their hydrotherapy facility for more than six months for refurbishment. Therefore, 
the recruitment was only six patients from the CMFT site. The results from these 
patients were used as a pilot study (section 5.2.3.2 Pilot study, p.134). Because of 
the closure of the CMFT recruitment site, the researcher relied solely on the SRFT 
site for recruitment to the study. From the SRFT site, 70 RA patients were invited 
to participate between August 2011 and July 2012; of these, 22 were not 
interested in participating in the study; reasons are shown in Figure 6.1 (p.169). At 
the end of planned study period, 48 participants were assessed and agreed to 
participate. 
 
In this chapter, section 6.2 presents the number of participants and reasons for 
drop out, and goes on to describe the patient demographic in each group. Section 
6.3 provides the inferential result of this RCT work. The primary outcome 
measure was compared firstly in separate tables. All secondary comparable 
outcome measures were conducted together in separate tables. Within appendices, 
the primary outcome measure of HAQ-DI was conducted in separate cells. 
 
169 
 
 
Figure 6.1: RCT study One outline. 
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6.2 Pilot results  
Table 6.1 shows the reasons for incomplete sessions attended by participants as 
prescribed by the study protocol in both groups. Six participants (two men and 
four women) were randomised into two groups; two in the hydrotherapy group 
and four in the land-therapy group.  
 
Table 6.1: Reasons for incomplete sessions of rehabilitation programme in pilot 
participants. 
ID Group 
Number of 
sessions 
attended 
Reason for incomplete sessions 
CMFT 1 Land 2 
Was in remission of disease activity and 
felt better 
CMFT 2 Hydrotherapy 4 
Had surgical knee replacement because of 
severe knee pain 
CMFT 3 Land 3 Severe leg pain 
CMFT 4 Hydrotherapy 6 Completed the programme 
CMFT 5 Land 3 
Had disease remission because of dramatic 
response to increase dose of C/S by 
physician 
CMFT 6 land 3 Upper arm skin rash 
Key: 
  
CMFT: Central Manchester Foundation Trust 
C/S: Corticosteroids 
 
 
Baseline characteristics of patients in the pilot study were comparable (Table 6.2, 
p.171). 
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Table 6.2: Characteristics at baseline of pilot participants. 
Variables Hydrotherapy group (n = 2) Land group (n = 4) 
Mean age (Years ± SD) 
Age (min-max) 
(44 ± 6. 4) 
(40 - 49) 
(55 ± 21.5) 
(25 - 72) 
Gender (Females %) 100% (n = 2) 50% (n = 2) 
Disease duration (Years ± SD) (11 ± 5) (10 ± 7) 
Occupation 
House wife 
Retired 
Unemployed 
Employed 
 
1 
0 
0 
1 
 
1 
2 
1 
0 
Medication 
NSAIDs 
DMARDs 
C/S 
Biologics 
 
2 
2 
1 
1 
 
3 
3 
1 
1 
RF Positive (2) 
Negative (0) 
Positive (2) 
Negative (2) 
Anti-CCP Positive (1) 
Negative (0) 
NR (1) 
Positive (1) 
Negative (1) 
NR (2) 
Mean height in cm 163 168 
Mean weight in kg 66 77 
Mean BMI 24 26 
  Primary outcome measure 
HAQ-DI
┼
 (overall score) 1.43 ±1 1.44 ± 1.03 
      Secondary outcome measures 
HAQ VAS
┼
 (Pain) 32 ± 31 59 ± 28 
HAQGWB
┼
 (Wellbeing) 40 ± 24 60 ± 36 
EQ-5D tariff
┼
 (QoL) 0.2 ± 0.65 0.3 ± 0.5 
EQ-5D VAS
┼
 (QoL) 51 ± 15.5 46.2 ± 32 
RADAI
┼
 (Disease activity) 3.8 ± 2.3 5.5 ± 2.3 
DAS28
┼
 (Disease activity) 6.5 ± 1.2 4.6 ± 1.1 
HADS
┼
 (Mood change) 17 ± 5.6 21 ± 11.5 
┼Values are in mean (SD) and by independent t-test  
Key: 
 
HAQ-DI: overall score range from 0-3, with 0 being best functioning, and 3 worst functioning 
HAQ VAS score (0-100), 0 being no pain, and 100 being severe pain 
HAQ GWB scores (0-100), 0 being very well, and 100 being very poor 
EQ-5D tariff: scores range from -0.594-1, with 1 being perfect health, and -0.594 being worse than death 
EQ-5D VAS: score range from 0-100, with 0 being low quality, and 100 being high quality 
RADAI: overall score range from 0-10, with 0 being no disease activity, and 10 being very severe 
DAS28: overall score range from 0-9.4, with 0 being no disease activity, and 9.4 being very severe 
HAD: overall score range from 0-42, with 0 being no depression and/or anxiety, and 42 being very severe 
depression and/or anxiety  
DD: disease duration  
Anti-CCP: anti-cyclic citrullinated peptide antibody (anti-citrullinated protein)  
RF: rheumatoid factor 
SD: standard deviation 
NR: not reported  
BMI: body mass index 
NSAIDs: non-steroidal anti-inflammatory drugs 
DMARDs: disease-modifying anti-rheumatic drugs 
C/S: cortico-steroids 
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6.3. Randomised controlled trial (RCT) results (Study One) 
Of the 48 potential participants that agreed to participate 2 out of 23, (8.6%) in the 
hydrotherapy group dropped out from the study after their initial agreement (one 
due to a chest infection and feeling that he/she could not spare the time for 
hydrotherapy treatment, another being unable to attend due to medical 
complications). Three participants out of 25 (12%) in the land-therapy group 
withdrew from the study after the first session (one because of an unrelated 
fractured femur, and the other two because they decided they were not interested 
in the study). 
 
Finally, 43 participants (11 male, 32 female) completed post-treatment study at 
Test 2 (21 in hydrotherapy versus 22 in land therapy). 28 out of 43 completed 
three months’ follow-up at Test 3 (14 in each group). 19 out of 43 completed six 
months follow-up at Test 4 (9 in land therapy versus 10 in hydrotherapy) (Figure 
6.1, p. 169).  
 
6.3.1 Patients’ demographics 
Table 6.3, p.173 displays the characteristics of those participants who entered the 
study at Test 1. The means (SD), medians (IQR) and percentages of Test 1 
characteristics of patients in both exercise groups were comparable. However, 
most of these demographic data will be discussed in more depth in chapter 7, as 
part of comparisons with Study Two and other literature rheumatology studies. 
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Table 6.3: Characteristics of RCT patients at baseline. 
Variables 
Hydrotherapy 
(n = 21) 
Land 
(n = 22) 
 
Age (years)* 
Age (range) 
 
58 (14) 
(29 – 74) 
 
62 (16) 
(23 – 82) 
Gender (Females %) 71.4 % 77.3 % 
Disease duration (Years)* 11 (12) 8 (6) 
Occupation 
House wife 
Retired 
Unemployed 
Employed 
 
9.5 % 
47.6 % 
14.3 % 
28.6 % 
 
4.5 % 
50 % 
4.5 % 
41 % 
Medication 
NSAIDs (n) 
DMARDs (n) 
C/S (n) 
Biologics (n) 
 
67 % (14/21) 
95 % (20/21) 
24 % (5/21) 
14 % (3/21) 
 
77 % (17/22) 
77 % (17/22) 
23 % (5/22) 
14 % (3/22) 
Height in cm
┼
 165 (10) 164 (10) 
Weight in kg* 73 (20) 75 (20) 
BMI* 27 (7) 27 (6) 
Rheumatoid Factor 
+ ve 
-  ve 
NR 
 
61.9 % 
33.3 % 
4.8 % 
 
63.6 % 
31.8 % 
4.6 % 
Anti-CCP 
+ ve 
-  ve 
NR 
 
19 % 
19 % 
61.9 % 
 
4.5 % 
36.4 % 
59.1 % 
Smoking positive 11 % 13 % 
Prevalence of depression 47 % 23 % 
Prevalence of anxiety 38 % 23 % 
Hypertension positive 28 % 31 % 
┼Values are in mean (SD) and by independent t-test 
*Values are in median (IQR) and by Mann-Whitney u-test 
 Note: Prevalence of depression in all RA participants is 35%; prevalence of anxiety in all RA participants   
is 30% 
 
 Key: 
 
Anti-CCP: anti-cyclic citrullinated peptide antibody (anti-citrullinated protein)  
NR: not reported  
BMI: body mass index 
NSAIDs: non-steroidal anti-inflammatory drugs 
C/S: corticosteroids  
DMARDs: disease-modifying anti-rheumatic drugs 
SD: standard deviation 
 
 
6.3.2 Baseline statistics  
Table 6.4 (p.174) demonstrates all outcome measures used in this study at 
baseline (Test 1). Because there were significant differences of HAQ-DI and 
HADs between groups at baseline, change scores were calculated for all outcome 
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measures between Tests 1 and 2; Tests 1 and 3; Tests 2 and 3, and were 
subsequently used for data analysis. 
 
Table 6.4: Mean (SD)/median (IQR) comparison of outcome measures between groups at 
baseline (Test 1). 
 
 
 
 
Variables 
Hydrotherapy 
(n = 21) 
Land 
(n = 22) 
p 
(95% CI) 
Primary outcome measure 
Functional ability 
 
HAQ-DI
┼
 
 
 
1.9 (0.6) 
 
 
1.4 (0.7) 
 
 
0.023 (-0.9 to -0.1 
Secondary outcome measures 
 
HAQ VAS
┼
 (Pain) 
HAQ-GWB
┼
 (Wellbeing) 
 
55 (24) 
57 (22) 
 
45 (28) 
42 (26) 
 
0.208 (-26  to 5.9) 
0.056 (-29 to 0.37) 
Quality of life: 
EQ-5D tariff* 
EQ-5D VAS
┼
 
 
0.587 (0.43) 
52 (18) 
 
0.587 (0.59) 
52 (30) 
 
0.434 
0.940 (-16 to 15) 
Disease activity: 
DAS28
┼
 
RADAI
┼
 
 
4.28 (1.8) 
4.5 (2.3) 
 
4.31 (1.6) 
3.9 (2. 4) 
 
0.960 (-1.1 to 1.1) 
0.355 (-2.1 to 0.77) 
Mood symptoms: 
HAD scale* 
HAD-D* 
HAD-A* 
 
13 (10.5) 
7 (5) 
7 (6.5) 
 
9 (12) 
4 (5.5) 
5 (6.25) 
 
0.037 
0.122 
0.078 
┼Values are in mean (SD) and by independent t-test  
*values are in median (IQR) and by Mann-Whitney u-test 
Significant p values are indicated in boldface 
 
Key: 
 
HAQ-DI overall scores (0-3), with 0 being best, and 3 worst functioning 
HAQ VAS score (0-100), 0 being no pain, and 100 being severe pain 
HAQ GWB scores (0-100), 0 being very well, and 100 being very poor 
EQ-5D tariff score (-0.594-1), with 1 being perfect health, and -0.594 being worse than death 
EQ-5D VAS score (0-100), with 0 being low quality, and 100 being high quality 
RADAI overall score (0-10), with 0 being no disease activity, and 10 being very severe 
DAS28 overall score (0 -9.4), with 0 being no disease activity, and 9.4 being very severe 
HAD overall score (0-42), with 0 being no depression and/or anxiety, and 42 being very severe 
depression and/or anxiety 
HAD-D overall score (0-21), with 0-7 being normal, 8-10 being a borderline case, and ≥ 11 a definite 
case 
HAD-A overall score (0-21), with 0-7 being normal, 8-10 being a borderline case, and ≥ 11 definite a 
definite case 
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From the eight categories of HAQ-DI at baseline (Test 1), only three categories 
showed significant differences between the two groups: eating (p = 0.011), 
walking (p = 0.012) and hygiene (p = 0.034) (Table 6.5).  
 
Table 6.5: HAQ-DI categories between hydrotherapy and land-therapy group at Test 1. 
HAQ-DI categories 
Hydrotherapy 
(n = 21) 
Mean (SD) 
Land therapy 
(n = 22) 
Mean (SD) 
p 
(95% CI) 
Dressing 
& 
Grooming 
1.6 (0.8) 1.3 (0.9) 0.239 (-0.80 to 21) 
Arising 1.5 (0.7) 1 (0.8) 0.062 (-0.88 to 0.02) 
Eating 1 (0.7) 1 (0.8) 0.011 (-1 to -0.14) 
Walking 1.9 (0.6) 1.2 (1) 0.012 (-0.3 to -0.17) 
Hygiene 2 (0.6) 1.4 (1) 0.034 (-1.1 to -0.05) 
Reach 1.9 (0.8) 1.6 (1) 0.259 (-0.87 to 0.24) 
Grip 1.8 (0.6) 1.5 (0.9) 0.178 (-0.77 to 0.15) 
Activities 2 (0.9) 1.6 (1) 0.109 (-1 to 0.11) 
Key: 
HAQ-DI overall scores (0 to 3), with 0 being best and 3 worst functioning 
Significant p values are indicated in boldface 
 
 
6.3.3 Post-treatment and follow-up statistics 
6.3.3.1 Primary outcome measure (HAQ-DI) - between groups 
For the primary outcome measure, comparisons were made using the mean (SD) 
change score of HAQ-DI (between Tests 1 and 2) in both groups. Table 6.6 
(p.176) displays the change score of HAQ-DI between the two groups. There were 
significant differences in the HAQ-DI change score in the hydrotherapy group 
compared to the land-therapy group (p < 0.001), indicating that patients 
experienced a greater benefit from the hydrotherapy than those patients who 
received the land therapy.  
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Table 6.6: Comparison of HAQ-DI change score between groups (Tests 1 & 2). 
Variables 
 
Hydrotherapy 
(n = 21) 
 
Land 
(n = 22) 
p 
(95% CI) 
Primary 
outcome 
 
T1 
 
T2 
Change 
score 
 
T1 
 
T2 
Change 
score 
 
 
HAQ-DI
┼
 
 
 
1.9 
(0.6) 
 
 
1.1 
(0.7) 
 
0.7 (0.8) 
 
1.4 
(0.7) 
 
1.4 
(0.8) 
-0.02 (0.4) 
 
 
< 0.001 
(-1.1 to -0.4) 
 
┼Values are in mean (SD) and by independent t-test for change score  
Significant p values are indicated in boldface 
  
Key: 
 
HAQ-DI overall scores (0-3), with 0 being best, and 3 being worst functioning 
T1: Test 1 at baseline 
T2: Test 2 post-treatment 
 
 
The change score of HAQ-DI between Tests 1 and 3, and Tests 2 and 3, revealed 
no significant differences in both groups (Appendix 23 and 24, respectively). This 
means that there was no improvement of HAQ-DI in the follow-up period of three 
months, either in post-hydrotherapy or land therapy. 
 
Moreover comparing the change score for each category of HAQ-DI between 
Tests 1 and 2 showed that there were significant differences in five categories of 
HAQ-DI, namely dressing and grooming, walking, hygiene, reach and activities. 
This indicated that most functional ability dimensions of HAQ-DI revealed a 
decline in this score, and hence an improvement in patients’ functional ability 
after hydrotherapy (Table 6.7, p.177).  
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Table 6.7: Comparison of HAQ-DI categories in change score between groups (Tests 1 & 2). 
HAQ-DI 
categories 
Hydrotherapy group (n= 21) 
 
Mean (SD) 
Land group (n = 22) 
 
Mean (SD) 
p 
 
(95% CI) 
 T1 T2 Change score* T1 T2 Change score*  
Dressing 
& 
grooming 
 
1.6 (0.8) 
 
1.1 (0.8) 
 
0.5 (0.81) 
 
1.3 (0.9) 
 
1.3 (0.9) 
 
-0.05 (0.72) 
 
0.032 (-0.99 to -0.05) 
Arising 1.5 (0.7) 1 (0.7) 0.5 (0.7) 1 (0.8) 1(0.8) 0.09 (0.68) 0.071 (-0.31 to 0.76) 
Eating 1 (0.7) 1 (0.6) -0.24 (0.8) 1 (0.8) 1.3 (0.8) -0.09 (1.3) 0.650 (-0.50 to 0.80) 
Walking 1.9 (0.6) 0.9 (0.6) 1 (0.6) 1.2 (1) 1.3 (1) -0.14 (0.9) < 0.001 (-1.7 to -0.54) 
Hygiene 2 (0.6) 1.3(1.1) 0.7 (0.90 1.4 (1) 1.5 (1) -0.1 (0.7) 0.001 (-1.3 to -0.35) 
Reach 1.9 (0.8) 1.2 (0.9) 0.7 (1.2) 1.6 (1) 1.7 (1) -0.09 (0.75) 0.019 (-1.4 to -0.13) 
Grip 1.8 (0.6) 1.4 (0.7) 0.4 (0.9) 1.5 (0.9) 1.4 (0.9) 0.09 (0.75) 0.180 (-0.84 to 0.16) 
Activities 2.1 (0.9) 1.3 (1) 0.8 (0.9) 1.6 (1) 1.6 (1) 0 (0.62) 0.004 (-1.3 to -0.26) 
*Independent t-test of change score difference  
Significant p values are indicated in boldface 
Key: 
 
T1: Test 1 at baseline 
T2: Test 2 post-treatment 
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6.3.3.2 Primary outcome measure (HAQ-DI) - within groups 
No significant differences in HAQ-DI scores were shown within the land-therapy 
group for the HAQ-DI (Appendix 21). Within the hydrotherapy group, significant 
differences in HAQ-DI scores were found between Tests 1 and 2 only (p = 0.014), 
meaning that the functional ability of RA patients was improved immediately after 
hydrotherapy (Table 6.8). However, this improvement was not statistically 
significant under Tests 1 and 3 or Tests 2 and 3. 
 
Table 6.8: Results of one-way repeated measures ANOVA of HAQ-DI in the 
hydrotherapy group between Tests 1, 2 & 3. 
HAQ-DI 
Statistics Test 1 Test 2 Test 3 
Mean 1.9 1.1 1.3 
SD 0.6 0.7 0.6 
F 5.998 
df 2 
p-value 0.003 
p* 
(95% CI) 
Test 1 - Test 2 
0.014 
(0.127 to 1.170) 
Test 1 - Test 3 
0.088 
(-0.064 to 1.114) 
Test 2 - Test 3 
0.989 
(-0.457 to 0.211) 
*p-value based on adjustment for Bonferroni set at 0.017 (0.05/3) 
Significant p values are indicated in boldface 
 
Key: 
  
HAQ-DI overall scores (0-3), with 0 being best functioning, and 3 being worst functioning 
SD: Standard deviation 
F: F-statistics  
DF: Degree of freedom 
Test 1 (baseline) 
Test 2 (post-treatment) 
Test 3 (three-months follow up) 
179 
 
6.3.3.3 Secondary outcome measures - between groups 
 
HAQ VAS (pain)  
Change score of pain was significant between Tests 1 and 2 (p < 0.001) in the 
hydrotherapy group compared to the land-therapy group (Table 6.9, p.180). This 
indicates that patients experienced greater benefits and relief of pain in the 
hydrotherapy compared to those in the land-therapy group. 
 
HAQ-GWB (wellbeing)  
Change scores were significantly different in the hydrotherapy group compared to 
the land-therapy group (p < 0.001) (Table 6.9, p.180). This means that RA 
patients had better improvements from the hydrotherapy treatment than from the 
land therapy treatment. 
 
EQ-5D VAS (QoL)  
The mean change score between Test 1 and 2, showed significant improvement (p 
= 0.021) (Table 6.9, p.180). Patients in the hydrotherapy group experienced a 
significantly greater improvement in general health status compared to those in 
the land-therapy group. 
 
EQ-5D tariff (QoL)  
Patients in both groups did not experience any change in HRQoL between Test 1 
and 2 measured by the EQ-5D tariff (Table 6.9, p.180).  
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 Table 6.9: Comparison of secondary outcome measures in change score between groups (Tests 1 & 2). 
 
Variables 
Hydrotherapy group (n= 21) 
┼
Mean (SD) 
*Median (IQR) 
 
Land group (n = 22) 
┼
Mean (SD) 
*Median (IQR) 
 
p 
 
(95% CI) 
 T1 T2 Change score T1 T2 Change score  
HAQ VAS
┼
 (pain) 
HAQ-GWB
┼
 (wellbeing) 
 
55 (24) 
57 (22) 
 
35.5 (18.3) 
33 (18) 
 
20 (21) 
24 (21) 
 
45 (28) 
42 (26) 
 
54 (28) 
51 (270 
 
-9 (20) 
-9 (23) 
 
< 0.001 (-41 to -16) 
< 0.001 (-46 to -19) 
Health status (QoL) 
 
EQ-5D tariff * 
EQ-5D VAS
┼
 
 
 
0.587 (0.43) 
52 (18) 
 
 
0.587 (0.17) 
73 (11) 
 
 
0 (0.21) 
-14 (13) 
 
 
0.587 
52 (30) 
 
 
0.587 (0.58) 
54 (24) 
 
 
0 (0.52) 
2 (33) 
 
 
0.842 
0.021 (3 to 34) 
Disease activity 
 
DAS28
┼
 
RADAI
┼
 
 
 
4.28 (1.78) 
4.5 (2.3) 
 
 
2.49 (1.24) 
4 (2.7) 
 
 
1.8 (1.7) 
0.5 (2.75) 
 
 
4.31 (1.57) 
3.9 (2.4) 
 
 
3.28 (1.38) 
4.5 (2.2) 
 
 
1 (2.3) 
-0.6 (1.56) 
 
0.613 (-1.6 to 0.94) 
0.094 (-2.5 to 0.20) 
Mood symptoms 
 
HAD scale* 
HAD-D* 
HAD-A* 
 
 
13 (10.5) 
7 (5) 
7 (6.5) 
 
 
12 (7.5) 
6 (5) 
7 (5) 
 
 
1 (8) 
1 (3) 
0 (6) 
 
 
9 (12) 
4 (5.5) 
5 (6.25) 
 
 
12 (7) 
7 (3) 
7 (3.5) 
 
 
-3 (9.5) 
-2 (4.25) 
-2 (4.25) 
 
 
0.023 
0.042 
0.038 
┼Values are in mean (SD) and by independent t-test for change score 
*values are in median (IQR) and by Mann-Whitney u-test for change score 
Significant p values are indicated in boldface 
 
Key: 
 
HAQ VAS score (0-100), 0 being no pain, 100 being severe pain 
HAQ GWB scores (0-100), 0 being very well, 100 being very poor 
EQ-5D tariff score (0.594-1), with 1 being perfect health, 0.594 being worse than death  
EQ-5D VAS score (0-100), with 0 being low quality, and 100 being high quality  
RADAI overall score (0-10), with 0 being no disease activity, and 10 being very severe disease activity 
DAS28 overall score (0-9.4), with 0 being no disease activity, and 9.4 very severe disease activity 
HAD overall score (0-42), with 0 being no depression and/or anxiety), 42 being very severe depression, and/or anxiety)  
HAD-D overall score (0-21), with 0-7 being normal, 8-10 being a borderline case, ≥ being a 11 definite case 
HAD-A overall score (0-21), with 0-7 being normal, 8-10 being a borderline case, ≥ being a 11 definite case 
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EQ-5D Dimensions (QoL) 
The descriptive part of EQ-5D dimension was compared between hydrotherapy 
and land therapy at Test 1, Test 2 and Test 3. Because the numbers of reported 
level-three ‘extreme problems’ were very low among participants, the EQ-5D 
levels were dichotomised into ‘no problems’ and ‘problems’ rather than ‘no 
problems’, ‘moderate problems’ or ‘extreme problems’ (EuroQol Group, 1990; 
Rabin et al., 2011a). Each subject per dimension could choose only one category 
(no problems, moderate problems or extreme problems).  
 
The graphs below show participants who reported no problems or problems in the 
five EQ-5D dimensions. At Test 1, results show that the high percentage of 
patients who experienced ‘problems’ revealed in the dimension of mobility, usual 
activity and pain in both groups (Figure 6.2, p.182 and Figure 6.3, p.182). The 
percentage of patients who reported problems in anxiety and depression increased 
in the hydrotherapy group compared with the land-therapy group (Figure 6.2, 
p.182 and Figure 6.3, p.182). At Test 2, few differences appeared between the two 
groups except in the pain dimension. Here, the percentage of patients who 
reported problems in pain and discomfort decreased markedly from 81% to 
66.7%, which means that there is some favourable improvement to pain level in 
the hydrotherapy group (Figure 6.2, p.182). Moreover, in spite of the small 
sample size of the three-month follow-up period (14 in the hydrotherapy group 
and 14 in the land-therapy group), the percentage of respondents who reported 
problems in pain level decreased clearly in the hydrotherapy group from 66.7% to 
28.6% (Figure 6.2, p.182). No obvious marked change was noticed in other 
dimensions in either group. Thus, only the pain dimension in the hydrotherapy 
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group showed improvement over time compared to the land-therapy group. 
However, the other dimensions fluctuated over time in both groups. 
 
 
Figure 6.2: Percentage of patients recording 'problems' to EQ-5D questions in the 
hydrotherapy group. 
 
 
 
Figure 6.3: Percentage of patients recording ‘problems’ to EQ-5D questions in the 
land-therapy group. 
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DAS28 (disease activity)  
The overall score of DAS28 declined from 4.28 in Test 1 to 2.49 in the 
hydrotherapy group, compared to 4.31 in Test 1 to 3.28 in Test 2 for the land-
therapy group (Table 6.9, p.180). The change score was not significant (p = 
0.613). However, in spite of no significant finding, this may be clinically 
important due to the fact that a DAS28 score of less than 2.6 corresponds to the 
remission stage of disease activity, and patients who begun the hydrotherapy 
treatment with a mean DAS28 score of 4.28 actually experienced a trend of 
remission in disease activity post-treatment. This trend, however, was not seen in 
post-treatment land therapy patients. 
 
RADAI (disease activity)  
RADAI did not detect any significant difference in change score between the 
hydrotherapy group and land-therapy group (p = 0.094), which indicates that 
disease activity measured by the self-administered questionnaire was not affected 
by hydrotherapy treatment compared to land therapy treatment (Table 6.9, p.180). 
 
Mood symptoms (HADs, HAD-D, HAD-A)  
Change scores of anxiety and depression between Test 1 and Test 2 showed 
significant differences (Table 6.9, p.180), indicating that changes in mood were 
significantly better in the hydrotherapy group compared to those in the land-
therapy group.  
 
6.3.3.4 Secondary outcome measures – within groups 
Three of the secondary outcome measures, HAQ VAS, HAQ-GWB and EQ-5D 
VAS, showed significant differences within the hydrotherapy group (Appendix 21). 
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No significant differences in the secondary outcome measures were shown within 
the land-therapy groups (Appendix 21).  
 
HAQ VAS within group 
Within the hydrotherapy group, significant changes were found for HAQ VAS 
between Tests 1 and 2 only (p = 0.015) (Table 6.10). However, at Test 3 the VAS 
score was reduced to 40 ± 26.5 which was not statistically significant different 
from Test 1 (p = 0.137) nor Test 2 (p = 0.556). These findings suggest that after 
six weeks of intervention, a significant reduction in pain score was observed, but 
this was not sustained at three months. 
 
Table 6.10: Results of repeated measures ANOVA of HAQ VAS in the hydrotherapy 
group between Tests 1, 2 & 3. 
HAQ VAS 
Statistics Test 1 Test 2 Test 3 
Mean 55 35.5 40 
SD 24 18.3 26.5 
F 4.882 
df 2 
p-value 0.004 
p* 
(95% CI) 
Test 1 - Test 2 
0.015 
(3.9 to 39.1) 
Test 1 - Test 3 
0.137 
(-3.7 to 34) 
Test 2 - Test 3 
0.556 
(-18.5 to 6) 
*p-value based on adjustment for Bonferroni set at 0.017 (0.05/3) 
Significant p values are indicated in boldface 
 
Key:  
HAQ VAS score (0-100), 0 being no pain, 100 being severe pain 
SD: Standard deviation  
F: F-Statistics  
DF: Degree of freedom 
Test 1 (baseline) 
Test 2 (post-treatment)  
Test 3 (three-months follow up) 
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HAQ-GWB  
In the hydrotherapy group, it can be seen that the HAQ-GWB was confirmed to be 
significant as shown by the repeated measure ANOVA, where p-value = 0.002 
(Appendix 21). From the post-hoc test, the significant differences were observed 
between Tests 1 and 2 (p = 0.002) and at Tests 2 and 3 (p = 0.027) (Table 6.11, 
p.186). However, at Test 3 the GWB score was reduced to 44.2 ± 19.3 which was 
statistically significantly different from Test 2 (p = 0.027), but not significant at 
Test 1 (p = 0.126). This indicated that the improvement in GWB is observed to be 
significant over time. 
 
Table 6.11: Results of repeated measures ANOVA of HAQ-GWB in the hydrotherapy 
group between Tests 1, 2 & 3. 
HAQ-GWB 
Statistics Test 1 Test 2 Test 3 
Mean 57 33 44.2 
SD 22 18 19.3 
F 5.084 
df 2 
p-value 0.002 
p* 
(95% CI) 
Test 1 - Test 2 
0.002 
(9.8 to 41) 
Test 1 - Test 3 
0.126 
(-3.3 to 33.6) 
Test 2 - Test 3 
0.027 
(-19 to -1.1) 
*p-value based on adjustment for Bonferroni set at 0.017 (0.05/3) 
Significant p values are indicated in boldface 
 
Key:  
HAQ GWB scores (0 – 100), 0 being very well, and100 being very poor 
SD: Standard deviation 
F: F-Statistics 
DF: Degree of freedom 
Test 1 (baseline) 
Test 2 (post-treatment) 
Test 3 (three months follow-up) 
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EQ-5D VAS 
In the hydrotherapy group, the EQ-5D VAS was confirmed to be significant as 
shown by the repeated measure ANOVA, where p-value = 0.009 (Appendix 21). 
Additionally, from the post-hoc analysis, the significant differences was found 
between Test 1 and Test 2 (p = < 0.001). This finding indicated that there was an 
improvement in HRQoL between baseline and post intervention (73 ± 11 vs. 52 ± 
18) (Table 6.12).  
 
Table 6.12: Results of repeated measures ANOVA of EQ-5D VAS in the hydrotherapy 
group between Tests 1, 2 & 3. 
 
 
In summary, patients with RA in the hydrotherapy group were found to have 
experienced significantly greater improvements in functional ability, pain, GWB, 
health status and psychological wellbeing, compared to the land-therapy group 
immediately post treatment.  
EQ - 5D VAS 
Statistics Test 1 Test 2 Test 3 
Mean 52 73 66.4 
SD 18 11 18.4 
F 4.251 
df 2 
p-value 0.009 
p* 
(95% CI) 
Test 1 - Test  2 
< 0.001 
(-29.3 to -13.7) 
Test 1 - Test 3 
0.179 
(-33 to 4.7) 
Test 2 - Test 3 
0.699 
(-8.8 to 23.5) 
*p-value based on adjustment for Bonferroni set at 0.017 (0.05/3) 
Significant p values are indicated in boldface 
 
Key: 
EQ-5D VAS score (0-100), 0 being low quality, and 100 being high quality  
SD: Standard deviation  
F: F-Statistics  
DF: Degree of Freedom 
Test 1 (baseline)  
Test 2 (post treatment)   
Test 3 (3 months follow up) 
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6.3.4 Correlation Results  
6.3.4.1 Relationship between RADAI and DAS28 at Test 2 
When looking at disease activity and observing patients conditions in both groups, 
there emerged a statistically significant positive relationship of disease activity 
between the DAS28 and RADAI (r = 0.328, p = 0.032). However, when looking 
at this correlation in both groups separately, a moderate and statistically 
significant correlation was found between DAS28 and RADAI in the land-therapy 
group at Test 2 (r = 0.501, p = 0.018), however, no correlation was observed in 
the hydrotherapy group (r = 0.145, p = 0.529) (Table 6.13). These findings 
indicate that while the scores from those self-administered questionnaires that 
measure disease activity (such as RADAI) may reflect or correlate with other 
tools used by physicians or health professionals when assessing disease activity, 
they may, however, not necessarily be compatible with the same score measuring 
the same index.  
 
Table 6.13: *Pearson’s correlations between (RADAI & DAS28) at Test 2. 
RADAI 
 
 
 
DAS28 
Hydrotherapy group  
(n = 21) 
Land-therapy   
 (n = 22) 
All patients 
n = 43 
 
r = 0.145 
p = 0.529 
 
r = 0.501 
p = 0.018 
 
r = 0.328 
p = 0.032 
Key:  
r = Pearson’s correlation coefficient [± r < 0.30 = low; ±  0.30 < r < 0.60 = moderate) and ± r > 0.60 = 
high] 
Significant p values are indicated in boldface 
*Pearson’s correlation was carried out because both DAS28 & RADAI are normally distributed at Test 
2 
RADAI overall score (0 – 10), with 0 no disease activity and 10 very severe  
DAS28 overall score (0 -9.4), with 0 no disease activity and 9.4 very severe 
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6.3.4.2 Relationship between depression score (HAD-D) and: educational 
levels, disease duration, morning stiffness, RF and disease activity indexes in 
patients with RA 
In Study One, the prevalence of depression at baseline was found to be 35% (n = 
15/43), which is relatively higher compared with that reported in the literature 
(Covic et al., 2012; Mella et al., 2010) (Table 6.3, p.173). The researcher 
hypothesised that there was a relationship between the depression score and low 
EL, severe MS, longer DD, positive RF, a high DAS28 score and a high RADAI 
score. 
 
To investigate the degree of relationship between the score of depression in Test 2 
with these variables, Spearman’s correlation coefficient was carried out (as the 
depression score (HAD-D) was not normally distributed in Test 2 (Appendix 20). 
There was not any statistically significant correlation of the depression score with 
all variables, with the exception that there was a moderate positive correlation 
between depression (HAD-D) and RADAI in the land-therapy group (r = 0.502, p 
= 0.017), and using all data (r = 0.578, p < 0.001) respectively. In the 
hydrotherapy group, moderate positive correlation was found between HAD-D 
and RADAI (r = 465, p = 0.033) (Table 6.14, p.189). 
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Table 6.14: *Spearman’s correlations between depression score (HAD-D) in Test 2 with 
other demographic data and outcome variables. 
 
Variables 
Hydrotherapy group 
(n = 21) 
Land-therapy group    
(n = 22) 
All patients 
(n = 43) 
 p r p r p r 
HAD-D 
& 
ELs 
0.425 -0.340 0.121 -0.184 0.075 -0.275 
HAD-D 
& 
MS 
0.118 -0.352 0.873 0.036 0.245 -0.118 
HAD-D 
& 
DD 
0.645 -0.162 0.472 -0.107 0.385 -0.136 
HAD-D 
& 
RF 
0.666 -0.100 0.485 0.157 0.782 0.043 
HAD-D 
& 
DAS28 
0.784 0.064 0.359 0.205 0.289 0.166 
HAD-D 
& 
RADAI 
0.033 0.465 0.017 0.502 < 0.001 0.578 
*Spearman’s correlation coefficient [± r < 0.30 = low; ± 0.30 < r < 0.60 = moderate) and ± r > 0.60 = 
high]. Significant p values are indicated in boldface 
Key: 
  
HAD-D: Depression  
ELs: Educational levels  
MS: Morning stiffness  
RF: Rheumatoid factor 
DD: Disease duration 
DAS28: Disease Activity Score 28 
RADAI: Rheumatoid Arthritis Disease Activity Index 
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6.3.4.3 Relationship between anxiety score (HAD-A) and: educational levels, 
disease duration, morning stiffness, RF and disease activity indexes in 
patients with RA 
In Study One, the prevalence of anxiety was found to be 30% (n = 13/43), which 
is relatively similar compared with those found in the literature (Covic et al., 
2012; Mella et al., 2010). Spearman’s Correlation coefficient was carried out as 
anxiety score (HAD-A) post-treatment was not normally distributed (Appendix 
20) to find out any association between anxiety score post-treatment with 
variables in categorical data and outcome measures in the previous section.  
 
Table 6.15 (p.191) showed no association between anxiety score and EL, MS, 
DD, RF and DAS28. The only exception was that there was a moderate positive 
association between anxiety score (HAD-A) and disease activity measured by 
RADAI in the land-therapy group (r = 0.544, p = 0.009), a moderate positive 
association with all patients (r = 0.425, p = 0.005). 
 
This significant positive correlation indicates that patients who have high scores 
of anxiety may also present with high scores of disease activity in the land-therapy 
group. However, these results were not very convincing, as this finding was not 
discovered in patients in the hydrotherapy group (r = 0.320, p = 0.157). 
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Table 6.15: *Spearman’s correlations between anxiety score (HAD-A) in Test 2 with 
other demographic data and outcome variables. 
 
 
In summary, no significant correlation was found between the depression or 
anxiety score in Test 2 except for disease activity measured by RADAI. This 
should be interpreted with care, as other parameters of disease activity showed no 
correlation. 
 
6.3.5 Results of regression analyses 
Table 6.16 (p.192) shows results of multivariate regression analysis of detailed 
independent variables when combined in the model. The GWB was the only 
predictor of functional disability in patients with RA p < 0.003. Multiple 
Variables 
Hydrotherapy group 
(n = 21) 
Land-therapy group   
(n = 22) 
All patients 
(n = 43) 
 p r p r p r 
HAD-A 
& 
ELs 
0.362 -0.210 0.295 - 0.234 0.169 -0.214 
HAD-A 
& 
MS 
0.922 0.023 0.874 0.036 0.912 0.017 
HAD-A 
& 
DD 
0.523 -0.148 0.184 -0.294 0.227 -0.188 
HAD-A 
& 
RF 
0.802 -0.058 0.813 0.054 0.994 -0.001 
HAD-A 
& 
DAS28 
0.302 -0.237 0.879 0.034 0.580 -0.087 
HAD-A 
& 
RADAI 
0.157 0.320 0.009 0.544 0.005 0.425 
*Spearman’s correlation coefficient [± r < 0.30 = low; ±  0.30 < r < 0.60 = moderate) and  ± r > 0.60 = 
high] 
Significant p values are indicated in boldface 
Key:  
HAD-A: Anxiety  
ELs: Educational levels  
MS: Morning stiffness  
RF: Rheumatoid factor 
DAS28: Disease Activity Score 28 
RADAI: Rheumatoid Arthritis Disease Activity Index 
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regression analysis results in a lower chance of predicting relationship because of 
the overlapping of symptoms and interaction of variables (Field, 2009). 
 
Table 6.16: Predictors of functional abilities of the (HAQ-DI) in patients with RA 
(multiple-regression analysis). 
Variables Beta SE 
p 
(95% CI) 
Depression score 0.157 0.034 0.410 (-0.041 to 0.099) 
Anxiety score 0.308 0.029 0.068 (-0.004 to 0.112) 
RADAI -0.054 0.064 0.799 (-0.146 to 0.113) 
HAQ-GWB 0.467 0.004 0.003 (0.005 to 0.002) 
EQ-5D tariff -0.044 0.304 0.766 (-0.706 to 0.524) 
Multiple regression analysis refers to predictive relationship (Beta). Significant p values are indicated in 
boldface. SE refers to standard error 
Key: 
HAQ-DI overall scores (0 to 3), 0 being best functioning, and 3 being worst functioning 
HAQ GWB scores (0–100), 0 being very well, 100 being very poor 
EQ-5D tariff score (0.594 to 1), 1 being perfect health, -0.594 being worse than death 
RADAI overall score (0–10), 0 being no disease activity, and 10 being very severe disease activity 
HAD-D overall score (0-21), 0-7 being normal, 8-10 being a borderline case, ≥ 11 being a definite case 
HAD-A overall score (0-21), 0-7 being normal, 8-10 being a borderline case, ≥ 11 being a definite case 
 
 
Table 6.17 (p.193) shows results of univariate regression analysis detailing 
variables with significant predictive effects on functional abilities. Higher 
depression and anxiety scores, RADAI, HAQ-GWB, and low EQ-5D tariff scores 
were associated with increased functional disability in patients with RA all with p 
< 0.001. However, the following variables that were tested using both multiple 
and univariate regression analyses were identified as not being predictors of 
functional disability such as age, gender, ELs, smoking, HT, BMI, DD, 
medication, marital status, DAS28, EQ-5D VAS or HAQ VAS. 
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Table 6.17: Predictors of functional abilities of the (HAQ-DI) in patients with RA 
(univariate regression analysis). 
Variables Beta SE 
p 
(95% CI) 
Depression score 0.544 0.024 < 0.001 (0.051 to 0.148) 
Anxiety score 0.513 0.023 < 0.001 (0.042 to 0.137) 
RADAI 0.561 0.039 < 0.001 (0.091 to 0.250) 
HAQ-GWB 0.603 0.004 < 0.001 (0.010 to 0.025) 
EQ-5D tariff -0.396 0.300 0.009 (-1.433 to -0.233) 
Univariate beta analysis refers to predictive relationship indicated in boldface (second column) 
 Significant p values are indicated in boldface (fourth column) 
 SE refers to standard error 
 
Key: 
HAQ-DI overall scores (0 to 3), 0 being best functioning, and 3 being worst functioning 
HAQ GWB scores (0–100), 0 being very well, 100 being very poor 
EQ-5D tariff score (0.594 to 1), 1 being perfect health, -0.594 being worse than death 
RADAI overall score (0–10), 0 being no disease activity, and 10 being very severe 
HAD-D overall score (0-21), 0-7 being normal, 8-10 being a borderline case, ≥ 11 being a definite case 
HAD-A overall score (0-21), 0-7 being normal, 8-10 being a borderline case, ≥ 11 being a definite case 
 
 
6.3.6 Exercise programmes 
Appendix 25 describes the intervention programme in the hydrotherapy and land-
therapy group. It illustrates the exercises tailored and designed for participants 
according to patients’ condition and capability. It is essential to emphasise that 
warm-up and cool-down exercises are not included here, as these were performed 
by all the participants. In both groups, it can be seen that exercise treatment 
details, aims and goals were similar. The only exception was that 14 out of 21 in 
hydrotherapy group were provided with education on how to manage flare-ups 
compared to eight out of 22 in the land-therapy group. 
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6.4 Overall summary of results 
This chapter has discussed the results of physical function (functional ability, 
pain, GWB), disease activity (self-administered and physician disease activity 
tool), mood changes (psychological wellbeing) and QoL (health status) in patients 
with RA. Patients with RA in the hydrotherapy group were found to have 
experienced significant improvements in functional ability, pain, GWB, health 
status and psychological wellbeing (i.e. lower HAQ-DI, lower HAQ-GWB, lower 
HAQ VAS, high EQ-5D VAS and lower HADs) compared with the land-therapy 
group. However, no differences were revealed in change score in disease activity 
measured by DAS28 and RADAI, HRQoL measured by the EQ-5D tariff. These 
findings indicate that patients with RA in the hydrotherapy group exhibited 
improvement in physical function, HRQoL and psychological wellbeing. HAQ-DI 
change score categories showed improvement in five categories between Tests 1 
and 2. 
  
While a moderate relationship was found between disease activity parameters 
(DAS28 and RADAI) in all patients in the land-therapy group, no relationship 
was found in the hydrotherapy group. Caution must be exercised in the 
interpretation of the current findings because of the contradictory result revealed 
and the small sample size. As expected, the moderate correlation between 
depression score and disease activity parameter (RADAI) clearly appeared in the 
land-therapy group and in all patients in Test 2. Moreover, a moderate correlation 
was found between anxiety score and RADAI in the land-therapy group and all 
patients at Test 2. Conversely, the anxiety score post-treatment failed to find this 
correlation in the hydrotherapy group only. A number of variables that were 
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identified to be predictive of functional disability were RADAI, depression, 
anxiety, GWB and EQ-5D tariff. Exercise intervention in both groups was 
undertaken with the patients stating both what they were aiming or planning to 
achieve in order to increase compliancy by attempting to have the motivation to 
continue to perform the HEP. 
  
The next chapter describes epidemiological characteristics of patients referred to 
hydrotherapy and the Kellgren Centre patients (Study Two). 
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7.1 Introduction 
The Kellgren Centre of Rheumatology is the main rheumatology department 
within central Manchester. It is responsible for diagnoses, treatment, referrals, and 
consultation for all rheumatic and musculoskeletal diseases such as connective 
tissue disease, psoriatic arthropathies, ankylosing disease, inflammatory arthritis 
disease, hypermobility syndrome, RA disease and crystal-induced arthropathies. 
The Kellgren Centre of Rheumatology at Manchester Royal Infirmary (MRI) 
within the CMFT is named after Professor Kellgren, the first Professor of 
Rheumatology in the UK. Professor Kellgren, a former Dean of the medical 
school helped to establish the first University Department of Rheumatology in the 
country at the CMFT in the late 1940s.  
 
When studying RA epidemiological profiles (descriptive epidemiology), there are 
many potential risk factors for RA, depending on the occurrence and variation of 
the disease. These include age, gender, social support group (occupational status, 
marital status) as well as duration of disease onset, influence of genetic or 
environmental risk factors such as smoking, RF, DAS28, and HT.  
 
Although a power calculation was performed for Study One (Chapter 5, p.163), 
the intended sample size was not reached. It was felt to be important that a 
comparison to a large sample of RA patients was necessary to support the external 
CHAPTER SEVEN: WHAT TYPES OF RHEUMATOID 
ARTHRITIS (RA) PATIENTS ARE REFERRED FOR 
HYDROTHERAPY? (STUDY TWO) 
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validity of the findings from Study One. This second study, therefore describes 
the characteristics of those patients referred to hydrotherapy in Study One from 
Salford Royal NHS Foundation Trust (SRFT) and compares them to patients from 
the Kellgren Centre and previous rheumatology studies in order to find out 
whether the features of Study One participants reflect those of a large regional 
centre in England and other international studies. 
 
Aims of Study Two 
The aim of this study is to: 
 Describe and compare the characteristics of patients from Study One to a 
representative cohort of patients from a regional rheumatology centre and 
previous rheumatology studies. 
 
7.2 Method 
7.2.1 Population 
In order to carry out this study, collecting information from a sample of 10%, n = 
200, of all patients at the Kellgren Centre was proposed. A sample of 200 was 
chosen because, firstly, it was a manageable number of records to collect in the 
time available, and secondly, this number gives a margin of error of 0.071 or 
7.1%, which was deemed acceptable (Niles, 2006). This means that if our random 
sample has an average age of 70 years, there is 95% probability that the average 
age of all patients is between 62.9 and 77.1 years.  
 
All the information was selected from the medical notes randomly and 
anonymised. The research nurse at the Kellgren Centre selected the notes from 
those patients attending clinics over a three-month period and completed a data 
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form (Appendix 26). No medical notes were removed from the Kellgren Centre 
and access to them was limited to the relevant authorised consultants and nurses. 
To preserve confidentiality and anonymity, the researcher did not know whose 
information was selected because no names and no identifiable patient 
information were used. 
 
This study had ethical approval from the North West 2 Research Ethics 
Committee-Liverpool Central (Appendix 29) with agreement of clinicians in the 
Kellgren Centre (Appendix 28). A letter was sent out to all patients to inform 
them that their notes might be selected and used for research purposes, and they 
were given the choice of opting out (Appendix 27). 
 
The information obtained from the medical notes included: 
 Age 
 Gender 
 DD 
 Occupational status (e.g. retired/working) 
 Current treatment (medication) 
 Body mass index (BMI) (height and weight) 
 DAS28 (if recorded)  
 RF (if recorded) 
  HT 
 Smoker or non-smoker 
 Marital status 
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The above data were transferred to the University and stored on password-
protected computers stored in lockable rooms. The information was grouped 
together and only the averages and frequencies of all the data gathered were 
reported, so individual characteristics were not described. The researcher looked 
at some parts of the data collected for the study; authorised people (clinicians, 
nurses and research development staff) were also able to look at the data from 
CMFT to check that the study was being carried out correctly. Demographic data 
are essential in each study as part of the comparison between the general RA 
population and those referred to hydrotherapy, these data are commonly collected 
in research studies in RA patients and have relevance for clinicians with regard to 
their practice (Silman & Pearson, 2002). 
 
7.2.2 Rationale for outcomes 
RA is a chronic disease that influences all the aspects of the lives of patients, 
whether physically, psychologically or socially (Fitzpatrick et al., 1991; NICE, 
2009). There has been substantial recent interest in understanding the 
epidemiology of RA. There have been several population studies in different 
countries around the world (Figure 2.1, p.37 and Table  2.3, p.38), and facets of 
differential occurrence have stimulated a number of analytical studies looking for 
both genetic and environmental risk factors for RA patients (Silman & Pearson, 
2002). The outcomes in Study Two were chosen because: 1) they are commonly 
reported in the medical notes, 2) they have been reported on in previous studies, 
and 3) they might affect a patient’s disease process or rehabilitation.  
   
Marital status: It has been suggested in many studies that social support is 
significant to the patients’ psychosocial adjustment and mental health (Affleck et 
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al., 1988; Fyrand et al., 1997; Goodenow et al., 1990). These studies 
recommended the need for more research about the potential negative impact of a 
lack of social support on the treatment of this chronic disease. The importance of 
marital status in predicting and explaining health risk has been emphasised in 
many studies (Ebrahim et al., 1995; Mallon et al., 2002; Orth-Gomér et al., 1993; 
Rosengren et al., 1989; Verbrugge & Balaban, 1989).  
 
It has been suggested that non-married people, whether divorced, widowed, 
separated or never married, have in general more health problems and higher 
mortality rates compared with people who are married (Berkman, 1988; Reisine, 
1993). The relationship between marital status and mortality is not well 
understood. Ward and Leigh (1993) found that unmarried people presented with a 
higher score on the physical function disability index of the HAQ, compared to 
those married. These results are consistent with those of other studies, suggesting 
that marriage is an alternative index for wider social support (Ebrahim et al., 
1995; Rosengren et al., 1989; Schoenbach et al., 1986). It is generally accepted by 
those in health psychology and behavioural medicine that the relationship between 
social support and health has received a great deal of research attention therefore 
results are considered reliable (DiMatteo, 2004). 
 
Hypertension (HT): There are many risk factors that are believed to be prevalent 
in RA, and that may be important contributors to the disease, such as HT and 
smoking (Panoulas et al., 2008). It has been suggested that one of the most 
important modifiable risk factors for the development of CVD in the general 
population is HT (Yusuf et al., 2004). The prevalence of HT is high in patients 
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with RA, and requires prompt diagnosis and appropriate management (Arthritis 
Research UK, 2011; Panoulas et al., 2008; Stavropoulos-Kalinoglou et al., 2011). 
However, Gonzalez et al. (2008) stated that the effect of HT on the development 
of CVD is the same among patients with RA as those non-RA subjects (Gonzalez 
et al., 2008). Conversely, the mortality rate attributed to HT among RA patients 
may be higher because cardiovascular mortality rates are already higher in RA 
compared to non-RA cases (Gabriel, 2008; Solomon et al., 2003; Wallberg-
Jonsson et al., 1997; Wolfe et al., 1994). Panoulas et al. (2008) assert that HT in 
RA patients should be actively treated with drugs and lifestyle measures, not 
passive monitoring. 
 
HT was reported in many ways in the medical notes. How it is defined in this 
study depends on how it was reported, often only that the participants were taking 
anti-HT. 
 
Smoking: Cigarette smoking has also been suggested as a possible cause of RA 
and other autoimmune diseases, and needs to be actively discouraged (Hardy et 
al., 1998; Krishnan et al., 2003). Smoking has by far the strongest association with 
RA among environmental factors (Tobón et al., 2010). Although some studies 
suggest that smoking habits may be related to RA severity, the impact of smoking 
on disease activity and outcomes remains unclear (Manfredsdottir et al., 2006; 
Papadopoulos et al., 2005; Saag et al., 1997; Wolfe, 2000). Smoking was reported 
in the medical notes as whether the patients actively smoked or not. A history of 
previous smoking was not included because of a lack of data reported. 
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Obesity and body mass index (BMI): In the general population, obesity is 
regarded as one of the well-established risk factors for developing CVD, HT, 
diabetes mellitus, gall bladder disease, and some forms of cancer (Bray & 
Bellanger, 2006). Obesity is common in RA patients (Bray & Bellanger, 2006; 
Jawaheer et al., 2010; Stavropoulos-Kalinoglou et al., 2011). Most of the studies 
assessing bodyweight in RA use the WHO definition for overweight and obesity 
(WHO Consultation, 2000).  
 
Bodyweight is routinely assessed and consistently reported in all health 
departments (Stavropoulos-Kalinoglou et al., 2011). Nevertheless, it is mainly 
indicated as a demographic of the population studies and is usually excluded from 
further analysis or interpretation (Stavropoulos-Kalinoglou et al., 2011). BMI has 
been used as the measure of obesity for both adults and children (Stavropoulos-
Kalinoglou et al., 2011; Zaninotto, 2006). The WHO (WHO, 2000) defined BMI 
as weight in kilograms divided by the height in meters squared. A normal BMI 
ranges between 18.5-25kg/m
2
; less than 18.5kg/m
2
 is regarded as underweight, 
overweight ranges between 25 and 29.9kg/m
2
, and individuals more than 30kg/m
2
 
are regarded as obese (Bray & Bellanger, 2006; Stavropoulos-Kalinoglou et al., 
2011; WHO Consultation, 2000). The BMI range is a common tool that assesses 
obesity at the whole-body level; it takes into account total weight but it does not 
distinguish between the different tissues that comprise it (Stavropoulos-
Kalinoglou et al., 2011). Fat mass and other tissues (skeletal muscle, bone, organs, 
skin and blood), collectively known as fat-free mass, are components of total 
weight and can vary enormously between individuals (Mattsson & Thomas, 
2006). 
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Disease Activity: (DAS28): This is one of the common indices used to measure 
disease activity in RA patients in clinical practice (Aletaha et al., 2005; Prevoo et 
al., 1995). The score is calculated by including the number of tender and swollen 
joints (out of a total of 28), the ESR and the patient’s own assessment of his/her 
global health, the latter of which indicates the wellbeing of an individual by 
marking a 10cm line between very good and very bad (Aletaha et al., 2005; 
Prevoo et al., 1995).  
 
Since the DAS28 contains reduced joint counts, it can also feasibly be used for the 
monitoring of RA disease activity in daily clinical practice (Fransen et al., 2003). 
Many studies have suggested that joint counts consisting of only 28 joints are as 
valid and reliable as the total joint count in RA patients (Fuchs & Pincus, 1994; 
Prevoo et al., 1995; Van Riel & Schumacher, 2001). A DAS28 score greater than 
5.1 suggests an active disease, less than 3.2 indicates that RA is well controlled, 
and less than 2.6 means that the disease is in remission status (Aletaha et al., 
2005; Prevoo et al., 1995). As part of monitoring and follow up, all 
rheumatologists and healthcare professionals make a medical record of disease 
activity for every RA patient at each visit. 
 
Rheumatoid Factor (RF): This is the first autoantibody present in serum and 
synovial fluid of RA patients (Song & Kang, 2010). It was first described by 
Waaler who developed the Rose Waaler test (Waaler, 1940). Later on, this factor 
was developed to be defined as an autoantibody that is activated against the 
fragment-crystallisable (FC) portion of immunoglobulin G (IgG). Three RF 
species are available, such as IgG, IgM and IgA, but the commonest and most 
important is IgM (Nell et al., 2005; Song & Kang, 2010; Waaler, 1940). RF is 
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present not only in RA but has been observed in many other autoimmune diseases 
such as systemic lupus erythematous, mixed connective tissue disease and 
primary Sjogren Syndrome, as well as in non-autoimmune conditions, such as in 
chronic infections and old age (Tehlirian & Bathon, 2008; Temprano & Smith, 
2011; Waaler, 1940).  
 
However, RF in RA is present in high titre, while in other conditions it presents 
with a low titre (Song & Kang, 2010). It has been suggested that RF plays a role 
in the pathogenesis of RA because of the strong association between high-titre RF 
and an unfavourable prognosis of the disease (Song & Kang, 2010). RF is shown 
to be associated with poor outcome for joint destruction and disability (Nell et al., 
2005; Song & Kang, 2010). Presence or absence of RF gives a hint to clinicians 
about the prognosis of disease process because +ve RF is regarded as one of the 
main factors of a poor prognosis. 
 
Comorbidity: Other medical conditions sometimes present in addition to RA 
when associated with the disease process, and its treatments are called 
comorbidities (Michaud & Wolfe, 2007). Comorbidity can be defined to describe 
a health condition whether in current, past or transient illness such as interstitial 
lung disease, asthma, ischaemic heart disease (IHD), myocardial infarction (MI), 
HT and old TB or previous malignancies (Michaud & Wolfe, 2007). 
Comorbidities in RA are an important factor for QoL and other outcomes and 
prognosis; therefore, it is essential to recognise illnesses such as cardiac diseases 
in order to understand research outcomes (Michaud & Wolfe, 2007). It is the 
responsibility of the physicians and healthcare professionals to accept and monitor 
the impact of comorbid conditions (Michaud & Wolfe, 2007). A number of 
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studies have been published over the past decades reporting disability at work 
(Barrett et al., 2000; Sokka & Pincus, 2001; Verstappen et al., 2004). During the 
course of the disease, the percentage of patients that become too disabled to work 
is high (Verstappen et al., 2004). Long-term disabilities, which interfere with 
permanent employment, have substantial impact on patients’ lives, family income, 
and indirect costs to society (Young et al., 2002). However, work-related 
disability in RA may result due to reasons other than the disease: demographic 
variables and social conditions (Sokka & Pincus, 2005). 
 
There are many studies from the USA and European countries that have reported 
work disabilities in patients with RA with inconclusive findings (Barrett et al., 
2000; Revenson & Felton, 1989; Sokka & Pincus, 2001; Wolfe & Hawley, 1998). 
This inconsistency/discrepancy might be due to differences in the diagnostic 
criteria of RA, DD, and follow-up periods, or might also be due to the methods 
employed for recruiting patients (Barrett et al., 2000). Therefore, it is difficult to 
make comparisons with these studies. 
 
In this chapter, in addition to patients from study One and Kellgren Centre 
participants, the results of this study were compared to four hydrotherapy studies 
(Bilberg et al., 2005; Eversden et al., 2007; Hall et al., 1996; HyDAT Team, 
2009), as well as other epidemiological studies in the literature. HyDAT authors 
are the HyDAT team from the UK. HyDAT is the National Hydrotherapy Data 
Collection project in aquatic physiotherapy, and is regarded as the first UK 
standard data collection project that provides an outline of aquatic physiotherapy 
provision within the NHS (HyDAT Team, 2009). Other outcomes such as BMI, 
smoking and HT were compared with other RA-related studies. Regarding marital 
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status and occupational status, there were no available study data with which to 
compare with the data from this study, therefore these data were compared 
between Kellgren participants (Study Two) and patients from Study One. 
 
 
7.2.3 Data management and analysis 
The Statistical Package for SPSS19 was used for analysis of the data (Armonk, 
New York 10504-1722, USA). Means (± SD) were calculated for all variables and 
used to describe the outcomes for the Kellgren Centre and patients from Study 
One. Data were presented descriptively using bar charts. 
 
Where outcomes were compared using inferential statistics, the Kolmogorov-
Smirnov test was used determine a normally distributed population (Field, 2009). 
The mean and SD of normally distributed data were calculated and reported 
(Morgan et al. 2010). Independent parametric and non-parametric tests were used 
to compare groups where appropriate. Statistical significance was set at p < 0.05. 
 
7.3 Results  
The aim of this study was to collect data for 10% of 2,000 patients at the Kellgren 
Centre during routine clinical contacts. The data of 200 participants (51 males and 
149 females) were collected during a three-month period in 2011. The study 
population consists of 200 participants from Kellgren Centre (Study Two) and 43 
participants in Study One. 
 
Patient details 
Age 
From Figure 7.1 (p.207), it can be seen that the highest percentage of age group 
was elderly patients in the two studies, mainly 61-70 years and then 71-80 years. 
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This indicates that RA commonly occurs in the elderly age group, concurring with 
all research results as well as with the literature. The lowest percentage appeared 
in the younger age group. Patients in the Kellgren group were in greater 
proportion in all age groups except the lowest and highest (2%, 17%). 
  
 
Figure 7.1: Comparison of age groups between participants of Kellgren Study Two and 
RCT Study One. 
 
Figure 7.2 (p.208) illustrates the main characteristics of the participants’ mean age 
of comparator studies. The mean age was similar between groups, with no 
difference greater than a few years observed. On average, the mean age was 
shown to be within the normal range. The mean age of Kellgren participant’s was 
59 years, which corresponds well with Study One (60). 
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Figure 7.2: Mean (± SD) age of six comparator studies. 
 
 
Occupation 
Figure 7.3 shows that 36% of the Kellgren participants were employed, 32% were 
retired and 1% were students. These findings are comparable with the Study One, 
which identified (points out) that more than 35% were employed and 49% were 
retired. Although RA affects older people, it also affects those who are younger 
and in work at the time of diagnosis. Data were not collected on reasons for 
retirement because of the difficulty in recording this information and it would 
have been a great burden on the clinicians. 
 
 
Figure 7.3: Occupational status of participants in both Kellgren Study Two and RCT 
Study One. 
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Gender 
Figure 7.4 shows that the percentage of females to males in Study One is very 
similar in the Kellgren Study Two. In comparator studies, the percentage of 
females ranged from 62% in the HyDAT study to 89% in the Bilberg et al study 
(2005). Bilberg et al. recruited a very high female percentage of patients (89%) 
compared to the others. There was a 27% difference between the highest (89%) 
and lowest (62%) female participation. It is significant that the findings of this 
study’s data concur with that found in the NICE guidelines (2009). The overall 
occurrence of RA is two to four times greater in women than men (NICE, 2009). 
Furthermore, Arthritis Research UK, (2011) reported that RA affects women three 
times more than it does men (Arthritis Research UK, 2011). The percentages of 
females among Study One participants and Kellgren participants were similar, 
being three-quarters female compared to one-quarter male. 
 
 
Figure 7.4: The percentage of female patients among six comparator studies. 
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Disease duration 
Figure 7.5 shows that there was little difference in mean DD between the study 
groups. The only exception is the Bilberg et al. (2005) study that recruited patients 
with DD between one to five years. In Eversden et al. (2007), the DD of patients 
ranged between 4 and 18 years, whereas in Hall et al. (1996) it was 7-12 years. 
Conversely, Kellgren participants’ duration of the disease ranged between 1 and 
43 years, and the range of Study One participants is 1-50 years. 
 
 
Figure 7.5: Mean (± SD) disease duration of RA participants among five comparator 
studies. 
 
Marital status 
With regard to marital status, approximately 65-75% of participants in both the 
RCT Study One and Kellgren participants were married, compared to 8-19% who 
were single in both groups (Figure 7.6, p.211). A small percentage of patients (2-
11%) presented with other marital status: divorced, widowed or separated. Not all 
comparator studies reported marital status. Therefore, comparisons between 
present patients and Kellgren patients were carried out. There were no specific 
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data found in NICE (2009) or Arthritis Research UK (2011) that could provide 
any specific marriage data with which to compare. 
 
 
Figure 7.6: Marital status of participants in Kellgren Study Two and RCT Study One. 
 
 
Body mass index (BMI) 
From Figure 7.7, it can be seen that the range of both normal weight and 
overweight BMI were similar in the two. Very few participants presented with 
BMI in the underweight range in either of the studies.  
 
 
Figure 7.7: BMI index of RA participants in Kellgren Study Two and RCT Study One. 
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As shown in Figure 7.8, the mean BMI reported for the Kellgren Centre and 
participants in Study One were similar to the general population in the UK and 
other RA studies such as Saravana & Gillott, (2004), Stavropoulos-Kalinoglou et 
al., (2011) and The Information Centre for Health & Social Care, (2011). 
 
 
Figure 7.8: Mean BMI index among five comparator studies. 
 
 
Hypertension (HT) 
Figure 7.9 shows the number of RA participants who have HT in both Study One 
and the Kellgren Centre. 67-70 % of participants in both groups did not have HT.  
 
Figure 7.9: Hypertension of RA participants in Kellgren Study Two and RCT Study One. 
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In Figure 7.10, the prevalence of HT in the general UK population in 2010 was 
around 30%, and this figure has remained steady over the last seven years, 
between 2003 and 2010 (The Information Centre for Health and Social Care, 
2011). In comparison with other studies, it has been found that the percentage of 
HT in RA patients varied depending on the studies reviewed. 
 
 
Figure 7.10: Hypertension among seven comparator studies with RA participants. 
 
 
Smoking 
According to the Figure 7.11 (p.214), the percentage of active smoking in the 
Study One was 12%, while in the Kellgren participants it was 6%.  However, 
other reviewed studies offered a different percentage of participants’ smoking 
habits, beginning at 42% in Hutchinson et al. (2001), 34% in Manfredsdottir et al. 
(2006), 29% in Papadopoulos et al. (2005) and 27% in Finckh et al. (2004). The 
health survey data for the general population in England (2011) reported that the 
percentage of men who were current smokers declined from 28% in 1993 to 22% 
in 2010, while in women the proportion of current smokers declined from 26% to 
18% for the same period (20% altogether in 2010, i.e. the total decline across both 
genders) (The Information Centre for Health and Social Care, 2011). 
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Figure 7.11: Percentage of smokers in study populations. 
 
 
DAS28 
In both groups most participants had a DAS28 score of between 3.2 (well 
controlled) and 5.1 (exacerbation of disease activity), which was double the 
percentage of those who had a DAS28 score of less than 2.6 (remission of disease 
activity) (Figure 7.12). 
  
 
Figure 7.12: DAS28 among RA participants in the Kellgren Study Two and RCT Study 
One. 
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Comparisons of DAS28 scores between the Kellgren Study Two and the RCT 
Study One were made using independent t-tests because the DAS28 baseline score 
was normally distributed (p = 0.075). The mean (± SD) Kellgren DAS28 score 
was 4.1 (± 1.5) compared to 4.3 (± 1.7) in the RCT Study. This was not 
statistically significant (p = 0.845) (Figure 7.13). 
 
 
Figure 7.13:  Mean DAS28 between RCT Study One and Kellgren Study Two. 
 
 
Rheumatoid factor (RF) 
Figure 7.14 (p.216) illustrates the percentage of participants who had positive RF. 
It can be seen from Figure 7.14 that more than 44% of Kellgren Study Two 
participants had +ve RF compared to 63% in the RCT Study One. The majority of 
participants in Rantapaa-Dahlqvist et al. (2003) have positive RF (73%) compared 
to 45% in Nell et al. (2005).  
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Figure 7.14: Proportion of Rheumatoid factor positive in RA participants among four 
studies. 
 
 
Treatment details 
Figure 7.15 (p.217) shows that the most common medications used in all RA 
populations among the studies reviewed were DMARDs and NSAIDs. Only Hall 
et al. (1996) found that more patients were taking NSAIDs than DMARDs. In the 
RCT study and the Kellgren Centre, biologics were used to treat RA patients. 
From Figure 7.15, it can be seen that 14% of Study One participants were on 
biologic drugs compared to 28% in the Kellgren Centre. None of the hydrotherapy 
studies reported any data about biologic drugs. 
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Figure 7.15: Treatment details of five comparator studies among RA participants. 
 
 
Comorbidities 
Figure 7.16 illustrates the commonest types of illnesses associated with RA in the 
Kellgren Study and the RCT Study. The interesting findings were that 40% of 
Study One and 33% of Kellgren participants did not have comorbidities. Both 
groups have various illnesses to be taken into consideration during rehabilitation. 
 
 
Figure 7.16: Comorbidities of RA participants in Kellgren Study Two and RCT Study 
One. 
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7.4 Limitation of Study Two 
In general, most of these data were commonly available in the clinical notes. 
Unfortunately, not all the participants’ medical notes contained full data. Because 
the data was collected by the research nurse and entered onto a form in writing, it 
relied on her interpretation of the notes and our interpretation of her writing. 
Numbers and words not clearly written could have been interpreted differently by 
another person reading the same notes.  
 
We accepted a margin of error of 7.1% as defined by Niles, (2006). A larger 
sample would have decreased the margin of error, possibly leading to different 
findings. However, a balance needed to be struck between feasibility and margin 
of error accepted. 
  
An initial attempt was made to find additional outcomes such as early 
environmental factors, birth weight, pollutant exposure, and laboratory tests such 
as anti-CCP; these items were not typically reported however, and future research 
would have to collect this information specifically. 
  
Few studies have attempted to explain the effects of several environmental factors 
on the risk and outcome of RA, such as environmental factors that might affect 
RA many years before its clinical occurrence (Mandl et al., 2009; Silman & 
Pearson, 2002; Tobón et al., 2010). Early environmental factors such as growth or 
lack of it and diet are regarded as high in the risk of developing RA (Tobón et al., 
2010). A large cohort study in USA followed 87,077 women prospectively as part 
of the Nurses' Health Study, and they have considered the positive relationship 
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between high birth weight (> 4.54kg) and RA compared to no relation to normal 
birth weight (Mandl et al., 2009).  
 
The relationship between pollutants and RA has been also investigated. The 
established link between air pollution and diseases involving pulmonary and 
systemic inflammation such as asthma and chronic bronchitis indirectly support 
this hypothesis (Tobón et al., 2010). Recent evidence suggests that a newly 
identified environmental risk factor for RA may be exposure to traffic pollution in 
adulthood (Hart et al., 2009). A recent study used in the Nurse's Health Study 
(90,297 women) examined the distance between the place of residence in 2000 
and the nearest road, which served as an indicator of exposure to traffic pollution 
(Hart et al., 2009). What is interesting in this data is that women living within 
50m of a road radius had an increased risk of RA compared to women living 
200m or more from the road radius (Hart et al., 2009). However, it could not be 
concluded without further evidence that this data could be confirmed. 
 
A relationship exists between some ethnic and racial groups and their incidence of 
a higher risk for RA than others (Tobón et al., 2010). The differences in the 
distribution and interactions of genetic and environmental factors might be related 
to this high risk.  
 
7.5 General findings  
 The mean age of the Kellgren Study Two and the RCT Study One 
participants was 60 years. This finding was comparable to what Arthritis 
Research UK (2011), NICE (2009) and other studies have reported. 
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 All comparator studies have reported that RA affects more women than 
men. 
 The DD between Kellgren and RCT Study was similar, which reflects the 
RA population who have been referred to hydrotherapy. 
 Most participants from the Kellgren Centre and in Study One were either 
in employment or retired. A higher proportion referred to hydrotherapy 
were retired. 
 Both studies reported that more than 55% of RA patients were overweight 
or obese, and these findings were comparable with other literature studies.  
 All studies that were reviewed had approximately similar mean BMI 
scores.  
 Variable percentages of smoking were reported among comparison 
studies. However, very low percentages of smokers were reported in both 
the Kellgren Study and the RCT Study. 
 A very wide range of HT prevalence has been reported between literature 
studies. 
 Several literature studies have reported variable percentages of RF in their 
studies.  
 No significant differences were shown between the DAS28 of the Kellgren 
study and RCT study. 
 Biologics drugs were reported only in the RCT Study and the Kellgren 
Study. No literature studies reported information about biologics drugs. 
However, biologics drugs have only recently been introduced for treatment 
of RA patients, and this might explain the reasons for no data having been 
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reported among comparator studies. The trends of drug medication were 
almost the same in the Kellgren Study Two and RCT Study One.  
 A number of comorbidities were reported in both Kellgren Study Two and 
Study One participants. 
 
The following chapter will discuss the results of economic evaluation (Study 
Three) of hydrotherapy modality for the RA patients compared to the land-therapy 
group from the perspectives of the provider, society and the patient. 
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8.1 Introduction 
Although clinical outcomes are important, they are not the only outcomes 
considered and applied by clinicians and policy makers in the evaluation of 
effectiveness treatment in healthcare (Bozic et al., 2003; Cohen & Reynolds, 
2008). It is due to the considerable rise in the cost of healthcare and the increase 
in restraints on economic resources that decision-makers have been caused to 
consider re-evaluating healthcare in terms of cost (Cohen & Reynolds, 2008; 
Donaldson et al., 2002). Decision-makers now aim at increasing the welfare of 
patients up to a given level equal to the allocation of resources. Thus, the 
combination of economic evaluation with clinical trials in order to evaluate 
effectiveness requires an economic analysis-shaped decision-making framework 
that can be used by clinicians, managers and policy makers (Goodwin et al., 
2003). In developing countries, the financial constraints of care are increasingly 
important for economic and political issues (Cohen & Reynolds, 2008). It has 
been realised that new medical products and technologies are one fundamental 
driver of increased healthcare costs (Goldman et al., 2005). This recognition has 
increasingly highlighted the need to assess the value of new methods of strategies 
CHAPTER EIGHT: AN ASSESSMENT OF 
HYDROTHERAPY COSTS TO THE NATIONAL 
HEALTH SERVICE (NHS), PATIENTS AND SOCIETY 
COMPARED WITH LAND-BASED EXERCISE 
THERAPY (STUDY THREE) 
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to discover the effects of tests, drugs, procedures, and medical devices relative to 
their costs (Cohen & Reynolds, 2008). Therefore, the analysis of CE should also 
include the evaluation of such problems (effect vs. cost) in order to inform 
clinicians (medical decision) and healthcare policy-makers. 
 
Over several decades, the discipline of CE analysis has developed as an approach 
to accurately assessing the value of new medical strategies by concurrently 
examining incremental health benefits in light of incremental costs (Cohen & 
Reynolds, 2008). Originally, the design of this study was a cost-effective analysis 
to determine the clinical and cost-effectiveness of hydrotherapy compared to land-
based exercise therapy in RA patients. However, it is accepted that it is impossible 
to specify the technique of analysis in advance when arranging a prospective 
economic evaluation (Donaldson et al., 1996; Donaldson et al., 2002; Drummond 
et al., 1997). Among individuals with musculoskeletal conditions it has been 
stated that arthritis, such as RA and OA, are regarded as a first- or second-rank 
cause of long-term disability, work disability, restricted activity days, frequent 
medical visits, and prescription and non-prescription drug use (Patrick et al., 
2001; Rothfuss et al., 1997). Intuitively, it may be easily predicted that providing 
an average of six sessions of hydrotherapy exercise by the NHS is more costly 
than land therapy (because the costs of hydrotherapy are higher than those on 
land). Those patients attending hydrotherapy impose more costs on healthcare 
than land sessions. Nevertheless, it should be appreciated that provision of 
hydrotherapy may reduce the NHS costs (which can be called the hidden costs). 
The lack of hydrotherapy sessions in a hospital can increase the cost to the NHS. 
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The patients who receive hydrotherapy cost less in the end than their counterparts 
who do not get treatment, and because of the reduction in hidden costs, this can 
also be claimed to be true for those receiving land-based treatments. 
  
This chapter is a cost analysis, examining the cost of providing hydrotherapy 
sessions compared to providing land-therapy sessions, where the effectiveness of 
both treatments has not proven to be equal, as in the HAQ-DI. The study 
considers the cost of the treatment from the viewpoint of healthcare providers, 
patients and society, in view of the limited health resources available. Decision-
makers choose the treatment strategies they want to implement in the context of 
the lowest cost per QALY (Detsky & Naglie, 1990; Tengs, 2004).  
 
Cost utility is measured in QALYs divided by the incremental cost, and it is 
defined as the ratio of the incremental effectiveness of one strategy, such as 
hydrotherapy, compared to another, such as land therapy (Epps et al., 2005; 
Fenwick et al., 2006; Gusi & Tomas-Carus, 2008; Willan, 2001). Studies reported 
in the literature have demonstrated evidence of the benefits of physiotherapy on 
HRQoL in RA patients, such as reducing pain and increasing fitness from short-
term programmes (Eversden et al., 2007; Hall et al., 1996; Rintala et al., 1996). 
However, the cost-analysis evaluation of these exercise programmes in RA 
patients is not readily available. It is important that the CE of a health service – 
which takes into account not only the perspective of the healthcare provider but 
also of the patients themselves, and society – is added to the evaluations; 
particularly in terms of the time spent on treatment, travel, and lost work hours. 
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These factors give decision-makers necessary information that will help them to 
provide the best possible healthcare within the limited resources allocated to them.  
Aim of Study Three 
The aim of this chapter was to evaluate the cost of hydrotherapy compared to the 
land-based treatment, from the viewpoint of the provider [NHS], patient and 
society. 
 
8.2 Rationale for undertaking a cost analysis study 
Arthritis such as RA and OA is the leading cause of disability among USA 
populations older than 15 years, and is regarded as the second most prevalent 
cause for work disability (Wing & Peterson, 2012). It has been stated that the 
economic cost of arthritis in the USA in 2003 was about $108 billion annually 
(Yelin et al., 2007). The total costs of RA in the UK including indirect costs and 
work-related disability have been estimated at between £3.8 and £4.75 billion per 
year, and these costs include NHS costs, career costs, nursing homecare, private 
expenditure, sick leave and work-related disability (NICE, 2009; The Comptroller 
and Auditor General, 2009). The wider cost to the general economy due to sick 
leave and work-related disability (lost employment) is £1.8 billion a year (NICE, 
2009). It has been found that about one third of patients have to give up work 
because of the disease within two years of its onset, and this prevalence increases 
thereafter (James et al., 2004; NICE, 2009). A survey by the National RA Society 
estimated that when a patient stops work due to RA it represents an average loss 
of productivity equivalent to £287,544 (NICE, 2009). Undoubtedly, this disease 
represents a huge cost to the UK economy and an enormous cost to individual 
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patients (NICE, 2010); it can therefore be accepted that RA results in a wide range 
of complications for the individual patient, their carers, the NHS and society in 
general (NICE, 2010). 
 
The economic impact of this disease includes (NICE, 2009): 
 Direct cost to the NHS with their associated healthcare support services. 
 Indirect costs to the economy in terms of the effects of early mortality and 
lost productivity. 
 Personal impact on patients and their families because of disease and 
subsequent complications. 
 
RA is a chronic and progressive disease for which there is no cure at present, 
necessitating complex treatment. The aims of hydrotherapy treatment in rheumatic 
diseases are to sustain or improve functional mobility and independence 
(Eversden et al., 2007; Fam, 1991; Rintala et al., 1996). Clinical trials have shown 
that exercise programmes, whether on land/or in water, might be helpful in 
relieving pain, increasing functional ability and improving depression due to the 
fact that these programmes increase strength and ROM in affected joints (Hall et 
al., 1996; Rintala et al., 1996; Suomi & Collier, 2003; Templeton et al., 1996; 
Vliet Vlieland & Van den Ende, 2011). Hydrotherapy is an accepted form of 
treatment administered in concurrence with usual care therapy and other 
physiotherapy rehabilitation programmes, such as land-based exercise and home 
exercise. Generally, RA patients are satisfied with the hydrotherapy services that 
are recommended by NICE guidelines for the management of this chronic disease 
(Epps et al., 2005; HyDAT Team, 2009; NICE, 2009). 
227 
 
Because of the chronicity of RA, any intervention that minimises deformity and 
disability without the use of drugs must be considered over prescribing drugs, 
which tend to have side effects that are significant due to the longevity of the 
disease. Although it can be seen through this study that the costs of hydrotherapy 
are higher than those of land-based physiotherapy treatment, costs may be 
neutralised against efficiency gains if less staff time is required with individual 
patients, and fewer drugs and resources are needed to support the development 
and functioning of the RA patients. The hypothesis is that hydrotherapy will be 
more costly than land-based physiotherapy in the treatment of RA patients, but 
that it will give more benefits in terms of pain relief, less disabilities and a better 
QoL. 
 
8.3 Economic evaluation: a review 
8.3.1 Materials and methods 
8.3.1.1 Identification and selection criteria 
An electronic database search of AMED, CINAHL, the Cochrane Library, 
EMBASE, MEDLINE, ProQuest, Pub Med, Science Direct, and the Web of 
Science was conducted (1988 to September 2013). The search was limited to 
human adults (age >18 years) and across all articles published in English. The 
keywords used were `rheumatoid arthritis`, `hydrotherapy`, `aquatic 
physiotherapy`, `aqua therapy`, `water therapy`, ‘costs’, ‘cost evaluation’, 
economic evaluation’, cost utility’, ‘cost effectiveness’. Keyword combinations 
were: ‘rheumatoid arthritis and hydrotherapy’, ‘rheumatoid arthritis and aquatic 
physiotherapy’, ‘rheumatoid arthritis and aqua therapy’, ‘rheumatoid arthritis and 
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water therapy’, ‘rheumatoid arthritis and costs’, rheumatoid arthritis and cost 
evaluation’. 
  
Studies that used the following keywords were excluded from this literature 
search: ‘colonic irrigation’, ‘water birth’, ‘Kneipp therapy’, ‘spa therapy’, 
‘whirlpool therapy’, ‘contrast baths’ and ‘balneotherapy’. The database search 
was supplemented by a manual search of: the Clinical Journal of Rheumatology, 
Annals of the Rheumatic Disease, British Medical Journal, Physiotherapy, 
Arthritis and Rheumatism, Rheumatology and Journal of Rheumatology and 
Physical therapy. A further search of the bibliographic references in the extracted 
articles and existing reviews was also conducted to identify potential studies that 
were not captured by the electronic database searches. 
 
This section identifies and summarises the economic evidence from RCTs in 
rheumatic diseases similar to RA, evaluating the use of hydrotherapy (aquatic 
exercise, pool therapy) in RA patients. From consequences of RCTs, the best 
economic evaluations are determined. In clinical outcomes, comprehensive 
costing can be undertaken to ascertain the true costs associated with the observed 
improvement in results if a well-designed RCT establishes a difference (Doig, 
2008). Few studies have included economic evaluations in rheumatic diseases, but 
they have included patients with juvenile idiopathic arthritis (JIA), FMS and 
osteoarthritis (OA) (Cochrane et al., 2005; Epps et al., 2005; Gusi & Tomas-
Carus, 2008; Patrick et al., 2001). 
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8.3.1.2 Inclusion and exclusion criteria for considering studies for this review 
 
Studies were included if:  
 They were RCTs; 
 They included participants in any age group who had been diagnosed with 
RA, JRA, OA, FMS and AS; 
 A water-based intervention (hydrotherapy) had been used in the study, and 
compared with alternative interventions; 
 They included an economic evaluation. 
 
Articles were excluded if: 
 They had insufficient information available (abstract only); 
 The treatment modality included balneotherapy, Kneipp therapy, mud 
therapy or sulphur therapy; 
 They were not written in English (even if the abstract was in English); 
 Participants were not primarily and predominantly diagnosed with 
common rheumatic disease. 
 
From the search, four articles were identified based on economic evaluations of 
hydrotherapy in OA, FMS and JIA upon RCTs named (Cochrane et al., 2005; 
Epps et al., 2005; Gusi & Tomas-Carus, 2008; Patrick et al., 2001). 
  
Patrick et al. (2001) recruited 249 adults diagnosed with OA using a stratified 
randomisation process in order to estimate cost and outcomes of the Arthritis 
Foundation’s 20-week aquatic exercise classes from a societal perspective. 
Participants in the treatment group took part in an Arthritis Foundation-certified 
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aquatic class, and class size ranged from six to 40 persons with an average of 16. 
This aquatic programme was run by practiced instructors and held in pools with a 
temperature of 85°F to 92°F. 
   
Participants performed gentle upper- and lower-body activities to help increase 
joint flexibility and ROM and maintain muscle strength. Participants were asked 
to attend classes at least twice weekly for the 20-week study period. Participants 
in the control group were withheld from new exercise programmes for the 
duration of the study and were asked to follow their usual pattern of activities. 
QALY gained was estimated using trial data. Sample size was based on 80% 
power to reject the null hypothesis that the cost/QALY gained would not exceed 
$50,000. The economic evaluation, the QWB – a generic measure of health status 
– was used in the Patrick et al. (2001) study to estimate cost utility (CE) analysis 
with a community-derived preference weighting (Kaplan & Anderson, 1988). This 
outcome measure was previously used in evaluating Auranofin medication in RA 
(Thompson et al., 1988). Additional outcome measures collected at baseline and 
post-class included the Current Health Desirability Rating (CHDR) scale; this was 
used with participants, who were asked to rate the desirability of current health 
(Tsevat et al., 1995), the arthritis-specific Health Assessment Questionnaire 
(HAQ) (Fries et al., 1980; Fries et al., 1982), the Centre for Epidemiologic 
Studies-Depression Scale (CES-D) (Kohout et al., 1993), and the Perceived 
Quality of Life Scale (PQoL) (Patrick et al., 1988; Patrick et al., 2000). 
 
To estimate costs, the use of healthcare facilities was assessed using 
diaries/questionnaires and Medicare reimbursement rates. Based on the observed 
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extents of clinical benefit, the authors calculated the CE of hydrotherapy for 
arthritis to be in excess of USD $50,000 per additional QALY gained, and 
considered this prohibitively expensive. The outcome measures were taken 
immediately after the finishing intervention and did not allow any analysis of 
longer-term effects; nevertheless, this trial was regarded as having high 
methodological quality (Epps et al., 2005). This study did not determine reduced 
costs and improved health outcomes compared with usual care. As a result the 
incremental cost-utility of the exercise programme (using the QWB community-
derived preference weighting) was not favourable compared with other common 
healthcare interventions (such as usual care) because the QWB was not sensitive 
enough to detect a significant difference with the sample size used (Patrick et al., 
2001). Conversely, preference weights obtained using the participant-specific 
CHDR improved significantly in the exercise group. Consequently, the cost-utility 
outcome of the aquatics exercise programme using the CHDR was more 
favourable. 
 
Cochrane et al. (2005) in the UK performed a subgroup economic evaluation. A 
pre-experimental matched-control study (106 participants) was used to estimate 
efficacy of water-based exercise treatment of over 12 weeks to check design 
assumptions and delivery processes. This was followed by the main study of 312 
participants in an RCT to determine the effectiveness of water-based exercise 
(treatment) compared with usual care (control) in older patients with hip and/or 
knee OA.  
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The main study by Cochrane et al. (2005) was accompanied by an economic 
evaluation comparing societal costs and consequences of the two treatments. A 
subgroup analysis of this trial focussed on the incremental CE in patients older 
than 60 with hip and/or knee OA. One hundred and six elderly patients (93 
women, 13 men) with confirmed hip and/or knee OA took part in the preliminary 
study.  
 
CE was evaluated from the incremental cost-effectiveness ratios (ICERs – 
difference in mean cost divided by difference in mean effect in the two groups). 
Primary analysis was performed on an intention-to-treat basis, with last available 
measurement carried forward. Mean cost difference estimates showed a saving in 
the water-exercise group of £123–£175 per patient per annum, and ICERs ranged 
from £3,838 to £5,951 per QALY. 
 
The water-exercise programme produced a favourable cost-benefit outcome, using 
reduction in pain score on the Western Ontario and McMaster Universities 
(WOMAC) OA index as the measure of benefit. Wide variation in both the 
individual costs and the utility measures, combined with small effect sizes, limited 
the power of the study to detect a difference between the groups on QALY-based 
analyses, so for this reason, the overall cost of this programme may be 
prohibitively expensive. 
 
Gusi and Tomas-Carus (2008) assessed the cost utility of adding an eight-month 
supervised warm-water exercise programme to the usual care of public health 
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service for women with FMS. Costs to the healthcare system and to society were 
considered in this study.  
 
The participants in this trial were randomly allocated using a random-number 
table and assigned a code number. After excluding five participants due to their 
participation in other therapies, 33 female patients aged 37 to 71 years of age were 
selected to participate. Seventeen participants were allocated to the experimental 
group, consisting of a one-hour session three times weekly for an eight-month 
duration. The remaining 16, who continued their daily activities (which did not 
include any form of physical exercise similar to that in the programme) were 
allocated to a control group. Provision was made for additional costs that are 
variable among patients, such as the cost and time needed for travel from the 
patient's residence to the hospital. This facility is unusual in health services. For 
this reason, the authors achieved two economic analyses, one from a health-
service perspective, the other from a societal perspective, to assess the costs to the 
patient and to the provider.  
 
The unit costs were expressed in Euros (€) based on prices in 2005. The main 
outcome measures used were the healthcare costs and the number of QALYs 
using the time trade-off elicitation technique from the EQ-5D utility (Drummond 
et al., 1997; Herdman et al., 2001). At the beginning of the programme and after 
three and eight months, participants completed the questionnaires, including the 
EQ-5D health status instrument (Drummond et al., 1997; Herdman et al., 2001). 
Private and public healthcare was recorded, during the same period, including 
hospital stays, drug usage and primary and secondary care appointments.  
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Gusi and Tomas-Carus (2008) showed that the mean incremental treatment costs 
exceeded those for usual care per patient by €517 from a healthcare-provider 
perspective, and €1,032 from a societal perspective. Each QALY gained in 
association with the exercise programme cost an additional €3,947/QALY (95% 
CI: 1,782 to 47,000) from a healthcare perspective, and €7,878/QALY (3,559 to 
93,818) from a societal perspective. Again, the addition of the water-based 
programme is potentially prohibitive per QALY in terms of both healthcare and 
societal costs. Before investing in such programmes, many factors need to be 
considered as a major determinant, such as characteristic facilities (distance from 
patients’ homes and number of patients in each session). 
 
In the UK, Epps et al. (2005) conducted a clinical trial in JIA that was 
commissioned by the NHS Research & Development Health Technology 
Assessment (HTA) Programme. This trial was designed as a multicentre 
randomised controlled, partially blinded trial. Two-hundred participants were 
randomly allocated into an intervention arm receiving a combination of 
hydrotherapy and land-based physiotherapy (combined group) compared to a 
control arm receiving land-based physiotherapy only (land-therapy group). 
Patients in both groups received 16 sessions (one hour/session) of treatment at one 
of the three centres over two weeks, followed by local physiotherapy attendances 
for two months. The inclusion criteria were: patients aged four to 19 years 
diagnosed more than three months previously with JIA, on stable medication with 
at least one active joint. 
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They were recruited from three centres in the UK. Costs per QALY gained at six 
months following the main intervention were calculated using a societal 
framework to reflect costs to society. This included calculating the hours of paid 
or unpaid work lost because of the patient’s illness. For example, a carer or their 
partner might have to stay at home to look after a child who has a disease flare, or 
take them to hospital or physiotherapy appointments. QALYs were derived using 
the EQ-5D (Drummond et al., 1997; EuroQol Group, 1990; Herdman et al., 2001). 
The measurement and calculation of costs and QALYs are described below. 
 
Two months after intervention 47% patients in the combined group and 61% 
patients in the land-therapy group had improved according to the EQ-5D scale, 
whereas 11% and 5% worsened, respectively. The analysis showed no significant 
differences in mean costs and QALYs between the two groups. It was not possible 
to carry out a sample size calculation relating to the exact context of this trial, as 
there was no firm evidence as to the proportion of patients with JIA likely to 
improve in the control arm of the study (Epps et al., 2005). Another explanation 
might be because there are no studies in this age group used for comparison to 
help resolve some of the findings of this trial. Moreover, the EQ-5D may not be 
responsive to real change in the paediatric population because it was not designed 
to measure children’s health status (Epps et al., 2005). 
 
It would appear from the studies discussed above that an economic analysis was 
not intended to be a major component, except in the study of Gusi and Tomas-
Carus (2008). A clear perspective was not stated in three of the reviewed studies 
(Cochrane et al., 2005; Epps et al., 2005; Patrick et al., 2001). The cost elements 
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of these studies should be considered with caution as they fall short of the 
recommendation proposed for a full analysis of costs, as well as due to the 
inconclusive findings, small sample sizes and lack of applicability to patients with 
RA (Drummond et al., 2005). Providing research for policy makers, which is 
intended to influence health-service provision, should include wide-ranging 
measurement of outcomes, and consideration of costs at the outlay (Kernick, 
2000). 
 
8.4 Methods of cost measuring & outcomes for economic analysis 
Because the resource is not available for its best alternative use, the appraisal 
principle used was the economic concept of opportunity cost, that is, the value of 
the foregone benefit (Drummond et al., 2005; Drummond et al., 1997). 
Opportunity cost is established on the basis that resources are rare, thus, every 
time resources are used in one way, the opportunity of using them in another way 
is removed. From an NHS perspective, the opportunity cost of using scarce 
resources to treat RA patients is the benefit. This might have been obtained from 
their best alternative use, for example the treatment of other patients with 
neurological and musculoskeletal injuries (Drummond et al., 2005; Drummond et 
al., 1997; Goodwin & Morrissey, 2003). Moreover, when considering costs 
incurred by patients, the opportunity costs are also important. It is believed that at 
the point of consumption, patients incur null costs because in a healthcare system 
the services are free (Ratcliffe et al., 1996). However, patients may be incurring 
costs because patients attending physiotherapy may incur travelling or childcare 
costs, or may forego income. 
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It has also been suggested that while some desirable interventions such as 
hydrotherapy may not modify life expectancy, they may provide remission and 
relieving effects and thus improve QoL, whereas others may meaningfully change 
both the quantity and QoL. Therefore, the cost-utility analyses are recommended, 
with QALYs serving as the preferred measure of effectiveness (Cohen & 
Reynolds, 2008; Gold et al., 1996). The costs to society and cost per QALY 
gained at six weeks following the main intervention were calculated because 
experts encourage the use of QALYs in cost utility studies mainly across a wide 
variety of health conditions such as RA (Cohen & Reynolds, 2008). From a 
societal perspective, the travelling time and time spent at the patient’s 
appointment has an alternative use – in the form of paid or unpaid work lost (work 
time or leisure time lost) as a consequence of the patient’s illness, for example the 
patient may be a student or homemaker, or a carer may have to stay in the home 
because of disease flare, hospital appointments for physicians or physiotherapists. 
 
This study estimated the incremental mean costs of the hydrotherapy programme, 
and the mean QALY was added to the programme from the perspectives of the 
healthcare provider, the patients and society. Costs were referred to as direct 
medical (NHS), direct non-medical (patient) and indirect (societal) costs. Due to 
the difficulties of their measurement and valuation, insubstantial costs in the form 
of pain and anxiety, related to the effect of receiving or not receiving treatment, 
have not been considered in this analysis (Goodwin et al., 2003). 
 
There are two methods of using QALY in the cost utility analysis. The standard 
method that is strongly recommended in economic theory is through directly 
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eliciting utilities from patients. Unfortunately, this method is difficult to apply 
practically in the UK for ethical reasons and because it is time consuming (Cohen 
& Reynolds, 2008; Gusi & Tomas-Carus, 2008; Torrance, 1986). The second 
method, which is more often used and called the ‘indirect method’, is where 
patients complete a generic health survey such as the EQ-5D (EuroQol Group, 
1990; Rabin et al., 2011a) or Short-Form 36 (Ware & Sherbourne, 1992). 
 
The cost utility analysis used the EQ-5D score (utility or tariff – see chapter 5, 
section 5.2.4.2, p.146) to calculate mean health-state values (plus measure of 
variance) of patients in the hydrotherapy group and land-therapy group at Test 1 
and Test 2. These scores were converted to QALYs. Estimates of mean costs and 
QALYs six weeks post-intervention were calculated (Epps et al., 2005). It is 
important to mention that total costs and QALYs remain undiscounted because 
the analysis was less than one year in duration. In this chapter, the costs included 
only the treatment patients actually received, irrespective of allocation or intended 
number of treatments, for which reason intervention-treatment sessions were 
recorded (Epps et al., 2005). Figure 8.1 (p.240) shows a schematic process of the 
points during the study, the cost data was collected. 
 
8.4.1 Direct medical (NHS) costs 
All these costs occurred within the healthcare sector relating to the provision of 
patient treatment, such as: 
 Staffing costs (physiotherapists, GP, physicians and consultants’ time); 
 Departmental costs (allocated overheads); 
 Medication (for example, prescribed by the GP/consultant); 
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 Other procedures (further surgery, examination, rehabilitation); 
 Equipment (allocation of fixed costs). 
 
Staffing time: Calculations of staffing time costs included the physiotherapist and 
assistant once a week for six weeks in the hydrotherapy group, and for the 
physiotherapist only in the land-therapy group. At the follow-up test, data were 
collected using questionnaires (Appendix 31) to determine the number of visits 
made to a GP or alternative therapist. Information on the cost of these visits to the 
patient was also collected after the six-week intervention period. General 
Practitioners’ (GP) time was calculated from an average surgery consultation of 
11.7 minutes (Curtis, 2011) and then multiplied by the number of visits made. The 
number of visits to the consultant rheumatologist was determined from the 
patient’s medical notes. 
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Figure 8.1:  Schematic processes for collecting data. 
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Staffing costs: these were calculated using the average wage rate (AWR) for GPs 
and physiotherapists (Table 8.1, p.242) (Curtis, 2011). GP costs were calculated 
using expected income for a full-time GP and an average surgery consultation 
time of 11.7 minutes and average cost of £36 per visit. The sum included practice 
expenses, qualifications, ongoing training, capital costs and overheads. Consultant 
rheumatologist costs were taken as the unit cost of a hospital medical outpatient 
attendance. Costs included the total net revenue expenditure for this service. For 
physiotherapists, costs were calculated based on the median full-time equivalent 
of a Band 5 clinician (Curtis, 2011) (Appendix 32). For assistants, costs were 
calculated based on the median full-time equivalent of a Band 3 Allied Health 
professional support worker (Curtis, 2011) (Appendix 33). Median full‐time 
equivalent total earnings included basic salary plus hours‐related pay, overtime, 
occupation payments, location payments, and other payments such as redundancy 
pay or payment of notice periods (Curtis, 2011). 
 
The sum included salary on costs, qualifications, indirect and capital overheads 
and training. An example of the unit estimation is taken from Curtis (2011) and 
shown in (Appendix 32). These data were applied from the NHS Reference Costs 
(Department of Health, 2011). Where subjects indicated that a visit to the GP had 
been made but no cost was incurred, it was supposed that no medication was 
prescribed. No cost to the NHS could be assumed as all of the subjects indicated 
that they were exempt from prescription charges (unemployed; over retirement 
age, full-time students under 19 and medical exemptions). Information regarding 
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medication prescribed by the consultant rheumatologists was obtained from the 
medical notes. 
 
Table 8.1: Key unit costs used to value resource use measured during the trial (prices = 
GBP £). 
Item Unit Cost (£) 
GP (Curtis, 2011) Per visit 36.00 
Consultant (medical) (Curtis, 2011) Per hour 89.40 
Physiotherapist (Curtis, 2011) Per 45min session 24.00 
Physiotherapy assistant (Curtis, 2011) Per 45min session 18.00 
AWR for male employer (Curtis, 2011) Per hour 8.70 
AWR for female employer (Curtis, 2011) Per hour 7.77 
AWR for housework and leisure time (Curtis, 
2011) 
Per hour 4.46 
Car usage (The Automobile Association Limited, 
2011) 
Per mile 0. 44 
Key: 
  
AWR: Average wage rate 
GP: GP 
Min: minutes 
 
 
Equipment Costs: During the physiotherapy treatment, these were calculated and 
expressed as the annual equivalent cost (Drummond et al., 2005; Drummond et 
al., 1997). The annual cost is based on a standardised 3.5% interest rate with an 
assumed life expectancy of equipment of five years, with an alternative 
assumption of 10 years (Building Cost Information Service, 2011; Curtis, 2011). 
The equipment purchased was used in the hydrotherapy pool for the treatment of 
all patients with variable diseases, therefore the capital outlay was a shared cost as 
patients with other injuries such as neurological disease or sports injuries were 
able to benefit from its use. The annual equivalent cost was apportioned to reflect 
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the time it was in use by these patients. Table 8.2 (p.244) shows the price of 
equipment, which was obtained from the 2012 catalogue for hydrotherapy and 
land-based therapy in the UK (JPLennard Ltd, 2012)
1
. Equivalent annual cost of 
equipment lasting more than one year was calculated, such as chlorination 
machine and gym-based equipment. The formula used to calculate the annual 
equivalent cost was (Drummond et al., 2005; Drummond et al., 1997):  
 
K = E/1-(1+R)
-n
/ r 
Where: 
K = Capital outlay  
E = Equivalent annual cost 
r = Discount rate (interest) 3.5% 
n = Useful life of equipment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
1 UK, Swift Point, Rugby, CV21 1PX 
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Table 8.2: Price of hydrotherapy and land-exercise equipment (adapted from 
JPLennard Ltd, 2012). 
Equipment 
Unit per 
annum 
Unit cost (£) 
Annual equivalent 
cost  (+VAT)* (£) 
Hydrotherapy consumables     
Woggle 6 5.9 35.40 
Ankle floats 4 5.52 22.08 
Ring 4 6.7 26.80 
Fins 1 12.49 12.49 
Paddles 1 10.5 10.50 
C collar 1 10.84 10.84 
Blocks 1 39.93 39.93 
Gloves 4 7.87 31.48 
Overshoes 100 pairs £8/50 pairs 16.00 
Chlorine tablets 2 12.95 25.90 
Maintenance 1 2300 2300.00 
Sodium hypochlorate 4 35.9 143.60 
Polyalum chloride 4 39.13 156.52 
Sodium bicarbonate 4 41.25 165.00 
Thyosulphate flakes 4 36.75 147.00 
Sodium biosulphate 4 32.62 130.48 
Delivery 4 55 220.00 
Plumbers 1 147 147.00 
Capital items    
Chlorination machine* 1 520 337.35 
 
Hydrotherapy Total 
  
 
£3978 
 
Land equipment    
Arm weights 1 20.76 20.76 
Floor Mat 3 18.75 56.25 
Exercise bike 2 260 520.00 
 
Land Total* 
  
 
£434 
 
 
Total 
  
 
£4.412 
 
*Annuitised 3.5*10 years 
 
8.4.2 Direct non-medical costs 
Direct non-medical costs are those foregone by the patient, family, or partner in 
the pursuit of treatment, such as out-of pocket expenses, including: 
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 Travel costs (patients, family, or partner); 
 Lost wages (patients, family, or partner); 
 Prescriptions costs; 
 Other costs. 
 
Travel costs: This describes all modes of travel to the hospital including car, bus, 
train, taxi, ambulance, walking and other such as Metrolink. Tickets on public 
transport were taken as the reported cost of a two-way ticket to the hospital. The 
cost of these journeys was doubled when accompanied by a companion who did 
not also have an appointment at the hospital. Car usage cost was determined at 44 
pence per mile based on a petrol car costing up to £12000 travelling an average of 
10,000 miles per year, including standing charges and running costs (The 
Automobile Association Limited, 2011). It was presumed that a car journey 
shared with a companion who also had an appointment at hospital halved the cost 
of that journey. Travel costs were excluded from any companions without 
appointments travelling by car, and walkers and cyclists incurred no travel costs 
on their journey (Goodwin et al., 2003). Parking fees were taken as the actual 
amount reported, and travel costs were not included if the subject was eligible for 
reimbursement. Lastly, we accounted for all journeys that included different 
modes of transport or involved one mode of transport to the hospital and a 
dissimilar one on return. 
 
Lost wages: These were included as out-of-pocket expenses only if the subject 
responded as taking ‘time off with loss of pay’ whilst attending physiotherapy. 
The out-of-pocket expense was taken as the AWR (£8.70 for males, £7.77 for 
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females) (PayScale, 2012). The AWR was substituted with the actual amount of 
pay lost, where it was reported. 
 
Prescription charges: Those resulting from GP visits were taken as the amount 
reported in the cost questionnaire (Appendix 31). If costs were omitted, but 
medication was prescribed, then the average cost of visiting a GP surgery was 
assumed. If medication was prescribed during a visit to the consulting 
rheumatologist, the average cost of attending a hospital outpatient appointment 
was assumed.  
 
Other costs: Those incurred whilst attending the physiotherapy appointment, extra 
to travel or medical costs, were gained from answers to a general question 
(Appendix 30) ‘Were there any other costs involved in visiting the hospital today 
which has not been covered above?’. 
 
8.4.3 Indirect costs 
Because of attending physiotherapy for hydrotherapy sessions, the lost 
productivity of a patient or family member or partner were the main indirect costs 
to be accounted. The rest of society tolerates these costs. Such costs include: 
 Value of time (travel and time spent at hospital). 
 Time lost from usual activities foregone, which could be: time lost from 
work or from non-working activities. 
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The value of time: This refers to the cost to the patient of the time foregone 
attending the physiotherapy appointment. Two aspects of time are considered and 
obtained from questions two and nine in Appendix 30:  
 Travel time; 
 Time spent at the hospital.  
To rate the time lost from usual activities foregone, data were collected on the 
opportunities forgone, that is, the activity subjects (and their companions) would 
have participated in had they not attended physiotherapy. 
 
Determining the usual activity forgone was by questionnaire (Appendix 30). 
Subjects were asked to indicate ‘what they (and their companion) would normally 
have been doing had they not had to visit the hospital’. The difference in the 
activity forgone is determined because savings in working time are of value to 
society as a whole, whereas savings in leisure or non-working time only benefit 
the individual.  
 
Subjects who would have otherwise been in ‘paid employment’ during their 
appointment were asked; ‘what arrangements they had made to be absent from 
work’. The value of time lost at the employer’s cost was the AWR raised by 
21.2% to reflect employers’ National Insurance and superannuation contributions 
(Department for Transport/Transport Analysis Guidance (TAG), 2011). This 
included those who responded as having ‘time off with pay’ whilst attending 
physiotherapy (Appendix 30). 
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The value of time lost to non-working activities was calculated for respondents 
who ‘arranged annual leave’, ‘rearranged their hours’, ‘would otherwise be 
looking after children, other relatives, or friends’, or who responded ‘other’. For 
those who would have otherwise been doing housework, the value of time was 
£4.46. For those who would have otherwise had leisure or non-working time, the 
value of time was £4.46 (Department for Transport/Transport Analysis Guidance 
(TAG), 2011). 
 
8.5 Data analysis 
Unit costs were taken from a variety of sources. To give a total cost per patient, 
the quantities of each resource used were multiplied by fixed unit-cost values and 
then summed up over the separate types of resources. Comparisons between 
groups were achieved using Levene’s test (for equality of variances) and the 
independent t-test. The t-test on untransformed data is the only test appropriate for 
costs, because it addresses a comparison of the arithmetic means (Thompson & 
Barber, 2000).  
 
To guide healthcare policy decision-making, a total annual budget is the relevant 
information required to provide a treatment at a specific hospital. An estimate of 
this total cost is obtained by multiplying the arithmetic mean cost of a particular 
treatment by the total number of patients (Thompson & Barber, 2000). 
Differences were determined statistically significant if the probability was less 
than 0.05. 
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8.6 Sensitivity analysis 
The number of participants treated per session was varied from one to four for 
both groups. By varying the number of patients treated at any one time, 
uncertainty around these results was dealt with using sensitivity analysis. 
 
8.7 Results 
Thirty-six (11 males and 25 females) out of 43 participants completed the cost 
questionnaire two weeks post-treatment. Therefore, the cost analysis was based on 
these data. 
 
8.7.1 The cost of staff 
 
8.7.1.1 NHS costs 
There was a significant difference (p = < 0.001) in the total NHS staffing cost per 
patient between the two groups. The mean total staffing cost per patient was £263 
in the hydrotherapy group compared to £145 in the land-therapy group (Table 8.3, 
p.250). No participants indicated visiting their consultant during the intervention 
period, and GP costs were the same for the two groups. The biggest difference 
was in physiotherapy staffing costs. 
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Table 8.3: The total NHS staffing costs of treating RA patients in the hydrotherapy and 
land-therapy groups. 
 
 
Because of the size of hydrotherapy pools [7.4 m
2
] it is possible to treat more than 
one patient at a time. At the two sites included in this study, it was usual to treat 
four patients at a time. Treating four patients at a time over six sessions, the total 
cost to the physiotherapy department per patient was £63 (Table 8.4, 251) 
meaning that the total staffing costs to the NHS would be £66 instead of £263, 
making hydrotherapy significantly cheaper. Treating four patients at a time on 
land would also reduce costs, however this is not normal clinical practice. 
 
  
 
 Total NHS staffing costs (£) 
Mean ± SD  (Range) 
 
Hydrotherapy group 
(n = 19) 
Land group 
(n = 17) 
 
p value 
(95% CI) 
 
 
Physiotherapist 
 
 
252 ± 0 
(252 to 252) 
135 ± 28 
(48 to 144) 
< 0.001 
(-132 to -103) 
GP 
 
11 ± 29 
(0 to 108) 
 
10 ± 27 
(0 to 108) 
0.936 
(-19 to 20) 
Consultant 
rheumatologists 
 
0 
 
0 N/A 
Total 
 
263 ± 29 
(252 to 360) 
145 ± 42 
(48 to 252) 
< 0.001 
(-143 to -94) 
Significant p values are indicated in boldface 
Key: 
  
N/A: Not applicable 
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Table 8.4: Physiotherapy staffing costs over an average of six sessions in two groups, 
varied for the number of RA patients treated. 
 
 
 
Patients in both groups reported visiting their GP during the intervention period 
with no statistically significant difference between the two. In the hydrotherapy 
group, three subjects (15.7%) visited their GP a total of six times compared to 
three subjects (17.6%) in the land-therapy group visiting a total of five times 
(Table 8.5, p.252). No subjects in the hydrotherapy group reported prescriptions 
for medication during GP visits, whereas the land-therapy group reported an 
average cost of £3.  
 
 
Total physiotherapy 
staffing costs in the 
hydrotherapy group 
(£) 
Total physiotherapy staffing 
costs in the land group 
(£) 
 
 
Ratio 
 of 
patients 
 
Mean 
 
SD 
 
Range 
 
Mean 
 
SD 
 
Range 
p value 
(95% CI) 
1:1 263 29 252 to 360 145 42 48 to 252 
 
< 0.001 
(94 to 148) 
 
2:2 
 
132 
 
15 
 
126 to 180 
 
72 
 
21 
 
 
24 to 72 
 
< 0.001 
(-47 to -2) 
 
3:3 
 
88 
 
10 
 
84 to 120 
 
48 
 
14 
 
16 to 84 
 
< 0.001 
(31 to 48) 
 
 
4:4 
 
66 
 
7 
 
63 to 90 
 
34 
 
7 
 
12 to 36 
 
< 0.001 
(57 to 86) 
 
 
4:1 
 
66 
 
7 
 
63 to 90 
 
145 
 
42 
 
48 to 252 
 
< 0.001 
(-101 to -57) 
Significant p values are indicated in boldface 
 
Key: 
 
SD:  Standard deviation 
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Table 8.5: Total medication and GP visitor cost to patient for the hydrotherapy and land-
therapy groups after intervention. 
 
Total NHS medication and procedure Costs (£)  
 
 
 
p value 
(95% CI) 
 
Hydrotherapy group 
(n=19) 
Land-therapy group 
 (n= 17) 
n 
Mean 
number 
of visits 
Mean ± 
SD 
(Range) 
n 
Mean 
number of 
visits 
Mean ± 
SD 
(Range) 
 
GP 3 2 
11 ± 29 
(0 to 108) 
3 1.6 
10 ± 27 
(0 to 108) 
0.936 
(-18 to 20) 
Medication 0 0 0 1 1 
3 ± 13 
(0 to 55) 
0.332 
(-10 to3.6) 
Total 
                2           11 ± 29 
                           (0 to 108) 
         2.6               13 ± 40 
                              (0 to 108) 
0.835 
(-26 to 21) 
Key: 
  
SD: Standard deviation  
 
 
The annual equivalent cost of hydrotherapy equipment was calculated as £4.412, 
which was based on a ten-year life span. The cost of equipment for a 45-minute 
session cost the NHS £10 for one patient, £5 for two, £3.3 for three and £2.5 for 
four patients compared to £0.06 for treating one patient on land. 
 
The total cost to the NHS of treating one patient for an average of six sessions in 
hydrotherapy was £325 compared to £148 on land (Table 8.6, p.253). When 
applying a real-world situation, the total cost of four patients treated at the same 
time in the hydrotherapy pool was £83 compared to treating one patient on the 
land, which was £148 – a saving of £65 (95% CI: -90 to -41; p < 0.001) (Table 
8.6, p.253). 
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Table 8.6: Comparison of total NHS costs between the hydrotherapy and land-therapy 
groups over an average of six sessions in two groups, varied for the number of RA 
patients treated. 
 
Total NHS cost 
in hydrotherapy 
(£) 
Total NHS cost 
in land-therapy group 
(£) 
 
Patients 
per class 
Mean ± SD 
(Range) 
Mean ± SD 
(Range) 
p value 
(95% CI) 
 
1 
325 ± 29.5 
(314 to 422) 
148 ± 52 
(48 to 307) 
< 0.001 
(149 to 205) 
2 
162 ± 15 
(157 to 211) 
74 ± 26 
(24 to 154) 
< 0.001 
(74 to 103) 
3 
108 ± 10 
(105 to 141) 
49 ± 17 
(16 to 102) 
< 0.001 
(50 to 68) 
4 
83 ± 9 
(78 to 105) 
37 ± 13 
(12 to 77) 
< 0.001 
(38 to 53) 
4* 
83 ± 9 
(78 to 105) 
148 ± 52 
(48 to 307) 
< 0.001 
(-90 to -41) 
*Compared four patients in the pool with one on land 
Significant p values are indicated in boldface 
 
Key: 
 
SD: Standard deviation 
 
 
8.7.1.2 Patient cost 
8.7.1.2.1 Direct non-medical costs 
The characteristic transport data are shown in (Table 8.7, p.255). Moreover, 
Figure 8.2 (p.254) showed work status of participants in both groups. 
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Figure 8.2: Work status of participants in both groups. 
 
In both groups, the average return distance travelled to hospital to attend 
physiotherapy was similar (hydrotherapy group = 13 miles; land-therapy group = 
14 miles). The majority of participants in both groups travelled to and from the 
hospital by car. One patient in the hydrotherapy group came by taxi. One patient 
in the land-therapy group walked to all hospital appointments. The mean total cost 
of travelling to and from physiotherapy for those in the hydrotherapy group was 
£41, compared to £25 for those in the land-therapy group. This difference was not 
statistically significant (p = 0.219) (Table 8.8, p.256). One patient in the land-
therapy group was eligible for reimbursement of travel costs by their employer. In 
both groups, the average return distance travelled to hospital to attend 
physiotherapy was similar. 
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Table 8.7: Transport characteristics in both the hydrotherapy and land-therapy groups, 
with the number of users in brackets. 
 
 
Table 8.8 (p.256) shows the total average out-of-pocket expenses incurred by 
patients in both the hydrotherapy and land-therapy groups. In total, the 
hydrotherapy group spent approximately £52 per patient compared to the land-
therapy group, who spent £45. This difference was not significant (p = 0.794). 
One patient in the land-therapy group attended two sessions of occupational 
therapy, and one patient in the hydrotherapy group attended six sessions of 
acupuncture. No participants in the hydrotherapy group reported any wages lost or 
                                                          
2 Taxi cost for only one patient in each visit 
3 Other in the hydrotherapy group refers to the Metrolink (Tram Network) 
 
Hydrotherapy group 
n = 19 
Land-therapy group 
n = 17 
Return travel distance (miles) 13 14 
Parking car fees (£) 4.5 2 
Taxi cost (£) 11 (1/19) ---- 
Method of transport 
 
Car 
Bus or train 
Taxi 2 
Walk 
Ambulance 
Other 3 
 
 
73.7% (14/19) 
10.4% (2/19) 
5.3% (1/19) 
------ 
5,3% (1/19) 
5.3% (1/19) 
 
 
76.4% (13/17) 
11.8% (2/17) 
----- 
11.8% (2/17) 
---- 
---- 
Reimbursement 
Yes 
No 
 
----- 
100% (19/19) 
 
5.9% (1/17) 
94.1% (16/17) 
Companions 
Yes 
No 
 
31.6% (6/19) 
68.4 (13/19) 
 
35.3 (6/17) 
64.7 (11/17) 
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prescription charges. However, one person reported lost wages and two persons 
reported prescription charges in the land-therapy group.  
  
Table 8.8: Patient out-of-pocket expenses incurred during the six-week intervention 
period for the hydrotherapy and land-therapy groups. 
 
Out of-pocket expenses per patient (£) 
Mean ± SD (Range) 
 
 
Hydrotherapy 
group 
n = 19 
Land-therapy 
group 
n = 17 
p value 
(95% CI) 
 
Travel to 
physiotherapy 
 
41± 50 
(0 to 219) 
25 ± 20 
(0 to 65) 
0.219 
(-10 to 42) 
Lost earnings whilst 
at physiotherapy 
 
0 
17 ± 72 
(0 to 300) 
N/A 
Prescription charges 
 
0 
 
2.5 ± 7.5 
(0 to 29) 
N/A 
 
Other 
4
 
 
11 ± 48 
(0 to 210) 
0.50 ± 1.50 
(0 to 6) 
0.368 
(-13 to 35) 
Total (£) 
52 ± 68 
(0 to 253) 
45 ± 78.7 
(0 to 336) 
0.794 
(-43 to 54) 
Key: 
 
SD: Standard deviation 
N/A: Not applicable 
 
 
8.7.1.2.2 Indirect costs 
Patients spent a similar amount of time travelling and at the hospital, whether they 
were attending hydrotherapy or physiotherapy on land. In the hydrotherapy group, 
the mean time lost travelling to the hospital over the course of the six weeks was 
64 ± 44 (range = 20 to 200) min. The mean time lost at the hospital attending 
physiotherapy, including waiting time was 58 ± 28 (range = 30 to 120) minutes. 
Therefore, the mean total time lost was 120 minutes ± 57 (range = 50 to 250) 
                                                          
4 Acupuncture in the hydrotherapy group and occupational therapy in the land-therapy group 
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minutes and the cost would be zero because no participants mentioned any wage 
lost during travelling (Table 8.9, p.259). 
 
In the land-therapy group, time lost travelling to the hospital over the course of 
the six weeks was 48 ± 23 (range = 20 to 90) min. The mean time lost at the 
hospital attending physiotherapy, including waiting time, was 61± 34 (range = 30 
to 150) min. Consequently, the mean total time lost was 110 ± 45 (range = 50 to 
190) min and the cost would be £17 ± 30 (range 4 to 133) because only one 
participant in the land-therapy group lost wages; approximately £300 for six 
sessions of land therapy. 
 
Figure 8.3 (p.258) shows the usual activities performed, had patients not had to 
visit the hospital, between two groups. Patients in the hydrotherapy group who 
said they would have otherwise been at work (n = 2) made alternative 
arrangements in their absence when attending the physiotherapy appointment 
(such as time off with pay). Patients in the land-therapy group who said they 
would have otherwise been at work (n = 4) made alternative arrangements in their 
absence (hours rearrangement n = 1; time off without loss of pay n = 2; time off 
with loss of pay n =1). However, this difference was not significant (Table 8.10, 
p.260 and Table 8.11, p.260). 
258 
 
 
Figure 8.3: Usual activities, performed had patients not had to visit the hospital, between 
two groups. 
 
While six patients (31.6%) attending hydrotherapy and four patients (23.5%) 
attending physiotherapy on land reported looking after a child, none reported 
incurring childcare costs. Six participants in each group were accompanied to 
physiotherapy. However, the companion in both groups did not have an 
appointment at hospital, was not in paid occupation and would not have been 
looking after a child had they not been accompanying the patient, thus no 
childcare costs were incurred. 
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Table 8.9: Summary of time travel and wait at hospital, and total time lost during one 
visit to physiotherapy. The number of treatments received in both groups was multiplied 
by the total cost of time (time with loss of pay). 
 
Hydrotherapy 
group (n = 19) 
 
Mean ± SD 
(Range) 
land-therapy  
group 
(n = 17) 
 
Mean ± SD 
(Range) 
p value 
(95% CI) 
 
 
Time lost travelling 
(min) 
64 ± 44 
(20 to 200) 
48 ± 23 
(20 to 90) 
0.366 
(-37 to 14) 
Time lost at hospital 
(min) 
58 ± 28 
(30 to 120) 
61 ± 34 
(30 to 150) 
0.712 
(-17 to 25) 
Total time lost (min) 
120 ± 57 
(50 to 250) 
110 ± 45 
(50 to 190) 
0.555 
(-46 to 25) 
Cost (£) of time lost 
during all visits 
0 ± 0 
(0 to 0) 
17 ± 30 
(4 to 133) 
N/A 
Key: 
 
SD: Standard deviation  
NA: Not applicable  
Min: minutes 
 
 
For either group, whether a patient should have been doing ‘other’ activities, or 
childcare, there were no significant differences in the cost of their time (Tables 
8.10, p.262 and 8.11, p.262). 
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Table 8.10: Time lost during hospital attendance and its total cost for those who would 
have otherwise been looking after a child whilst attending hospital in both groups. 
 
Hydrotherapy group 
(n= 19) 
 
Mean ± SD 
(Range) 
Land-therapy 
group 
(n= 17) 
 
Mean ± SD 
(Range) 
p value 
(95% CI) 
 
n = (%) 6 (31.6) 4 (23.5)  
Time lost from 
travel (min) 
76.6 ± 28.7 
(40 to120) 
60 ± 21.6 
(40 to 90) 
0.397 
(-20 to 45) 
Time lost at 
hospital (min) 
57.5 ± 22 
(30 to 90) 
52.5 ± 9.6 
(40 to 60) 
0.745 
(-49 to 36) 
Total time lost 
(min) 
129 ± 43 
(75 to180) 
112 ± 28.7 
(90 to 150) 
0.806 
(-51 to 64) 
Cost (£) of time 
lost during all 
visits 
38.5 ± 19 
(13 to 503) 
16.7 ± 15.7 
(7 to 40) 
0.097 
(-39 to 26) 
Key: 
  
SD: Standard deviation 
Min: minutes 
 
 
Table 8.11: Time lost during hospital attendance and its total cost for those who would 
have undertaking ‘other’ activities whilst attending hospital in both group. 
 
Hydrotherapy group 
(n= 19) 
 
Mean ± SD 
(Range) 
Land-therapy group 
(n= 17) 
 
Mean ± SD 
(Range) 
p value 
(95% CI) 
n= (%) 
11 
(57.8) 
9 
(52.9) 
 
Time lost from 
travel (min) 
59 ± 51 
(20 to 200) 
43 ± 16 
(20 to 60) 
0.100 
(-64 to 5.4) 
Time lost at 
hospital (min) 
68.6 ± 4 1.8 
(30 to 150) 
43 ± 9 
(30 to 60) 
0.774 
(-26 to 35) 
Total time lost 
(min) 
127.7 ± 65.5 
(50 to 250) 
86.6 ± 21.6 
(60 to 120) 
0.301 
(-75 to 24) 
Cost (£) of time 
lost during all 
visits 
41 ± 36 
(3.72  to 111) 
35 ± 33 
(6 to 108) 
0.690 
(-39 to 26) 
Key: 
 
SD: Standard deviation 
Min: minutes 
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8.7.1.3 Societal cost 
Hydrotherapy and land therapy showed similar costs to society (Table 8.12). Both 
groups lost similar amounts of time and attended a similar number of sessions. 
The value of time was similar in both groups. In the hydrotherapy group, the 
average total cost to society was £60 per patient compared to £64 in the land-
therapy group (p = 0.790). 
 
Table 8.12: The total cost to society per patient, including time lost in physiotherapy 
attendance and time spent at hospital, multiplied by number of sessions and value of time 
(time without loss of pay). 
Total cost to society per patient (£) 
Mean ± SD 
(Range) 
 
Hydrotherapy 
group (n = 19) 
Land-therapy 
group (n = 16) 
p value 
(95% CI) 
Value of time 
(£/hour) 
5 ± 1 
(4 to 8) 
6  ± 2 
(4 to 9) 
0.214 
(-2 to 8) 
Time lost (hour) 
 
2 ± 1 
(1 to 4) 
2 ± 1 
(1 to 3) 
0.554 
(-0.75 to 0.41) 
Average number 
of sessions 
6 ± 0 
(6 to 6) 
6 ± 1 
(2 to 6) 
0.168 
(-1 to 0.19) 
Total 
 
60 ± 43 
(13 to 198) 
64 ± 48 
(12 to 179) 
0.790 
(-27 to 35) 
Key: 
 
SD: Standard deviation 
 
8.7.1.4 Cost utility and cost effectiveness 
The change in QALYs over six weeks of intervention (between Test 1 and Test 2) 
was not significantly different (p = 0.88) (Table 8.13, p.262). 
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Table 8.13: Cost-utility (tariff) analysis of EQ-5D tariff between hydrotherapy and land-
therapy groups. 
Variables 
Hydrotherapy 
group 
(n = 19) 
 
Mean ± SD 
(Range) 
Land group 
(n = 17) 
 
Mean ± SD 
(Range) 
 
p value 
(95% CI) 
 
EQ-5D tariff at 
baseline 
0.62 ± 0.3 
(-0.02 to 1) 
0.51 ± 0.3 
(-0.2 to 1) 
0.579 
(-0.1 to 0.2) 
EQ-5D tariff at 
6 weeks 
0.61 ± 0.2 
(0.1 to 1) 
0.51 ± 0.3 
(-0.4 to 1) 
0.450 
(-0.1 to 0.3) 
QALY change 
-0.01 ± 0.3 
(-0.5 to 0.7) 
0 ± 0.4 
(-1 to 0.8) 
0.88 
(-0.2 to 0.2) 
QALY: 1= Perfect health 
 
Key: 
 
QALY: Quality Adjustive life year  
SD: Standard deviation  
EQ-5D tariff score (0.594 to 1), with 1 being perfect health, and 0.594 being worse than death 
 
 
In Study One, the primary outcome measure was the HAQ-DI. The change score 
was used to measure the effect between groups. Based on the HAQ-DI, the ICER 
(Figure 8.4, p.263) was calculated. Every one unit of improvement on the HAQ-
DI scale using hydrotherapy would cost an additional £197. This was calculated 
by dividing total NHS cost of one patient treated in hydrotherapy minus total NHS 
cost of one patient treated on land (Table 8.6, p.253) over change score of HAQ-
DI in the hydrotherapy group between Tests 1 and 2 (0.7), minus change score of 
HAQ-DI in the land-therapy group between Tests 1 and 2 (0.2) (Kobelt, 1996). 
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ICER   = £197 per increase in HAQ-DI score 
 
Figure 8.4: Incremental cost effectiveness ratio (ICER) of treatment on a 1:1 basis. 
 
 
8.8 Numbers needed to treat (NNT) 
The NNT in Study Three was 2.5 (Table 8.14); the cost of producing an overall 
improvement in the HAQ-DI in one patient over six weeks (NNT x the total NHS 
cost) was £197. 
 
Table 8.14: Number needed to treat (NNT). 
 
N of 
patients 
N of 
events
5
 
Risk differences 
Number needed to 
treat 
(NNT) 
Hydrotherapy 21 16 16/21-8/22 = 0.4 
(40%) 
1/0.4 (= 100/40) = 2.5 
Land therapy 22 8 
 
 
8.9 Limitations of the cost chapter 
From a cost point of view, it would have been interesting if the data had been 
collected at three or six months after the intervention, as well as at six weeks. 
Although it is important to understand the immediate impact hydrotherapy has 
during treatment, for a long-term disease such as RA, long-term costs are equally 
as essential. An understanding of long-term costs would have provided a greater 
                                                          
5 Overall improvement in the HAQ-DI score 
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insight into the affect hydrotherapy had on the NHS in terms of GP and consultant 
costs; it would have also given an insight into societal costs in terms of the 
benefits of returning to work or being able to undertake usual activities, as well as 
the direct and indirect savings made that were related to the patient. 
 
In Study One, the sample size was based, a priori, on the HAQ-DI. Sample size 
calculations are generally based on clinical rather than cost data because economic 
trials run alongside clinical trials. Conventionally, cost data is more variable than 
clinical data, making it difficult to identify statistical differences at the same level 
of inferential error (Drummond et al., 2005). To overcome this, the options are to 
either accept lower levels of precision, for example increase the accepted level of 
significance (p > 0.05), or extend the data collection beyond the point at which the 
clinical question had been answered. However, to treat and test patients beyond 
the point at which the clinical question had been answered would be unethical. 
Issues around determining what size of difference would be economically 
important and choosing the relevant resource quantity are the major drivers for 
therapy costs (Drummond et al., 2005). 
 
The aim here was to calculate the cost per QALY using the EQ-5D. This would 
provide cost-utility results that could be compared across conditions. However, 
the QALY did not detect any improvements over the six-weeks intervention 
period. Studies have found problems using the EQ-5D with RA patients. Hurst et 
al. (1997) has previously described the reliability of the EQ-5D index and EQ-5D 
VAS as good or better than that of other instruments, including the HAD (Zigmond 
& Snaith, 1983), ACR (Felson et al., 1993), ESR and VAS-pain except the HAQ-
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DI. Some patients with a severe, long-standing case of the disease reported health 
states of less than 0, i.e. 'worse than death'. Alava et al. (2013) demonstrated that 
better estimates of the benefits of RA treatments in terms of QALYs will be 
gained if the HAQ-DI and pain are simultaneously considered instead of the EQ-
5D (Alava et al., 2013). This is a new technique and not one that was adopted in 
this study. Harrison et al. (2010) recommended the inclusion of preference-based 
scores (e.g. EQ-5D) alongside disease specific measures (e.g. HAQ), as in Study 
One, because predicting one from the other is unreliable. In an attempt to predict 
EQ-5D and SF-6D scores from the HAQ, they found that predicted utility scores 
overestimated baseline values but underestimated change. Predicting utility values 
from the HAQ will therefore likely underestimate the QALYs of interventions, 
particularly for patients with active disease. Using the HAQ-DI instead of the EQ-
5D facilitated the calculation of ICER and NNT, but it permits disease-specific 
comparisons only. 
 
This study is the start point for economic evaluations in adult hydrotherapy. A 
paucity of other studies for comparison means that there is little context upon 
which to base the findings. Clinicians and managers wishing to use the positive 
results from this study to inform their own services will require a notion of their 
own willingness to pay and budget (resources available to them), rather than 
whether it is good value compared to other physiotherapy interventions.  
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8.10 Summary  
This chapter set out to determine the cost of providing RA patients with 
hydrotherapy compared to land-based physiotherapy from NHS, patient and 
societal perspectives. 
 
On a 1:1 basis, the NHS will spend, on average, £177 more per patient on 
hydrotherapy treatment than on land-therapy treatment. However, when treating 
patients on a 4:1 basis, that is, four patients at a time in hydrotherapy compared to 
a single patient on land, hydrotherapy is a more cost-effective treatment and the 
NHS can save, on average, £65 per patient. For the patient and society, there is no 
difference in cost whether treated in the hydrotherapy pool or on land. 
 
Because no improvements were found in either group using the EQ-5D, the 
incremental cost per QALY was not calculated. The ICER was calculated using 
the HAQ-DI. Providing six sessions of hydrotherapy to four patients is more 
effective and less costly than providing treatment to one patient on land when 
measured using the HAQ-DI and so therefore should be adopted. 
  
The overall findings from this chapter have revealed that the provision of 
hydrotherapy on a class basis for patients with RA is cheaper and more effective 
to the NHS than treating one patient on land. However, this provision did reduced 
neither the cost of GP or consultant time, nor that of prescribed medication or to 
the patient or society.  
 
The following chapter will discuss the findings of the three studies. 
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9.1 Introduction 
The null hypothesis (H0) for Study One stated: ‘There will be no significant 
difference in HAQ-DI score between hydrotherapy and land-therapy arms in 
patients with RA.’ This has been rejected by the evidence from this research 
study, which has demonstrated that hydrotherapy is an effective treatment for RA 
in functional improvement. However, there are many factors that have a direct 
bearing on this statement, all of which have to be considered in their own right. 
Each factor will be compared and discussed in light of this finding. 
   
Because of the different nature of the three studies, this discussion will be based 
on the findings from the three interrelated studies and their interpretations: Study 
One, which evaluated the difference in outcomes and explains the reasons for the 
difference between those receiving hydrotherapy and those subject to land 
therapy, Study Two examined the demographic characteristics of the participants 
and discussed them in relation to other comparator studies, and Study Three, in 
which the cost of treatments was evaluated. Therefore, the discussions will be 
presented under three separate headings for ease of reading. Conclusions drawn 
from this discussion chapter will include the main findings of the three studies and 
provide areas for future research.  
 
CHAPTER NINE: DISCUSSION 
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9.2 Study One (RCT) 
9.2.1 Introduction 
This RCT evaluated the efficacy of hydrotherapy compared to that of land-based 
exercise for RA patients. The results of the evaluation of physical function 
(functional ability, pain, and GWB), disease activity, HRQoL and mood 
symptoms in patients with RA have been presented in Chapter 6. The RCT Study 
One findings demonstrated that a six-week, once-weekly exercise programme for 
people with RA treated in the hydrotherapy pool resulted in improvement in 
functional ability score, reduction in pain score, improvement in GWB, QoL and 
psychological wellbeing, with no corresponding improvement in the land 
treatment. 
  
9.2.2 Comparisons of primary outcome measure  
HAQ-DI 
The HAQ-DI is limited to areas of functional status concerned with the 
performance of daily tasks (Van den Ende et al., 1997). The positive finding of 
HAQ-DI change score between both groups (p < 0.001) reflects this certainty. 
  
In Study One, improving the functional ability of participants may be at least 
partially attributable to the warm-water environment of the hydrotherapy pool. 
Warm water may encourage muscle relaxation and improves muscle strength, 
endurance, suppleness and aerobic fitness, thus reducing guarding around joints 
and enhancing movement (Hinman et al., 2007). The physical properties of water 
such as buoyancy, thermodynamics and viscosity might provide suitable media to 
maintain joint mobility and strength. Although it is possible that some benefits of 
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hydrotherapy will be attributable to warm water immersion alone, Hall et al. 
(1996) confirmed this in a previous RCT in RA, demonstrating superior effects of 
hydrotherapy over seated immersion alone. Perhaps this indicates that the most 
important property of the hydrotherapy is the buoyancy of the water, rather than 
its warmth.  
 
Buoyancy reduces the physical load on the joints and promotes muscle relaxation, 
thus allowing more pain-free movement and enabling exercise against water 
resistance. This improves functional ability and stimulates more active exercise of 
the muscles and joints than would otherwise be possible (Eversden et al., 2007; 
Hall et al., 1996; Prins, 2009; Schrepfer, 2002). As the warmth of the water has a 
sedative effect on nerve endings, it therefore reduces pain and discomfort that 
occurs when nerve endings are stimulated, further to this, joints have more 
freedom of movement as a result or reduced pain (Bender et al., 2005; Kjellgren et 
al., 2001).  
 
The positive finding in this study that hydrotherapy improves functional ability is 
encouraging. However, it is in contrast from the two previous hydrotherapy 
studies, which have both shown negative findings, namely Sanford Smith et al. 
(1998) (p > 0.05) and Eversden et al. (2007) (p > 0.09). However, Bilberg et al. 
(2005) showed that hydrotherapy significantly improves the overall score of the 
HAQ-DI in the six months following treatment (p < 0.05); however, their study 
did not show any immediate improvements following treatment. Bilberg et al., 
(2005) did not use a comparator group in the follow-up period. The small sample 
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size in the study by Sanford Smith et al. (1998) (n = 24) may be another factor 
that can account for the negative results of HAQ post treatment. 
 
In Study One, the significant post-treatment improvement in HAQ-DI and its 
categories (dressing and grooming, walking, hygiene, reach and activities) may be 
due to the responsiveness of HAQ-DI to the hydrotherapy and itis physical 
properties. Therefore, this may explain, in part, the reason for the trend of 
improvement in functional ability directly after hydrotherapy sessions. Buoyancy 
offers the patient joint unloading with relative weightlessness, which enabled 
performance of active motion with increased ease (Schrepfer, 2002). It seems 
possible that these results are due to physical properties of water, which enhanced 
functional activity through improved ROM, strength and decreased pain. This 
means that for participants in this study, the performance of daily tasks were 
improved by hydrotherapy. 
 
In the follow-up period at three and six months, the reasons for non-significant 
findings of HAQ-DI are not clear, but may have something to do with number of 
participants involved, as 14 out of 21 and 10 out of 21 participants in the 
hydrotherapy groups completed the programme, respectively, compared to 14 out 
of 22 and nine out of 22 in the land-therapy group, respectively (Figure 6.1, 
p.169). Additionally, since this difference has not been found elsewhere in follow-
up periods, it is probably due to the physical properties of water having no long-
term benefits to improve functional ability. Other explanations of failure to 
improve functional ability at the follow-up periods might be either that the 
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participants would have adversely affected their self-efficacy expectations, or that 
they were not aware of their physical limits (Michael et al., 1995). 
 
Studies have reported limitations in using HAQ-DI for measuring functional 
ability. Pincus et al. (1983) noted that the degree of patient dissatisfaction from 
using HAQ-DI might be associated with the amount of perceived difficulty with a 
task (Pincus et al., 1983), their study demonstrated that the stated capacity of 
patients might improve or decline significantly within the responses [‘with some 
difficulty’ or ‘with much difficulty’] because these responses do not give enough 
boundaries. An alternative is that the patients were sometimes not able to describe 
their physical limitations because they found it difficult to interpret the question or 
translate the limitations to fit the answers available. 
 
De Jong et al. (2003) evaluated the effects of long-term land exercise in 309 RA 
patients. They used HAQ-DI to measure functional ability. However, they found 
no significant differences in HAQ-DI after two years (p = 0.09). They justified 
these results by claiming that changes in physical impairments and physical 
function may be weakly associated with changes in the HAQ score. A major 
weakness of the study is, however, that they have included patients with relatively 
mild functional impairment in patients with RA; this might explain the HAQ’s 
lack of sensitivity to change. 
 
Conversely, Van den Ende et al. (1997) used the HAQ to determine changes in 
100 RA patients following a short-term land exercise programme (12 weeks, three 
times weekly). The findings suggested that the HAQ was not useful as a 
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functional outcome measure in short-term exercise trials. However, this study 
analysed data of patients who were only mildly disabled as measured by HAQ, 
and this may therefore explain the lack of significant results.  
 
Study One results differed from De Jong et al. (2003) and Van den Ende et al. 
(1997) in two respects. Firstly, at Test 1, HAQ-DI scores had moderate to severe 
difficulty or disability showing an overall score of HAQ-DI (1.1 to 2) (Bruce & 
Fries, 2003). Secondly, the physical properties of water in six sessions per six 
weeks, as recommended by HyDAT team (2009), provided favourable results. 
Thus, the findings indicate that HAQ-DI is a worthwhile instrument for use in a 
hydrotherapy exercise study, at least in the short term. Our participants also 
showed a marked decrease in pain and increase in function ability. 
 
An implication of this is the possibility that functional ability assessment by 
HAQ-DI should be considered when assessing patients with RA, and that they 
may benefit from therapeutic intervention of hydrotherapy directed towards 
improving their function. 
 
9.2.3 Comparisons of secondary outcome measures 
9.2.3.1 Pain (HAQ VAS) and general wellbeing (HAQ-GWB) 
HAQ VAS 
VAS was used in this study to measure pain, which is part of the two short pages 
of HAQ. Originally considered to assess arthritis-related pain (presence or 
absence), VAS was used for pain assessment, measuring the severity of pain in the 
past week (Bruce & Fries, 2003). This instrument has frequently been used to 
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evaluate the efficacy of exercises on patients with RA. Pain is one of the most 
common rheumatological complaints that is assessed in RA patients (Huskisson, 
1974). 
 
Huskisson (1974) was the first to report pain intensity in patients with RA by 
using VAS. In Study One, the participants were asked about pain experienced in 
the previous week before entering the study, and initial mean VAS scores for pain 
were recorded as being higher than those reported in previous studies such as 
Eversden et al. (2007) and Rintala et al. (1996). 
  
The reduction in pain found in the hydrotherapy group is a very significant benefit 
for such patients. In this sample of patients with RA disease, HAQ VAS was 
sensitive to change following the six-week programme. These findings further 
support the idea of pain being relieved after hydrotherapy (Ahern et al., 1995).  
 
A number of different factors may explain reduction in pain post-hydrotherapy. 
The improvement might be due to the physiological effects of hydrotherapy that 
induce release of opioid peptides such as Alpha-endorphin, or methionine 
encephalin (Bender et al., 2005; Coruzzi et al., 1988). Hydrotherapy has the 
capability to induce methionine encephalin plasma levels, associated with a fall in 
blood pressure and heart rate (Coruzzi et al., 1988). Endorphins and encephalins 
are suggested to play a leading role in endogenous anti-nociception because 
endogenous opioid peptides are released from immune cells and have strong 
immune-modulatory effects (Lesniak & Lipkowski, 2011). 
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There are, however, other possible explanations for reduction of pain that might 
be related to a pain-gate theory.  The gate-control theory of pain by Melzack & 
Wall (1965), suggests that the transmission of nerve impulses from afferent fibres 
to spinal cord transmission (T) cells is modulated by a spinal gating mechanism in 
the dorsal horn (Melzack, 1993). A mechanism in the dorsal horns of the spinal 
cord acts like a gate that inhibits nociceptors’ transmission from the body to the 
spinal cord and then to the brain through polysynaptic interneurons (Melzack & 
Wall, 1965; Melzack, 1993). 
 
The spinal gating mechanism is influenced also by nerve impulses that descend 
from the brain. The observed decrease in pain could be attributed to the pain gate 
theory that pain is relieved through exercises in warm water that enhance the 
blood flow and facilitate the closure of the ‘gate’ in the spinal cord (Melzack, 
1993). This is why hydrotherapy is used as a pain-relieving treatment and patients 
experience an immediate effect with short-term carry over, but does not last over 
time. Further studies are required to determine the pathway in which hydrotherapy 
reduces pain in patients with RA. 
 
There is an important theory in personality psychology, the ‘locus of control’ 
(Phares, 1976; Spector, 1988). Psychological factors like locus of control play a 
role in adaptation to chronic illness such as RA (Phares, 1976; Spector, 1988). 
The main question addressed in this section is whether improvement in pain and 
other psychological-wellbeing terms, such as depression and wellbeing, might be 
attributed to locus of control, and whether this might be another possible 
explanation for relieved pain. 
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Locus-of-control theory was developed in 1954 by Julian Rotter, who discussed 
how the degree of control individuals believe they over events will affect their 
behaviour (Rotter, 1954; Rotter, 1966). There are two type of locus of control – 
internal and external (Rotter, 1954; Rotter, 1966). Internal control is when the 
person believes they can control the events that happen in their life (Rotter, 1954; 
Rotter, 1966). Conversely, external locus of control means that their decisions and 
life events are controlled by environmental factors, which they cannot influence 
(Cross et al., 2006).  
 
It has been proposed that patients with chronic pain and external locus of control 
do not believe in recovery, and thus avoid increasing their activity level, and 
report poor ability to reduce and control their pain, compared to those with 
internal locus of control, who may develop strategies to deal with pain and thus 
report lower pain-intensity (Crisson & Keefe, 1988; Cross et al., 2006; Gustafsson 
& Gaston-Johansson, 1996). This means that their response to the intervention 
may depend on which locus of control is dominant.  
 
For instance, if patients with high internal locus of control believe that they have 
improved post-hydrotherapy, they might attribute this to their performance in the 
pool and reflect this response when completing the questionnaires. On the other 
hand, if patients with high internal locus of control felt that they had not improved 
post-treatment, they might attribute this to their tiredness or lack of focus on their 
performance in the pool.  
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When it comes to participants with high external locus of control who believe they 
had improved after the pool treatment, they might attribute this to the expertise of 
the therapist who had treated them, while those who felt they had not improved 
might attribute this to the lack of expertise of the physiotherapists. This type of 
behaviour might play a role when the participants filled out the questionnaires. 
Similarly, this type of behaviour in personality psychology might also have an 
impact on health behaviour, as those with an internal locus of control are likely to 
feel in control of their own health and feel capable of performing the necessary 
behaviours to preserve health (Cross et al., 2006). 
 
In the follow-up period (3 months) in Study One, no significant changes were 
found in either of the two groups. A possible explanation for some of our results 
may lie with other factors relating to the disease itself, which might have 
contributed to the lessening of pain; however, there is no definitive factor that this 
can be explained by.   
 
In the literature, VAS was used in three studies: Eversden et al. (2007), Rintala et 
al. (1996) and Stenström et al. (1991). Study One’s findings are consistent with 
those of Rintala et al. (1996) (p ≤ 0.05), which used VAS pain as a primary 
outcome measure, while both studies found that there was a statistically 
significant reduction in the pain level of RA patients after hydrotherapy. However, 
Eversden et al. (2007) (p = 0.40) and Stenström et al. (1991) (p > 0.05) found no 
significant improvement in the pain level following their interventions. Hall et al. 
(1996) found that all patients demonstrated a significant pain reduction (p ≤ 0. 
005) when using the McGill pain Questionnaire (scale, 0-100) (Melzack, 1975). 
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Therefore, our patients’ response was in accordance with other findings in the 
literature. 
 
The major finding in Study One was the fact that pain experienced by the 
hydrotherapy group decreased significantly during the six-week treatment period. 
The implication of this study’s findings is that pain intensity should be measured 
when assessing RA patients, and that they may therefore benefit from therapeutic 
intervention directed towards alleviating their pain in the short-term. However, the 
long-term efficacy of hydrotherapy is inconclusive. Furthermore, knowing pain 
intensity in these patients will help clinicians to evaluate the effectiveness of pain 
management in RA. 
 
HAQ-GWB 
HAQ-GWB measures the global health status of the patients’ GWB. In the Study 
One, HAQ-GWB was shown to have significant positive findings among RA 
hydrotherapy participants compared to the land-therapy group. The significant 
finding of global wellbeing indicates that RA patients, when treated using 
hydrotherapy, experienced better global health status compared to those in the 
land-based exercise group. Unfortunately, however, no available data were found 
in the literature relating to HAQ-GWB for comparison with these findings. 
 
All the previous studies only used HAQ-DI to measure functional ability rather 
than physical function. It has already been stated that GWB could be called 
psychological wellbeing (Bowling, 2004) because it could be used to measure 
self-reporting of intrapersonal affective or emotional states reflecting a sense of 
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subjective wellbeing or distress (Badia et al., 1996; Dupuy, 1984). The reason for 
improved GWB post-hydrotherapy is not clear, but it may have something to do 
with locus of control due to the fact that pain was improved, and this still reflects 
a general improvement in wellbeing.  
 
The present researcher is unaware of any study that has reported the effectiveness 
of any of these treatment methods for GWB management in patients with RA. 
Therefore, future studies may be directed towards developing a strategy for 
improving GWB in patients with RA. 
 
The implication of this finding is that GWB should be considered when assessing 
RA patients, and that they might benefit from therapeutic intervention. The 
reported improvement in wellbeing among these patients should give practitioners 
ideas for promoting and increasing wellbeing. 
 
9.2.3.2 Health related quality of life (HRQOL or QoL) 
HRQoL was measured by EQ-5D – that is, a two-part instrument, EQ-5D tariff 
(with it is descriptive profile) and EQ-5D VAS. 
 
EQ-5D VAS 
The second part of HRQoL, called EQ-5D VAS, records the subject’s self-assessed 
VAS, rating health on a vertical line on which the best- and worst-imaginable 
health states score 100 and 0, respectively. One of the most interesting findings in 
Study One was that the self-rated global health status measured by the EQ-5D VAS 
showed significant findings between the group comparison post-treatment (p = 
0.002), change score between Test 1 and Test 2 (p = 0.021), and within the 
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hydrotherapy group between Test1 and Test 2 (p < 0.001). This result may be 
explained by the fact that hydrotherapy improved pain, functional ability, 
psychological wellbeing and consequently, improved general-health status. The 
findings in this study further support the claim of Hurst et al. (1997) who state that 
the EQ-5D VAS is reliable and clearly useful for measuring changes in perceived 
health. These results suggest that the EQ-5D VAS is a helpful self-valuation tool for 
patients with chronic diseases such as RA. 
 
The non-significant findings in the score of EQ-5D VAS over time (follow-up 
period of three and six months, or change-score difference between Test 1 and 3 
or Test 2 and 3) might be explained when patients appraise their own health using 
this scale (EQ-5D VAS), however it cannot be expected that RA patients will assess 
their health in the same way over time because their perceptions of the disease 
severity will alter. 
 
Another explanation might be due to other factors influencing their disease 
course, such as exacerbation of disease activity and pain, as it is impossible to 
predict the trajectory of a systemic inflammatory disease such as RA. The EQ-5D 
VAS is recommended to clinicians who wish to use it as a quick and easy tool to 
measure a patient’s overall health and recovery.  
 
EQ-5D tariff and EQ-5D profile 
In this study, a time trade off (TTO) procedure was used to elicit utility weights 
for EQ-5D tariff health state because since the start of this study, a set of values 
has been obtained from a large sample (3,395) of the adult population of England, 
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Scotland and Wales (Dolan et al., 1995; Kind et al., 1998). This weighting 
presents on a scale on which full health and death score one and zero, 
respectively. 
 
In this study, the descriptive profile of EQ-5D was summarised demonstrating the 
frequency or the proportion of reported problems in each level for each 
dimension. Two studies investigated the validity\reliability and responsiveness of 
EQ-5D tariff in patients with RA (Eversden et al., 2007; Hurst et al., 1997). The 
present research findings on EQ-5D tariff are discussed in relation to these two 
studies. 
 
Study One produced no changes in the mean score of EQ-5D tariff in either group 
of RA patients at Test 1, Test 2, Test 3 or Test 4. No change was noted in the 
change score either. This could be due to a lack of sensitivity of the EQ-5D 
(Rabin et al., 2011a) when observing patients with mild to moderate RA. A lack 
of sensitivity was one reason as to why the EQ-5D 5L was developed. The EQ-5D 
5L increases the number of alternative health states to 3,127 from 245 in the 3L 
(Rabin et al., 2011b). 
 
The reason for the lack of effect measured using the EQ-5D tariff is not clear; one 
possible explanation might be the patient’s denial of adjustment to chronic 
disease, and it has been previously stated that health-state assessments differ 
according to experience of illness (Hurst et al., 1997). In the reviewed 
hydrotherapy literature, Eversden et al. (2007) was the only study that used QoL 
tools in terms of EQ-5D tariff and EQ-5D VAS, but no significant finding was 
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found in either HRQoL. The finding was similar even in a larger study by 
Eversden et al. (2007). However, the findings of Study One do not support the 
research study by Hurst et al. (1997), which stated that the EQ-5D tariff was 
highly responsive to self-reported improvement. 
  
There is no generally accepted definition or method to measure HRQoL, as the 
boundaries between health and disease are poorly defined; consequently, 
measurement of health is problematic (Carr et al., 1996; Hurst et al., 1997). The 
essential requirement of any instrument claiming to measure health outcomes is 
the ability to detect clinically important changes (Hurst et al., 1997). Analysing 
EQ-5D profile dimensions individually allowed this study to identify which 
activities presented problems for RA patients, this was possible because the RA 
sample in the study was small (43 patients). 
 
Firstly, it was shown that more than two thirds of patients reported problems in all 
dimensions at Test 1, Test 2 and Test 3. Secondly, as expected, elderly people 
reported more problems in all dimensions. Thirdly, no improvements were noted 
in all dimensions between groups except for the pain and discomfort dimension in 
the hydrotherapy group alone, and the number of patients who reported problems 
at Test 1 (n = 17/21) declined in Test 2 (n = 14/21)  and in Test 3 (n = 4/14) 
(Figure 6.2 and 6.3 in page 182). 
 
It was not expected that improvement in pain and discomfort would continue 
during the follow-up period, but this was a very positive finding. It was not 
possible for this study to determine the reason for this improvement where 
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responses were given using agreement scales. One major drawback of analysing 
individual dimensions is that it reduces the external validity by reducing the 
numbers available for comparison between each group. 
  
Study One has been unable to explain why the anxiety/depression dimension of 
EQ-5D profile did not show any improvement over time, especially in the 
hydrotherapy group, as the outcome measures of psychological wellbeing showed 
significant improvement in change score when measured by the HADs, HAD-D 
and HAD-A. The reason for this is not clear but it may reflect the responses of the 
patients who did not completely understand the direct questions within EQ-5D 
profile when they filled in the questionnaires. It may also reflect its lack of depth 
and sensitivity for this domain. The EQ-5D profile may be indicated as a simple 
health profile, clarifying the areas in which a patient or group of patients is 
recording problems, and the areas in which changes have arisen over time.  
  
The contradictive results of both EQ-5D profile and EQ-5D VAS may be explained 
by the fact that the two instruments are measuring different aspects of health 
status or HRQoL. The tariff for EQ-5D is derived from using TTO methodology 
as the EQ-5D tariff is commonly used to evaluate cost utility studies and resource 
allocation (Drummond et al., 2005) compared to direct scoring of self-valuation 
health status. However, both EQ-5D profile and EQ-5D VAS showed good results 
in this study and it can be determined that these instruments are highly responsive 
to self-reported improvement in RA, and that this reveals clinically important 
changes. 
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It is hoped that the results of Study One will help clinicians improve the level of 
QoL in RA patients by providing appropriate treatment. Such treatment may 
include medical and/or psychological support and counselling, all of which should 
benefit the patient (Strand & Singh, 2010). 
  
9.2.3.3 Disease-activity parameters 
DAS28 
This thesis did not find any significant difference in the disease activity indices 
measured by DAS28 score between hydrotherapy and land exercise group. In the 
hydrotherapy group, DAS28 improved from 4.28 in Test 1 to 2.49 in Test 2 
compared to the land-therapy group, where it improved from 4.31 in Test 1 to 
3.28 in Test 2. Despite these data not reaching a statistically significant difference 
(p = 0.613), this score change has a trend to remission of the disease, as DAS28 < 
2.6 corresponds with being in remission according to the ACR criteria (Fransen et 
al., 2003). 
 
There was no previous literature that had used this tool to measure disease activity 
in hydrotherapy. Sanford Smith et al. (1998), Stenström et al. (1991) and Hall et 
al. (1996) all used the Ritchie Articular Index (RAI) to assess disease activity 
(Ritchie et al., 1968). However, their results, showed no significant difference. In 
contrast, Hall et al. (1996) found significant reduction in joint tenderness in their 
hydrotherapy group post-treatment. These inconsistent results may be explained 
by the fact that a number of different factors affect disease activity parameters. In 
the DAS28, for example, when all other markers of inflammation and RA disease 
activity are in remission, the patient remains with many tender joints and therefore 
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the score may be misleadingly high. Alternatively, if the patient never had a very 
high ESR blood result (even during a flare-up), or if RA affected the feet (feet are 
not included in the 28-joint count), the score may be misleadingly low.  
  
It can sometimes be challenging to decide whether an individual joint is swollen 
or tender, even when assessed by the same person on different occasions or when 
assessed by several people on a single occasion and this uncertainty may lead to 
misleading inconsistencies in the scores. Even with supervision (which occurred 
in this study), the participants found it difficult to make decisions about the 
swelling of a joint. Measurement of DAS28 is routinely employed in 
rheumatology departments, giving the rheumatologist the opportunity to change 
the treatment accordingly. 
 
The study did not show a statistically significant difference (p = 0.613) in disease 
activity measured by DAS28 after hydrotherapy. Although these results differ 
from the study carried out by Hall et al. (1996), which found a significant 
reduction in joint tenderness in a number of joints in the hydrotherapy group (p = 
0.03), but they are consistent with some other published studies that measured 
other disease activity indices (Bilberg et al., 2005; Sanford Smith et al., 1998; 
Stenström et al., 1991). The findings of this study suggest that RA as a chronic 
disease is particularly difficult to assess. This is because the symptoms are 
extensive in terms of joint pain and stiffness with subsequent loss of function and 
later deformity, and they often vary spontaneously from day to day. 
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RADAI  
The RADAI is an alternative method to clinician assessment of disease activity. 
The main aim of the RADAI is to offer an easy to use assessment in disease 
activity where laboratory measurements or clinical assessments may not be 
possible or are too demanding (Fransen, 2003; Mason et al., 1992; Stucki et al., 
1995). In this study, the overall score of RADAI was not improved clinically or 
statistically in either group and remained unchanged in the hydrotherapy group 
(4.5 in Test 1 to 4 in Test 2) and (3.9 in Test 1 and 4.5 in Test 2) in the land-
therapy group.  
 
This result may be explained by the fact that RA is an inflammatory systemic 
disease, and disease activity features such as tenderness, swelling and blood 
markers reflect directly whether the course of disease is in exacerbation or in 
remission. Thus, these disease activity indices might not be affected directly or 
easily by hydrotherapy or land therapy. Other possible explanations for these 
results may be that the participants cannot rate swelling accurately as was 
remarked on earlier, or it might be difficult for patients to discriminate between 
RA signs and symptoms such as pain, swelling and stiffness. Another possible 
explanation for the negative results is that the small sample size in Study One – 
mainly in the follow-up period – could perhaps explain the non-significant finding 
for the RADAI. 
 
The major goal of RADAI score in RA patients’ management and in RA clinical 
studies is to evaluate disease activity over time. Further large sample studies will 
be needed in the future to find out if RADAI is sufficient to guide clinicians in RA 
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management strategy compared to the DAS28. Both DAS28 and RADAI aim to 
measure the same underlying construct, namely arthritis inflammatory activity, 
but from different content and perspectives (Fransen et al., 2003); i.e. DAS28 
depends on physician judgment, whereas RADAI depends on patient’s perception 
of the complaint (Fransen, 2003). However, there may be some reasons (practical 
and economic) to replace the assessment performed by the physicians (DAS28) 
with a patients’ questionnaire (RADAI). The fact that both disease activity indices 
perform similarly well does not mean that one can be automatically replaced with 
the other (Fransen, 2003). Both RADAI and DAS28 have different content and 
because the non-significant difference that were observed in Study One for both 
of them, it seems other factors might influence its findings. 
 
Three studies have tried to evaluate grip strength following hydrotherapy such as 
Hall et al. (1996), Sanford Smith et al. (1998) and Bilberg et al. (2005). However, 
their findings were contradictory. In Study One, the grip strength was not 
measured for the following reasons: 
 It is never measured in clinical practice as a disease activity index in 
SRFT; 
 The equipment to measure it was not available in (i) clinics, (ii) the gym, 
(iii) physio outpatient or (iv) hydrotherapy; 
 Inter-rater reliability concerns (because this is not routinely measured at 
SRFT). 
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Another essential feature of RA is fatigue, which is a frequently occurring 
symptom in RA patients. Unfortunately, in this study fatigue was not investigated 
for the following reasons: 
 Causes and mechanisms that lead to fatigue in RA and other autoimmune 
diseases are conflicting, with several variables acting at different amounts 
in different patients at different times, either singly or in combination 
(Hewlett et al., 2011; Hewlett et al., 2008) (See page 30). 
 Fatigue need to be investigated and derived more likely by using cross-
sectional study rather than longitudinal study to find out the cause at 
certain time (Hewlett et al., 2011). 
 9.2.3.4 Psychological wellbeing (mood symptoms) (HADs) 
HADs  
HADs were developed as a screening tool to identify probable cases of anxiety 
and depression among individuals in hospital clinics with non-psychiatric 
conditions (Bjelland et al., 2002). The hydrotherapy group showed significant 
improvement between Test 1 and Test 2 for HADs and its subdivisions (HAD-D 
and HAD-A) compared to the land group, but this improvement was not 
maintained in the follow-up period. In the hydrotherapy literature, only one study 
done by Hall et al. (1996), investigated the psychological functioning of RA 
patients. Hall et al. (1996) measured the psychological wellbeing of mood and 
tension by using AIMS-2 (Meenan et al., 1992), and found greater improvements 
in hydrotherapy during the follow-up period only.  
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The researcher believes that it is unfair to compare the results reported by Hall et 
al. (1996) with those observed in Study One for three reasons: 
 The study design was completely different; Hall et al. (1996) used four 
groups with randomisation concealment allocation, compared to the two 
groups in Study One. 
 The duration and frequency of aquatic exercise intervention was variable 
in the study by Hall et al. (1996). 
 Hall et al. (1996) examined mood and tension as part of a functional 
ability questionnaire called (AIMS-2), while HADs was used in Study 
One as a separate questionnaire to measure depression and anxiety. 
  
In Study One, improvement in anxiety and depression in the hydrotherapy group 
might be related to the fact that the improvement on functional ability skills and 
pain relief reflects directly on the improvement in mood changes among RA 
hydrotherapy participants. Moreover, increased production of opioid peptides 
such as methionine-encephalin post-hydrotherapy has a strong anticonvulsant, 
antidepressant and antianxiety effect (Coruzzi et al., 1988; Lesniak & Lipkowski, 
2011). 
 
Other possible explanations as to improvement in aspects of patients’ 
psychological wellbeing, such as anxiety and depression, may be due to Rotter’s 
psychological theory of personality related to the locus of control. 
 
289 
 
In the RA population, the prevalence of depression and anxiety have been 
reported to range from 13 to 20% (Covic et al., 2012; Dickens et al., 2002) and 
from 21 to 70%, respectively (Uguz et al., 2009; Covic et al., 2012). In Study 
One, the prevalence of depression was 35% – which is far higher than the general 
RA population – and the prevalence of anxiety was 30%. However, the study 
sample representing the general RA population (n = 169) (Covic et al., 2012), was 
substantially larger than the current study sample in Study One (n = 43). 
  
Both studies have used self-report measures, and the prevalence of depressive 
symptoms was about 40%. Even if the symptoms of depression and/or anxiety 
may be subclinical, they have a major impact on physical function (Covic et al., 
2009). The results of increased prevalence of depression may be due to disease 
chronicity or clinical fluctuation of disease between exacerbation and remission in 
RA. All these factors may contribute to psychological morbidity in patients with 
RA. It is important to consider the psychological effects of RA, as this relates not 
only to physical functions, but also to many social interaction, which has a direct 
effect on wellbeing. 
 
 
 9.2.4 Correlations discussion  
Correlation between RADAI & DAS28 
Both land and all combined RA patients show significant positive moderate 
correlation compared to no correlation in the hydrotherapy group. Stucki et al. 
(1995) found moderate correlation between RADAI and CRP (r = 0.54, p < 0.010) 
and RADAI and swelling-joint count (r = 0.43, p < 0.01) in RA patients. 
However, the findings of Study One do not support the findings of previous 
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research studies, which report no or relatively low correlation of other types of 
patient questionnaires, such as EQ-5D VAS and AIMS2, with laboratory 
parameters of disease activity such as CRP or ESR (Hurst et al., 1997; Riemsma 
et al., 1996). Literature study showed that the DAS28 and RADAI are realistically 
moderately related (r = 0.53) (Fransen, 2003), however, this does not 
automatically mean that one can be replaced by the other. 
 
To our knowledge, no hydrotherapy literature used RADAI, DAS28, or even 
association between them. The result of Study One showed that the rating of 
patient perception for pain, swelling, tenderness and MS in RA patients was 
essential in order to assess the problem of disease activity in some circumstances. 
This is necessary to achieve valid patient perceptions. Moreover, compatibility of 
patient perception with physician’s judgement will enhance the reliability of 
interpretations about the underlying disease process for patient management.  
 
Furthermore, the different content and focus of RADAI and DAS28 could explain 
the contradictory results between them in the hydrotherapy group. The main 
advantage of the DAS28 is that it compared 28 joint counts rather than 44 joints, 
however, blood samples still had to be analysed which is time consuming and 
sometimes costly. Self-assessment of RA disease activity by the patient may save 
work for the physician (Fransen et al., 2003) but its reliability is open to question. 
RADAI as a self-administered questionnaire of disease activity is related to, but 
does not automatically replace, other indices of disease activity, such as the 
DAS28. 
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The relationships between depression scores (HAD-D) and educational levels, 
RF, disease duration, morning stiffness, DAS28 and RADAI 
The aim of this section was to determine any association between depression or 
anxiety with low education level, DD, MS, RF and disease activity indices. In this 
study, the prevalence of depression in the hydrotherapy group was 47% and 23% 
in the land-therapy group, and it is approximately 35% in all patients, which is 
relatively higher than that reported in the literature (Covic et al., 2012). Initially it 
was intended to include anti-CCP in the analysis of the data, but there was a lack 
of available data because two-thirds of cases did not report this test in their 
medical notes. Therefore, this research study was unable to include anti-CCP in 
the analysis. Only RADAI in Test 2 shows a positive significant correlation with 
depression score.  
 
Prior studies have noted the association of depression and anxiety with low 
education levels, longer DD and poor clinical outcome in RA cases (Evers et al., 
2002; Isik et al., 2007). However, Isik et al. (2007) justified the reasons as to why 
the prevalence of depression highly correlated with low ELs in their Turkish 
study, these reasons being low socioeconomic status, insufficient social support 
and a chronic disabling disease (Isik et al., 2007). 
 
In Study One, the reasons for finding no correlation are not clear, however it 
might be due to the small sample size in the study. There was a significant 
correlation between depression score and RADAI score in all patients post-
treatment (p < 0.001, r = 0.578). This finding is consistent with those of Katz and 
Yelin (1993). On the other hand, no correlation was found between the depression 
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score and DAS28 post-treatment. This discrepancy of correlation between 
depression score and DAS28, and depression score and RADAI score, may be 
because of using a self-report questionnaire such as HADs to measure depressive 
symptoms, and the self-report questionnaire such as RADAI to measure disease 
activity, because as discussed earlier, DAS28 content differs from RADAI. 
 
In reviewing the literature, no data were found on the association between 
depression or anxiety and MS. As MS is part of disease activity indices and 
RADAI categories, the non-association between them is not clear. 
 
It has been argued in the literature about the association of RF levels with cases of 
psychiatric disorders. In Study One, no correlation was found between depression 
score and RF. Although the thesis findings were different to some published 
studies (Ahokas, 1986; Isik et al., 2007; Legros et al., 1985), they are consistent 
with others (DeLisi et al., 1984; Sane et al., 1990). For instance, in Study One, RF 
was positive in about 60% of the RA cases, however, there was no significant 
correlation with depression score (p = 0.782). It has been recommended that a 
high depression score may be of greater importance to RA patients with positive 
RF rather than other measurable variables (Isik et al., 2007). This was not 
supported in Study One.  
 
These findings may help us to understand how many factors have an association 
with a higher score of depression in chronic diseases such as RA. Therefore, 
future studies to examine this correlation should be carried out with a larger 
sample of patients with RA (Isik et al., 2007). 
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The relationships between anxiety scores (HAD-A) and educational levels, RF, 
disease duration, morning stiffness, DAS28 and RADA 
The prevalence of anxiety in hydrotherapy, land therapy and all patients were 
38%, 23% and 30% respectively. All these percentages are within the range of 
anxiety prevalence in the general RA population. Again, no correlations were 
found between anxiety score and EL, MS, DD, RF and DAS28. 
  
A moderate positive correlation was found between the anxiety score and RADAI 
in the land-therapy group and in all patients. Although anxiety and depression are 
not the same, they do often present the same symptoms and therefore the 
explanations for anxiety might be similar to the depression score in the former 
section. Isik et al. (2007) found that DD was less correlated in anxiety scores than 
depression. They found moderate positive correlation between the degree of 
depression and DD (r = 0.341, p = 0.05,) and strong negative correlation between 
the DD and degree of anxiety (r = -0.642, p = 0.05). 
  
A previous study by VanDyke et al. (2004) reported that in RA cases, the clinical 
feature of anxiety occurred earlier than depression, and it preceded the clinical 
finding of depression. This idea is supported by Isik et al. (2007) who emphasised 
that when DD is prolonged, the anxiety score declined and depression score 
increased. However, in this study this is not the case, as no correlations were 
found between DD and anxiety. Hawley & Wolfe (1988) stated that the level of 
anxiety is the same whether the condition is inflammatory such as RA, or non-
inflammatory such as OA, FMS and backache. 
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A number of studies have reported the association of psychiatric disorders with 
the immune system (Herbert & Cohen, 1993; Irwin, 2002). However, it was not 
possible in this study to establish a firm association between the immune system 
parameters (RF and anti-CCP) and psychiatric disorders. Because more than two-
thirds of the participants in Study One did not have confirmation of anti-CCP 
antibodies included in their medical notes, the researcher was unable to include 
this important immunological parameter in the correlation section. This test is 
done at diagnosis, and as the notes available for the study were only from 2003, if 
the doctors had not transferred this data to the more recent post-2003 electronic 
notes, then they were not available for analysis in this study. However, NICE 
guidelines (2009) stated that in patients with suspected RA, testing of anti-CCP 
should be considered only if RF is negative and/or in decision-making 
combination therapy. An implication of this is the possibility to determine factors 
responsible or those, which correlate with high score of anxiety or depression in 
RA. 
 
9.2.5 Predictive factors for functional disability (HAQ-DI)  
The results of this section yielded important findings about the potential relation 
of predictors of the functional disability as measured by HAQ-DI. Functional 
disability in RA patients was predicted by poor QoL, high depression and anxiety 
scores, poor GWB and by a high score of RADAI. Further analysis, using the 
multivariate regression analysis suggests that of these variables, the only 
significant predictor was poor GWB.  
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Predictors of functional disability were analysed previously by several 
longitudinal retrospective and prospective studies. These studies have examined 
the possible link of predictors between different parameters, such as radiological 
and biological factors in the development of disability in patients with RA 
(Toussirot, 2010). However, either the results of such studies – which aimed to 
determine prognostic factors – are heterogeneous because of variations in the 
length of the observation period, or the choice of criteria used to measure physical 
disability was at fault (Toussirot, 2010; Wolfe et al., 2003; Leigh & Fries, 1992). 
In addition, there were inconsistencies and variations in baseline parameters, 
treatments modalities, patient selection criteria and DD (Toussirot, 2010). 
 
In Study One, five independent variables were found as potential predictors of 
functional disability. This reflects the multidimensional nature of functional 
disability in RA. The HAQ score provides an insight into the overall 
consequences of the RA disease in terms of disease severity and the impact it has 
on psychological wellbeing and QoL (Toussirot, 2010). 
 
In Study One, psychological wellbeing such as depression and anxiety were 
predictors of functional impairment in patients with RA. The relationships 
between elevated depression/anxiety scores with functional disability signify that 
RA patients may have difficulties in managing household chores in their daily 
activities. However, it is unclear from this present cross-sectional study whether 
functional disability is a cause of poor psychological wellbeing or vice versa, and 
it therefore requires a longitudinal study to determine the direction of causality.  
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The impact of anxiety and depression in RA patients’ lives is most likely to be 
enormous. The positive association between increased depressive symptoms with 
high HAQ DI scores in RA patients show that they may have difficulties in social 
interaction and caring for themselves at home. This finding is consistent with 
previous studies such as Wolfe & Hawley (1993) and Abdel-Nasser et al. (1998), 
who found that patients with high depressive symptoms are most likely to 
experience intense pain as measured by VAS pain and physical disability (Wolfe 
& Hawley, 1993). 
  
Additionally, it has been reported that a high anxiety score was related to 
increased physical disability in patients with RA (Wolfe & Hawley, 1998; 
VanDyke et al., 2004). Others have commented that anxious RA patients are less 
likely to cope with their normal work-related activities because of pain and 
increased physical disability, which may lead to early retirement and dependency 
on families and carers (Lillegraven & Kvien, 2007; De Croon et al., 2004). 
Ødegård et al. (2005) identified that poor psychological-health status, such as 
helplessness, was a predictor of inability to work in RA patients. 
  
 
Disease activity measured by RADAI was one of the predictive factors of physical 
disability in RA patients. It reflects that intense/high disease activity has a 
detrimental effect in coping with daily activities. Therefore, RA patients have to 
be regularly monitored and encouraged to be involved in a mild general exercise 
programme such as daily walking to reduce the impact of the disease. 
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It is interesting that in this study DAS28 (which assesses the degree of disease 
severity in RA patients) was not a predictor of functional disability in RA patients. 
Therefore, caution is required in the interpretation of this finding because of the 
small sample size of the study. The researcher is not aware of any previous study 
using RADAI as a predictor in patients with RA. 
  
Few studies have reported other disease activity indices such as pain, MS and 
decrease in grip strength, which were all predictors of disability (Wolfe & Cathey, 
1991). Moreover, Leigh & Fries (1992) found tender-joint count was a predictor 
of poor outcome in RA patients. Van Zeben et al. (1993) found that the number of 
swollen joints and Richie index were predictive of increased physical disability 
using HAQ-DI (Van Zeben et al., 1993). Van Leeuwen and colleagues (1994) 
followed 149 patients with early RA for three years and showed that a high 
functional disability score appeared to be determined and predicted by joint 
tenderness with no clear relationship to joint swelling. 
 
Additionally, Study One, GWB and HRQoL measured by EQ-5D tariff were 
found to be the best predictors of functional disability in RA patients. This finding 
is consistent with Leigh & Fries (1992), who also confirmed that overall health 
status was found to be a predictor for functional outcome in RA patients (Leigh & 
Fries, 1992). There are no other studies that examined EQ-5D tariff and its 
predictive ability of HAQ-DI. Therefore, replication of this study’s findings in 
other settings with larger sample sizes is worthy of consideration.  
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To sum up, a variety of independent variables were revealed in this section as 
predictors for functional disability at baseline in all RA patients. The findings of 
this section show that higher score of depression, anxiety, RADAI and GWB and 
low score of EQ-5D tariff were predictors of functional disability in RA patients. 
Therefore, patients presenting with numerous recognised predictive factors for 
‘poor outcome’, including physical disability, should be closely monitored and 
provided with appropriate educational support and psychological intervention 
(Toussirot, 2010). 
 
9.2.6 Discussion of the exercise protocol between hydrotherapy and land-
therapy in RA patients 
The mean number of sessions attended by participants in both groups were the 
same (six sessions each). This demonstrated that all RA participants had equal 
participation in the treatment protocol. It has been suggested by many 
authors/researchers that failure to adhere to an exercise programme is a common 
problem in RA patients (Roddy et al., 2005; Campbell et al., 2001). One of the 
mandatory factors for improving physical function, QoL and GWB is the patient’s 
adherence (Belza et al., 2002).  
 
However, the adherence rate in Study One seems to be acceptable for the 
following reasons: 
 RCT occurred within NHS services with easy access for all participants;  
 It was carried out under the supervision of highly qualified health 
professions and in a supportive environment; 
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 It was offered as part of a full MDT package of care in a large 
rheumatology department within SRFT, which may have encouraged 
participants to attend the full programme. 
 
A daily diary was provided to all patients by the physiotherapist, but not as part of 
the study, as a reminder to perform the exercise programme every day, especially 
as the patients knew that the therapist would be reviewing the diary at the next 
session as part of follow-up (Heine et al., 2012). This diary might be used as an 
opening discussion about the success or difficulties in the performance of the 
exercise programme since the last appointment, and could be used in deciding 
progression or regression of the exercise programme. In Study One, the numbers 
of sessions are carried out in accordance with a recent survey in the UK HyDAT 
Team (2009). However, there is no consensus about frequency or duration of 
hydrotherapy sessions in any literature study. 
 
All participants in both groups performed similar exercise programmes in terms of 
aims, short- and long-term goals, HEPs, general rehabilitation, mobility and 
functional treatment, and education and advice. The only exception was 
instructions around on how to manage flare-ups (Appendix 25). 
  
General fitness level, pain and joint symptoms are an important concern in 
patients with RA in order to reduce flare-ups. Thus, the main goal of any 
therapeutic intervention should be to reduce this clinical component of the 
disease. Although  an average of six treatments was received by both groups, it is 
unclear whether the improvements in the hydrotherapy group resulted from 
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exercise or from other factors, such medical therapy, the degree of participant 
attention or motivation, or the care provided by the healthcare professionals. It is 
possible that most of the improvement seen was attributable to the interventions 
used, as RA is an autoimmune disease and would be expected to cause a 
progressive exacerbation or even remission of the participants’ conditions. 
  
All efforts were made to reduce the amount of the researcher’s bias due to 
treatment. The gatekeeper physiotherapist responsible for instruction in the 
exercise programme was aware of the purpose of the study and tried to be 
impartial with both groups. Hydrotherapy staff were different from land-therapy 
staff and the therapists were not involved with testing. However, bias might be a 
factor because they were not blind.  
 
 
9.3 Study Two (Kellgren study) 
9.3.1 Descriptive comparison of mean age, gender, disease duration and 
social support  
This study demonstrated that the mean age for referral to hydrotherapy was 60 
years. Findings from Arthritis Research UK (2011) and NICE (2009) supported 
this. When comparing the finding of mean age with other hydrotherapy studies, 
there was little difference between Eversden et al. (2007) and Hall et al. (1996), 
who both concurred with the findings of this study, whereas a relatively slight 
difference with HyDAT Team (2009) and Bilberg et al. (2005) was shown. The 
HyDAT team emphasised that the optimal age of patients referred to the 
hydrotherapy treatment among UK patients with chronic disease was 51 years 
(HyDAT Team, 2009). 
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The knowledge gained through this research shows that there is no certain 
evidence suggesting a standard age and DD of RA patients. The NICE guidelines 
(2009) identified that the peak age of incidence of RA in the UK for both genders 
is in the 70s, which is supported by Arthritis Research UK (2011). This researcher 
maintains that although there is no evidence giving the exact mean age that RA 
patients are referred for hydrotherapy. However, the researcher believes that 
referral of patients to hydrotherapy might happen any time after diagnosis. The 
referral depends on many factors such as patient’s need, treatment goal, and 
physicians’ satisfaction. This comparison between the participants in Study One, 
the general RA population in the Kellgren Centre and general RA population in 
the UK implies that our sample does reflect the RA population, and that there are 
no differences that might affect or influence the findings in mean age and DD. In 
spite of that, patients with any long-term DD should have the facility to access 
hydrotherapy (HyDAT Team, 2009). 
 
Most studies have emphasised that the incidence of RA is higher in women than 
in men (Arthritis Research UK, 2011). This finding was confirmed in Study Two, 
which showed that more than 70% of current participants who were referred to 
either group were female. The female/male ratio varied between 2:1 (Arthritis 
Research UK, 2011), 3:1 (Temprano & Smith, 2011), 4:2 (NICE, 2009) and 2.5:1 
(Tehlirian & Bathon, 2008). The differences in the ratio of women to men can be 
explained in part by an influence of reproductive and hormonal factors such as 
oestrogen and progesterone in females, which could potentially explain some of 
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the gender effects, thus predisposing females to RA; this has been discussed in 
research performed by Silman & Pearson (2002). 
 
Between the comparator studies, the percentage of females was relatively smaller 
approximately between 62% and 89% in all reviewed studies. Bilbeg et al. (2005) 
included forty-two females and five males, and the small size of his sample means 
it is difficult to make his findings generalisable. This may therefore explain in part 
the reason for the limitations of his study, which did not allow for gender bias. It 
remains unclear as to what the precise explanation is for the greater prevalence of 
RA in females and what the physiological role of hormones is in this gender 
divide (Silman & Pearson, 2002). Although their studies did offer evidence of the 
predisposition of female hormones towards RA, their conclusions were not 
satisfactorily proven. 
 
There is very little discussion about DD in epidemiological studies. In this study, 
participants had lived for 10 years with RA, but the DD and expected survival of 
RA patients might be related to the disease severity and the age when the patient 
developed RA. The most important point is that the DD between the patients of 
the Kellgren Centre and those in Study One was the same, reflecting the same 
features of the general RA population that had been referred to hydrotherapy (as 
found in Chapter 7, p.210). This is clinically important as both groups have the 
same survival period with relatively different conditions. It presents a factor, 
which increases this study’s generalisability, again a significant point for future 
research. Within this study, the disablement of the participants bears witness to 
the downhill trajectory of the motor facility of those with RA. 
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No certain data or exact figures were obtained regarding socio-economic items, 
such as occupation or marital status that influenced the prognosis and the course 
of the disease, rather than the risk of developing RA (Albers et al., 1999). There is 
general agreement throughout research studies that this disease does have a very 
significant impact on individuals’ work ability and family income, as well as on 
society (Arthritis Research UK, 2011). These data demonstrate that there are 
many different factors that may influence the risk of developing RA. Providing 
this information to patients and society is essential in providing the knowledge 
about the trajectory of the disease and the ability to assess the needs of the health 
service in the future.  
 
However, in Study Two most participants referred to the exercise programmes 
were generally between employments or retired rather than unemployed or work-
disabled. Approximately one third of people had stopped working within two 
years of onset because of the disease, and this prevalence increases thereafter 
(NICE, 2009; Verstappen et al., 2004). 
 
 9.3.2 Descriptive comparison of obesity and body mass index (BMI) 
The study carried out in the Kellgren Centre and in the hydrotherapy pool found 
that the number of obese patients was consistent with that of other studies in the 
UK, such as Zaninotto et al. (2006). They suggest that more than 35% of patients 
were overweight and 25% were obese. Several studies have addressed the effects 
of obesity on CVD risk in RA, and show that obesity does present extra risk 
(Stavropoulos-Kalinoglou et al., 2011). Very few studies have reported the role of 
obesity in RA patients, as evidence from the general population leads to a very 
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clear assumption that obesity might influence RA patients’ health status and 
outcome (Stavropoulos-Kalinoglou et al., 2011). 
 
A worldwide study done by Naranjo et al. (2008) included 4,363 patients from 48 
sites in 15 countries, and found that more than 18% of RA patients were obese. 
Conversely, a UK-based study by Armstrong et al. (2006) found that 31% of RA 
patients were obese. Both studies reported that more than 55% of RA patients 
were overweight or obese. It is interesting to note that in RA, the prevalence of 
overweight and obese sufferers seems to be subject to geographical variation 
(WHO Consultation, 2000).  
 
In Study Two, the exact cause of increased prevalence of obesity and 
overweightness in RA patients remains unknown. However, there are many 
possible contributors that might influence BMI in RA patients (Stavropoulos-
Kalinoglou et al. 2009). Increased bodyweight might be associated with low level 
of physical activity and an inactive lifestyle. Inflammation, even though this is 
suggested to affect body composition, might be a reason for an increase or 
decrease in BMI.  
 
An underweight state might be associated with other factor such as a low energy 
intake. Therefore, increasing physical activity is important for obesity control and 
improving energy, and thus nutritional intake may prevent an underweight state. 
To the knowledge of the present researcher, there are no widely accepted 
validated strategies to control obesity in RA. Overall, obesity is a very poorly 
studied subject in RA. Its causes and the potential interventions to prevent or 
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reverse it have received even less scientific attention (Stavropoulos-Kalinoglou et 
al., 2009). To conclude, patients who were referred to hydrotherapy or a land-
based programme for rehabilitation were similar in BMI scores in comparison to 
general RA patients. 
 
9.3.3 Descriptive comparison of smoking and hypertension (HT) 
Over the past century, there has been a dramatic increase in the use of tobacco 
(Alamanos & Drosos, 2005). Cigarette smoking has been suggested to influence 
both the risk and course of RA and other autoimmune diseases (Alamanos & 
Drosos, 2005; Papadopoulos et al., 2005; Hardy et al., 1998). Several 
epidemiological studies (cross-sectional or longitudinal studies) have investigated 
the relationship between smoking, severity and outcome of the disease and 
increased risk of RA (Wilson & Goldsmith, 1999; Saag et al., 2008; Harrison, 
2002; Symmons et al., 1997). This association was very clear in patients who 
were heavy smokers and in those with seropositive RF. At present, the mechanism 
by which smoking could influence RA activity and severity is vague 
(Papadopoulos et al., 2005). Harrison, (2002) points out this mechanism may be 
due to the direct effect of smoking on the disease process by inducing the 
production of RF or by activating the immune system (Harrison, 2002). However, 
the percentages of active smokers in both the Kellgren and the RCT study were 
clearly very low (6% and 12% respectively) in comparison with the general health 
population in England and other comparator studies such as Hutchinson et al. 
(2001) (42%), Manfredsdottir et al. (2006) (34%) and The Information Centre for 
Health and Social Care in England (2011) (20%). This might be explained by the 
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emphasis of education programmes in recent years on explaining the dangers of 
smoking in RA, or it might be because of the change in smoking laws. 
 
It is interesting to note that in all previous RA studies related to HT there is a very 
wide range of HT prevalence between studies. It ranges from 3.8% to 78% 
(Panoulas et al., 2008). It is difficult to explain why HT studies show such wide 
prevalence, but it could be related to the different populations assessed, the 
diverse sample sizes and significant differences in the definition of HT used 
(Panoulas et al., 2008). Some of these studies, for example, such as McEntegart et 
al. (2001), Solomon et al. (2004) and Wolfe et al. (2003), compared the RA 
population with general RA population, whereas other studies, such as Chung et 
al. (2008), Del Rincón el al. (2001), Dessein et al. (2002) and Dessein et al. (2005) 
compared RA with controls. Moreover, the sample sizes among these studies were 
variable. Solomon et al. (2004) used a sample of 287 RA patients compared to the 
87,019 sample of the general RA population. Conversely, Dessein et al. (2002) 
used 79 RA patients compared to 39 OA patients. In Study Two, approximately 
30% of participants referred to the exercise programme have HT. 
 
Many factors might be directly or indirectly associated with increased prevalence 
of HT in RA patients. These factors can be classified into disease, lifestyle, and 
medication. Chronic inflammatory diseases such as RA have been associated with 
arterial stiffness, which may subsequently lead to increased arterial BP, and might 
explain the high prevalence of HT in RA (Franklin, 2005). The development of 
HT in chronic systemic inflammatory diseases such as RA might be caused by 
many mechanisms, such as an increase level of CRP, vasoconstriction, leucocyte 
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adherence and platelet activation (Devaraj et al., 2003). NSAIDs, C/S and 
DMARDs, which are used to treat RA patients, cause fluid retention and might 
cause an increase in blood pressure. This again is a consideration for future 
research. Sometimes a lack of adherence to long-term therapy for a usually 
asymptomatic condition such as HT might be another reason for increased 
prevalence of HT in RA (Panoulas et al., 2008). Other conditions such as IHD and 
atherosclerosis, which increase the prevalence of HT, are common in RA, mainly 
in the elderly age group (Panoulas et al., 2008). Despite this, extrapolations such 
as these cannot be made to all patients, as direct evidence as to whether the 
prevalence of HT is greater among patients with RA than in the general 
population is still inconsistent (Solomon et al., 2003; Han et al., 2006). 
 
 
9.3.4 Descriptive comparison of rheumatoid factor (RF) 
Presence of RF in RA has prognostic significance (Bas et al., 2003; Jansen et al., 
2002). It has been recommended that RA patients with seropositive RF have a 
more aggressive disease, whereas in those with sero-negative RA, the disease is 
less severe and less deforming (Dörner et al., 2004; Jansen et al., 2002). In Study 
Two, more than 60% of participants reported positive RF in their medical notes, 
which reflects the general population of RA. IgG and IgM are present in up to 
90% of RA patients (Waldburger & Firestein, 2008; Dörner et al., 2004). 
However, these autoantibodies are also produced during any chronic infection, 
malignancy and a variety of autoimmune and inflammatory syndromes (Waaler, 
1940; Temprano & Smith, 2011). Moreover, 1-4% of healthy individuals and 
more than 25% of elderly people have RF detectable in their serum in low titre 
(Waldburger & Firestein, 2008).  
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The presence of RF does not confirm RA, because, as stated by Arthritis Research 
UK (2011), one out of 20 people have positive RF but do not have RA, and eight 
out of 10 patients with RA have positive RF. The results of this investigation 
show that some people with RA never develop RF, and at the onset of the 
condition, only approximately half of people with RA have positive RF (Arthritis 
Research UK, 2011). Accordingly, negative RF does not confirm the absence of 
RA (Arthritis Research UK, 2011). When checking the past results of our patients 
it was possible to see that not all of them were shown to have positive RF on 
diagnosis (Table 6.3, p. 173). 
 
One of the research questions that could be asked in future planning include 
whether the result findings will differ between RF positive or negative in RA 
patients with larger sample sizes. 
 
9.3.5 Descriptive comparison of disease activity measured by DAS28  
Clinical, laboratory and radiographic measures are important components in the 
assessment of RA patients, and play a key role in the evaluation, treatment and 
prognosis of disease course (Waldburger & Firestein, 2008). DAS28 is one of the 
main common formulas used in clinical practice. It incorporates both clinical and 
laboratory variables such as tender-joint count, swollen-joint count, patient self-
assessment of disease activity VAS and ESR (Prevoo et al., 1995; Aletaha & 
Smolen, 2005). DAS28 is increasingly being used as an endpoint in clinical trials 
and is widely indicated for use in clinical practice for monitoring and guiding 
disease activity and treatment decisions (Prevoo et al., 1995; Waldburger & 
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Firestein, 2008). In clinical practice, the overall assessment of disease activity 
depends on the number of tender and swollen joints, which are regarded as 
dominant variables (Waldburger & Firestein, 2008). 
  
It has been suggested in the literature that hydrotherapy might decrease joint 
tenderness and increase range of movement. This may be because the hydrostatic 
pressure of water immersion leads to reduced oedema (Campion, 1997; Hall et al., 
1996). In the Kellgren Study Two, only 171/200 patients had reported the DAS28 
score in their medical notes compared to all 43 of the patients in Study One. 
However, the trend for DAS28 in both groups was similar. The key problem with 
this explanation is that DAS28 reflects directly the inflammatory process of RA, 
and this might not influenced directly by hydrotherapy or land therapy. 
 
9.3.6 Descriptive comparison of medication and comorbidities  
Treatment of RA included several classes of drugs such as NSAIDs, DMARDs, 
C/S and biologics drug modifier (Temprano & Smith, 2011). This study has found 
that, generally, biologic drugs were reported in both Study One and Study Two 
compared to the reviewed hydrotherapy studies, which did not report any 
biologics medication (Figure 7.15, p.217). This might be explained by the fact that 
biologic drugs were introduced recently, after comparison studies were carried 
out. It might also be because they require specific criteria for indication and were 
excluded from previous studies.  
 
All studies in Figure 7.15 (p.217) reported variable medication, being either 
combination or single-drug therapy. The highest percentage of drug treatment 
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commonly reported and used by patients was DMARDs and NSAIDs. All studies 
reported using combination therapy. Combination therapy appears to be helpful 
for RA patients whose disease outcomes fail to respond to monotherapy with 
DMARDs (O'Dell et al., 1996). As a result, it is difficult to exclude patients from 
a trial because they are using medication. Medication may always exist, therefore, 
as an uncertain confounder. 
 
It is recommended that DMARDs are the most important treatment modality in 
the successful management of RA, mainly when they are introduced early (Singh 
et al., 2012; Temprano & Smith, 2011). The research studies reported combination 
therapy rather than mono-therapy in their participants’ medical notes. This was 
also the case in our participants’ notes. Recently, it has been suggested that the 
most common combination therapy, lately updated from 2008 to 2012 by the 
ACR criteria, to be between DMARDs and biologics drugs. In the 2012 statement, 
it now includes more than eight types of biologics drugs, while the 2008 statement 
included only five types (Singh et al., 2012). The more modern combination 
therapy should offer an avenue for more research. In the literature studies 
reviewed and presented in Figure 7.15 (p.217), only a few percent reported using 
C/S. This might be explained by the controversy regarding of the use of this 
medication (Myasoedova et al., 2011).  
 
It has been implied that there may be a complex relationship between RA and 
comorbid conditions (Michaud & Wolfe, 2007). Thus, it is important to recognise 
and account for such illnesses in the holistic care of the patient, as well as in 
understanding research outcomes. Because RA has numerous outcomes, 
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including, among others, functional ability, hospitalisation, work disability, QoL 
and increased medical costs, a different pattern of comorbid illness is evident in 
Figure 7.16 (p.217) (Michaud & Wolfe, 2007). Diverse comorbid conditions 
influence such outcomes differently. 
 
Diverse comorbid conditions with RA, such as Diabetes Mellitus, thyroid 
problems, respiratory disease and cardiac disease, have been reported in the RCT 
Study One and the Kellgren Study Two. Consequently, these comorbid conditions 
make them significant for RA outcomes research because they interfere with 
important RA outcomes.  
 
9.4 Study Three 
9.4.1 Introduction 
Study Three is the first to evaluate the cost of hydrotherapy in RA. Previously, 
only six studies have examined the effectiveness of hydrotherapy in an RA 
population. There are no published studies of the costs or cost-effectiveness of 
hydrotherapy in the RA population. Chapter 8 was designed in order to evaluate 
the cost of hydrotherapy and land-based therapy in an RA population from an 
NHS, patient and societal perspective. 
 
Previous studies have reported the economic efficacy of hydrotherapy on other 
rheumatic diseases such as OA, FMS and JIA (Cochrane et al., 2005; Epps et al., 
2005; Gusi & Tomas-Carus, 2008; Patrick et al., 2001). Unfortunately, there are 
no studies available for appraisal to help resolve some of the contradictory 
findings. The major finding of this study was that hydrotherapy was more 
312 
 
effective and less costly in treating four patients in the pool compared to one 
patient on land.  
  
9.4.2 NHS Costs  
Using hydrotherapy to treat RA patients on a 1:1 basis is intuitively more costly 
than treatment on land. The greatest contributor to this extra average cost of £177 
per patient was the physiotherapy staffing costs. In this study, as per hospital 
protocol, staffing for the hydrotherapy group included a physiotherapist and 
assistant. Assistance may be required to help patients enter and exit the pool and 
in case of emergencies. This is for several reasons, namely that 25% of patients 
have a pathology or dysfunction described as severe; 20% of patients have some 
communication or sensory difficulties; 74% of patients have some mobility, or co-
existing mobility difficulties; and 27% of patients have associated risk factors 
such as heart conditions or epilepsy (HyDAT Team, 2009). Therefore, from a 
staffing viewpoint, hydrotherapy will, on average, be two times more costly than 
land treatment.  
 
In Study Three, physiotherapist and assistant costs were calculated using the 
median full-time equivalent of Band 5 and 3, respectively. Seventeen per cent of 
clinicians involved in the treatment of hydrotherapy patients are Band 5 or 
equivalent, 48.5% are Band 6 or 7, and 12% are at specialist or consultant level 
(HyDAT Team, 2009). The researcher found that it was the same physiotherapist 
treating the patients on land and in hydrotherapy. The researcher therefore realised 
that staffing costs could be increased or decreased accordingly, but that it is 
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probable that the same level of staffing costs should be applied to land therapy 
and hydrotherapy. 
 
Hydrotherapy pools come in different shapes and sizes according to monetary 
resources and the space available prior to the installation. Size will dictate the 
ability to treat patients individually or in groups. Treating more than one patient at 
a time will reduce costs, assuming that the staffing level for those extra patients 
does not also increase. Previous studies have used group hydrotherapy, including 
Patrick et al. (2001), whose group sizes ranged from six to 40; Eversden et al. 
(2007), which used groups of one to four; Bilberg et al. (2005) which used groups 
of eight to nine; and Stenström et al. (1991), which used groups of five. The 
HyDAT Team (2009) reported that 31% of hydrotherapy occurs in groups, 
although there was no information about the size of the group, the ratio of staff to 
patients, the size of pool, or the type of pathology most commonly treated in 
groups (HyDAT Team, 2009). 
 
Clinically, patients with RA are offered one-to-one treatment on land rather than 
group work due to concerns about their risk of flare up and the non-uniformity of 
their presentation. In the Study Three, a sensitivity analysis on the number of 
patients treated in hydrotherapy and on land was carried out. The cost of treating 
one extra person in hydrotherapy was £83 based on four subjects in a group, 
compared to £37 on land. Although this can be calculated in cost terms, it is not 
certain that the effect of the treatment in a group on land would be the same as in 
the current study. However, treating four patients in the pool was much cheaper 
(£83) than treating one patient on the land (£148). It should also be acknowledged 
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that land-based group therapy is becoming more common, partly because 
hydrotherapy pools are closing, and further research is required to determine 
whether land-based group therapy can produce similar benefits to individual 
therapy. This would have important implications for delivery cost. 
 
The second contributor to the discrepancy in NHS costs was equipment, although 
this discrepancy was not as large as first imagined. It is important to emphasise 
that in this study the cost of installing a pool was not included. Firstly, the cost of 
pool installation at the hospitals studied was not available, and secondly, costs 
would vary depending on the size, age and position of the pool in the hospital. It 
was the intention of this study to determine the incremental cost of treatment, 
including equipment, not capital outlay of pool. Hospitals that already have pools 
can use the results of Study Three to calculate ongoing costs. Those that do not 
have pools can use the results plus the capital outlay of a new pool. 
 
The advice for clinicians and managers is that if there is already a hydrotherapy 
pool that permits group therapy, better outcomes may be observed from 
hydrotherapy compared to those on land. If resource allocators are planning a 
hydrotherapy service for RA patients, a pool large enough to accommodate a 
minimum of four patients should be considered. 
 
There were no observed differences regarding the number of physiotherapy 
sessions attended between groups. Due to the ongoing nature of the disease, 
hydrotherapy was restricted to six sessions; all participants in this trial received an 
average of six sessions of treatment. Although this number differs from the 
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frequency of hydrotherapy sessions provided in other studies appraised in the 
literature (see Chapter Four, p.115), the median number of hydrotherapy sessions 
in the UK is six (HyDAT Team, 2009). 
 
From an NHS perspective, over the six-week course of treatment, average GP and 
medication costs between groups were similar, and no consultant costs were 
incurred. The treatment for both groups meant that consultant appointments were 
not necessary, and one group did not visit their GP more than the other. This 
could be explained by the short follow-up period of six weeks. It is possible that 
costs would have been different if they had been collected over a longer term.   
 9.4.3 Patient costs  
Time, travel and other costs, such as out-of-pocket expenses borne by patients 
who use NHS services are an important part of an economic evaluation because 
they are associated with utilisation of health services (Epps et al., 2005; Gusi & 
Tomas-Carus, 2008; Goodwin & Morrissey, 2003; Drummond et al., 2005). 
 
Travel expenses were similar in each group, as was the distance travelled to and 
from hospital. One person in the hydrotherapy group required an ambulance to 
and from hospital and another used a taxi, which increased the average cost, 
whilst two patients in the land-therapy group lived close enough to walk. Only 
one person used the tram to get to hospital, a mode of transport peculiar to Salford 
and Manchester. One person in the land-therapy group was referred to 
occupational therapy that incurred a cost of £6.40, whilst one patient received six 
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sessions of acupuncture at the same time as hydrotherapy, incurring a cost of 
£210.  
 
Around half of the participants in each group were retired and 5% in the 
hydrotherapy group considered themselves to be a homemaker. The HyDAT 
Team (2009) also reported that almost half of all hydrotherapy patients did not 
consider themselves to be employed, and that a third had been retired for more 
than two years. Time associated with travel and clinical attendance was costed 
according to forgone activities. The demographics of the patients in this study and 
their activities are reflected in the small cost of time lost with loss of pay. Overall, 
the costs patients incurred were not statistically different, whether they attended 
hydrotherapy or land therapy. 
 
9.4.4 Costs to society 
The cost to society was similar whether patients received hydrotherapy or land 
therapy. There were similarities between the groups in terms of the time lost 
travelling, time lost at the hospital and total time lost, probably due to the 
similarity in the groups’ demographics. From the societal perspective, for those 
participants claiming housework or leisure activities, the value of time (AWR) 
was multiplied by £4.46, and the value of time at employer’s cost was calculated 
at £7.77 for females and £8.7 for men. The value of participants who were 
employed in the hydrotherapy group (four) and in the land-therapy group (six) 
was calculated by multiplying the cost by 21.2% to reflect employers’ National 
Insurance and superannuation contributions.  
 
317 
 
For this thesis study population, approximately half of the RA patients were 
retired and a minority employed, the cost incurred to society and the patient was 
similar. Where more of the population are employed, the cost to society would 
potentially be greater. Although the number of participants in both groups was 
different, 16 in the land-therapy group versus 19 in hydrotherapy, there were more 
than twice the number of employed patients in the land-therapy group than those 
in the hydrotherapy group.  
 
9.4.5 Cost effectiveness 
In Study Three, the ICER was calculated using the HAQ-DI. This study 
demonstrated that with a patient ratio of 4:1, hydrotherapy was more effective and 
less costly than land therapy and should therefore be implemented. However, 
where this is not possible and the alternative of 1:1 is used, for every one unit of 
improvement on the HAQ-DI scale from hydrotherapy, it would cost an additional 
£197 more than land therapy. 
 
The CE plane can demonstrate where the maximum acceptable ICER lies and 
where in relation to that the intervention of interest lies. The maximum acceptable 
ICER is dependent on the resources available and the willingness to pay. Figure 
8.5 (p.318) demonstrates that when the ratio of patients treated in the pool to those 
treated on land is 4:1, hydrotherapy is dominant in terms of cost and effectiveness. 
Hypothetically, when the ratio is changed to 1:1, it moves into the area where it 
becomes more effective, but more costly. 
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 = Hydrotherapy treatment with a patient ratio of either: 4:1 [four in 
hydrotherapy and one on land] or 1:1 [one in hydrotherapy and one on land].  
 
Figure 8.5: Cost effectiveness plane. 
 
The NNT in Study Three, is the number of people needed to receive hydrotherapy 
to produce an overall improvement in the HAQ-DI in one patient (McQuay & 
Moore, 1997). The optimal NNT is one; meaning that every time a treatment is 
used on the defined patient group, it will result in a desired positive outcome that 
would not have occurred without treatment (Dalton & Keating, 2000). Therefore, 
in the current study, a NNT of 2.5 means that 10 patients need to be treated with 
hydrotherapy before they can be sure of achieving improvements in the HAQ-DI 
in four patients, that would not be gained by treatment on land. A NNT between 
two and five is categorised as a successful therapy, and NNT of 20 or more may 
be useful in prophylaxis (McQuay & Moore, 1997). Knowing that the treatment is 
successful in terms of the cost and the number of patients that need to be treated 
1:1 
4:1 
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helps calculate how much the expected gains will cost, both in financial terms and 
in terms of the demands on the patient to continue the therapy (Dalton & Keating, 
2000). 
 
Dalton and Keating (2000) described the use of NNT, its use in physiotherapy and 
its benefits to clinicians. Despite this, it is not widely used in physiotherapy 
literature. To be useful, other studies of hydrotherapy are needed that, firstly, offer 
alternatives to this study, and secondly, have calculated the NTT. Comparisons 
can then be made using the NNT amongst other factors such as cost, age, 
epidemiology, population needs, social factors and other local priorities (Watt & 
Burrell, 2001). 
 
9. 5 Overall summary of discussion 
The first section of this chapter discussed the merits of hydrotherapy against the 
land exercise programme when assessing functional ability, disease activity, QoL 
and psychological wellbeing. Again, the focus in this chapter was discussing the 
differences and assessing the merits of each programme. There was discussion on 
the longer-term effects of hydrotherapy and no very clear conclusion was reached; 
but with a disease that has a high pain-content, any relief of pain, for however 
long, can be considered to have some success. The protocols for each treatment 
were similar, but one finding from this study emphasised the need for adherence 
to the regime by the patients for more positive outcomes.  
 
This second part of this chapter has compared and discussed the main factors in 
the two groups of RA patients who participated in this study. Comparisons have 
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been made between the demographic similarities and differences, which were 
discussed in the literature and were assessed with the findings in this study. Any 
differences that appeared between the hydrotherapy and the land-therapy group 
could be attributed to the choice of patient which, although was random, had to be 
at the discretion of the professionals – namely the physiotherapists and 
consultants.  
 
The final section of this chapter discussed the financial implications of the two 
treatments. The findings of this study demonstrated that although hydrotherapy 
was less costly in treatment and personnel there was very little difference in other 
variables. The beneficial effects and lower cost of hydrotherapy over land 
exercises might mean that hydrotherapy is considered the better choice of 
treatment. This chapter also examined the generalisability of this study. Despite 
the small number of participants, the rigorousness of the methodology gives 
veracity to the results, and it could be accepted that these findings do have 
relevance for other units and will give a sound base for further research. 
  
The following chapter discusses the summary, economic evaluation, strength, 
weakness, recommendations and implications of this study. 
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10.1 Introduction  
A few studies have investigated the effects of hydrotherapy as a treatment 
modality for RA patients, but their findings have been inconclusive and unclear. 
This research team’s knowledge of the effects of hydrotherapy in RA patients in 
terms of healthcare utilisation is limited by the lack of published results. The 
central research problem evaluated in this work concerned the effects of 
hydrotherapy compared to the land therapy in RA individuals (Study One) in 
terms of the physical function, disease activity, psychological wellbeing and QoL. 
 
Few studies have investigated the epidemiological features of RA compared to a 
sample of RA population within the same area. Therefore, this study compared the 
characteristics of RA patients from Study One with the patients in the Kellgren 
rheumatology centre of CMFT and previous rheumatology studies.  
 
Healthcare utilisation was also evaluated in this study (Study Three) to 
demonstrate whether hydrotherapy is more costly than other interventions, such as 
land therapy, from the perspectives of the healthcare provider, patients and 
society. This final chapter presents the summary of the findings, 
recommendations, strengths, limitations, methodological quality, learning key and 
conclusions drawn from the present investigations. 
 
CHAPTER TEN:  
SUMMARY, RECOMMENDATIONS AND 
CONCLUSIONS 
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10.2 Summary 
Aims of the thesis 
 
The primary aim of this thesis was to: 
Evaluate the difference in outcomes for RA patients when treated with 
hydrotherapy as opposed to land-based therapy. 
 
The secondary aims of this thesis were to: 
 Determine the effect of hydrotherapy in the management of patients with 
RA by conducting a systematic review;  
 Identify and evaluate the differences in demographic factors between the 
hydrotherapy and land-therapy groups; 
  Identify and understand the reasons for the difference in functional ability 
measured by HAQ-DI between those receiving hydrotherapy and those 
receiving land therapy;  
 Evaluate whether or not hydrotherapy could improve pain and GWB, 
HRQoL, disease activity and mood symptoms (depression and anxiety) 
more effectively than land therapy in patients with RA;  
 Determine the association between variables measuring disease activity; 
determine the association between variables measuring psychological 
status with socio-demographic features and disease activity indices;  
 Determine which factors predict functional disability; 
  Describe and compare patient characteristics from Study One with 
patients from a regional rheumatology centre and previous rheumatology 
studies;  
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 To evaluate the cost of hydrotherapy compared to the land-based 
treatment, from the viewpoint of the provider [NHS], patient and society. 
 
10.2.1 Findings of the study 
To fulfil the aims of the research study, the functional ability of patients was 
measured by HAQ-DI, which showed that the hydrotherapy group benefited more 
than the land-exercise group in the short term. 
 
The secondary aims of this thesis included many factors. The systematic literature 
review highlighted and provided the encouraging evidence to suggest that 
hydrotherapy is an effective intervention for relieving pain, health status 
compared to an alternative such as land therapy, home exercise and control group. 
 
Study One demonstrated that pain, which is a significant factor in chronic disease, 
was mitigated by hydrotherapy. The benefits of this pain relief were not sustained 
after the 6-week follow-up period. These findings demonstrate that there is better 
functional ability and respite from pain, even if only for short periods for those 
with RA. Therefore, because of these research findings, the research might offer a 
well-supported argument for treatment of RA patients by hydrotherapy rather than 
with land therapy. Additionally, these findings provide suggestions and a base for 
further research work giving supporting references through this study. 
 
There was a significant improvement in GWB for the hydrotherapy group 
compared to the land-therapy group in post treatment and follow-up, which led to 
a better health status for these patients. This must be considered when addressing 
hydrotherapy provision. 
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HRQoL measured by EQ-5D VAS showed significant improvement for the 
hydrotherapy group compared to the land-therapy group. The descriptive profile 
of EQ-5D dimension for pain and discomfort showed a trend of improvement in 
the hydrotherapy group (post-treatment and in the follow-up period) compared to 
the land-therapy group. Again, this would offer opportunities for further research 
into the importance of pain relief in long-term diseases. Because RA is a chronic 
disease with strong associations to pain it opens the question of the long-term 
effects of short-term benefits.  
  
Positive moderate correlation was found between disease activities indices 
(RADAI and DAS28) in all RA patients and in the land-therapy group. Similarly, 
moderate correlation of depression scores was found with disease activity 
measured by RADAI in all RA patients in both the land-therapy and hydrotherapy 
groups. Additionally, moderate associations were found between anxiety score 
and RADAI in all RA patients, in both the land-therapy and hydrotherapy groups. 
Further studies should consider to examine the association between the disease 
activity and depression. 
 
Predictors of functional disability at baseline in all RA patients were RADAI, EQ-
5D tariff, HAQ-GWB, depression score and anxiety score. However, combined 
univariate regression showed that HAQ-GWB was the only predictor of functional 
ability. 
 
Study Two provided evidence that the sample in Study One showed similar 
demographic data in terms of: mean age, DD, gender, BMI, RF, HT, DAS28 
initial mean score, medication, comorbidities and occupational status, to that of 
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literature on a similar topic and a sample of 200 patients from a regional centre for 
RA in Manchester. Limitations of data reported in the medical notes were 
considered. Further research could be done into the external validity of RCTs, 
particularly in relation to the measured treatment effect. 
 
Study Three was the first to examine the costs of providing hydrotherapy 
compared to those of providing land-therapy from the perspectives of provider, 
patients and society. The findings have revealed that the provision of 
hydrotherapy on a group basis for RA patients was cheaper and more effective 
than that of one-to-one land therapy. 
 
10.3 Strengths and weaknesses of the study 
All studies have inherent strengths and limitations; these are highlighted in this 
section. 
The innovations and benefits of this thesis 
This thesis is the first that has examined and evaluated the economic costs of 
hydrotherapy compared to those of land-based therapy in RA patients. It involved 
36 RA patients (11 males and 25 females). Therefore, the inclusion of an 
economic analysis provides strength to the study. 
  
Only one study in the RA hydrotherapy literature investigated psychological 
wellbeing as part of functional outcome measure called AIMS2 (Hall et al., 1996). 
This is the first study in RA hydrotherapy literature studies to use HADs to 
determine the effectiveness of hydrotherapy on ‘psychological wellbeing’. 
Therefore, further studies are required to examine the efficacy of hydrotherapy in 
improving psychological wellbeing in the long-term. 
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The periods of follow-up in Study One were three and six months. It was an 
attempt to provide further evidence regarding the longer-term effects of 
hydrotherapy compared to land therapy. The rationales of having follow-up 
intervals were to ascertain for how long the benefits of hydrotherapy would last. 
Because it was shown that the benefits of hydrotherapy were not long term, more 
research is need to discover how to extend these benefits for longer. Inadequate 
duration of treatment and/or follow-up is another common difficulty for the 
external validity of RCTs (Rothwell, 2005). 
 
This thesis is the first that has examined a wide range of outcome measures. The 
assessment methods used in Study One are regarded as comprehensive methods to 
measure physical function, QoL, disease activity, and psychological wellbeing. 
Moreover, the outcome measures used in this study are mandatory when used as 
an expression of clinical implications in disease activity, physical function, 
psychological wellbeing and QoL; these are all being used in clinical practice.  
 
The external validity of an RCT also depends on whether the outcomes were 
clinically relevant (Rothwell, 2005). Few studies have considered disease activity 
such as tenderness, swelling, grip strength and MS. This study has examined 
disease activity by including the DAS28 and RADAI and the correlation between 
them. The study instruments used were a self-administered questionnaire and the 
physicians’ assessment of disease activity. The DAS28 is commonly used in 
rheumatology departments within the NHS. 
 
Correlations of psychological wellbeing, such as the depression score and anxiety 
score, along with categorical data such as EL, MS, RF and DD were tested in 
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Study One. There is no literature showing that hydrotherapy studies have 
examined this before. The wider ranges of correlation given in this study would be 
helpful in providing a base for further study in the future as part of the assessment 
and treatment in RA patients. 
 
The sample size in Study One was appropriately powered based on HAQ existing 
data (Bilberg et al., 2005). This sample size is larger than the studies of Sanford 
Smith et al. (1998) and Rintala et al. (1996) who studied 24 and 34 RA patients 
respectively. However, it is possible to question the sample size as the intended 
sample size was not met, but research has shown that if the methodology is 
rigorous, the small size of the sample can be negated when looking for 
generalisation (Slavin & Smith, 2009; Rothwell, 2005). This further provides 
evidence in support of the originality of the studies in this thesis. 
 
No previous hydrotherapy RA studies have examined the predictors of disability 
in patients with RA. This is another major advantage of the present research, as no 
other literature on hydrotherapy studies were found investigating predictors for 
functional disability in a group of patients with RA. 
 
The main limitations  
The researcher did not achieve the sample size for this study, which was to recruit 
86 patients excluding six participants in the pilot study. Therefore, it could be 
claimed that this study might be underpowered to detect clinically significant 
differences between hydrotherapy and land therapy using the HAQ-DI score.  
 
However, seventy participants were invited to take part in the study; 48 (68.6%) 
expressed an interest in taking part, 22 (31.4%) did not wish to take part, and gave 
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no clear reasons. Five (10.4%) of 48 were withdrawn from the study after they 
signed the data access sheet and agreed to participate and the reasons for that are 
shown (Figure 6.1, p.169).  Finally, 43 (61.4%) participants completed the 
intervention. 15/43 dropped out at three-month follow up, and 24/43 dropped out 
at six-month follow up. 
  
Unfortunately, we did not collect data regarding reasons as to why patients were 
not interested in the study because it would have been a great burden on the 
clinicians. Therefore, it is not known if the participation rate was more or less than 
might be expected. However, the feasibility and the clinical acceptability of 
hydrotherapy and land-therapy intervention was assessed from both recruitment 
rate and participation through the programme; this proved inconsistent, because of 
a significant shortage in follow-up periods but a high adherence rate in all 
sessions. 
 
Another factor that might determine clinical acceptability is the inclusion of the 
views of participants before and after the programme. This is the main drawback 
of this study, as patient perception was not investigated. Patient perception should 
be evaluated by using qualitative techniques rather than quantitative techniques. 
Future research should advocate the use of the qualitative interviewing approach 
exploring the views of patients about their treatment. 
 
The main reason for small sample sizes in experimental studies in medicine, as 
advanced by methodologists, is that publication bias is more serious in small-
sample research than in studies involving large samples (Slavin & Smith, 2009). 
However, studies with small sample sizes tend to have much larger positive-effect 
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sizes than do studies with larger sample sizes (Slavin & Smith, 2009). Most 
researchers involving small trials are considered to be unethical because they 
expose participants to the burdens and risks of human research, with a limited 
chance to provide any useful answers (Bacchetti et al., 2005; Biau & Kernéis, 
2008). However, it can be stated that any similarly sized RCT is likely to be 
underpowered and inadequate. Therefore, it is advisable that a more 
comprehensive study with a suitable sample size should be conducted with a less 
restrictive inclusion and exclusion criteria. 
 
In spite of the small sample size of this study, multiple statistical tests were used 
in this thesis, not just the t-test. These are of value, because for instance using 
only the t-test is tedious when more than one group are present. Using all the data 
increases stability and increases the chances of type-1 error. Conversely, using a 
large number of comparisons leads to the fact that some findings may appear 
significant by chance, and all the other non-significant findings would be ignored 
in order to favour the positive one. 
 
The follow-up time was too short, despite accounting for the non-attendance at 
follow-up appointments. Considering the type of disease (life-long), a longer 
follow-up time would have given more relevance to the data, which could give 
more validity to the findings. 
 
The research was undertaken at a single centre (SRFT). Although attempts were 
made to determine the external validity of the findings by comparing the patients 
to a local regional centre and other published work, it is not known what the 
characteristics are of patients at other regional centres. Further multicentre work is 
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required and confirmation of these findings with large sample size in other 
settings would be valuable. 
 
No data were found in the literature about the HAQ-GWB. Being the first to 
include an outcome measure does preclude discussion or comparison with other 
findings. Previous studies have used HAQ-DI to measure functional ability rather 
than physical function. 
 
Although it was demonstrated that there were significant differences in most of 
the outcomes included in Study One, it is accepted that some of these outcomes 
will be more important than others. Results from a self-assessment questionnaire 
cannot always be guaranteed because there is no way of checking the quality of 
individual answers.  
 
Outcome measures 
All the outcome measures were chosen for this study because of their importance 
to patients and clinicians, their ease of use, their practicality in analysis, and 
because they had to have good reliability and validity for RA patients. The 
measures were indicated to detect any treatment effects and the resultant 
differences between the two groups. However, the researcher considers that some 
of these outcome measures may not be suitable to detect differences in exercise 
studies in chronic disease such as RA. The best example is EQ-5D three-level 
dimensions (EQ-5D 3L also called EQ-5D tariff). The EQ-D5 tariff was used in 
Study One because it is general, simple, easy to use, short and it is often used in 
other studies. It is acknowledged that there are two other questionnaires used to 
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measure QoL. One is called ‘EQ-5D 5L’, which was developed in 2011 (after 
carrying out Study Three).  
 
The second one is used specifically in RA and called rheumatoid arthritis quality 
of life (RAQoL) (De Jong et al., 1997). RAQoL, consisting of 29 questions, was 
too long and would have been more burdensome for participants if it had been 
included in the RCT Study One, as there were already two lengthy questionnaires 
in place. This is the reason for its exclusion here but in the future, it might be 
recommended for use.  
 
Another limitation of the study is that it included patients with a normal score of 
psychological wellbeing, i.e. a HADs score of < 14, which is the borderline 
between normal and a probable condition of anxiety-depression. Future research 
could target a specific group of patients, for example, excluding patients with a 
HAD score of >14 in order to evaluate the effectiveness of hydrotherapy on the 
symptoms of anxiety-depression in patients with RA. 
 
In conclusion, there are strengths and limitations in this thesis. It is evident that 
the major strengths of these quantitative outcome measures lie in their ability to 
measure a wide range of essential parameters in patients with RA. These outcome 
measures such as HAQ-DI, HAQ VAS, HAQ-GWB, RADAI and HADs could be 
used for clinical assessment of RA patients. However, it is envisaged that the 
limitations discussed could be addressed in future studies of RA patients. 
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10.4 Methodological quality of the RCT 
The methodological quality of the RCT Study One scored 8 out of 10 on the 
PEDro scale of internal validity, which is regarded as high quality (Kollen et al., 
2009; Maher et al., 2003; Moseley et al., 2002). This result was because Study 
One was randomised, used concealed allocation and blinded the researcher. 
However, there was no blinding during data collection in Study One for healthcare 
providers and participants, and this could have led to bias. This study design used 
single blinding due to the nature of the treatment, and although the same therapists 
did not treat patients in both groups, it was not possible for blinding to be carried 
out for both physiotherapist and participants. 
  
In a study such as this, it is very hard to blind the physiotherapists and participants 
from the type of intervention they attend. If participants are not blinded, 
knowledge of group assignment can affect responses to the treatment received 
(Kendall, 2003). Participants who receive a new treatment that they know has 
been assigned to them might have positive expectations or might be more anxious. 
Those assigned to the standard treatment, however, might feel deprived or 
relieved. In both conditions, an awareness of what they are about to receive, and 
perceptions of that treatment might affect the psychological or physical responses 
of the participants (Ferrucci, et al., 2004; Kendall, 2003).  
 
Awareness of treatment allocation can also affect compliance and retention of trial 
participants (Kendall, 2003). It might have been useful to obtain the views of 
therapists regarding the allocation of participants in order to assess the potential 
bias, as is carried out in many drug trials, but this was not done. The researcher 
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acknowledges the importance of blinding in a clinical study whenever possible, as 
it represents an essential, distinct aspect of RCTs. 
 
10.5 Economic evaluation 
This study provides valuable cost-effectiveness data comparing hydrotherapy with 
land therapy in RA patients. Along with Study One, this can be used in healthcare 
decision-making and service organisation. This study might provide an overview 
of important sources of health-economic information. This study is the first to 
examine the costs of hydrotherapy for patients with RA. Despite this, 
methodological weaknesses have been outlined in this economic trial. First, the 
full economic evaluation was only undertaken in the short term, that is, an eight 
weeks period between the baseline and two weeks post-intervention There may 
still be important longer-term healthcare costs that have not been captured, such 
as extra GP, consultant and physiotherapy treatment.  
 
Second, the accuracy of time spent with patients was not verified. We considered 
an average, standard cost for consultant time, GP time, physiotherapist and 
physiotherapy assistant time based on data from the Personal Social Services 
Research Unit (PSSRU) (Curtis, 2011). A different cost might have been found 
had we calculated individual direct and indirect cost of time. 
 
It is recognised that appointment times or waiting times might take longer. In 
Study Three (p. 222), we did not consider sensitivity analysis according to grade 
and salary. This is because it is unlikely that clinicians at different grades would 
treat land-therapy and hydrotherapy patients. Finally, because there was no 
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difference in EQ-5D tariff between the two groups, it was not possible to calculate 
the cost per QALY, which eliminates the ability for comparisons to other studies. 
  
10.6 Key learning from the research 
Despite the study not producing the conclusion that was hoped for, a great many 
ideas have emerged from the findings. The ideas and focus the researcher had at 
the outset have been altered. The research started as very impersonal and 
scientific, but the participants and how they personally responded to treatment 
became a focus. Despite being given much support and help from the 
physiotherapists and the RA consultants, as well as having the co-operation of the 
participants, it was expected that the answers he had expected would be found 
without too many problems. However this was not to be the case; there were 
problems with recruiting the participants, then one of the hydrotherapy centres 
closed. There were many issues that were required by the ethics committee to 
change the study protocols, which led to the lengthy delay to start the study. In 
addition, many patients showed a lack of interest in returning for follow-up 
questionnaires.  
   
This study reinforce the importance of early diagnosis of RA. The actual diagnosis 
is still under debate, which means that studies to define factors to give an accurate 
early diagnosis would be of benefit to the healthcare system and the patient. The 
early initiation of treatment, as it was discussed in Chapter 9, is also of great 
importance – if the treatment was initiated earlier, it would mean that the disease 
progression is most likely to be abated , which is so important for the patient and 
potentially may reduce healthcare costs. 
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Hydrotherapy once per week for six weeks improved physical function, 
psychological wellbeing and pain to those with RA. Not known is the optimal 
duration of treatment to give maximum benefit and whether this varies from 
patient to patient. Study One demonstrated short-term benefit but did not provide 
evidence of longer term benefit. It might be that longer-term effects are unlikely 
to be found due to the nature of the physiological and psychological effects of 
hydrotherapy. From the findings in this thesis, it is possible to appreciate how 
important it is to have long-term follow up. Not only has this study not been able 
to give definitive answers, but also the results are inconclusive.  
 
It is apparent for the need to choose important outcome measures for patients, as 
well as interventions that can be easily applied without exerting pressure on or 
burdening patients. The external validity of any study also depends on whether the 
outcomes were clinically relevant. This can depend on subtle considerations, such 
as who actually measured the outcome, but is more often dependent on what was 
measured and when. 
  
The association between disease activity indices and anxiety and depression is 
another factor that needs further research. There are few studies with this focus, 
but because RA is a long-term disease without much respite, there is a vital need 
to understand more about remitting disease activity and mitigating anxiety and 
depression to enhance QoL. 
 
It became apparent how little health workers knew about the cost of treatments. 
Maybe if more was understood about costs, more could be put in place to help 
save money, or at least to know where and why it is being spent. This is an area, 
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mainly in RA hydrotherapy, that lacks enough research, and given the constraints 
of the NHS, it should be considered. 
 
By carrying out this study, the researcher has, in his opinion, become more 
empathetic towards staff and patients, and has come to understand more about 
chronic illness and people. This research has provided a better understanding 
about RA patients and it is hoped that better care will result because of it. Finally, 
it is intended that in future colleagues have an appreciation about the finances 
involved in health services provision. 
 
10.7 Implications and recommendations 
10.7.1 Implications for practice 
For clinicians: This research has established that hydrotherapy provides more 
successful short-term outcomes than land exercises for those with RA. All 
clinicians should be encouraged to explore the possibility of prescribing 
hydrotherapy for patients with RA. Communication between physiotherapy 
departments and GPs and consultants should increase the awareness of the 
benefits of hydrotherapy. An increased awareness might allow colleagues to target 
patients who might benefit from treatment.  
 
There are no studies that have led to the creation of guidelines for the referral of 
RA patients to physiotherapy in general and hydrotherapy specifically. Referrals 
by rheumatologists are often on an unplanned basis (Hurley et al., 2002). For this 
reason, the referral processes may vary from unit to unit depending on timing and 
other reasons (Hurley et al., 2002). It is important for all RA patients to be given 
the opportunity to receive hydrotherapy, where possible. 
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For decision makers: This research has outlined the detailed expense and 
effectiveness of hydrotherapy over land therapy on a 4:1 basis. It should 
encourage the safe treatment of patients on the minimum of a 4:1 basis in those 
departments with pools. For those planning on building pools, it should justify the 
exploration of providing a large enough area for group therapy rather than on a 
1:1 basis. For those intending on closing a pool, it might be more cost effective to 
keep it open if group therapy is feasible, as it is not known whether group land 
treatment is a cheaper or more effective option. Hydrotherapy can also be used for 
conditions other than RA. 
 
Presently, it is only known that hydrotherapy is effective in the short term. It is 
not feasible to provide hydrotherapy ad infinitum, and other alternatives to 
attending hydrotherapy in the hospital must be considered once maximum 
improvement has been made. 
 
For patients: Patients should be provided with enough information, based on 
current research,  for them to understand the benefits of hydrotherapy and to make 
an informed choice when offered it or consider giving it up.  
 
10.7.2 Implications for research 
This is the first study that has investigated the economic evaluation of 
hydrotherapy for RA patients. Future studies should consider investigating the 
cost-effectiveness of hydrotherapy and the best aquatic exercise for RA patients in 
the longer term. It is not clear whether the short-term effects of hydrotherapy have 
long-term impacts on costs to the provider, the patient or society. 
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Using the findings of this research, there is a need for more work to be done in 
order to determine the effectiveness of hydrotherapy on disease activity, 
psychological aspects of RA and aspects of physical function, by utilising the 
accurate outcome measures involved. There is also a need for more adequately 
powered studies to determine the effectiveness of hydrotherapy. 
 
It is acknowledged that there may be other factors associated with RA such as 
fatigue or grip strength that were not measured in Study One. However, in order 
for patients with this condition to receive appropriate treatment for their condition, 
the identified parameters (section 9.2.3.3, p.283) should be optimised in the future 
using other methodologies. Moreover, future research should examine the 
association of anxiety and/or depression with disease activity, and this should be 
measured by a self-administered questionnaire such as the RADAI.  
 
Further research should examine the effects of hydrotherapy, not only comparing 
various interventions, but also other trials comparing interventions with a no-
treatment control group. When possible, the beneficial effect of the aquatic 
environment should be considered as a confounder or effect modifier, and should 
be accounted for in the design of the study, although this has ethical implications. 
 
Although short-term gains have been shown, it is not known how hydrotherapy 
affects locus of control. Some patients choose not to, or are unable to, continue 
water-based treatment independently. Other patients are advised or choose to 
continue water-based treatment by themselves, or in local groups. These water-
based treatments can be in a hydrotherapy pool or local swimming pool at a 
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leisure centre. It is not known whether the same effects observed during 
hydrotherapy, will be replicated if they are continued as self-management. 
 
10.8 Conclusion  
Hydrotherapy for patients with arthritis is one of the oldest forms of therapy. 
Hydrotherapy has an important role in the management of RA and aims to 
maximise physical function and reduce functional disabilities. Study One found 
favourable evidence of the benefit of aquatic exercise when compared to the land 
exercises after six-week intervention period. 
 
The scientific evidence from all three studies is valid because of the good 
methodological quality, adequate statistical analysis, and for the patient the use of 
essential outcome measures. It provides some evidence that compared to land 
therapy, hydrotherapy is more beneficial and cheaper for people with RA. As the 
cost of managing RA is high, further research is needed to determine the efficacy 
and CE of hydrotherapy, and to create appropriate intervention strategies to 
optimise the management of the physiotherapy service. Providing six sessions of 
hydrotherapy to RA patients is more effective than land-exercise therapy, and that 
it is less costly to the NHS than land-therapy. 
 
The hypothesis: ‘There will be no significant difference in HAQ-DI score between 
hydrotherapy and land-therapy arms in patients with RA’ can be rejected.
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Appendix 1: Letter to clinicians 
Dear Colleagues:                                                                                     
May I introduce myself and the reason for my letter? 
My name is Khamis Al-Qubaeissy; I have a higher diploma degree in Rheumatology and 
Medical Rehabilitation from College of Medicine/ Baghdad University. Now, I am a 
postgraduate student from Manchester Metropolitan University. I am writing on the 
recommendation of my Advisory team (Dr. Peter Goodwin, Dr Abebaw Yohannes and Dr 
Francis Fatoye) who suggested that I might contact you to discuss the possibility of 
collaborating with you and all outpatients Rheumatology clinicians on an upcoming 
research project. Currently I am conducting my PhD research in Medical rehabilitation of 
Rheumatoid Arthritis (RA). I will try to give you a brief outline of the proposed research. 
The research will focus on effects of Aquatic physiotherapy in RA. The effects of aquatic 
physiotherapy in RA has been investigated in previous studies, however, their findings 
are inconclusive and unclear.  
The objectives of my current research are to determine the outcomes of Aquatic 
physiotherapy for improving pain, function and quality of life in patients with RA. 
Furthermore, investigate the effective role of Aquatic physiotherapy in terms of Health 
care utilisation in comparison with land therapy and usual care. In addition, to determine 
the cost effectiveness of combined Aquatic physiotherapy and usual treatment in RA. It is 
intended that this research will help all RA patients to develop an appropriate intervention 
method, which will help to prevent further damage of the joint or irreversible disability, 
and achieve maximum function with physical improvement. 
This research will require the recruitment of 86 RA patients according to American 
College of Rheumatology (ACR) 1987 revised criteria. The choice of the candidates for 
this study will depend on the inclusion and exclusion criteria in order to avoid any risk 
and discomfort that might happen during research. 
I have attached a flow chart, which outlines the research protocol, outcome measures and 
inclusion/exclusion criteria. We hope to involve several research sites across the Greater 
Manchester area in order to aid recruitment and ensure a representative patient sample. 
We are very interested in collaborating with yourself and all Rheumatologists in 
outpatients Rheumatology clinic and wonder if you would consider being involved in the 
study. If you have any questions or would like any further information, please do not 
hesitate to contact me. I look forward to hearing from you soon. 
 
 
 
 
Khamis Al-Qubaeissy 
Postgraduate Student                                                    
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Appendix 2: Data Access Sheet  
 
Study Title: Medical rehabilitation: The effect of aquatic physiotherapy  
in patients with Rheumatoid Arthritis 
 
Name:  
____________________________________________________________ 
 
Address:___________________________________________________________
__________________________________________________________________
__________________________________________________________________
__________________________________________________________________
____ 
Tel:  Home ________________________  Mobile _________________________ 
 
I give permission  
I do not give my permission 
I would like more time before giving my permission 
…for Khamis Al-Qubaeissy to contact me regarding the above study. 
 
The best time to call is    
am _____________ 
pm _____________ 
 
 
Signed:  _______________________________________Date:  ______________ 
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Appendix 3: Patient information sheet 
Version V  
Date: 28/2/2011 
Part 1. 
1. Project Title.  
Medical rehabilitation: the effects of aquatic physiotherapy (hydrotherapy) in 
patients with Rheumatoid Arthritis (RA). 
2. Invitation paragraph 
I would like to invite you to take part in a research study, which will be conducted by Mr. 
Khamis AL-Qubaeissy, a postgraduate researcher in Medical Rehabilitation in the 
Manchester Metropolitan University. Before you decide to participate, it is important for 
you to understand why the research is being done and what it will involve.  Please take 
time to read the following information carefully. Feel free to talk to others about the study 
if you wish.  
•Part 1 tells you the purpose of this study and what will happen to you if you take part.   
•Part 2 gives you more detailed information about the conduct of the study.  
Please ask me if there is anything that is not clear or if you would like more information.  
Take time to decide whether you wish to take part. 
3. What is the purpose of the study? 
The main purpose of this research is to look at what happens when patients take part in 
aquatic physiotherapy (exercises in a warm water pool), we are interested how this will 
affect pain, movement and quality of life in patients with Rheumatoid Arthritis (RA), and 
we are interested in how much this treatment costs the NHS patients and employers. It is 
hoped that the results of this study will help clinicians to develop appropriate treatment 
for all patients with RA, to prevent further damage of the joint or irreversible disability, 
achieve maximum function, and ultimately improve quality of life. Patients might need 
other types of therapy in addition to drugs treatment to improve their general function, 
e.g. occupation therapy.  
4. Why have I been chosen? 
You have been chosen because you have a diagnosis of RA. The volunteers who take part 
in this study are screened and selected carefully by the treatment team involved in their 
treatment programme. It is anticipated that up to 86 volunteers will participate in this 
trial. During the trial, there is no need to withhold any type of treatment prescribed by 
your physician. 
5. Do I have to take part? 
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Appendix 3 (continued) 
Participation in the research is voluntary, and if you decide to participate, you will be 
given the information sheet and a consent form to read and keep, you will also be asked 
to sign a Data Information Sheet, which says you are happy for us to contact you. You are 
still free to withdraw at any time and without giving a reason.  A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care you receive. 
6. What will happen to me if I take part? 
If you have decided to take part, then please read the following guidelines carefully: 
• The study will recruit 86 patients with RA from the outpatient rheumatology clinic in 
Manchester Royal Infirmary. 
• The research will last up to a maximum of 6-8 months. 
• All volunteers will be divided into two groups: a group who exercise on land and in 
water, or a group who only exercise on dry land. 
• All volunteers will be asked to complete some questionnaires, which are simple to fill 
out, and will take about 15 to 30 minutes. You will be asked to fill out the questionnaires 
before the study starts, then 6 weeks, 3 months and 6 months later. You should continue 
taking your usual medication during the study. 
• If you are chosen to receive treatment on dry land you will be asked to attend the 
physiotherapy department where a physiotherapist will guide you through the best 
treatment for your needs. 
• If you are chosen to exercise on land and in warm water, you will be asked to attend 
physiotherapy once a week for 6 weeks. As well as being guided through the best 
treatment for your needs, you will exercise in a warm pool for approximately 30 minutes 
following each physiotherapy appointment.  This will be with two to three other patients 
and you will then spend 4-5 minutes relaxing afterwards. 
 • Your participation is voluntary; you are free to withdraw at any time, without giving a 
reason. If you agree to take part, then all details will be explained to you. We will ask you 
to sign a consent form. This will not affect any of the care you receive. 
• One of our team will go through the information sheet with you and answer any 
questions you have and this should take about (20-30) minutes. 
• If there is anything that is not clear please contact Mr. AL-Qubaeissy in the first 
instance (contact details below). 
• Mr. Al-Qubaeissy will follow ethical and legal practice and all information about you 
will be handled in confidence. 
• Your name will not be identified in any publication or thesis 
• There are no restrictions on the type of clothing that you may wear. 
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Appendix 3 (continued) 
• To maintain your privacy, only the clinical team from the physiotherapy department and 
Mr. Al-Qubaeissy will be present during most of the trial.  Occasionally Mr. Al-
Qubaeissy academic supervisors may be present.   
7. What do I have to do? 
During the trial, you will be guided throughout the procedures. A thorough explanation 
will be given at each session attended.  
8. What is the procedure that is being tested? 
The nature of the trial will involve comparing usual treatment (control group), 
physiotherapy on dry land, with the usual therapy plus an aquatic session in RA 
(intervention group). The intervention group will therefore receive sessions of aquatic 
physiotherapy (exercises in a warm pool) led by senior physiotherapists (at a water 
temperature of between 34-36° Celsius). Every aquatic physiotherapy session includes 
between 2-4 patients per session because of the size of the aquatic therapy pools. Before 
the session, participants will perform warm up exercise for 10 minutes in the water while 
the main exercises will focus on joints movement, muscle strength and functional 
activity. Patients will receive a 30-minute session of hydrotherapy once weekly for 6 
weeks. Each session will take place in the aquatic pool in the Manchester Royal Infirmary 
under supervision of highly experienced physiotherapists. The design of the exercise 
programme is standardized in consultation with the physiotherapists. The therapist in 
response to individual ability will adjust patient progression.  
9. What are the possible disadvantages and risks of taking part? 
There will be no disadvantages taking part in this study. Patient’s safety is paramount for 
this study. Therefore, we take the following action where appropriate: 
a) Patients who experience excessive fatigue during exercise in the aquatic pool will be 
allowed to stop whenever they feel tired. 
b) Exclusion criteria will be employed to prevent patients being included that will not 
benefit from, or will be at risk from entering the pool, for example: those with chlorine 
sensitivity, epilepsy or hydrophobia. If a patient develops a sudden adverse reaction, for 
example chlorine sensitivity, treatment will be stopped. Advice will be given to the 
patient to see their GP to discuss chlorine sensitivity. As patients have been referred to 
physiotherapy by their consultant rheumatologist and are deemed suitable for aquatic 
physiotherapy, no extra burden for the patients by attending treatment is anticipated. 
c) In case of emergency, the hospital’s emergency protocol will be adopted; This 
procedure is practiced 3-4 times annually, for example: testing of the emergency alarm, 
response time and use of emergency pool evacuation equipment. 
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Appendix 3 (continued) 
D) For safety, if patients do not speak English, it will be a requirement that a translator is 
present in the pool and when completing the questionnaires. 
10. What are the possible benefits of taking part? 
This study is of an experimental nature, and we cannot promise the study will help you, it 
is hoped that the results of this study will help clinicians to develop appropriate 
interventions for patients with RA, to prevent further damage of the joint or irreversible 
disability, pain and achieve maximum function and ultimately improve quality of life. 
Patients need additional therapy to drugs for longer-term effects. Water is regarded as an 
appropriate environment for treating RA patients as warm water relaxes tense muscles 
and increases blood flow to the tissues.  
11. What happens when the research study ends? 
 When the study comes to its natural end, should patients still require physiotherapy they 
will still be able to attend either land based treatment or aquatic physiotherapy as is 
deemed appropriate to their ongoing care.  This can be discussed with the physiotherapist. 
12. What if there is a problem? 
If you need to seek clarification about this study, please contact Mr. Khamis AL-
Qubaeissy or his Academic Supervisor (contact details below) who will do their best to 
answer your questions 
If you have a concern about any aspect of the conduct of this study, please contact either 
the University or the NHS Trust below. 
Central Manchester University Hospitals NHS Foundation Trust – Dr Lynne Webster, 
Head of Research Office, 1
st
 Floor Postgraduate Centre, Manchester Royal Infirmary, 
Oxford Road, Manchester M13 9WL. Tel: 0161 276 4125, lynne.webster@cmft.nhs.uk 
Manchester Metropolitan University – Professor Valerie Edwards-Jones, Director of 
Research, Research and Enterprise Services, Ormond Building, Lower Ormond Street, 
Manchester M15 6BX. Tel: 0161 247 1025 
 
In the event of any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer, please refer to the NHS Patient Advice & Liaison 
(PALS) Team. 
How to contact the PALS team - Telephone: 0161 276 8686, E-mail: pals@cmft.nhs.uk 
Please note that you may withdraw from the study at any time during the trial without any 
effect on your care and treatment.  Every effort will be made to ensure your continued 
comfort and safety. 
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Appendix 3 (continued) 
In the event that something does go wrong, you are harmed during the research study, and 
this is due to negligence of the researchers or clinical team, both the Manchester 
Metropolitan University and Central Manchester University Hospitals NHS Foundation 
Trust maintain insurance in the event of such a claim due to negligence of their students 
and employees.   You may have grounds for legal action; however, you may have to pay 
your legal costs.  Further information can be provided via the PALS team within the NHS 
or via the Manchester Metropolitan University through their Institutional contact. 
13. Will my taking part in the study be kept confidential?  
If you join the study, all the information about your participation in this study will be kept 
confidential. The lead researcher will look at some parts of your medical records and the 
data collected for the study. Authorised people may also look at them from Central 
Manchester University Hospitals NHS Foundation Trust to check that the study is being 
carried out correctly. All will have a duty of confidentiality to you as a research 
participant and nothing that could reveal your identity will be disclosed outside the 
research site.  You details will not be passed on to a third party and no data will be 
transferred for the purpose of processing or analysing outside the European Economic 
Area.  All names will be replaced with codes so that individuals cannot be identified. We 
intend to publish the results of the study, that is, which treatment was the most successful, 
but names or details of individuals will not be published. 
14. Contact Details: 
For more information, please refer to:  
Khamis AL-Qubaeissy, Doctoral Researcher/Medical Rehabilitation,  
Manchester Metropolitan University,  
Elizabeth Gaskell Campus, Hathersage Road,  
Manchester. M13 0JA.  
Tel: 07588695372, email: 09981701@stu.mmu.ac.uk  
Academic Supervisor: 
Dr. Peter Goodwin 
Manchester Metropolitan University,  
Elizabeth Gaskell Campus, 
Hathersage Road,  
Manchester. M13 0JA.  
Tel: 0161 247 2941, email p.goodwin@mmu.ac.uk 
This completes Part 1 of the Information Sheet. 
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Appendix 3 (continued) 
If the information in Part one has interested you and you are considering participation, 
please continue to read the additional information in Part two before making any 
decision. 
Part 2:  
15. What if relevant new information becomes available?  
 A letter explaining such information, when it becomes available would be given to the 
subjects and you would be encouraged to discuss the implications of such with the 
research team if you so wished. If new data becomes available that would affect your 
participation in the study you will be asked to re-consent. 
16. What will happen if I do not want to carry on with the study? 
If you withdraw from the study, we would like to use the data collected up to your 
withdrawal, or you can choose to have your data withdrawn from the study also. 
17. Involvement of the General Practitioner/Family doctor (GP) 
If you are recruited in the research, then a letter will be sent to your G.P. notifying 
him/her of your desire to partake in the trial and if they have, any concerns then the G.P. 
should let me know. 
18. What will happen to the results of the research study? 
The results will be used in a PhD thesis, and may be published in a scientific journal or 
presented at a scientific conference. 
19. Who is organising and funding the research?  
The project is part of a PhD and no funding has been sought for this trial. 
20. Who has reviewed the study?  
Finally, before any research goes ahead, all research in the NHS is looked at by an 
independent group of people, called a Research Ethics Committee to protect your safety, 
rights, wellbeing and dignity. This study has been reviewed and given a favorable opinion 
by Research Ethics Committee. Central Manchester University Hospitals NHS 
Foundation Trust has reviewed and authorised the study and the study has been given a 
favorable ethical opinion by the Manchester Metropolitan University Research Ethics 
Committee. 
Thank you for reading this – please ask 
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Appendix 4: Consent form 
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Appendix 5: Health Assessment Questionnaire 
 
 
 
 
 
 
352 
 
Appendix 5 (continued) 
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Appendix 6: EQ-5D 3L (EQ-5D tariff) 
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Appendix 7: EQ-5D VAS 
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Appendix 8: Rheumatoid Arthritis Disease Activity Index (RADAI) 
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Appendix 8 (continued) 
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Appendix 9: DAS28 form    
  Patient name…………………………………Date of Birth   ……-……-…….  
 
Observer name………………………………Date ……-……-…… 
 
 
 Left  Right  
 Swollen tender Swollen Tender 
Shoulder     
Elbow     
Wrist     
MCP 1     
 2     
 3     
 4     
 5     
PIP 1     
 2     
 3     
 4     
 5     
Knee     
Subtotal     
Total swollen  Tender  
 
 
 
 
No disease activity      high disease activity 
 
 
 
Swollen (0-28)  
Tender (0-28)  
ESR  
VAS disease activity (0-100mm)  
  
DAS28 = 0.56*(t28) + 0.28*(sw28) + 
0.70*Ln(ESR) + 0.014*VAS 
 
 
                   
358 
 
Appendix 10: Hospital Anxiety Depression scale (HADs) 
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Appendix 11: Treatment Strategy form  
 
Participant number: 
 
 
 
Physiotherapy 
diagnosis: 
 
 
 
Aims of intervention: 
 
1] 
2] 
3] 
4] 
5] 
 
 
Short term goals: 
 
1] 
2] 
3] 
 
 
Long term goals: 
 
1] 
2] 
3] 
 
Category of 
intervention 
Interventions in this category Physiotherapy sessions (tick RX 
provided) 
1 2 3 4 5 6 7 8 
 
Mobility and 
functional 
treatment 
Walking aid assessment         
Gait re-education         
Stairs         
Activities of daily living 
assessment 
        
Splinting         
         
         
Education and advice Flare-up management advice         
Return to activity and work 
advice 
        
Education group attendance         
Pacing advice         
Joint protection advice         
         
         
General rehabilitation Progression of exercises         
Graded functional exercises         
         
Paced increase in activity         
General fitness exercises         
General strength training         
Low intensity exercises         
High intensity exercises         
Short and long term goal 
setting 
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Home 
exercises/programme 
Tailored programme         
Generalised exercise 
programme 
        
         
         
Core stability         
Range of movement exercises         
Strengthening exercises         
Heat/cold advice         
Pain relief How to manage flare-ups         
Wax baths         
TENS         
Acupuncture         
Other electrotherapy         
         
Hydrotherapy exercises Range of movement         
Sustained stretches         
Core stability exercises         
Balance exercises         
          
          
Land Exercise: Range of movement         
Strengthening         
Fitness Exercises         
Gym-based group exercise         
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Appendix 12: Hydrotherapy and Home exercise programme 
[(Salford Royal Foundation NHS Trust, 2007) with permission] 
 
Home exercise programme 
 
Stretching exercises 
Range of movement exercises 
Fitness exercises 
 
Home exercises start in form of range of movement to each part of body such as neck, 
shoulder, hip joints, feet, ankles, wrists, fingers and back.  
 
Warm-up start routinely for 2-3 minutes in order to increase body temperature and heart 
rate (cardiovascular fitness). This started by marching on the spot, lifting knee high and 
swinging arms. Then step touch to the left and right, keep good pacing going. 
 
 
Warm-up exercise 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After that, start stretching exercises. It is recommended that all these exercises should be 
done slowly. Start with about five repetitions and build up the number gradually. If the 
patients have more pain either in the muscles or in the joints, stop. We recommend that 
you hold the position for 5–10 seconds. Do twice daily. 
 
Stretching exercises for knee joints start as 
 
Sit on edge of table or bed. Cross your ankles over. Push front leg backwards and back 
leg forwards against each other until the thigh muscles become tense. Hold for 10 
seconds, and then relax. Switch legs and repeat.  
 
Sit on edge of table or bed, keeping an upright posture with feet on the floor. Place 
weights around ankles or feet. Straighten one knee fully. Hold, and then slowly lower.  
 
 
If the knee is hot or swollen, do not use weights. 
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For wrist joints, stretching start as 
 
1) Place your left hand face down on the table and lift the fingers up away 
from the table.  
2) Place your other hand across the knuckles at 90º and with your right hand, 
push down as the left hand tries to pull up.  
3) Feel the muscles of your forearms contracting. Swap hands and repeat. 
 
For finger stretching start as: 
 
1) Begin with palm of your hand on a towel on a table, fingers apart.  
2) Pull fingers together by pressing your hand down into the table and bunching 
up the towel between your fingers. 
 
For Arm stretching start as Arms 
 
1) Stand with arm straight, bend elbow, and then straighten out again. (Hold 
a weight in your hand such as a bag of sugar or a potato)  
2) Stand with a weight in each hand, or use wrist weights. Raise your arms 
overhead as far as you can and slowly lower. 
3) Stand with a weight in each hand, or use wrist weights. Place your arms by 
your sides. Slowly lift arms away from your body, keeping the elbows 
straight. Hold for 5 seconds and slowly lower.  
4) Breathe steadily as you exercise. It is normal to feel muscle ache but stop 
if you get any lingering joint pain.  
5) For range of movement should hold the stretch for about 5–10 seconds, 
then relax and repeat the movement 5–10 times. Do twice daily. If the 
joints are especially hot and swollen do these exercises gently and only do 
five repetitions once a day. 
 
Neck 
1) Sit with good posture, turn head to the right and then left slowly. 
2) Sit or stand with good posture. Lower your chin to your chest, and then    
return     to starting position    
3) Sit or stand with good posture. Keeping your head level, pull your chin 
back. Relax, and then repeat. 
  
         Stop if you feel dizzy doing any of these exercises. 
 
 
Shoulders 
 
1) Stand with your arms relaxed at your sides. 
2) Raise arms as far as you can. 
3) Place hands behind head, then behind back. 
4) Lie on your back. Raise arms overhead as far as you can.  
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Hips 
 
1) Sit with knees bent and feet together as shown. Press knees down towards 
the floor using hands as needed. 
2) Alternatively lie on your back and part your knees, keeping your feet 
together. 
3) Lie on your back. Pull each knee in turn to chest, keeping the other leg 
straight.  
Feet and ankles 
 
1) Bend ankle up towards your body as far as possible. Now point toes away 
from your body.  
2) Move your ankle around slowly in a large circle. Repeat in the opposite 
direction.  
Fingers 
 
1) Make a fist, and then straighten fingers.  
2) Bend first two joints of your fingers down as shown, and then straighten 
again. 
Back 
 
1) Lie on your back, hands behind your head (or by your side if your 
shoulders are painful). Bend your knees and, keeping your feet to the floor, 
roll your knees to one side slowly. Hold this position for 10 seconds. 
Repeat this three times for each side. 
2) Lie on your back. Bring one knee up and pull it gently to the chest. Push 
your back into the floor when doing this exercise. Hold, and then swap 
legs. 
3) Straighten arms to press trunk upwards, letting hips sag to the floor.  
                Not recommended for people with rheumatoid arthritis who have wrist pain. 
4) Place hands on hips as shown and bend slowly to one side until you feel a 
stretch. Hold, and then repeat on the other side. 
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Hydrotherapy programme 
 
Warm up exercise in form of walking in the pool and sidestepping, knee to chest 
walking / heel to bottom walking, hip abduction / adduction & flexion / extension. 
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Sustained Stretching exercises: included  
Upper limb stretches for rhomboids muscles, pectorals, deltoid, biceps, and triceps. 
              
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Lower limb stretches for gastrocnemius, soleus, hamstrings, hip-abduction, quadriceps 
Lower Limb Buoyancy Assistance/Buoyancy Resistance: Straight Leg Raising as 
hamstring stretch. 
Lower Limb hip Medial Rotation / Lateral Rotation in standing with woggle. 
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Range of movement: in addition to usual movement in the pool for knee to chest, heel to 
bottom, hip abduction and adduction, hip flexion and extension, there are many activities 
for range of motion exercises included: 
 
a) Breast stroke arms with floats. 
b) Lumber extensions: rotation in corner. 
c) Extension/flexion side flexion at wall. 
d) Thoracic rotation with woggle. 
e) Upper limb buoyancy assistant: Gleno-Humeral Joint flexion / abduction.   
f) Hands on poolside horizontal flexion stretch. 
g) Hands behind back stretch with dumbbells. 
h) Lower Limb Buoyancy Assistant/Buoyancy Resistant: abduction as adductor        
stretch / muscle strengthening. 
i) flexion/extension as extensor/flexor stretch muscle strengthening. 
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Trans -abdominals with float / woggle 
Rowing with woggle forwards / backwards 
Supine floats work: cycling / hip abduction / knee rolling / Lumber Side Flexion. 
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Balance exercises: included walking / side stepping 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proprioception: included walking on oblong floats and Walking against turbulence. 
 
7) Muscle strengthening: included the following exercises: 
a) Elbow curls with dumbbells 
b) Upper Limb Buoyancy Resistance: Gleno-humeral Joint flexion / extension with bats 
or gloves. 
c) Gleno-humeral Joint abduction / adduction with bats or gloves. 
d) Elevation / depression with float or woggle. 
e) Protraction / retraction with float or woggle. 
f) Shoulder adduction / extension with dumbbells / bats. 
g) Elbow flexion / extension muscle strengthening with dumbbells / bats. 
h) Elbow flexion / extension with bats or gloves. 
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i) Lower Limb Buoyancy Resistance/Buoyancy Assistance abduction as adductor stretch 
muscle strengthening. 
j) flexion/extension as extensor/flexor stretch muscle strengthening. 
k) Lower limb buoyancy resistance hip/knee extension with float / woggle. 
l) Step upside / eccentric step-downs. 
m) Heel raises. 
n) Drag ring walking / leg swings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cool down: include walking in the pool and sidestepping, knee to chest walking / heel to 
bottom walking, hip abduction / adduction & flexion / extension 
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Appendix 13: Land and home exercise programme 
 
[(Salford Royal Foundation NHS Trust, 2007) with permission] 
Home exercise: included  
 
Stretching exercises 
Range of movement exercises 
Fitness exercises 
 
Gym-based exercises (land): includes 
 
A) Squats 
B) Abdominals 
C) Shuttle walk or run, or treadmill 
D) Press-ups 
E) Star steps and jumps 
F) Arm exercises 
G) Step-ups 
H) Back exercises 
 
Home exercises start in form of range of movement to each part of body such as neck, 
shoulder, hip joints, feet, ankles, wrists, fingers and back. Warm-up start routinely for 2-
3 minutes in order to increase body temperature and heart rate (cardiovascular fitness). 
This started by marching on the spot, lifting knee high and swinging arms. Then step 
touch to the left and right, keep good pacing going. 
Warm-up exercise 
 
 
 
 
After that, start stretching exercises. It is recommended that all these exercises should be 
done slowly. Start with about five repetitions and build up the number gradually. If the 
patients have more pain either in the muscles or in the joints, stop. We recommend that 
you hold the position for 5–10 seconds. Do twice daily. 
 
Stretching exercises for knee joints start as 
 
Sit on edge of table or bed. Cross your ankles over. Push front leg backwards and back 
leg forwards against each other until the thigh muscles become tense. Hold for 10 
seconds, and then relax. Switch legs and repeat.  
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Sit on edge of table or bed, keeping an upright posture with feet on the floor. Place 
weights around ankles or feet. Straighten one knee fully. Hold, and then slowly lower.  
 
If the knee is hot or swollen, do not use weights. 
 
For wrist joints, stretching start as 
 
 • Place your left hand face down on the table and lift the fingers up away from the table.  
 
• Place your other hand across the knuckles at 90º and with your right hand, push down as 
the left hand tries to pull up.  
 
• Feel the muscles of your forearms contracting. Swap hands and repeat. 
 
For finger stretching start as: 
 
 • Begin with palm of your hand on a towel on a table, fingers apart.  
 
• Pull fingers together by pressing your hand down into the table and bunching up the 
towel between your fingers. 
 
For Arm stretching start as Arms 
 
 Stand with arm straight, bend elbow, and then straighten out again. (Hold a 
weight in your hand such as a bag of sugar or a potato)  
  
 Stand with a weight in each hand, or use wrist weights. Raise your arms 
overhead as far as you can and slowly lower. 
 Stand with a weight in each hand, or use wrist weights. Place your arms by 
your sides. Slowly lift arms away from your body, keeping the elbows 
straight. Hold for 5 seconds and slowly lower.  
 
 Breathe steadily as you exercise. It is normal to feel muscle ache but stop if 
you get any lingering joint pain.  
 
 For range of movement should hold the stretch for about 5–10 seconds, then 
relax and repeat the movement 5–10 times. Do twice daily. If the joints are 
especially hot and swollen do these exercises gently and only do five 
repetitions once a day. 
Neck 
1) Sit with good posture, turn head to the right and then left slowly. 
      2)  Sit or stand with good posture. Lower your chin to your chest, and then    return     
to starting position. 
 
        3) Sit or stand with good posture. Keeping your head level, pull your chin back. 
Relax, and then repeat. 
Stop if you feel dizzy doing any of these exercises. 
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Shoulders 
1) Stand with your arms relaxed at your sides. 
2) Raise arms as far as you can. 
3) Place hands behind head, then behind back. 
4) Lie on your back. Raise arms overhead as far as you can.  
Hips 
1) Sit with knees bent and feet together as shown. Press knees down towards 
the floor using hands as needed. 
2) Alternatively lie on your back and part your knees, keeping your feet 
together. 
3) Lie on your back. Pull each knee in turn to chest, keeping the other leg 
straight.  
Feet and ankles 
1) Bend ankle up towards your body as far as possible. Now point toes away 
from your body.  
2) Move your ankle around slowly in a large circle. Repeat in the opposite 
direction.  
Fingers 
1) Make a fist, and then straighten fingers.  
2) Bend first two joints of your fingers down as shown, and then straighten 
again. 
Back 
1) Lie on your back, hands behind your head (or by your side if your 
shoulders are painful). Bend your knees and, keeping your feet to the floor, 
roll your knees to one side slowly. Hold this position for 10 seconds. 
Repeat this three times for each side. 
 
2) Lie on your back. Bring one knee up and pull it gently to the chest. Push 
your back into the floor when doing this exercise. Hold, and then swap 
legs. 
 
3) Straighten arms to press trunk upwards, letting hips sag to the floor.  
            Not recommended for people with rheumatoid arthritis who have wrist. 
 
4)  Place hands on hips as shown and bend slowly to one side until you feel a stretch.     
Hold, and then repeat on the other side. 
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For gym-based group exercises, circuit exercises, 2 minutes per station,  
Exercises of 
 
Squats: this type of exercise help in lifting and bending through strengthen the powerful 
leg muscles in order to improve functional rehabilitation, muscle strength, core stability 
and balance. 
 
Intensity level 1 – sit to stand. Stand straight with your feet shoulder width apart. Slowly 
squat to a sitting position on the chair. Then stand, and repeat. Remember to tighten your 
abdominal muscles 
 
Intensity level 2 – squats. Squat to the level of the chair but stand again without sitting 
down. Remember to tighten your abdominals 
 
Intensity level three – squat and hold. Squat to the level of the chair but without sitting 
down. Hold squat position just above the chair for 5 seconds before standing again. 
Remember to tighten your abdominal muscles 
 
 
 
 
           Level 1                                       Level 2                                           Level 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abdominals: to improve core-stability and muscle strengthening by strengthen muscles 
of stomach, which maintain the posture. 
 
Intensity level 1 – Pelvic tilt and abdominal hollowing. Lie on your back with knees bent 
and feet flat on the floor. Rest your hands by your side. Perform a pelvic tilt by pulling 
your stomach in, pressing the small of your back into the floor so that your pelvis tilts 
backwards and your groin lifts upwards. 
Intensity levels 2 – Pelvic tilt and curl to knees. Lie on your back with knees bent and feet 
flat on the floor. Place your hands on your thighs. Perform a pelvic tilt. Next, lift your 
head and shoulders to look between your knees. At the same time, slide your hands up 
your knees to touch your knees. Make sure you tuck your chin in. Slowly round your 
spine rather than straining your neck. 
 
Intensity level 3 – Pelvic tilts and curls with hands behind head. Perform a pelvic tilt, and 
curl, as before. But with your hands held loosely behind your head. 
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Level 1                                                                Level 2 
                       
 
Level 3 
 
 
 
 
 
 
 
 
Shuttle walk or run, or treadmill: in order to improve muscle strengthening, 
cardiovascular fitness, core-stability, balance and functional rehabilitation  
 
Intensity level 1 – walk at a brisk pace 
Intensity level 2 – jog 
Intensity level 3 – run 
 
             Level 1                                            Level 2                           Level 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Press-ups: to improve or maintain muscle strength and core-stability mainly for muscles 
of the chest and arms (Salford Royal Foundation NHS Trust, 2007) 
 
Intensity level one – wall press up. Lean against wall with elbows straight and hands 
slightly wider apart than shoulder width. Perform a press-up against the wall 
remembering to tighten your abdominal muscles as you do 
 
Intensity level 2 – box press-up. Start on all fours. Hands under shoulders and knees 
under hips. Perform a press up in this kneeling position 
 
Intensity level 3 – floor press-up. Hands on floor slightly wider apart than shoulder width. 
Feet shoulder width apart with toes in contact with the floor. Perform a full press-up, 
remembering to tighten your abdominal muscles as you do so. 
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       Level 1                                                            Level 2                                         
 
 
 
 
 
 
 
 
 
 
 
Level 3 
 
 
 
 
 
 
 
 
 
Star steps and jumps: to improve muscle strength, co-ordination, core stability and 
balance 
 
Intensity level 1 – Star steps. Step and touch to the left and right. Hands on hips. 
Remember to tighten your abdominal muscles. 
 
Intensity level 2 – Star steps with arms. Step and touch to the left and right. At the same 
time, lift your arms up and down to the sides. Remember to tighten your abdominals. 
 
Intensity level 3 – Star jump. Start with feet together and arms down by your sides. Then 
jump up, land in a star shape, with feet apart and arms outstretched to the side.  
 
Remember to tighten your abdominal muscles. 
 
            Level 1                                          Level 2                                     Level 3 
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Arm exercises important in lifting up and carry things through strengthen muscle of arms 
in order to improve muscle strength and core stability.  
 
Shoulder press 
Shoulder fly’s 
Bicep curls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step-ups for functional rehabilitation, strengthening and balance (Salford Royal 
Foundation NHS Trust, 2007) 
 
Intensity level 1 – low step 
Intensity level 2 – medium step 
Intensity level 3 – high step 
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Back exercises to strengthen the muscles of the back 
 
4 to 3 point kneel  
 
4 to 2 point kneel 
 
Supine contralateral leg and arm lift 
 
 
 
 
 
Level 1                                                                           Level 2 
 
 
 
Level 3 
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Appendix 15: North West NHS 2 Research Ethics Committee-
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Appendix 19:  Block randomisation of the RCT study (Study One) 
 
Block Randomisation: Method 
Each possible permutation of groups A and B in blocks of four was assigned a number 
(Figure 4). Blocks were repeated to reflect the number of patients in the study (92). A 
random number sequence was then generated from a computer and was used to choose a 
particular block, which in turn sets the allocation order for the first four subjects. 
Numbers in the random number sequence greater than the number of permuted blocks are 
not used to select blocks (Beller et al, 2002). 
The stratified block randomisation process for a block size of four, with A and B being 
treatment groups (A= land; B= hydrotherapy). 
Step 1: 
Permuted blocks 
Step 2: 
Random number 
sequence 
Step 3: 
Randomisation list 
 
AABB 
ABAB 
BBAA 
BBAA 
BABA 
BAAB 
AABB 
ABAB 
BBAA 
BBAA 
BABA 
BAAB 
 
 
 
 
 
1 
4 
8 
6 
5 
7 
A 
A     block 1 
B 
B 
 
B 
B     block 4 
A 
A 
 
A 
B     block 8 
A 
B 
 
B 
A     block 6        
B 
A 
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Appendix 20: Shapiro-Wilk tests of normality for hydrotherapy and 
land groups of RA patients 
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Appendix 21: Within group comparison of outcome measures at Test 
1, 2 and 3 in the both groups (n = 14). 
Variables p values Variables p values 
 
Land group Hydrotherapy group 
HAQ-DI
┼
 0.626 HAQ-DI
┼
 0.003 
HAQ VAS
┼
 0.441 HAQ VAS
┼
 0.004 
HAQ-GWB
┼
 0.147 HAQ-GWB
┼
 0.002 
EQ-5D tariff* 0.798 EQ-5D tariff* 0.839 
EQ-5D VAS
┼
 0.095 EQ-5D VAS
┼
 0.009 
RADAI
┼
 0.792 RADAI
┼
 0.568 
HADs* 0.266 HADs* 0.199 
HAD-D* 0.746 HAD-D* 0.259 
HAD-A* 0.612 HAD-A* 0.613 
†Values were measures by repeated measures ANOVA 
 *values were measured by Friedman test  
Significant p values set at 0.017 are indicated in boldface 
Key: 
 
HAQ-DI overall scores (0 to 3), with 0 being best and 3 worst functioning 
HAQ VAS score (0-100), 0 = no pain, 100 = severe pain 
HAQ GWB scores (0 – 100), 0 = very well, 100 = very poor 
EQ-5D tariff score (- 0.594 to 1), with 1= perfect health, - 0.594 worse than death 
EQ-5D VAS score (0-100), with 0 low quality and 100 high quality 
RADAI overall score (0 – 10), with 0 no disease activity and 10 very severe 
DAS28 overall score (0 -9.4), with 0 no disease activity and 9.4 very severe 
HAD overall score (zero – 42), with zero (no depression, anxiety), 42 (very severe depression, anxiety) 
HAD-D overall score (0-21), with 0-7 normal, 8-10 borderline case, ≥ 11 definite 
HAD-A overall score (0-21), with 0-7 normal, 8-10 borderline case, ≥ 11 definite 
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Appendix 22: HAQ-DI categories between hydrotherapy and land 
group at Test 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAQ-DI categories 
Hydrotherapy 
(n = 21) 
Mean (SD) 
Land therapy 
(n = 22) 
Mean (SD) 
p 
(95% CI) 
Dressing  
&  
Grooming 
1.1 (0.8) 1.3 (1) 0.40 (- 0.31 to 0.76) 
Arising 1 (0.7) 1 (0.8) 0.062 (- 0.88 to 0.02) 
Eating 1 (0.6) 1.3 (0.8)   0.23 (- 0.2 to 0.7) 
Walking 0.9 (0.9) 1.3 (1) 0.2 (- 0.2 to – 1.1) 
Hygiene 1.3 (1.1) 1.5 (1) 0.44 (- .41 to 0.92) 
Reach 1.2 (0.9) 1.7 (1) 0.13 (- 0.14 to 1.1) 
Grip 1.4 (0.7) 1.4 (0.9) 0.91 (- 0.55 to 0.5) 
Activities 1.3 (1) 1.6 (1)    0.34(- 0.33 to 0.95) 
Key: 
HAQ-DI overall scores (0 to 3), with 0 being best and 3 worst functioning 
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Appendix 23: Comparison of outcome measures for difference in 
change score between groups (Test 1 and 3). 
 
 
 
 
Variables Hydrotherapy 
(n = 14) 
Land 
(n = 14) 
p 
(95% CI) 
Primary outcome measure 
Functional ability 
  
HAQ-DI
┼
 
 
 
0.52 (0.81) 
 
 
0.14 (0.71) 
 
 
0.217 (- 0.97 to 0.23) 
Secondary outcome measure 
HAQ VAS 
┼
 (Pain) 
HAQ-GWB
┼
 (Wellbeing) 
15.2 (25.8) 
15.1 (25.15) 
- 19 (24.5) 
2.2 (19.4) 
0.124 (- 35.4 to 4.6) 
0.149 (- 30.9  to 5) 
Health status (QoL) 
EQ-5D tariff* 
EQ-5D VAS
┼
 
 
0 (0.35) 
- 14 (26) 
 
0  (0.22) 
- 19 (33) 
 
0.329 
0.686 (- 28 to 19) 
Disease activity 
RADAI
┼ 
DAS28
┼
 
 
0.13 (3.1) 
1.4 (1.8) 
 
- 0.1 (2.2) 
0.37 (2.1) 
 
0.824 (- 2.38 to 1.9) 
0.189 (- 2.5 to 0.53) 
Mood symptoms 
HAD scale * 
HAD-D * 
HAD-A * 
 
0.5 (10.5) 
0.5 (5.5) 
1 (5.5) 
 
- 2 (9.5) 
0 (4. 5) 
1 (4) 
 
0.350 
0.830 
0.793 
┼ 
Values are in mean (SD) and by independent t-test 
 *values in median (IQR) and by Mann-Whitney U test  
Significant p values are indicated in boldface 
Key: 
 
HAQ-DI overall scores (0 to 3), with 0 being best and 3 worst functioning 
HAQ VAS score (0-100), 0 = no pain, 100 = severe pain 
HAQ GWB scores (0 – 100), 0 = very well, 100 = very poor 
EQ-5D tariff score (- 0.594 to 1), with 1= perfect health, - 0.594 worse than death 
EQ-5D VAS score (0-100), with 0 low quality and 100 high quality 
RADAI overall score (0 – 10), with 0 no disease activity and 10 very severe 
DAS28 overall score (0 -9.4), with 0 no disease activity and 9.4 very severe 
HAD overall score (zero – 42), with zero (no depression, anxiety), 42 (very severe depression, anxiety) 
HAD-D overall score (0-21), with 0-7 normal, 8-10 borderline case, ≥ 11 definite 
HAD-A overall score (0-21), with 0-7 normal, 8-10 borderline case, ≥ 11 definite 
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Appendix 24: Comparison of outcome measures for difference in 
change score between groups (Test 2 and 3). 
 
 
 
 
 
Variables Hydrotherapy 
(n = 14) 
Land 
(n = 14) 
p 
(95% CI) 
Primary outcome measure 
Functional ability 
HAQ-DI
┼  
 
- 0.12 (0.46) 
 
- 0.12 (0.48) 
 
0.999 (- 0.37 to 0.37) 
Secondary outcome measure 
 
HAQ VAS 
┼ 
 (Pain) 
HAQ-GWB
┼  
(Wellbeing) 
 
15.3 (25.8) 
15.2 (25.8) 
 
- 0.19 (24.5) 
2.2 (19.4) 
 
0.124 (- 35.4 to 4.6) 
0.148 (- 30.9  to 5) 
Health status (QoL) 
EQ-5D tariff* 
EQ-5D VAS
┼
 
 
0 (0.18) 
7.4 (22) 
 
0 (0.29) 
- 17 (27.6) 
 
0.941 
0.057 (- 44 to – 4.8) 
Disease activity 
RADAI
┼
 
DAS28
┼
 
 
- 0.49 (2.4) 
- 0.32 (1.45) 
 
0.25 (2.2) 
- 0.80 (1.5) 
 
0.418 (- 1.1 to 2.6) 
0.385 (- 1.6 to 0.65) 
Mood symptoms 
HAD scale * 
HAD-D * 
HAD-A * 
 
- 1.5 (6.5) 
- 1 (3.5) 
0 (4.5) 
 
0 (6) 
0 (4) 
1 (6) 
 
0.436 
0.714 
0.118 
┼ Values are in mean (SD) and by independent t-test  
*values in median (IQR) and by Mann-Whitney U test 
Significant p values are indicated in boldface 
Key: 
 
HAQ-DI overall scores (0 to 3), with 0 being best and 3 worst functioning 
HAQ VAS score (0-100), 0 = no pain, 100 = severe pain 
HAQ GWB scores (0 – 100), 0 = very well, 100 = very poor 
EQ-5D tariff score (- 0.594 to 1), with 1= perfect health, - 0.594 worse than death 
EQ-5D VAS score (0-100), with 0 low quality and 100 high quality 
RADAI overall score (0 – 10), with 0 no disease activity and 10 very severe 
DAS28 overall score (0 -9.4), with 0 no disease activity and 9.4 very severe 
HAD overall score (zero – 42), with zero (no depression, anxiety), 42 (very severe depression, anxiety) 
HAD-D overall score (0-21), with 0-7 normal, 8-10 borderline case, ≥ 11 definite 
HAD-A overall score (0-21), with 0-7 normal, 8-10 borderline case, ≥ 11 definite 
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Appendix 26: Kellgren Rheumatology Outpatient data form of Study 
Two 
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Appendix 27: Covering infromation letter to the Kellgren participants 
(Study Two) 
 
 
 
Covering information letter 
Version I 
Date: 17/06/2011 
Project Title: Medical rehabilitation: the effects of aquatic physiotherapy in patients 
with Rheumatoid Arthritis (RA). 
We would be grateful if you would take the time to read the following information 
carefully. Feel free to talk to others about it if you wish. 
Background 
Researchers at the Kellgren Centre and Manchester Metropolitan University are working 
together on a study looking at the effects of aquatic physiotherapy (hydrotherapy) in 
patients with RA. There are over 2000 patients with RA attending the Kellgren Centre 
and a proportion of those are referred to aquatic physiotherapy at Manchester Royal 
Infirmary (MRI).  
Aim 
As part of the larger study, we would like to carry out a smaller one. We are trying to see 
if those patients with RA referred to aquatic physiotherapy have different characteristics 
to those who do not. We think this is important because it will enable doctors and 
physiotherapists to look out for those patients who are likely to need aquatic 
physiotherapy and provide a more efficient service. 
Plan 
In order to carry out this study we plan to gather information from a sample of 10% (200) 
of all patients at the Kellgren Centre. You will not have to do anything as all the 
information can be obtained from medical notes. The notes will be chosen at random so 
you may or may not be involved. Researchers will not know whose information is being 
used because no names or any other patient identifiable information will be used. 
 Information will include no more than: 
Age 
Gender 
Duration of disease [date of diagnosis] 
Occupation status [e.g. retired / working] 
Comorbidities 
Current treatment [drug regimens] 
Height  
Weight 
Disease Activity Score [DAS] 28 [if recorded] 
 
We are working together with the support of your clinical team. The research nurse 
[Lindsey Barnes] at the Kellgren Centre will select the notes from those on clinic days 
and fill in the above information for the researchers. Medical notes will not leave the 
Kellgren Centre nor will anyone have access to the notes other than your consultant and 
nurse. 
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Only the above data will be transferred to the University and then stored on computers 
with passwords in lockable rooms. The information will be grouped together and only 
averages of all the data will be reported, so individual characteristics will not be 
described. The lead researcher will look at some parts of the data collected for the study; 
authorised people may also look at them from Central Manchester University Hospitals 
NHS Foundation Trust to check that the study is being carried out correctly. All will have 
a duty of confidentiality to you as a research participant and nothing that could reveal 
your identity will be disclosed outside the research site.  
 
Because we think that this is important, we hope to publish the findings in a medical 
journal. 
 You do not need to do anything if you are happy for your information to 
be used should it be selected. 
 If you would not like your information to be used should it be chosen or if 
you would like any further information about the study, please contact the 
Researcher, below.  
 
 Researcher contact details: 
Khamis AL-Qubaeissy, Doctoral Researcher/Medical Rehabilitation,  
 
Elizabeth Gaskell Campus, Hathersage Road,  
Manchester. M13 0JA 
Tel: 01612472610  
Email: 09981701@stu.mmu.ac.uk 
Yours sincerely, 
Khamis AL-Qubaeissy, Doctoral Researcher/Medical Rehabilitation 
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Appendix 28: Letter from clinicians in the Kellgren Centre  
                                    (Study Two) 
 
1 August 2011 
Chairman 
National Research Ethics Service 
North West 2 Research Ethics Committee-Liverpool Central 
3 
rd
 Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Dear Ethics Committee:  
 
Re: Study Title: Medical Rehabilitation: the effects of aquatic physiotherapy in 
patients with Rheumatoid Arthritis (RA). 
 
This letter is to confirm that the clinical team at the Kellgren Centre, MRI are happy to 
collaborate in the above study.  
We agree to provide administrative support via our research nurse, Lindsey Barnes (who 
is part of our clinical team and routinely sees our patients).  Patients would be sent a letter 
informing them that their clinical data may be used anonymously and giving them the 
opportunity to object and have their data withdrawn from the study. Anonymous data 
would then be provided to the researchers at Manchester Metropolitan University.   
 
Yours sincerely, 
 
 
  
 
 
 
 
Drs Rachel Gorodkins and Pauline Ho        Lindsey Barnes  
Consultant Rheumatologists                                   Research Nurse 
Kellgren Centre for Rheumatology  Kellgren Centre for Rheumatology 
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Appendix 29: North West NHS 2 Research Ethics Committee-
Liverpool Central approval letter of Study Two 
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Appendix 29 (Continued) 
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Appendix 30: Patient costs questionnaire 1  
 
Study Title: The effect of aquatic physiotherapy in patients 
with Rheumatoid Arthritis 
 
 
 
 
 
 
 
 
  
 
 
 
 
We are interested in how people travel to hospital and the costs they incur for 
patients who have RA and who are currently attending or have recently attended 
hydrotherapy or land-based therapy. Would you please return the completed 
questionnaire to Khamis Al-Qubaeissy and his address is below. 
The information you provide will be treated in complete confidence and will not 
affect the service you receive.  Thank you for your help. 
 
 
 
 
 
 
Khamis Al-Qubaeissy 
PhD Student 
Manchester Metropolitan University 
Elizabeth Gaskell Campus 
Hathersage Road 
Manchester M13 0JA 
Tel: 0161 2472610  
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Appendix 30 (continued)  
 
We would like you to think about the journey you made to attend your 
hydrotherapy. 
 
 
1a. How did you travel to and from the hospital? 
  (You may tick more than one box, if appropriate) 
                        
                       Car Bus or train  Taxi      Walk   Ambulance   Other 
Journey to                                            
Hospital 
 
Journey                                        
From  
Hospital 
 
 
1b. If you ticked ‘Other’ Please specify............................................ 
 
............................................................................................................ 
  
 
 
1c. If you ticked ‘bus or train, or ‘taxi’, please indicate the approximate return 
fare: 
 
£................. 
 
 
 
1d. Are you eligible for reimbursement for the costs you have incurred in 
attending this appointment. 
 
                                                                                                                    Yes    No 
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Appendix 30 (continued)  
 
2. How long was the journey from home to hospital? Please give the approximate 
time from door to door: 
 
................. Hours .................Minutes  
 
 
3. Approximately how far did you travel from home to the hospital? 
 
...................Miles 
 
 
4. If you came by car, how much have you had to pay for parking?  
 
£.................. 
             
                                                           Yes   No                                       
5. Did someone accompany you to the hospital?                       
 
             
                                                           Yes No                       
6. If you were accompanied, did your companion          
also have an appointment at the hospital?   
 
 
7a. What would you (and your companion, if relevant) normally have been doing 
had you not had to visit the hospital? (Please tick the appropriate boxes). 
 
 
 
 
Self 
 
Companion 
 
Paid Occupation 
 
 
 
 
 
Looking after children, 
other relatives, friends 
 
 
 
 
 
Other (please describe) 
 
............................ 
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7b. If you have ticked 'Paid Occupation' above, please indicate what arrangements 
you made to be absent from work.  (Please tick the appropriate boxes). 
 
 
 
 
Self 
 
Companion 
 
Annual Leave 
 
 
 
 
 
Hours Rearranged 
 
 
 
 
 
Time Off Without Loss of Pay 
 
 
 
 
 
Time Off With Loss of Pay 
 
 
 
 
 
Other (please describe) 
 
............................ 
 
 
 
 
 
 
7c. If you have ticked 'Time off with Loss of Pay'  
Please indicate the approximate sum you have lost.        
  
 
 
£..................... 
 
 
8a. Were there any other costs involved in visiting the hospital, which have not 
been covered above?  If so, please give details. 
 
....................................................................................................... 
 
....................................................................................................... 
 
8b. What was the total cost incurred by these other expenses?   
      
 
£...................... 
 
9. Please give the total time, in minutes, spent at the 
hospital on this visit (excluding travelling time). 
 
...................Minutes 
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Appendix 31: Patient Costs Questionnaire 2 
    
 
Patient Costs Questionnaire   (all Patients after 6 weeks of intervention) 
 
Have you visited your GP about your RA after 6 weeks of aquatic therapy?  
Yes / No 
 
 
If YES, how many times? 
 
______  
 
 
How much did you spend on travel and prescription charges in total?     
 
£______ 
 
 
Have you attended any therapy sessions other than hydrotherapy for your RA? 
 
Yes / No 
 
 
If YES, what type of therapy was it? 
 
_______________________________ 
 
 
How many sessions did you attend? 
 
______ 
 
 
How much did you spend on travel and therapy charges in total?  
 
£______ 
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Appendix 32: The hospital physiotherapist costs (Adapted from Curtis, 2011) 
 
Unit estimation and 
costs 
2010 / 2011 Notes 
A.Wages /salary £22,700 per year Based on the median full‐time equivalent basic salary for Agenda for 
Change Band 5 of the January ‐ March 2011 NHS Staff Earnings for 
qualified Allied Health Professionals. Median full‐time equivalent 
total earnings, which include basic salary plus hours‐related pay, 
overtime, occupation payments, location payments, and other 
payments such as redundancy pay or payment of notice periods, were 
£24,100 (The Information Centre for health and social care, 2011). 
More specialist grades range from AfC band 6 to 8C for a 
physiotherapist specialist to consultant. 
 
B. Salary oncosts £5,352 per year Employers’ national insurance plus 14 % of salary for employers’ 
contribution to superannuation 
 
C. Qualifications £4,927 per year The equivalent annual cost of pre-registration education after the 
total investment cost has been annuitized over the expected working 
life (Netten et al., 1998). The Department of Health and the Higher 
Education Funding Council have provided current cost information 
for England (HEFCE). 
 
D. Overheads 
 
Management, 
administration and 
estates staff 
 
Non‐staff 
 
 
£5,330 per year 
 
 
£11,782 per year 
Taken from NHS (England) Summarised Accounts  
( National Health Service Act 2006, 2010) 
 
Management and other non‐care staff costs were 19.1 % of direct 
care salary costs and included administration and estates staff. 
 
Non‐staff costs were 41.6 per cent of direct care salary costs. They 
include costs to the provider for office, travel/transport and 
telephone, education and training, supplies and services (clinical and 
general), as well as utilities such as water, gas and electricity. 
E. Capital overheads £4,541 per year Based on the new‐build and land requirements of NHS facilities, but 
adjusted to reflect shared use of both treatment and non‐treatment 
space (Building Cost Information Service, 2011; Department for 
communities and local government, 2011). No allowance has been 
made for the cost of equipment. Capital costs have been annuitised 
over 60 years at a discount rate of 3.5% 
 
F. Travel  No information available on average mileage covered per visit. 
Current guideline for reimbursement: 54 pence per mile up to 3,500 
miles, 18 pence over 3,500 miles ( NHS Employers, 2012 a) 
 
Working time 41.3 weeks per 
annum 
37.5 hours per 
week 
Includes 29 days annual leave and 8 days statutory leave (NHS 
Employer, 2012 b). Assumes 5 study/training days and 12 days 
sickness leave (The Information Centre for health and social care, 
2021). Unit costs based on 1549 hours per annum. 
Ratio of direct to 
indirect time 
 No current information available. 
Duration of contacts 32.9 minutes 
23.3 minutes 
13.1 minutes 
Surgery consultation. 
Clinic consultations. 
Telephone consultations. 
All based on information taken from the 2006/07 General Practice 
Workload Survey (The Information Centre knowledge for care, 
2007) 
Non‐London multiplier 0.97 x E Allows for the lower costs associated with working outside London 
compared to the national average cost (Building Cost Information 
Service, 2011; Department for communities and local government, 
2011). 
Unit costs available 2010/2011 (costs including qualifications given in brackets) 
 
£32 (£35) per hour. 
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Appendix 33: The hospital physiotherapist assistant costs (Adapted from Curtis, 
2011) 
Unit estimation 
and costs 
2010 / 2011 Notes 
A.Wages /salary £17,600 per 
year 
Based on the median full‐time equivalent basic salary 
for Agenda for Change Band 3 of the January‐March 
2011 NHS Staff Earnings estimates for unqualified 
allied health professionals. Median full‐time equivalent 
total earnings, which include basic salary plus hours‐
related pay, overtime, occupation payments, location 
payments, and other payments such as redundancy pay 
or payment of notice periods, were £18,400(The 
Information Centre for health and social care, 2011). 
B. Salary oncosts £3,985 per 
year 
Employers’ national insurance is included plus 14 per 
cent of salary for employers’ contribution to 
superannuation. 
C. Qualifications £0 Training costs are assumed to be zero, although many 
take NVQ courses. 
D. Overheads 
 
Management, 
administration and 
estates staff 
 
Non‐staff 
 
 
 
£4,123 per 
year 
 
 
£8,979 per 
year 
Taken from NHS (England) Summarised Accounts. ( 
National Health Service Act 2006, 2010) 
 
Management and other non‐care staff costs were 19.1 
per cent of direct care salary costs and included 
administration and estates staff. 
 
Non‐staff costs were 41.6 per cent of direct care salary 
costs. They include costs to the provider for office, 
travel/transport and telephone, education and training, 
supplies and services (clinical and general), as well as 
utilities such as water, gas and electricity. 
E.Capital overheads £2,970 per 
year 
Based on the new‐build and land requirements of NHS 
facilities, but adjusted to reflect shared use of both 
treatment and non‐treatment space (Building Cost 
Information Service, 2011; Department for 
communities and local government, 2011).  Capital 
costs have been annuitised over 60 years at a discount 
rate of 3.5 per cent. 
Working time 42.3 weeks 
per 
annum 
37.5 hours per 
week 
Includes 29 days annual leave, 8 days statutory leave 
and 12 days sickness leave (NHS Employer, 2012 b; 
The Information Centre for health and social care, 
2021). No study/training days have been assumed. Unit 
costs based on 1585 hours per annum 
Ratio of direct to 
indirect time 
 No current information available. 
Non‐London 
multiplier 
0.97 x E Allows for the lower costs associated with working 
outside London compared to the national average cost 
(Building Cost Information Service, 2011; Department 
for communities and local government, 2011). 
Unit costs available 2010/2011 
£24 per hour 
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